<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<corpus source="miRNA-corpus">
    <document id="miRNA-corp.d0" origId="21346322">
        <sentence id="miRNA-corp.d0.s0" origId="21346322.s3" text="This can translate into global effects on cellular health and differentiation state. "/>
        <sentence id="miRNA-corp.d0.s1" origId="21346322.s4" text="Recently, several reports have identified crucial roles for miRNAs in controlling the production, differentiation, and health of myelinating cells of the mammalian nervous system. ">
            <entity charOffset="60-65" id="miRNA-corp.d0.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d0.s2" origId="21346322.s2" text="As single miRNAs are often predicted to target up to hundreds of individual transcripts, miRNAs are able to broadly affect the overall protein expression state of the cell. ">
            <entity charOffset="10-15" id="miRNA-corp.d0.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="27-45" id="miRNA-corp.d0.s2.e1" text="predicted to target" type="Relation_Trigger"/>
            <entity charOffset="89-94" id="miRNA-corp.d0.s2.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d0.s3" origId="21346322.s5" text="In this review, we will discuss how individual miRNAs regulate these various processes, and also how miRNA production in general is required for several stages of myelin generation and maintenance.   ">
            <entity charOffset="47-52" id="miRNA-corp.d0.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="54-61" id="miRNA-corp.d0.s3.e1" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="101-105" id="miRNA-corp.d0.s3.e2" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d0.s4" origId="21346322.s1" text="MicroRNAs (miRNAs) are a class of small (approx. 22 nt) noncoding RNAs that are capable of post-transcriptionally silencing mRNAs that contain sequences complementary to the miRNAs' 7- to 8-bp 'seed' sequence. ">
            <entity charOffset="0-8" id="miRNA-corp.d0.s4.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d0.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
			<entity charOffset="174-179" id="miRNA-corp.d0.s4.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d0.s5" origId="21346322.s0" text="MicroRNAs in oligodendrocyte and Schwann cell differentiation.  ">
            <entity charOffset="0-8" id="miRNA-corp.d0.s5.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d1" origId="19941032">
        <sentence id="miRNA-corp.d1.s0" origId="19941032.s5" text="Our data suggests that down-regulation of miRNA-128 may contribute to glioma and GBM, in part, by coordinately up-regulating ARP5 (ANGPTL6), Bmi-1 and E2F-3a, resulting in the proliferation of undifferentiated GBM cells.   ">
            <entity charOffset="23-37" id="miRNA-corp.d1.s0.e0" text="down-regulation" type="Relation_Trigger"/>
            <entity charOffset="42-50" id="miRNA-corp.d1.s0.e1" text="miRNA-128" type="Specific_miRNAs"/>
            <entity charOffset="70-75" id="miRNA-corp.d1.s0.e2" text="glioma" type="Diseases"/>
            <entity charOffset="81-83" id="miRNA-corp.d1.s0.e3" text="GBM" type="Diseases"/>
            <entity charOffset="111-123" id="miRNA-corp.d1.s0.e4" text="up-regulating" type="Relation_Trigger"/>
            <entity charOffset="125-128" id="miRNA-corp.d1.s0.e5" text="ARP5" type="Genes/Proteins"/>
            <entity charOffset="131-137" id="miRNA-corp.d1.s0.e6" text="ANGPTL6" type="Genes/Proteins"/>
            <entity charOffset="141-145" id="miRNA-corp.d1.s0.e7" text="Bmi-1" type="Genes/Proteins"/>
            <entity charOffset="210-212" id="miRNA-corp.d1.s0.e8" text="GBM" type="Diseases"/>
            <pair e1="miRNA-corp.d1.s0.e1" e2="miRNA-corp.d1.s0.e2" id="miRNA-corp.d1.s0.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s0.e1" e2="miRNA-corp.d1.s0.e3" id="miRNA-corp.d1.s0.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s0.e1" e2="miRNA-corp.d1.s0.e5" id="miRNA-corp.d1.s0.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s0.e1" e2="miRNA-corp.d1.s0.e6" id="miRNA-corp.d1.s0.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s0.e1" e2="miRNA-corp.d1.s0.e7" id="miRNA-corp.d1.s0.p4" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s0.e1" e2="miRNA-corp.d1.s0.e8" id="miRNA-corp.d1.s0.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d1.s1" origId="19941032.s4" text="Addition of exogenous miRNA-128 to CRL-1690 and CRL-2610 GBM cell lines (a) restored 'homeostatic' ARP5 (ANGPTL6), Bmi-1 and E2F-3a expression, and (b) significantly decreased the proliferation of CRL-1690 and CRL-2610 cell lines. ">
            <entity charOffset="22-30" id="miRNA-corp.d1.s1.e0" text="miRNA-128" type="Specific_miRNAs"/>
            <entity charOffset="99-102" id="miRNA-corp.d1.s1.e1" text="ARP5" type="Genes/Proteins"/>
            <entity charOffset="105-111" id="miRNA-corp.d1.s1.e2" text="ANGPTL6" type="Genes/Proteins"/>
            <entity charOffset="115-119" id="miRNA-corp.d1.s1.e3" text="Bmi-1" type="Genes/Proteins"/>
            <entity charOffset="152-174" id="miRNA-corp.d1.s1.e4" text="significantly decreased" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d1.s1.e0" e2="miRNA-corp.d1.s1.e1" id="miRNA-corp.d1.s1.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s1.e0" e2="miRNA-corp.d1.s1.e2" id="miRNA-corp.d1.s1.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s1.e0" e2="miRNA-corp.d1.s1.e3" id="miRNA-corp.d1.s1.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d1.s2" origId="19941032.s3" text="Three bioinformatics-verified miRNA-128 targets, angiopoietin-related growth factor protein 5 (ARP5; ANGPTL6), a transcription suppressor that promotes stem cell renewal and inhibits the expression of known tumor suppressor genes involved in senescence and differentiation, Bmi-1, and a transcription factor critical for the control of cell-cycle progression, E2F-3a, were found to be up-regulated. ">
            <entity charOffset="30-38" id="miRNA-corp.d1.s2.e0" text="miRNA-128" type="Specific_miRNAs"/>
            <entity charOffset="40-46" id="miRNA-corp.d1.s2.e1" text="targets" type="Relation_Trigger"/>
            <entity charOffset="49-92" id="miRNA-corp.d1.s2.e2" text="angiopoietin-related growth factor protein 5" type="Genes/Proteins"/>
            <entity charOffset="95-98" id="miRNA-corp.d1.s2.e3" text="ARP5" type="Genes/Proteins"/>
            <entity charOffset="101-107" id="miRNA-corp.d1.s2.e4" text="ANGPTL6" type="Genes/Proteins"/>
            <entity charOffset="127-136" id="miRNA-corp.d1.s2.e5" text="suppressor" type="Relation_Trigger"/>
            <entity charOffset="174-196" id="miRNA-corp.d1.s2.e6" text="inhibits the expression" type="Relation_Trigger"/>
            <entity charOffset="207-222" id="miRNA-corp.d1.s2.e7" text="tumor suppressor" type="Relation_Trigger"/>
            <entity charOffset="274-278" id="miRNA-corp.d1.s2.e8" text="Bmi-1" type="Genes/Proteins"/>
            <entity charOffset="385-396" id="miRNA-corp.d1.s2.e9" text="up-regulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d1.s2.e0" e2="miRNA-corp.d1.s2.e2" id="miRNA-corp.d1.s2.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s2.e0" e2="miRNA-corp.d1.s2.e3" id="miRNA-corp.d1.s2.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s2.e0" e2="miRNA-corp.d1.s2.e4" id="miRNA-corp.d1.s2.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s2.e0" e2="miRNA-corp.d1.s2.e8" id="miRNA-corp.d1.s2.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d1.s3" origId="19941032.s2" text="The down-regulation of miRNA-128 was found to inversely correlate with WHO tumor grade. ">
            <entity charOffset="46-64" id="miRNA-corp.d1.s3.e0" text="inversely correlate" type="Relation_Trigger"/>
            <entity charOffset="4-18" id="miRNA-corp.d1.s3.e1" text="down-regulation" type="Relation_Trigger"/>
            <entity charOffset="23-31" id="miRNA-corp.d1.s3.e2" text="miRNA-128" type="Specific_miRNAs"/>
            <entity charOffset="75-79" id="miRNA-corp.d1.s3.e3" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d1.s3.e2" e2="miRNA-corp.d1.s3.e3" id="miRNA-corp.d1.s3.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d1.s4" origId="19941032.s1" text="High density micro-RNA (miRNA) arrays, fluorescent-reporter miRNA assay and Northern miRNA dot-blot analysis show that a brain-enriched miRNA-128 is significantly down-regulated in glioblastoma multiforme (GBM) and in GBM cell lines when compared to age-matched controls. ">
            <entity charOffset="13-21" id="miRNA-corp.d1.s4.e0" text="micro-RNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="24-28" id="miRNA-corp.d1.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="60-64" id="miRNA-corp.d1.s4.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="85-89" id="miRNA-corp.d1.s4.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="136-144" id="miRNA-corp.d1.s4.e4" text="miRNA-128" type="Specific_miRNAs"/>
            <entity charOffset="163-176" id="miRNA-corp.d1.s4.e5" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="181-203" id="miRNA-corp.d1.s4.e6" text="glioblastoma multiforme" type="Diseases"/>
            <entity charOffset="206-208" id="miRNA-corp.d1.s4.e7" text="GBM" type="Diseases"/>
            <entity charOffset="218-220" id="miRNA-corp.d1.s4.e8" text="GBM" type="Diseases"/>
            <pair e1="miRNA-corp.d1.s4.e0" e2="miRNA-corp.d1.s4.e6" id="miRNA-corp.d1.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s4.e0" e2="miRNA-corp.d1.s4.e7" id="miRNA-corp.d1.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s4.e0" e2="miRNA-corp.d1.s4.e8" id="miRNA-corp.d1.s4.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s4.e1" e2="miRNA-corp.d1.s4.e6" id="miRNA-corp.d1.s4.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s4.e1" e2="miRNA-corp.d1.s4.e7" id="miRNA-corp.d1.s4.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s4.e1" e2="miRNA-corp.d1.s4.e8" id="miRNA-corp.d1.s4.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s4.e2" e2="miRNA-corp.d1.s4.e6" id="miRNA-corp.d1.s4.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s4.e2" e2="miRNA-corp.d1.s4.e7" id="miRNA-corp.d1.s4.p7" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s4.e2" e2="miRNA-corp.d1.s4.e8" id="miRNA-corp.d1.s4.p8" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s4.e3" e2="miRNA-corp.d1.s4.e6" id="miRNA-corp.d1.s4.p9" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s4.e3" e2="miRNA-corp.d1.s4.e7" id="miRNA-corp.d1.s4.p10" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s4.e3" e2="miRNA-corp.d1.s4.e8" id="miRNA-corp.d1.s4.p11" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s4.e4" e2="miRNA-corp.d1.s4.e6" id="miRNA-corp.d1.s4.p12" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s4.e4" e2="miRNA-corp.d1.s4.e7" id="miRNA-corp.d1.s4.p13" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s4.e4" e2="miRNA-corp.d1.s4.e8" id="miRNA-corp.d1.s4.p14" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d1.s5" origId="19941032.s0" text="Micro-RNA-128 (miRNA-128) down-regulation in glioblastoma targets ARP5 (ANGPTL6), Bmi-1 and E2F-3a, key regulators of brain cell proliferation.  ">
            <entity charOffset="0-12" id="miRNA-corp.d1.s5.e0" text="Micro-RNA-128" type="Specific_miRNAs"/>
            <entity charOffset="15-23" id="miRNA-corp.d1.s5.e1" text="miRNA-128" type="Specific_miRNAs"/>
            <entity charOffset="26-40" id="miRNA-corp.d1.s5.e2" text="down-regulation" type="Relation_Trigger"/>
            <entity charOffset="45-56" id="miRNA-corp.d1.s5.e3" text="glioblastoma" type="Diseases"/>
            <entity charOffset="58-64" id="miRNA-corp.d1.s5.e4" text="targets" type="Relation_Trigger"/>
            <entity charOffset="66-69" id="miRNA-corp.d1.s5.e5" text="ARP5" type="Genes/Proteins"/>
            <entity charOffset="72-78" id="miRNA-corp.d1.s5.e6" text="ANGPTL6" type="Genes/Proteins"/>
            <entity charOffset="82-86" id="miRNA-corp.d1.s5.e7" text="Bmi-1" type="Genes/Proteins"/>
            <entity charOffset="104-113" id="miRNA-corp.d1.s5.e8" text="regulators" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d1.s5.e0" e2="miRNA-corp.d1.s5.e3" id="miRNA-corp.d1.s5.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s5.e0" e2="miRNA-corp.d1.s5.e5" id="miRNA-corp.d1.s5.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s5.e0" e2="miRNA-corp.d1.s5.e6" id="miRNA-corp.d1.s5.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s5.e0" e2="miRNA-corp.d1.s5.e7" id="miRNA-corp.d1.s5.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s5.e1" e2="miRNA-corp.d1.s5.e3" id="miRNA-corp.d1.s5.p4" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s5.e1" e2="miRNA-corp.d1.s5.e5" id="miRNA-corp.d1.s5.p5" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s5.e1" e2="miRNA-corp.d1.s5.e6" id="miRNA-corp.d1.s5.p6" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s5.e1" e2="miRNA-corp.d1.s5.e7" id="miRNA-corp.d1.s5.p7" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d2" origId="21712563">
        <sentence id="miRNA-corp.d2.s0" origId="21712563.s6" text="Follow up functional enrichment analysis of these FFLs uncovered some functions important to carcinogenesis but also some unique functions specific to the FFLs we identified.   "/>
        <sentence id="miRNA-corp.d2.s1" origId="21712563.s3" text="Transcriptional aberrations may play a vital role in the etiology of glioblastoma, which might be caused by both genomic alterations and other regulation molecules. ">
            <entity charOffset="69-80" id="miRNA-corp.d2.s1.e0" text="glioblastoma" type="Diseases"/>
            <entity charOffset="143-152" id="miRNA-corp.d2.s1.e1" text="regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d2.s2" origId="21712563.s2" text="Illustrating the functions being disturbed during carcinogenesis and how they are deregulated is very important for us to understand its underlying mechanism. ">
            <entity charOffset="82-92" id="miRNA-corp.d2.s2.e0" text="deregulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d2.s3" origId="21712563.s5" text="We searched glioblastoma-specific regulatory networks by integrating glioblastoma related miRNAs, TFs and genes, and identified 54 feed-forward loops (FFLs). ">
            <entity charOffset="12-23" id="miRNA-corp.d2.s3.e0" text="glioblastoma" type="Diseases"/>
            <entity charOffset="34-43" id="miRNA-corp.d2.s3.e1" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="69-80" id="miRNA-corp.d2.s3.e2" text="glioblastoma" type="Diseases"/>
            <entity charOffset="90-95" id="miRNA-corp.d2.s3.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d2.s3.e3" e2="miRNA-corp.d2.s3.e0" id="miRNA-corp.d2.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s3.e3" e2="miRNA-corp.d2.s3.e2" id="miRNA-corp.d2.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d2.s4" origId="21712563.s4" text="In this study, we investigated possible cooperative deregulation of microRNAs (miRNAs) and transcription factors (TFs) in glioblastoma, under the hypothesis that miRNAs and TFs might have a combinational regulatory effect on glioblastoma genes. ">
            <entity charOffset="79-84" id="miRNA-corp.d2.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="68-76" id="miRNA-corp.d2.s4.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="122-133" id="miRNA-corp.d2.s4.e2" text="glioblastoma" type="Diseases"/>
            <entity charOffset="162-167" id="miRNA-corp.d2.s4.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="204-213" id="miRNA-corp.d2.s4.e4" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="225-236" id="miRNA-corp.d2.s4.e5" text="glioblastoma" type="Diseases"/>
            <entity charOffset="52-63" id="miRNA-corp.d2.s4.e6" text="deregulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d2.s4.e3" e2="miRNA-corp.d2.s4.e5" id="miRNA-corp.d2.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s4.e3" e2="miRNA-corp.d2.s4.e2" id="miRNA-corp.d2.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s4.e0" e2="miRNA-corp.d2.s4.e5" id="miRNA-corp.d2.s4.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s4.e0" e2="miRNA-corp.d2.s4.e2" id="miRNA-corp.d2.s4.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s4.e1" e2="miRNA-corp.d2.s4.e5" id="miRNA-corp.d2.s4.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s4.e1" e2="miRNA-corp.d2.s4.e2" id="miRNA-corp.d2.s4.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d2.s5" origId="21712563.s1" text="Glioblastoma is the most common and most lethal brain tumour in humans. ">
            <entity charOffset="0-11" id="miRNA-corp.d2.s5.e0" text="Glioblastoma" type="Diseases"/>
            <entity charOffset="48-59" id="miRNA-corp.d2.s5.e1" text="brain tumour" type="Diseases"/>
            <entity charOffset="64-69" id="miRNA-corp.d2.s5.e2" text="humans" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d2.s6" origId="21712563.s0" text="Gene regulation in glioblastoma: a combinatorial analysis of microRNAs and transcription factors.  ">
            <entity charOffset="19-30" id="miRNA-corp.d2.s6.e0" text="glioblastoma" type="Diseases"/>
            <entity charOffset="61-69" id="miRNA-corp.d2.s6.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="5-14" id="miRNA-corp.d2.s6.e2" text="regulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d2.s6.e1" e2="miRNA-corp.d2.s6.e0" id="miRNA-corp.d2.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d3" origId="21094214">
        <sentence id="miRNA-corp.d3.s0" origId="21094214.s1" text="Although microRNAs are expressed extensively in the central nervous system in physiological and pathological conditions, their expression in neurological disorder of epilepsy has not been well characterized. ">
            <entity charOffset="141-161" id="miRNA-corp.d3.s0.e0" text="neurological disorder" type="Diseases"/>
            <entity charOffset="9-17" id="miRNA-corp.d3.s0.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="166-173" id="miRNA-corp.d3.s0.e2" text="epilepsy" type="Diseases"/>
            <pair e1="miRNA-corp.d3.s0.e1" e2="miRNA-corp.d3.s0.e0" id="miRNA-corp.d3.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d3.s0.e1" e2="miRNA-corp.d3.s0.e2" id="miRNA-corp.d3.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d3.s1" origId="21094214.s0" text="Expression profile of microRNAs in rat hippocampus following lithium-pilocarpine-induced status epilepticus.  ">
            <entity charOffset="22-30" id="miRNA-corp.d3.s1.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="89-106" id="miRNA-corp.d3.s1.e1" text="status epilepticus" type="Diseases"/>
            <entity charOffset="35-37" id="miRNA-corp.d3.s1.e2" text="rat" type="Species"/>
            <pair e1="miRNA-corp.d3.s1.e0" e2="miRNA-corp.d3.s1.e1" id="miRNA-corp.d3.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d3.s2" origId="21094214.s3" text="Rat MicroRNA array and differential analysis had detected 19 up-regulated microRNAs and 7 down-regulated microRNAs in rat hippocampus, and four randomly selected deregulated microRNAs (microRNA-34a, microRNA-22, microRNA-125a, microRNA-21) were confirmed by qRT-PCR, then their expression alterations in rat peripheral blood were analyzed. ">
            <entity charOffset="0-2" id="miRNA-corp.d3.s2.e0" text="Rat" type="Species"/>
            <entity charOffset="4-11" id="miRNA-corp.d3.s2.e1" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="61-72" id="miRNA-corp.d3.s2.e2" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="90-103" id="miRNA-corp.d3.s2.e3" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="105-113" id="miRNA-corp.d3.s2.e4" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="74-82" id="miRNA-corp.d3.s2.e5" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="118-120" id="miRNA-corp.d3.s2.e6" text="rat" type="Species"/>
            <entity charOffset="162-172" id="miRNA-corp.d3.s2.e7" text="deregulated" type="Relation_Trigger"/>
            <entity charOffset="174-182" id="miRNA-corp.d3.s2.e8" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="185-196" id="miRNA-corp.d3.s2.e9" text="microRNA-34a" type="Specific_miRNAs"/>
            <entity charOffset="199-209" id="miRNA-corp.d3.s2.e10" text="microRNA-22" type="Specific_miRNAs"/>
            <entity charOffset="212-224" id="miRNA-corp.d3.s2.e11" text="microRNA-125a" type="Specific_miRNAs"/>
            <entity charOffset="227-237" id="miRNA-corp.d3.s2.e12" text="microRNA-21" type="Specific_miRNAs"/>
            <entity charOffset="304-306" id="miRNA-corp.d3.s2.e13" text="rat" type="Species"/>
            <entity charOffset="278-299" id="miRNA-corp.d3.s2.e14" text="expression alterations" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d3.s3" origId="21094214.s2" text="Here we investigated microRNA expression pattern in post status epilepticus rats (24h after status). ">
            <entity charOffset="21-28" id="miRNA-corp.d3.s3.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="57-74" id="miRNA-corp.d3.s3.e1" text="status epilepticus" type="Diseases"/>
            <entity charOffset="76-79" id="miRNA-corp.d3.s3.e2" text="rats" type="Species"/>
            <pair e1="miRNA-corp.d3.s3.e0" e2="miRNA-corp.d3.s3.e1" id="miRNA-corp.d3.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d3.s4" origId="21094214.s5" text="Thus, our results have not only characterized the microRNA expression profile in post status epilepticus rat hippocampus but also demonstrated that some rat hippocampal microRNAs were probably associated with rat peripheral blood microRNAs. ">
            <entity charOffset="50-57" id="miRNA-corp.d3.s4.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="86-103" id="miRNA-corp.d3.s4.e1" text="status epilepticus" type="Diseases"/>
            <entity charOffset="105-107" id="miRNA-corp.d3.s4.e2" text="rat" type="Species"/>
            <entity charOffset="153-155" id="miRNA-corp.d3.s4.e3" text="rat" type="Species"/>
            <entity charOffset="169-177" id="miRNA-corp.d3.s4.e4" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="193-202" id="miRNA-corp.d3.s4.e5" text="associated" type="Relation_Trigger"/>
            <entity charOffset="209-211" id="miRNA-corp.d3.s4.e6" text="rat" type="Species"/>
            <entity charOffset="230-238" id="miRNA-corp.d3.s4.e7" text="microRNAs" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d3.s4.e0" e2="miRNA-corp.d3.s4.e1" id="miRNA-corp.d3.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d3.s4.e4" e2="miRNA-corp.d3.s4.e1" id="miRNA-corp.d3.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d3.s4.e7" e2="miRNA-corp.d3.s4.e1" id="miRNA-corp.d3.s4.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d3.s5" origId="21094214.s4" text="We found that these four deregulated microRNAs were also differentially expressed in rat peripheral blood, and trends for their blood expression alterations were just the same as their counterparts in rat hippocampus. ">
            <entity charOffset="134-155" id="miRNA-corp.d3.s5.e0" text="expression alterations" type="Relation_Trigger"/>
            <entity charOffset="25-35" id="miRNA-corp.d3.s5.e1" text="deregulated" type="Relation_Trigger"/>
            <entity charOffset="37-45" id="miRNA-corp.d3.s5.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="57-80" id="miRNA-corp.d3.s5.e3" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="85-87" id="miRNA-corp.d3.s5.e4" text="rat" type="Species"/>
            <entity charOffset="201-203" id="miRNA-corp.d3.s5.e5" text="rat" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d3.s6" origId="21094214.s6" text="Moreover, targets of these deregulated microRNAs were analyzed using bioinformatics and the identified enriched MAPK pathway and long-term potentiation pathway might have been involved in molecular mechanisms concerning neuronal death, inflammation and epileptogenesis.   ">
            <entity charOffset="10-16" id="miRNA-corp.d3.s6.e0" text="targets" type="Relation_Trigger"/>
            <entity charOffset="27-37" id="miRNA-corp.d3.s6.e1" text="deregulated" type="Relation_Trigger"/>
            <entity charOffset="39-47" id="miRNA-corp.d3.s6.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="253-267" id="miRNA-corp.d3.s6.e3" text="epileptogenesis" type="Diseases"/>
            <entity charOffset="236-247" id="miRNA-corp.d3.s6.e4" text="inflammation" type="Diseases"/>
            <entity charOffset="220-233" id="miRNA-corp.d3.s6.e5" text="neuronal death" type="Diseases"/>
            <pair e1="miRNA-corp.d3.s6.e2" e2="miRNA-corp.d3.s6.e3" id="miRNA-corp.d3.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d3.s6.e2" e2="miRNA-corp.d3.s6.e4" id="miRNA-corp.d3.s6.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d3.s6.e2" e2="miRNA-corp.d3.s6.e5" id="miRNA-corp.d3.s6.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d4" origId="18194678">
        <sentence id="miRNA-corp.d4.s0" origId="18194678.s5" text="The study of this novel layer of gene regulation therefore promises to enrich our knowledge of brain function and pathology.   ">
            <entity charOffset="38-47" id="miRNA-corp.d4.s0.e0" text="regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d4.s1" origId="18194678.s3" text="MiRNAs function at all stages of neuronal development, ranging from the initial specification of neuronal cell types to the formation and plasticity of synaptic connections between individual neurons. ">
            <entity charOffset="0-5" id="miRNA-corp.d4.s1.e0" text="MiRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d4.s2" origId="18194678.s4" text="Moreover, links between miRNA dysfunction and neurological diseases become more and more apparent. ">
            <entity charOffset="24-28" id="miRNA-corp.d4.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="30-40" id="miRNA-corp.d4.s2.e1" text="dysfunction" type="Relation_Trigger"/>
            <entity charOffset="46-66" id="miRNA-corp.d4.s2.e2" text="neurological diseases" type="Diseases"/>
            <pair e1="miRNA-corp.d4.s2.e0" e2="miRNA-corp.d4.s2.e2" id="miRNA-corp.d4.s2.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d4.s3" origId="18194678.s1" text="The development and function of the nervous system is orchestrated by a plethora of gene regulatory mechanisms. ">
            <entity charOffset="89-98" id="miRNA-corp.d4.s3.e0" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d4.s4" origId="18194678.s2" text="MicroRNAs (miRNAs), an abundant class of small non-coding RNAs, are emerging as important post-transcriptional regulators of gene expression in the brain. ">
            <entity charOffset="0-8" id="miRNA-corp.d4.s4.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d4.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d4.s5" origId="18194678.s0" text="MicroRNA function in neuronal development, plasticity and disease.  ">
            <entity charOffset="0-7" id="miRNA-corp.d4.s5.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d5" origId="17562377">
        <sentence id="miRNA-corp.d5.s0" origId="17562377.s0" text="Mice deficient in cystathionine beta synthase display altered homocysteine remethylation pathway.  ">
            <entity charOffset="0-3" id="miRNA-corp.d5.s0.e0" text="Mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d5.s1" origId="17562377.s2" text="In order to show the effects of CBS deficiency onto the activity of the enzymes involved in the remethylation pathway, we used the well characterized genetic model of severe hyperhomocysteinemia in mice. ">
            <entity charOffset="32-45" id="miRNA-corp.d5.s1.e0" text="CBS deficiency" type="Diseases"/>
            <entity charOffset="167-193" id="miRNA-corp.d5.s1.e1" text="severe hyperhomocysteinemia" type="Diseases"/>
            <entity charOffset="198-201" id="miRNA-corp.d5.s1.e2" text="mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d5.s2" origId="17562377.s1" text="Cystathionine beta synthase (CBS) deficiency is a metabolic disorder that is biochemically characterized by severe hyperhomocysteinemia. ">
            <entity charOffset="50-67" id="miRNA-corp.d5.s2.e0" text="metabolic disorder" type="Diseases"/>
            <entity charOffset="0-43" id="miRNA-corp.d5.s2.e1" text="Cystathionine beta synthase (CBS) deficiency" type="Diseases"/>
            <entity charOffset="108-134" id="miRNA-corp.d5.s2.e2" text="severe hyperhomocysteinemia" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d5.s3" origId="17562377.s3" text="We showed that CBS deficiency in mice reduced hepatic methionine synthase and betaine-homocysteine methyltransferase activities, whereas 5,10-methylene tetrahydrofolate reductase activity was increased.   ">
            <entity charOffset="15-28" id="miRNA-corp.d5.s3.e0" text="CBS deficiency" type="Diseases"/>
            <entity charOffset="54-72" id="miRNA-corp.d5.s3.e1" text="methionine synthase" type="Genes/Proteins"/>
            <entity charOffset="33-36" id="miRNA-corp.d5.s3.e2" text="mice" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d6" origId="20514462">
        <sentence id="miRNA-corp.d6.s0" origId="20514462.s0" text="Reduction of miR-21 induces glioma cell apoptosis via activating caspase 9 and 3.  Extensive data indicate that miR-21 plays a critical role in gliomagenesis, however, knowledge is limited on the mechanism of action of miR-21, including cell proliferation, apoptosis, and migration. ">
            <entity charOffset="65-73" id="miRNA-corp.d6.s0.e0" text="caspase 9" type="Genes/Proteins"/>
            <entity charOffset="54-63" id="miRNA-corp.d6.s0.e1" text="activating" type="Relation_Trigger"/>
            <entity charOffset="13-18" id="miRNA-corp.d6.s0.e2" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="28-33" id="miRNA-corp.d6.s0.e3" text="glioma" type="Diseases"/>
            <entity charOffset="112-117" id="miRNA-corp.d6.s0.e4" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="219-224" id="miRNA-corp.d6.s0.e5" text="miR-21" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d6.s0.e2" e2="miRNA-corp.d6.s0.e0" id="miRNA-corp.d6.s0.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d6.s0.e2" e2="miRNA-corp.d6.s0.e3" id="miRNA-corp.d6.s0.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d6.s0.e4" e2="miRNA-corp.d6.s0.e0" id="miRNA-corp.d6.s0.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d6.s0.e4" e2="miRNA-corp.d6.s0.e3" id="miRNA-corp.d6.s0.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d6.s0.e5" e2="miRNA-corp.d6.s0.e0" id="miRNA-corp.d6.s0.p4" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d6.s0.e5" e2="miRNA-corp.d6.s0.e3" id="miRNA-corp.d6.s0.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d6.s1" origId="20514462.s2" text="Moreover, reduction of miR-21 activated caspase 9 and 3, which may be mediated by modulating multiple potential target genes, such as TIMP3. ">
            <entity charOffset="102-117" id="miRNA-corp.d6.s1.e0" text="potential target" type="Relation_Trigger"/>
            <entity charOffset="30-38" id="miRNA-corp.d6.s1.e1" text="activated" type="Relation_Trigger"/>
            <entity charOffset="23-28" id="miRNA-corp.d6.s1.e2" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="40-48" id="miRNA-corp.d6.s1.e3" text="caspase 9" type="Genes/Proteins"/>
            <entity charOffset="82-91" id="miRNA-corp.d6.s1.e4" text="modulating" type="Relation_Trigger"/>
            <entity charOffset="134-138" id="miRNA-corp.d6.s1.e5" text="TIMP3" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d6.s1.e2" e2="miRNA-corp.d6.s1.e3" id="miRNA-corp.d6.s1.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d6.s1.e2" e2="miRNA-corp.d6.s1.e5" id="miRNA-corp.d6.s1.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d6.s2" origId="20514462.s1" text="In this study, we showed that down-regulation of miR-21 expression by antisense oligonucleotides inhibited glioma cell proliferation and induced cell apoptosis. ">
            <entity charOffset="49-54" id="miRNA-corp.d6.s2.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="30-65" id="miRNA-corp.d6.s2.e1" text="down-regulation of miR-21 expression" type="Relation_Trigger"/>
            <entity charOffset="107-112" id="miRNA-corp.d6.s2.e2" text="glioma" type="Diseases"/>
            <entity charOffset="97-105" id="miRNA-corp.d6.s2.e3" text="inhibited" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d6.s2.e0" e2="miRNA-corp.d6.s2.e2" id="miRNA-corp.d6.s2.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d6.s3" origId="20514462.s3" text="Together, these findings indicate that miR-21 plays a key role in regulating cell apoptosis in gliomas and may serve as a target for effective therapies.   ">
            <entity charOffset="39-44" id="miRNA-corp.d6.s3.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="66-75" id="miRNA-corp.d6.s3.e1" text="regulating" type="Relation_Trigger"/>
            <entity charOffset="95-101" id="miRNA-corp.d6.s3.e2" text="gliomas" type="Diseases"/>
            <entity charOffset="122-127" id="miRNA-corp.d6.s3.e3" text="target" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d6.s3.e0" e2="miRNA-corp.d6.s3.e2" id="miRNA-corp.d6.s3.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d7" origId="21248728">
        <sentence id="miRNA-corp.d7.s0" origId="21248728.s0" text="The emerging therapeutic role of RNA interference in disorders of the central nervous system.     ">
            <entity charOffset="53-91" id="miRNA-corp.d7.s0.e0" text="disorders of the central nervous system" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d8" origId="21622133">
        <sentence id="miRNA-corp.d8.s0" origId="21622133.s0" text="MicroRNA-210 as a novel blood biomarker in acute cerebral ischemia.  ">
            <entity charOffset="0-11" id="miRNA-corp.d8.s0.e0" text="MicroRNA-210" type="Specific_miRNAs"/>
            <entity charOffset="49-65" id="miRNA-corp.d8.s0.e1" text="cerebral ischemia" type="Diseases"/>
            <pair e1="miRNA-corp.d8.s0.e0" e2="miRNA-corp.d8.s0.e1" id="miRNA-corp.d8.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d8.s1" origId="21622133.s1" text="MicroRNA-210 (miR-210), a master and pleiotropic hypoxia-microRNA, plays multiple roles in brain ischemia. ">
            <entity charOffset="49-55" id="miRNA-corp.d8.s1.e0" text="hypoxia" type="Diseases"/>
            <entity charOffset="0-11" id="miRNA-corp.d8.s1.e1" text="MicroRNA-210" type="Specific_miRNAs"/>
            <entity charOffset="14-20" id="miRNA-corp.d8.s1.e2" text="miR-210" type="Specific_miRNAs"/>
            <entity charOffset="57-64" id="miRNA-corp.d8.s1.e3" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="91-104" id="miRNA-corp.d8.s1.e4" text="brain ischemia" type="Diseases"/>
            <pair e1="miRNA-corp.d8.s1.e1" e2="miRNA-corp.d8.s1.e0" id="miRNA-corp.d8.s1.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d8.s1.e1" e2="miRNA-corp.d8.s1.e4" id="miRNA-corp.d8.s1.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d8.s1.e2" e2="miRNA-corp.d8.s1.e0" id="miRNA-corp.d8.s1.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d8.s1.e2" e2="miRNA-corp.d8.s1.e4" id="miRNA-corp.d8.s1.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d8.s1.e3" e2="miRNA-corp.d8.s1.e0" id="miRNA-corp.d8.s1.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d8.s1.e3" e2="miRNA-corp.d8.s1.e4" id="miRNA-corp.d8.s1.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d8.s2" origId="21622133.s2" text="However, miR-210 expression and its function in humans have not been explored. ">
            <entity charOffset="9-15" id="miRNA-corp.d8.s2.e0" text="miR-210" type="Specific_miRNAs"/>
            <entity charOffset="48-53" id="miRNA-corp.d8.s2.e1" text="humans" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d8.s3" origId="21622133.s3" text="The aim of our study is to evaluate the correlation of blood miR-210 with clinical findings in acute ischemic stroke. ">
            <entity charOffset="40-50" id="miRNA-corp.d8.s3.e0" text="correlation" type="Relation_Trigger"/>
            <entity charOffset="61-67" id="miRNA-corp.d8.s3.e1" text="miR-210" type="Specific_miRNAs"/>
            <entity charOffset="95-115" id="miRNA-corp.d8.s3.e2" text="acute ischemic stroke" type="Diseases"/>
            <pair e1="miRNA-corp.d8.s3.e1" e2="miRNA-corp.d8.s3.e2" id="miRNA-corp.d8.s3.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d8.s4" origId="21622133.s4" text="Blood samples were obtained from stroke patients (n=112) and healthy controls (n= 60). ">
            <entity charOffset="33-38" id="miRNA-corp.d8.s4.e0" text="stroke" type="Diseases"/>
            <entity charOffset="40-47" id="miRNA-corp.d8.s4.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d8.s5" origId="21622133.s5" text="MiR-210 was measured at within 3, 7 and 14 days after stroke using a quantitative PCR technique. ">
            <entity charOffset="0-6" id="miRNA-corp.d8.s5.e0" text="MiR-210" type="Specific_miRNAs"/>
            <entity charOffset="54-59" id="miRNA-corp.d8.s5.e1" text="stroke" type="Diseases"/>
            <pair e1="miRNA-corp.d8.s5.e0" e2="miRNA-corp.d8.s5.e1" id="miRNA-corp.d8.s5.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d8.s6" origId="21622133.s6" text="Stroke severity and clinical outcome were evaluated by NIHSS and modified Rankin Score. ">
            <entity charOffset="0-5" id="miRNA-corp.d8.s6.e0" text="Stroke" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d8.s7" origId="21622133.s7" text="Both blood and brain miR-210 in ischemic mice was examined and the correlation was investigated. ">
            <entity charOffset="21-27" id="miRNA-corp.d8.s7.e0" text="miR-210" type="Specific_miRNAs"/>
            <entity charOffset="41-44" id="miRNA-corp.d8.s7.e1" text="mice" type="Species"/>
            <entity charOffset="67-77" id="miRNA-corp.d8.s7.e2" text="correlation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d8.s8" origId="21622133.s8" text="Compared to healthy controls, blood miRNA-210 was significantly decreased in stroke patients (0.93 vs. 1.36; P=0.001), especially at 7 days (0.56 vs. 1.36; P=0.001) and 14 days of stroke onset (0.50 vs. 1.36; P=0.001). ">
            <entity charOffset="50-72" id="miRNA-corp.d8.s8.e0" text="significantly decreased" type="Relation_Trigger"/>
            <entity charOffset="36-44" id="miRNA-corp.d8.s8.e1" text="miRNA-210" type="Specific_miRNAs"/>
            <entity charOffset="77-82" id="miRNA-corp.d8.s8.e2" text="stroke" type="Diseases"/>
            <entity charOffset="84-91" id="miRNA-corp.d8.s8.e3" text="patients" type="Species"/>
            <entity charOffset="180-185" id="miRNA-corp.d8.s8.e4" text="stroke" type="Diseases"/>
            <pair e1="miRNA-corp.d8.s8.e1" e2="miRNA-corp.d8.s8.e2" id="miRNA-corp.d8.s8.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d8.s8.e1" e2="miRNA-corp.d8.s8.e4" id="miRNA-corp.d8.s8.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d8.s9" origId="21622133.s9" text="The cut off point of miR-210 in diagnosis was 0.505 with 88.3 per cent sensitivity. ">
            <entity charOffset="21-27" id="miRNA-corp.d8.s9.e0" text="miR-210" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d8.s10" origId="21622133.s10" text="MiR-210 level in stroke patients with good outcome was significantly higher than patients with poor outcome (1.2 vs. 0.44; P=0.012). ">
            <entity charOffset="55-74" id="miRNA-corp.d8.s10.e0" text="significantly higher" type="Relation_Trigger"/>
            <entity charOffset="0-6" id="miRNA-corp.d8.s10.e1" text="MiR-210" type="Specific_miRNAs"/>
            <entity charOffset="17-22" id="miRNA-corp.d8.s10.e2" text="stroke" type="Diseases"/>
            <entity charOffset="24-31" id="miRNA-corp.d8.s10.e3" text="patients" type="Species"/>
            <entity charOffset="81-88" id="miRNA-corp.d8.s10.e4" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d8.s10.e1" e2="miRNA-corp.d8.s10.e2" id="miRNA-corp.d8.s10.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d8.s11" origId="21622133.s11" text="The correlation between blood and brain miR-210 in ischemic mice was positive (R2=0.57, P=0.001). ">
            <entity charOffset="4-14" id="miRNA-corp.d8.s11.e0" text="correlation" type="Relation_Trigger"/>
            <entity charOffset="40-46" id="miRNA-corp.d8.s11.e1" text="miR-210" type="Specific_miRNAs"/>
            <entity charOffset="60-63" id="miRNA-corp.d8.s11.e2" text="mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d8.s12" origId="21622133.s12" text="Blood miR-210 is a novel sensitive biomarker for clinical diagnosis and prognosis in acute cerebral ischemia.   ">
            <entity charOffset="6-12" id="miRNA-corp.d8.s12.e0" text="miR-210" type="Specific_miRNAs"/>
            <entity charOffset="85-107" id="miRNA-corp.d8.s12.e1" text="acute cerebral ischemia" type="Diseases"/>
            <pair e1="miRNA-corp.d8.s12.e0" e2="miRNA-corp.d8.s12.e1" id="miRNA-corp.d8.s12.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d9" origId="20471450">
        <sentence id="miRNA-corp.d9.s0" origId="20471450.s2" text="In particular, SNP rs12720208 in the 3' untranslated region (3' UTR) was linked to PD-risk through a mechanism that would implicate a differential binding to microRNA-433 (miR-433). ">
            <entity charOffset="147-156" id="miRNA-corp.d9.s0.e0" text="binding to" type="Relation_Trigger"/>
            <entity charOffset="83-84" id="miRNA-corp.d9.s0.e1" text="PD" type="Diseases"/>
            <entity charOffset="158-169" id="miRNA-corp.d9.s0.e2" text="microRNA-433" type="Specific_miRNAs"/>
            <entity charOffset="172-178" id="miRNA-corp.d9.s0.e3" text="miR-433" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d9.s0.e3" e2="miRNA-corp.d9.s0.e1" id="miRNA-corp.d9.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d9.s0.e2" e2="miRNA-corp.d9.s0.e1" id="miRNA-corp.d9.s0.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d9.s1" origId="20471450.s3" text="The reduction of the affinity of miR-433 to the 3' UTR would result in increased FGF20 expression and upregulation of alpha-synuclein, which could in turn promote dopaminergic neurons degeneration. ">
            <entity charOffset="33-39" id="miRNA-corp.d9.s1.e0" text="miR-433" type="Specific_miRNAs"/>
            <entity charOffset="81-85" id="miRNA-corp.d9.s1.e1" text="FGF20" type="Genes/Proteins"/>
            <entity charOffset="71-96" id="miRNA-corp.d9.s1.e2" text="increased FGF20 expression" type="Relation_Trigger"/>
            <entity charOffset="102-113" id="miRNA-corp.d9.s1.e3" text="upregulation" type="Relation_Trigger"/>
            <entity charOffset="118-132" id="miRNA-corp.d9.s1.e4" text="alpha-synuclein" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d9.s1.e0" e2="miRNA-corp.d9.s1.e1" id="miRNA-corp.d9.s1.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d9.s1.e0" e2="miRNA-corp.d9.s1.e4" id="miRNA-corp.d9.s1.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d9.s2" origId="20471450.s0" text="FGF20 rs12720208 SNP and microRNA-433 variation: no association with Parkinson's disease in Spanish patients.  ">
            <entity charOffset="0-4" id="miRNA-corp.d9.s2.e0" text="FGF20" type="Genes/Proteins"/>
            <entity charOffset="25-36" id="miRNA-corp.d9.s2.e1" text="microRNA-433" type="Specific_miRNAs"/>
            <entity charOffset="69-87" id="miRNA-corp.d9.s2.e2" text="Parkinson's disease" type="Diseases"/>
            <entity charOffset="100-107" id="miRNA-corp.d9.s2.e3" text="patients" type="Species"/>
            <entity charOffset="52-62" id="miRNA-corp.d9.s2.e4" text="association" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d9.s2.e1" e2="miRNA-corp.d9.s2.e0" id="miRNA-corp.d9.s2.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d9.s2.e1" e2="miRNA-corp.d9.s2.e2" id="miRNA-corp.d9.s2.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d9.s3" origId="20471450.s1" text="DNA variation at the FGF20 gene has been associated with Parkinson's disease (PD). ">
            <entity charOffset="21-25" id="miRNA-corp.d9.s3.e0" text="FGF20" type="Genes/Proteins"/>
            <entity charOffset="57-75" id="miRNA-corp.d9.s3.e1" text="Parkinson's disease" type="Diseases"/>
            <entity charOffset="78-79" id="miRNA-corp.d9.s3.e2" text="PD" type="Diseases"/>
            <entity charOffset="41-50" id="miRNA-corp.d9.s3.e3" text="associated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d9.s4" origId="20471450.s7" text="In conclusion, our work did not confirm the association between rs12720208 and PD, or an effect of miR-433 variants on this disease.   ">
            <entity charOffset="79-80" id="miRNA-corp.d9.s4.e0" text="PD" type="Diseases"/>
            <entity charOffset="99-105" id="miRNA-corp.d9.s4.e1" text="miR-433" type="Specific_miRNAs"/>
            <entity charOffset="44-54" id="miRNA-corp.d9.s4.e2" text="association" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d9.s4.e1" e2="miRNA-corp.d9.s4.e0" id="miRNA-corp.d9.s4.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d9.s5" origId="20471450.s6" text="None of the patients had miR-433 variants. ">
            <entity charOffset="12-19" id="miRNA-corp.d9.s5.e0" text="patients" type="Species"/>
            <entity charOffset="25-31" id="miRNA-corp.d9.s5.e1" text="miR-433" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d9.s6" origId="20471450.s5" text="We did not find significant differences in allele and genotype frequencies between patients and controls. ">
            <entity charOffset="83-90" id="miRNA-corp.d9.s6.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d9.s7" origId="20471450.s4" text="We genotyped the rs12720208 SNP in a total of 512 PD patients and 258 healthy controls from Spain, and searched for miR-433 variants in the patients. ">
            <entity charOffset="50-51" id="miRNA-corp.d9.s7.e0" text="PD" type="Diseases"/>
            <entity charOffset="53-60" id="miRNA-corp.d9.s7.e1" text="patients" type="Species"/>
            <entity charOffset="116-122" id="miRNA-corp.d9.s7.e2" text="miR-433" type="Specific_miRNAs"/>
            <entity charOffset="140-147" id="miRNA-corp.d9.s7.e3" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d9.s7.e2" e2="miRNA-corp.d9.s7.e0" id="miRNA-corp.d9.s7.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d10" origId="20451875">
        <sentence id="miRNA-corp.d10.s0" origId="20451875.s5" text="Blood collection for RNA studies is a new direction. "/>
        <sentence id="miRNA-corp.d10.s1" origId="20451875.s6" text="Genetic studies of longitudinal phenotypes hold promise for elucidating disease mechanisms and risk, development of therapeutic strategies, and refining selection criteria for clinical trials.   "/>
        <sentence id="miRNA-corp.d10.s2" origId="20451875.s3" text="Genome-wide array data have been publicly released and updated, and several neuroimaging GWAS have recently been reported examining baseline magnetic resonance imaging measures as quantitative phenotypes. "/>
        <sentence id="miRNA-corp.d10.s3" origId="20451875.s4" text="Other preliminary investigations include copy number variation in mild cognitive impairment and Alzheimer's disease and GWAS of baseline cerebrospinal fluid biomarkers and longitudinal changes on magnetic resonance imaging. ">
            <entity charOffset="96-114" id="miRNA-corp.d10.s3.e0" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="66-90" id="miRNA-corp.d10.s3.e1" text="mild cognitive impairment" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d10.s4" origId="20451875.s1" text="The role of the Alzheimer's Disease Neuroimaging Initiative Genetics Core is to facilitate the investigation of genetic influences on disease onset and trajectory as reflected in structural, functional, and molecular imaging changes; fluid biomarkers; and cognitive status. ">
            <entity charOffset="16-34" id="miRNA-corp.d10.s4.e0" text="Alzheimer's Disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d10.s5" origId="20451875.s2" text="Major goals include (1) blood sample processing, genotyping, and dissemination, (2) genome-wide association studies (GWAS) of longitudinal phenotypic data, and (3) providing a central resource, point of contact and planning group for genetics within the Alzheimer's Disease Neuroimaging Initiative. ">
            <entity charOffset="254-272" id="miRNA-corp.d10.s5.e0" text="Alzheimer's Disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d10.s6" origId="20451875.s0" text="Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans.  ">
            <entity charOffset="0-18" id="miRNA-corp.d10.s6.e0" text="Alzheimer's Disease" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d11" origId="18262516">
        <sentence id="miRNA-corp.d11.s0" origId="18262516.s10" text="Our work places apl-1 in a developmental timing pathway and may provide new insights into the time-dependent progression of AD.   ">
            <entity charOffset="16-20" id="miRNA-corp.d11.s0.e0" text="apl-1" type="Genes/Proteins"/>
            <entity charOffset="124-125" id="miRNA-corp.d11.s0.e1" text="AD" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s1" origId="18262516.s9" text="Moreover, the levels of the apl-1 transcription are modulated by the activity of let-7 family microRNAs. ">
            <entity charOffset="28-32" id="miRNA-corp.d11.s1.e0" text="apl-1" type="Genes/Proteins"/>
            <entity charOffset="52-60" id="miRNA-corp.d11.s1.e1" text="modulated" type="Relation_Trigger"/>
            <entity charOffset="81-85" id="miRNA-corp.d11.s1.e2" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="94-102" id="miRNA-corp.d11.s1.e3" text="microRNAs" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d11.s1.e2" e2="miRNA-corp.d11.s1.e0" id="miRNA-corp.d11.s1.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d11.s1.e3" e2="miRNA-corp.d11.s1.e0" id="miRNA-corp.d11.s1.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s2" origId="18262516.s8" text="apl-1 expression is upregulated during the last larval stage in hypodermal seam cells which is transcriptionally regulated by hbl-1, lin-41 and lin-42. ">
            <entity charOffset="0-4" id="miRNA-corp.d11.s2.e0" text="apl-1" type="Genes/Proteins"/>
            <entity charOffset="6-30" id="miRNA-corp.d11.s2.e1" text="expression is upregulated" type="Relation_Trigger"/>
            <entity charOffset="95-121" id="miRNA-corp.d11.s2.e2" text="transcriptionally regulated" type="Relation_Trigger"/>
            <entity charOffset="126-130" id="miRNA-corp.d11.s2.e3" text="hbl-1" type="Genes/Proteins"/>
            <entity charOffset="133-138" id="miRNA-corp.d11.s2.e4" text="lin-41" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s3" origId="18262516.s4" text="On the other hand, the pathogenesis of amyloid plaque deposition in AD is thought to be the result of age-related changes with unknown mechanisms. ">
            <entity charOffset="39-52" id="miRNA-corp.d11.s3.e0" text="amyloid plaque" type="Diseases"/>
            <entity charOffset="68-69" id="miRNA-corp.d11.s3.e1" text="AD" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s4" origId="18262516.s5" text="Here we show that the Caenorhabditis elegans homolog of APP, APP-like-1 (apl-1), functions with and is under the control of molecules regulating developmental progression. ">
            <entity charOffset="22-43" id="miRNA-corp.d11.s4.e0" text="Caenorhabditis elegans" type="Species"/>
            <entity charOffset="56-58" id="miRNA-corp.d11.s4.e1" text="APP" type="Genes/Proteins"/>
            <entity charOffset="134-143" id="miRNA-corp.d11.s4.e2" text="regulating" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s5" origId="18262516.s6" text="In C. elegans, the timing of cell fate determination is controlled by the heterochronic genes, including let-7 microRNAs. ">
            <entity charOffset="3-12" id="miRNA-corp.d11.s5.e0" text="C. elegans" type="Species"/>
            <entity charOffset="105-109" id="miRNA-corp.d11.s5.e1" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="111-119" id="miRNA-corp.d11.s5.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s6" origId="18262516.s7" text="C. elegans apl-1 shows significant genetic interactions with let-7 family microRNAs and let-7-targeted heterochronic genes, hbl-1, lin-41 and lin-42. ">
            <entity charOffset="11-15" id="miRNA-corp.d11.s6.e0" text="apl-1" type="Genes/Proteins"/>
            <entity charOffset="0-9" id="miRNA-corp.d11.s6.e1" text="C. elegans" type="Species"/>
            <entity charOffset="61-65" id="miRNA-corp.d11.s6.e2" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="74-82" id="miRNA-corp.d11.s6.e3" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="88-92" id="miRNA-corp.d11.s6.e4" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="124-128" id="miRNA-corp.d11.s6.e5" text="hbl-1" type="Genes/Proteins"/>
            <entity charOffset="131-136" id="miRNA-corp.d11.s6.e6" text="lin-41" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d11.s6.e2" e2="miRNA-corp.d11.s6.e0" id="miRNA-corp.d11.s6.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d11.s6.e2" e2="miRNA-corp.d11.s6.e5" id="miRNA-corp.d11.s6.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d11.s6.e2" e2="miRNA-corp.d11.s6.e6" id="miRNA-corp.d11.s6.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d11.s6.e3" e2="miRNA-corp.d11.s6.e0" id="miRNA-corp.d11.s6.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d11.s6.e3" e2="miRNA-corp.d11.s6.e5" id="miRNA-corp.d11.s6.p4" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d11.s6.e3" e2="miRNA-corp.d11.s6.e6" id="miRNA-corp.d11.s6.p5" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d11.s6.e4" e2="miRNA-corp.d11.s6.e0" id="miRNA-corp.d11.s6.p6" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d11.s6.e4" e2="miRNA-corp.d11.s6.e5" id="miRNA-corp.d11.s6.p7" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d11.s6.e4" e2="miRNA-corp.d11.s6.e6" id="miRNA-corp.d11.s6.p8" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s7" origId="18262516.s0" text="The expression of the Alzheimer's amyloid precursor protein-like gene is regulated by developmental timing microRNAs and their targets in Caenorhabditis elegans.  ">
            <entity charOffset="127-133" id="miRNA-corp.d11.s7.e0" text="targets" type="Relation_Trigger"/>
            <entity charOffset="22-32" id="miRNA-corp.d11.s7.e1" text="Alzheimer's" type="Diseases"/>
            <entity charOffset="34-58" id="miRNA-corp.d11.s7.e2" text="amyloid precursor protein" type="Genes/Proteins"/>
            <entity charOffset="73-81" id="miRNA-corp.d11.s7.e3" text="regulated" type="Relation_Trigger"/>
            <entity charOffset="107-115" id="miRNA-corp.d11.s7.e4" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="138-159" id="miRNA-corp.d11.s7.e5" text="Caenorhabditis elegans" type="Species"/>
            <pair e1="miRNA-corp.d11.s7.e4" e2="miRNA-corp.d11.s7.e1" id="miRNA-corp.d11.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d11.s7.e4" e2="miRNA-corp.d11.s7.e2" id="miRNA-corp.d11.s7.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s8" origId="18262516.s1" text="Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the accumulation of dense plaques in the brain, resulting in progressive dementia. ">
            <entity charOffset="0-18" id="miRNA-corp.d11.s8.e0" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="21-22" id="miRNA-corp.d11.s8.e1" text="AD" type="Diseases"/>
            <entity charOffset="30-55" id="miRNA-corp.d11.s8.e2" text="neurodegenerative disorder" type="Diseases"/>
            <entity charOffset="147-154" id="miRNA-corp.d11.s8.e3" text="dementia" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s9" origId="18262516.s2" text="A major plaque component is the beta-amyloid peptide, which is a cleavage product of the amyloid precursor protein (APP). ">
            <entity charOffset="32-51" id="miRNA-corp.d11.s9.e0" text="beta-amyloid peptide" type="Genes/Proteins"/>
            <entity charOffset="89-113" id="miRNA-corp.d11.s9.e1" text="amyloid precursor protein" type="Genes/Proteins"/>
            <entity charOffset="116-118" id="miRNA-corp.d11.s9.e2" text="APP" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s10" origId="18262516.s3" text="Studies of dominant inheritable familial AD support the hypothesis that APP is critical for AD development. ">
            <entity charOffset="41-42" id="miRNA-corp.d11.s10.e0" text="AD" type="Diseases"/>
            <entity charOffset="72-74" id="miRNA-corp.d11.s10.e1" text="APP" type="Genes/Proteins"/>
            <entity charOffset="92-93" id="miRNA-corp.d11.s10.e2" text="AD" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d12" origId="19075669">
        <sentence id="miRNA-corp.d12.s0" origId="19075669.s8" text="In this review, we focus on studies addressing the role of various microRNAs in heart, muscle, liver, pancreas, central nervous system, and hematopoiesis.   ">
            <entity charOffset="67-75" id="miRNA-corp.d12.s0.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d12.s1" origId="19075669.s1" text="Large numbers and quantities of different, small RNA molecules are present in the cytoplasm of animal and plant cells. "/>
        <sentence id="miRNA-corp.d12.s2" origId="19075669.s0" text="MicroRNAs in organogenesis and disease.  ">
            <entity charOffset="0-8" id="miRNA-corp.d12.s2.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d12.s3" origId="19075669.s3" text="Since their discovery in the 1990s a multitude of basic information has accumulated, which has identified their function in post-transcriptional control, either via degradation or translational inhibition of target mRNAs. ">
            <entity charOffset="180-203" id="miRNA-corp.d12.s3.e0" text="translational inhibition" type="Relation_Trigger"/>
            <entity charOffset="208-213" id="miRNA-corp.d12.s3.e1" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d12.s4" origId="19075669.s2" text="One subclass of these molecules is represented by the noncoding microRNAs. ">
            <entity charOffset="64-72" id="miRNA-corp.d12.s4.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d12.s5" origId="19075669.s5" text="MicroRNA expression profiles are highly dynamic during embryonic development and in adulthood. ">
            <entity charOffset="0-7" id="miRNA-corp.d12.s5.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="9-38" id="miRNA-corp.d12.s5.e1" text="expression profiles are highly" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d12.s6" origId="19075669.s4" text="This function is in most of the cases a finetuning of gene expression, working in parallel with transcriptional regulatory processes. ">
            <entity charOffset="112-121" id="miRNA-corp.d12.s6.e0" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d12.s7" origId="19075669.s7" text="Evidence from gain- and loss-of function studies indicates roles for microRNAs in pathophysiologic states including cardiac hypertrophy, muscle dystrophy, hepatitis infection, diabetes, Parkinson syndrome, hematological malignancies and other types of cancer. ">
            <entity charOffset="69-77" id="miRNA-corp.d12.s7.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="116-134" id="miRNA-corp.d12.s7.e1" text="cardiac hypertrophy" type="Diseases"/>
            <entity charOffset="137-152" id="miRNA-corp.d12.s7.e2" text="muscle dystrophy" type="Diseases"/>
            <entity charOffset="155-173" id="miRNA-corp.d12.s7.e3" text="hepatitis infection" type="Diseases"/>
            <entity charOffset="176-183" id="miRNA-corp.d12.s7.e4" text="diabetes" type="Diseases"/>
            <entity charOffset="186-203" id="miRNA-corp.d12.s7.e5" text="Parkinson syndrome" type="Diseases"/>
            <entity charOffset="206-231" id="miRNA-corp.d12.s7.e6" text="hematological malignancies" type="Diseases"/>
            <entity charOffset="252-257" id="miRNA-corp.d12.s7.e7" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d12.s7.e0" e2="miRNA-corp.d12.s7.e1" id="miRNA-corp.d12.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d12.s7.e0" e2="miRNA-corp.d12.s7.e2" id="miRNA-corp.d12.s7.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d12.s7.e0" e2="miRNA-corp.d12.s7.e3" id="miRNA-corp.d12.s7.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d12.s7.e0" e2="miRNA-corp.d12.s7.e4" id="miRNA-corp.d12.s7.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d12.s7.e0" e2="miRNA-corp.d12.s7.e5" id="miRNA-corp.d12.s7.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d12.s7.e0" e2="miRNA-corp.d12.s7.e6" id="miRNA-corp.d12.s7.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d12.s7.e0" e2="miRNA-corp.d12.s7.e7" id="miRNA-corp.d12.s7.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d12.s8" origId="19075669.s6" text="Misexpression of microRNAs can perturb embryogenesis, organogenesis, tissue homeostasis and the cell cycle. ">
            <entity charOffset="0-12" id="miRNA-corp.d12.s8.e0" text="Misexpression" type="Relation_Trigger"/>
            <entity charOffset="17-25" id="miRNA-corp.d12.s8.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d13" origId="20067101">
        <sentence id="miRNA-corp.d13.s0" origId="20067101.s9" text="The proliferation inhibition and induced apoptosis by this recombinant with an apoptosis ratio of 21.89% in U87 cell were also observed. ">
            <entity charOffset="18-27" id="miRNA-corp.d13.s0.e0" text="inhibition" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d13.s1" origId="20067101.s8" text="The results of Western blot indicated the expression of Flag of No 1 recombinant plasmid group was inhibited heavily with a 34.3% expression level by compared with control group. ">
            <entity charOffset="130-145" id="miRNA-corp.d13.s1.e0" text="expression level" type="Relation_Trigger"/>
            <entity charOffset="99-107" id="miRNA-corp.d13.s1.e1" text="inhibited" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d13.s2" origId="20067101.s5" text="The expressed Flag protein was detected by Western blot to evaluate the inhibition effect of targeting sequences. ">
            <entity charOffset="93-101" id="miRNA-corp.d13.s2.e0" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="72-81" id="miRNA-corp.d13.s2.e1" text="inhibition" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d13.s3" origId="20067101.s4" text="The confirmed pGCSIL-GFP recombinants by combining with pEGFP-miR-221 were transfected into 293T cells seperately. ">
            <entity charOffset="62-68" id="miRNA-corp.d13.s3.e0" text="miR-221" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d13.s4" origId="20067101.s7" text="RESULTS: The resulting recombinants were confirmed by sequencing which demonstrated that the recombinant plasmids contained the correct sequences of designed transcript templates. "/>
        <sentence id="miRNA-corp.d13.s5" origId="20067101.s6" text="Then a recombinant with the highest anti-miR-221 effect was screened and transfected into U87 glioma cell, and its anti-tumor effect was evaluated by MTT and FCM. ">
            <entity charOffset="94-99" id="miRNA-corp.d13.s5.e0" text="glioma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d13.s6" origId="20067101.s0" text="[Construction and screening an effective anti-miR-221 RNAi vector in vitro].  "/>
        <sentence id="miRNA-corp.d13.s7" origId="20067101.s1" text="OBJECTIVE: To construct and screen an effective anti-miR-221 vector of siRNA. "/>
        <sentence id="miRNA-corp.d13.s8" origId="20067101.s2" text="METHODS: Four hairpin structure of siRNA transcript templates targeting miR-221 and a negative control were synthesized, then ligated with pGCSIL-GFP vector and a pEGFP-miR-221 which express pre-miR-221 was also constructed. ">
            <entity charOffset="62-70" id="miRNA-corp.d13.s8.e0" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="72-78" id="miRNA-corp.d13.s8.e1" text="miR-221" type="Specific_miRNAs"/>
            <entity charOffset="169-175" id="miRNA-corp.d13.s8.e2" text="miR-221" type="Specific_miRNAs"/>
            <entity charOffset="191-201" id="miRNA-corp.d13.s8.e3" text="pre-miR-221" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d13.s9" origId="20067101.s3" text="All the recombinants were sequenced. "/>
        <sentence id="miRNA-corp.d13.s10" origId="20067101.s10" text="CONCLUSION: The anti-miR-221 expression siRNA espression recombinants were constructed successfully, and one sequence with the highest inhibition efficiency was screened out, which could inhibit U87 cell proliferation and induce cell apoptosis, and could be used to suppress target gene for further study in tumor biology.   ">
            <entity charOffset="135-144" id="miRNA-corp.d13.s10.e0" text="inhibition" type="Relation_Trigger"/>
            <entity charOffset="187-193" id="miRNA-corp.d13.s10.e1" text="inhibit" type="Relation_Trigger"/>
            <entity charOffset="266-273" id="miRNA-corp.d13.s10.e2" text="suppress" type="Relation_Trigger"/>
            <entity charOffset="275-280" id="miRNA-corp.d13.s10.e3" text="target" type="Relation_Trigger"/>
            <entity charOffset="308-312" id="miRNA-corp.d13.s10.e4" text="tumor" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d14" origId="20516477">
        <sentence id="miRNA-corp.d14.s0" origId="20516477.s7" text="These findings identify specific microRNAs as attenuators of growth factor signaling and oncogenesis.   ">
            <entity charOffset="33-41" id="miRNA-corp.d14.s0.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d14.s1" origId="20516477.s6" text="In line with roles as suppressors of EGF receptor (EGFR) signaling, we report that the abundance of this early subset of microRNAs is decreased in breast and in brain tumors driven by the EGFR or the closely related HER2. ">
            <entity charOffset="22-32" id="miRNA-corp.d14.s1.e0" text="suppressors" type="Relation_Trigger"/>
            <entity charOffset="37-48" id="miRNA-corp.d14.s1.e1" text="EGF receptor" type="Genes/Proteins"/>
            <entity charOffset="51-54" id="miRNA-corp.d14.s1.e2" text="EGFR" type="Genes/Proteins"/>
            <entity charOffset="121-129" id="miRNA-corp.d14.s1.e3" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="161-172" id="miRNA-corp.d14.s1.e4" text="brain tumors" type="Diseases"/>
            <entity charOffset="188-191" id="miRNA-corp.d14.s1.e5" text="EGFR" type="Genes/Proteins"/>
            <entity charOffset="216-219" id="miRNA-corp.d14.s1.e6" text="HER2" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d14.s1.e3" e2="miRNA-corp.d14.s1.e1" id="miRNA-corp.d14.s1.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d14.s1.e3" e2="miRNA-corp.d14.s1.e2" id="miRNA-corp.d14.s1.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d14.s1.e3" e2="miRNA-corp.d14.s1.e4" id="miRNA-corp.d14.s1.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d14.s1.e3" e2="miRNA-corp.d14.s1.e5" id="miRNA-corp.d14.s1.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d14.s1.e3" e2="miRNA-corp.d14.s1.e6" id="miRNA-corp.d14.s1.p4" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d14.s2" origId="20516477.s5" text="This step permitted rapid induction of oncogenic transcription factors, such as c-FOS, encoded by immediate early genes. ">
            <entity charOffset="80-84" id="miRNA-corp.d14.s2.e0" text="c-FOS" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d14.s3" origId="20516477.s0" text="EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors.  ">
            <entity charOffset="0-2" id="miRNA-corp.d14.s3.e0" text="EGF" type="Genes/Proteins"/>
            <entity charOffset="31-39" id="miRNA-corp.d14.s3.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d14.s3.e1" e2="miRNA-corp.d14.s3.e0" id="miRNA-corp.d14.s3.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d14.s4" origId="20516477.s4" text="The earliest event involved a decrease in the abundance of a subset of 23 microRNAs. ">
            <entity charOffset="74-82" id="miRNA-corp.d14.s4.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d14.s5" origId="20516477.s3" text="Using genome-wide approaches, we showed that EGF stimulation initiates a coordinated transcriptional program of microRNAs and transcription factors. ">
            <entity charOffset="45-47" id="miRNA-corp.d14.s5.e0" text="EGF" type="Genes/Proteins"/>
            <entity charOffset="112-120" id="miRNA-corp.d14.s5.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d14.s5.e1" e2="miRNA-corp.d14.s5.e0" id="miRNA-corp.d14.s5.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d14.s6" origId="20516477.s2" text="MicroRNAs, which attenuate gene expression by binding complementary regions in messenger RNAs, are broadly implicated in cancer. ">
            <entity charOffset="0-8" id="miRNA-corp.d14.s6.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="17-41" id="miRNA-corp.d14.s6.e1" text="attenuate gene expression" type="Relation_Trigger"/>
            <entity charOffset="46-52" id="miRNA-corp.d14.s6.e2" text="binding" type="Relation_Trigger"/>
            <entity charOffset="121-126" id="miRNA-corp.d14.s6.e3" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d14.s6.e0" e2="miRNA-corp.d14.s6.e3" id="miRNA-corp.d14.s6.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d14.s7" origId="20516477.s1" text="Epidermal growth factor (EGF) stimulates cells by launching gene expression programs that are frequently deregulated in cancer. ">
            <entity charOffset="0-22" id="miRNA-corp.d14.s7.e0" text="Epidermal growth factor" type="Genes/Proteins"/>
            <entity charOffset="25-27" id="miRNA-corp.d14.s7.e1" text="EGF" type="Genes/Proteins"/>
            <entity charOffset="120-125" id="miRNA-corp.d14.s7.e2" text="cancer" type="Diseases"/>
            <entity charOffset="105-115" id="miRNA-corp.d14.s7.e3" text="deregulated" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d15" origId="20305481">
        <sentence id="miRNA-corp.d15.s0" origId="20305481.s0" text="Regeneration of neuromuscular synapses: action of microRNA-206.     ">
            <entity charOffset="50-61" id="miRNA-corp.d15.s0.e0" text="microRNA-206" type="Specific_miRNAs"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d16" origId="19377621">
        <sentence id="miRNA-corp.d16.s0" origId="19377621.s8" text="The expression levels of most miRNAs were in accordance with previously published results by microarray. ">
            <entity charOffset="4-20" id="miRNA-corp.d16.s0.e0" text="expression levels" type="Relation_Trigger"/>
            <entity charOffset="30-35" id="miRNA-corp.d16.s0.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d16.s1" origId="19377621.s7" text="Their frequency distribution was approximately a normal distribution. "/>
        <sentence id="miRNA-corp.d16.s2" origId="19377621.s9" text="However, the positive rate was higher than that detected by microarray. "/>
        <sentence id="miRNA-corp.d16.s3" origId="19377621.s0" text="[Profiling of microRNAs in mouse brain with real-time PCR array].  ">
            <entity charOffset="14-22" id="miRNA-corp.d16.s3.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="27-31" id="miRNA-corp.d16.s3.e1" text="mouse" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d16.s4" origId="19377621.s2" text="METHODS: Low molecular weight RNA from cerebrum of five C57BL/6J mice were tailed and reverse transcribed by extended RT-primer. ">
            <entity charOffset="65-68" id="miRNA-corp.d16.s4.e0" text="mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d16.s5" origId="19377621.s1" text="OBJECTIVE: To examine global expression levels of microRNAs(miRNAs) in mouse cerebrum and to provide an important basis for detailed studies of individual miRNAs, their target genes, the miRNA-related regulatory networks in the mammalian central nervous system, and their implications in diseases. ">
            <entity charOffset="29-45" id="miRNA-corp.d16.s5.e0" text="expression levels" type="Relation_Trigger"/>
            <entity charOffset="169-174" id="miRNA-corp.d16.s5.e1" text="target" type="Relation_Trigger"/>
            <entity charOffset="50-58" id="miRNA-corp.d16.s5.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="60-65" id="miRNA-corp.d16.s5.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="71-75" id="miRNA-corp.d16.s5.e4" text="mouse" type="Species"/>
            <entity charOffset="155-160" id="miRNA-corp.d16.s5.e5" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="187-191" id="miRNA-corp.d16.s5.e6" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="201-210" id="miRNA-corp.d16.s5.e7" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d16.s6" origId="19377621.s4" text="PCR was carried out at different annealing temperatures using a gradient real-time PCR instrument. "/>
        <sentence id="miRNA-corp.d16.s7" origId="19377621.s3" text="miRNA primers were carefully designed and arrayed on plates according to the Tm of each primer. ">
            <entity charOffset="0-4" id="miRNA-corp.d16.s7.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d16.s8" origId="19377621.s6" text="RESULTS: Among the 285 miRNAs detected, 260 were positive with varying abundance. ">
            <entity charOffset="23-28" id="miRNA-corp.d16.s8.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d16.s9" origId="19377621.s5" text="The relative expression level of each miRNA was calculated using 5sRNA for normalization. ">
            <entity charOffset="13-28" id="miRNA-corp.d16.s9.e0" text="expression level" type="Relation_Trigger"/>
            <entity charOffset="38-42" id="miRNA-corp.d16.s9.e1" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d16.s10" origId="19377621.s11" text="Clusters of proximal miRNAs were similar or quite different in abundance. ">
            <entity charOffset="21-26" id="miRNA-corp.d16.s10.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d16.s11" origId="19377621.s10" text="miRNAs originating from the same hairpin precursors expressed at similar or significantly different levels. ">
            <entity charOffset="0-5" id="miRNA-corp.d16.s11.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="76-105" id="miRNA-corp.d16.s11.e1" text="significantly different levels" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d16.s12" origId="19377621.s12" text="It is suggested that the fate of miRNA after transcription determined their abundance. ">
            <entity charOffset="33-37" id="miRNA-corp.d16.s12.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d16.s13" origId="19377621.s13" text="CONCLUSION: Using the RNA-tailing and primer-extension PCR array method, we obtained expression profile of miRNA in mouse cerebrum, especially the relative expression data of many low abundant miRNA in mouse cerebrum, which will be of special help for studying the fine-tuning function of low-level miRNAs.   ">
            <entity charOffset="156-191" id="miRNA-corp.d16.s13.e0" text="expression data of many low abundant" type="Relation_Trigger"/>
            <entity charOffset="107-111" id="miRNA-corp.d16.s13.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="193-197" id="miRNA-corp.d16.s13.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="202-206" id="miRNA-corp.d16.s13.e3" text="mouse" type="Species"/>
            <entity charOffset="299-304" id="miRNA-corp.d16.s13.e4" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="116-120" id="miRNA-corp.d16.s13.e5" text="mouse" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d17" origId="19720868">
        <sentence id="miRNA-corp.d17.s0" origId="19720868.s1" text="Vascular injury triggers dedifferentiation and cytoskeletal remodeling of smooth muscle cells (SMCs), culminating in vessel occlusion. ">
            <entity charOffset="117-132" id="miRNA-corp.d17.s0.e0" text="vessel occlusion" type="Diseases"/>
            <entity charOffset="0-14" id="miRNA-corp.d17.s0.e1" text="Vascular injury" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d17.s1" origId="19720868.s0" text="MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury.  ">
            <entity charOffset="106-111" id="miRNA-corp.d17.s1.e0" text="injury" type="Diseases"/>
            <entity charOffset="0-8" id="miRNA-corp.d17.s1.e1" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="10-16" id="miRNA-corp.d17.s1.e2" text="miR-143" type="Specific_miRNAs"/>
            <entity charOffset="22-28" id="miRNA-corp.d17.s1.e3" text="miR-145" type="Specific_miRNAs"/>
            <entity charOffset="30-37" id="miRNA-corp.d17.s1.e4" text="modulate" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d17.s1.e1" e2="miRNA-corp.d17.s1.e0" id="miRNA-corp.d17.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d17.s1.e2" e2="miRNA-corp.d17.s1.e0" id="miRNA-corp.d17.s1.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d17.s1.e3" e2="miRNA-corp.d17.s1.e0" id="miRNA-corp.d17.s1.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d17.s2" origId="19720868.s2" text="Serum response factor (SRF) and its coactivator, myocardin, play a central role in the control of smooth muscle phenotypes by regulating the expression of cytoskeletal genes. ">
            <entity charOffset="0-20" id="miRNA-corp.d17.s2.e0" text="Serum response factor" type="Genes/Proteins"/>
            <entity charOffset="23-25" id="miRNA-corp.d17.s2.e1" text="SRF" type="Genes/Proteins"/>
            <entity charOffset="49-57" id="miRNA-corp.d17.s2.e2" text="myocardin" type="Genes/Proteins"/>
            <entity charOffset="126-150" id="miRNA-corp.d17.s2.e3" text="regulating the expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d17.s3" origId="19720868.s3" text="We show that SRF and myocardin regulate a cardiovascular-specific microRNA (miRNA) cluster encoding miR-143 and miR-145. ">
            <entity charOffset="13-15" id="miRNA-corp.d17.s3.e0" text="SRF" type="Genes/Proteins"/>
            <entity charOffset="21-29" id="miRNA-corp.d17.s3.e1" text="myocardin" type="Genes/Proteins"/>
            <entity charOffset="31-38" id="miRNA-corp.d17.s3.e2" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="66-73" id="miRNA-corp.d17.s3.e3" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="76-80" id="miRNA-corp.d17.s3.e4" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="100-106" id="miRNA-corp.d17.s3.e5" text="miR-143" type="Specific_miRNAs"/>
            <entity charOffset="112-118" id="miRNA-corp.d17.s3.e6" text="miR-145" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d17.s3.e3" e2="miRNA-corp.d17.s3.e0" id="miRNA-corp.d17.s3.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d17.s3.e3" e2="miRNA-corp.d17.s3.e1" id="miRNA-corp.d17.s3.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d17.s3.e4" e2="miRNA-corp.d17.s3.e0" id="miRNA-corp.d17.s3.p2" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d17.s3.e4" e2="miRNA-corp.d17.s3.e1" id="miRNA-corp.d17.s3.p3" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d17.s3.e5" e2="miRNA-corp.d17.s3.e0" id="miRNA-corp.d17.s3.p4" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d17.s3.e5" e2="miRNA-corp.d17.s3.e1" id="miRNA-corp.d17.s3.p5" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d17.s3.e6" e2="miRNA-corp.d17.s3.e0" id="miRNA-corp.d17.s3.p6" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d17.s3.e6" e2="miRNA-corp.d17.s3.e1" id="miRNA-corp.d17.s3.p7" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d17.s4" origId="19720868.s4" text="To assess the functions of these miRNAs in vivo, we systematically deleted them singly and in combination in mice. ">
            <entity charOffset="33-38" id="miRNA-corp.d17.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="109-112" id="miRNA-corp.d17.s4.e1" text="mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d17.s5" origId="19720868.s5" text="Mice lacking both miR-143 and miR-145 are viable and do not display overt abnormalities in smooth muscle differentiation, although they show a significant reduction in blood pressure due to reduced vascular tone. ">
            <entity charOffset="143-163" id="miRNA-corp.d17.s5.e0" text="significant reduction" type="Relation_Trigger"/>
            <entity charOffset="0-3" id="miRNA-corp.d17.s5.e1" text="Mice" type="Species"/>
            <entity charOffset="18-24" id="miRNA-corp.d17.s5.e2" text="miR-143" type="Specific_miRNAs"/>
            <entity charOffset="30-36" id="miRNA-corp.d17.s5.e3" text="miR-145" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d17.s6" origId="19720868.s6" text="Remarkably, however, neointima formation in response to vascular injury is profoundly impeded in mice lacking these miRNAs, due to disarray of actin stress fibers and diminished migratory activity of SMCs. ">
            <entity charOffset="21-39" id="miRNA-corp.d17.s6.e0" text="neointima formation" type="Diseases"/>
            <entity charOffset="56-70" id="miRNA-corp.d17.s6.e1" text="vascular injury" type="Diseases"/>
            <entity charOffset="97-100" id="miRNA-corp.d17.s6.e2" text="mice" type="Species"/>
            <entity charOffset="116-121" id="miRNA-corp.d17.s6.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d17.s6.e3" e2="miRNA-corp.d17.s6.e0" id="miRNA-corp.d17.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d17.s6.e3" e2="miRNA-corp.d17.s6.e1" id="miRNA-corp.d17.s6.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d17.s7" origId="19720868.s7" text="These abnormalities reflect the regulation of a cadre of modulators of SRF activity and actin dynamics by miR-143 and miR-145. ">
            <entity charOffset="32-41" id="miRNA-corp.d17.s7.e0" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="57-66" id="miRNA-corp.d17.s7.e1" text="modulators" type="Relation_Trigger"/>
            <entity charOffset="71-73" id="miRNA-corp.d17.s7.e2" text="SRF" type="Genes/Proteins"/>
            <entity charOffset="106-112" id="miRNA-corp.d17.s7.e3" text="miR-143" type="Specific_miRNAs"/>
            <entity charOffset="118-124" id="miRNA-corp.d17.s7.e4" text="miR-145" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d17.s7.e3" e2="miRNA-corp.d17.s7.e2" id="miRNA-corp.d17.s7.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d17.s7.e4" e2="miRNA-corp.d17.s7.e2" id="miRNA-corp.d17.s7.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d17.s8" origId="19720868.s8" text="Thus, miR-143 and miR-145 act as integral components of the regulatory network whereby SRF controls cytoskeletal remodeling and phenotypic switching of SMCs during vascular disease.   ">
            <entity charOffset="6-12" id="miRNA-corp.d17.s8.e0" text="miR-143" type="Specific_miRNAs"/>
            <entity charOffset="18-24" id="miRNA-corp.d17.s8.e1" text="miR-145" type="Specific_miRNAs"/>
            <entity charOffset="60-69" id="miRNA-corp.d17.s8.e2" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="87-89" id="miRNA-corp.d17.s8.e3" text="SRF" type="Genes/Proteins"/>
            <entity charOffset="164-179" id="miRNA-corp.d17.s8.e4" text="vascular disease" type="Diseases"/>
            <pair e1="miRNA-corp.d17.s8.e0" e2="miRNA-corp.d17.s8.e3" id="miRNA-corp.d17.s8.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d17.s8.e0" e2="miRNA-corp.d17.s8.e4" id="miRNA-corp.d17.s8.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d17.s8.e1" e2="miRNA-corp.d17.s8.e3" id="miRNA-corp.d17.s8.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d17.s8.e1" e2="miRNA-corp.d17.s8.e4" id="miRNA-corp.d17.s8.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d18" origId="18701917">
        <sentence id="miRNA-corp.d18.s0" origId="18701917.s5" text="This work represents the first experimental study showing that an miR-30-based shRNA construct prevents Oas1 pathway associated off-target effects, which we consider as an essential prerequisite for shRNA use in future gene therapeutic approaches.   ">
            <entity charOffset="66-71" id="miRNA-corp.d18.s0.e0" text="miR-30" type="Specific_miRNAs"/>
            <entity charOffset="104-107" id="miRNA-corp.d18.s0.e1" text="Oas1" type="Genes/Proteins"/>
            <entity charOffset="117-126" id="miRNA-corp.d18.s0.e2" text="associated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d18.s0.e0" e2="miRNA-corp.d18.s0.e1" id="miRNA-corp.d18.s0.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d18.s1" origId="18701917.s4" text="Modification of the shRNA construct by implementing features of the naturally occurring microRNA-30 (miR-30) precursor avoided Oas1 induction in transduced primary cultures, whereby modification of the passenger strand seems to be a crucial feature to circumvent interferon-stimulated gene expression. ">
            <entity charOffset="88-98" id="miRNA-corp.d18.s1.e0" text="microRNA-30" type="Specific_miRNAs"/>
            <entity charOffset="101-106" id="miRNA-corp.d18.s1.e1" text="miR-30" type="Specific_miRNAs"/>
            <entity charOffset="127-130" id="miRNA-corp.d18.s1.e2" text="Oas1" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d18.s1.e0" e2="miRNA-corp.d18.s1.e2" id="miRNA-corp.d18.s1.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d18.s1.e1" e2="miRNA-corp.d18.s1.e2" id="miRNA-corp.d18.s1.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d18.s2" origId="18701917.s3" text="We found that lentiviral vector (LV)-mediated expression of shRNAs in primary cortical cultures resulted in strong expression of the interferon-stimulated gene oligoadenylate synthetase 1 (Oas1), which was accompanied by accelerated apoptosis and substantial net neuron loss. ">
            <entity charOffset="160-186" id="miRNA-corp.d18.s2.e0" text="oligoadenylate synthetase 1" type="Genes/Proteins"/>
            <entity charOffset="189-192" id="miRNA-corp.d18.s2.e1" text="Oas1" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d18.s3" origId="18701917.s0" text="Prevention of interferon-stimulated gene expression using microRNA-designed hairpins.  ">
            <entity charOffset="58-65" id="miRNA-corp.d18.s3.e0" text="microRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d18.s4" origId="18701917.s2" text="However, growing evidence exists that the expression of short hairpin RNAs (shRNAs) can trigger cellular immune response resulting in unspecific cellular phenotypes and severe side effects. "/>
        <sentence id="miRNA-corp.d18.s5" origId="18701917.s1" text="RNA interference allows selective gene silencing, and is widely used for functional analysis of individual genes in vertebrate cells and represents an attractive therapeutic option for treating central nervous system diseases. ">
            <entity charOffset="194-224" id="miRNA-corp.d18.s5.e0" text="central nervous system diseases" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d19" origId="21636706">
        <sentence id="miRNA-corp.d19.s0" origId="21636706.s1" text="MicroRNAs (miRNAs) are small, noncoding RNAs that play a critical role in developmental and physiological processes and are implicated in the pathogenesis of several human diseases, including cancer. ">
            <entity charOffset="0-8" id="miRNA-corp.d19.s0.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d19.s0.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="166-170" id="miRNA-corp.d19.s0.e2" text="human" type="Species"/>
            <entity charOffset="192-197" id="miRNA-corp.d19.s0.e3" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d19.s0.e0" e2="miRNA-corp.d19.s0.e3" id="miRNA-corp.d19.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s0.e1" e2="miRNA-corp.d19.s0.e3" id="miRNA-corp.d19.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d19.s1" origId="21636706.s0" text="Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo.  ">
            <entity charOffset="0-13" id="miRNA-corp.d19.s1.e0" text="Downregulation" type="Relation_Trigger"/>
            <entity charOffset="27-32" id="miRNA-corp.d19.s1.e1" text="mir-21" type="Specific_miRNAs"/>
            <entity charOffset="18-22" id="miRNA-corp.d19.s1.e2" text="Pdcd4" type="Genes/Proteins"/>
            <entity charOffset="46-57" id="miRNA-corp.d19.s1.e3" text="glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d19.s1.e1" e2="miRNA-corp.d19.s1.e2" id="miRNA-corp.d19.s1.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s1.e1" e2="miRNA-corp.d19.s1.e3" id="miRNA-corp.d19.s1.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d19.s2" origId="21636706.s3" text="In this study, we examined the role of oncogenic mir-21 in the pathogenesis of glioblastoma, the most aggressive form of primary brain tumor. ">
            <entity charOffset="49-54" id="miRNA-corp.d19.s2.e0" text="mir-21" type="Specific_miRNAs"/>
            <entity charOffset="79-90" id="miRNA-corp.d19.s2.e1" text="glioblastoma" type="Diseases"/>
            <entity charOffset="129-139" id="miRNA-corp.d19.s2.e2" text="brain tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d19.s2.e0" e2="miRNA-corp.d19.s2.e1" id="miRNA-corp.d19.s2.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s2.e0" e2="miRNA-corp.d19.s2.e2" id="miRNA-corp.d19.s2.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d19.s3" origId="21636706.s2" text="They function by regulating target gene expression post-transcriptionally. ">
            <entity charOffset="28-33" id="miRNA-corp.d19.s3.e0" text="target" type="Relation_Trigger"/>
            <entity charOffset="17-49" id="miRNA-corp.d19.s3.e1" text="regulating target gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d19.s4" origId="21636706.s5" text="We demonstrate that downregulation of mir-21 in glioblastoma-derived cell lines results in increased expression of its target, programmed cell death 4 (Pdcd4), a known tumor-suppressor gene. ">
            <entity charOffset="48-59" id="miRNA-corp.d19.s4.e0" text="glioblastoma" type="Diseases"/>
            <entity charOffset="20-33" id="miRNA-corp.d19.s4.e1" text="downregulation" type="Relation_Trigger"/>
            <entity charOffset="38-43" id="miRNA-corp.d19.s4.e2" text="mir-21" type="Specific_miRNAs"/>
            <entity charOffset="91-110" id="miRNA-corp.d19.s4.e3" text="increased expression" type="Relation_Trigger"/>
            <entity charOffset="119-124" id="miRNA-corp.d19.s4.e4" text="target" type="Relation_Trigger"/>
            <entity charOffset="127-149" id="miRNA-corp.d19.s4.e5" text="programmed cell death 4" type="Genes/Proteins"/>
            <entity charOffset="152-156" id="miRNA-corp.d19.s4.e6" text="Pdcd4" type="Genes/Proteins"/>
            <entity charOffset="168-183" id="miRNA-corp.d19.s4.e7" text="tumor-suppressor" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d19.s4.e2" e2="miRNA-corp.d19.s4.e5" id="miRNA-corp.d19.s4.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s4.e2" e2="miRNA-corp.d19.s4.e6" id="miRNA-corp.d19.s4.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s4.e2" e2="miRNA-corp.d19.s4.e0" id="miRNA-corp.d19.s4.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d19.s5" origId="21636706.s4" text="We have previously reported that mir-21 is expressed at higher levels in primary glioblastoma-tissue and glioblastoma-derived cell lines than in normal brain tissue. ">
            <entity charOffset="105-116" id="miRNA-corp.d19.s5.e0" text="glioblastoma" type="Diseases"/>
            <entity charOffset="33-38" id="miRNA-corp.d19.s5.e1" text="mir-21" type="Specific_miRNAs"/>
            <entity charOffset="43-68" id="miRNA-corp.d19.s5.e2" text="expressed at higher levels" type="Relation_Trigger"/>
            <entity charOffset="81-92" id="miRNA-corp.d19.s5.e3" text="glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d19.s5.e1" e2="miRNA-corp.d19.s5.e0" id="miRNA-corp.d19.s5.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s5.e1" e2="miRNA-corp.d19.s5.e3" id="miRNA-corp.d19.s5.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d19.s6" origId="21636706.s7" text="Using a glioblastoma xenograft model in immune-deficient nude mice, we observe that glioblastoma-derived cell lines in which mir-21 levels are downregulated or Pdcd4 is over-expressed exhibit decreased tumor formation and growth. ">
            <entity charOffset="84-95" id="miRNA-corp.d19.s6.e0" text="glioblastoma" type="Diseases"/>
            <entity charOffset="57-65" id="miRNA-corp.d19.s6.e1" text="nude mice" type="Species"/>
            <entity charOffset="8-19" id="miRNA-corp.d19.s6.e2" text="glioblastoma" type="Diseases"/>
            <entity charOffset="8-19" id="miRNA-corp.d19.s6.e3" text="glioblastoma" type="Diseases"/>
            <entity charOffset="125-130" id="miRNA-corp.d19.s6.e4" text="mir-21" type="Specific_miRNAs"/>
            <entity charOffset="132-155" id="miRNA-corp.d19.s6.e5" text="levels are downregulated" type="Relation_Trigger"/>
            <entity charOffset="160-164" id="miRNA-corp.d19.s6.e6" text="Pdcd4" type="Genes/Proteins"/>
            <entity charOffset="169-182" id="miRNA-corp.d19.s6.e7" text="over-expressed" type="Relation_Trigger"/>
            <entity charOffset="202-206" id="miRNA-corp.d19.s6.e8" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d19.s6.e4" e2="miRNA-corp.d19.s6.e0" id="miRNA-corp.d19.s6.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s6.e4" e2="miRNA-corp.d19.s6.e3" id="miRNA-corp.d19.s6.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s6.e4" e2="miRNA-corp.d19.s6.e6" id="miRNA-corp.d19.s6.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s6.e4" e2="miRNA-corp.d19.s6.e8" id="miRNA-corp.d19.s6.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s6.e4" e2="miRNA-corp.d19.s6.e2" id="miRNA-corp.d19.s6.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d19.s7" origId="21636706.s6" text="In addition, our data indicate that either downregulation of mir-21 or overexpression of its target, Pdcd4, in glioblastoma-derived cell lines leads to decreased proliferation, increased apoptosis, and decreased colony formation in soft agar. ">
            <entity charOffset="43-56" id="miRNA-corp.d19.s7.e0" text="downregulation" type="Relation_Trigger"/>
            <entity charOffset="111-122" id="miRNA-corp.d19.s7.e1" text="glioblastoma" type="Diseases"/>
            <entity charOffset="61-66" id="miRNA-corp.d19.s7.e2" text="mir-21" type="Specific_miRNAs"/>
            <entity charOffset="71-84" id="miRNA-corp.d19.s7.e3" text="overexpression" type="Relation_Trigger"/>
            <entity charOffset="93-98" id="miRNA-corp.d19.s7.e4" text="target" type="Relation_Trigger"/>
            <entity charOffset="101-105" id="miRNA-corp.d19.s7.e5" text="Pdcd4" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s7.e2" e2="miRNA-corp.d19.s7.e5" id="miRNA-corp.d19.s7.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s7.e2" e2="miRNA-corp.d19.s7.e1" id="miRNA-corp.d19.s7.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d19.s8" origId="21636706.s8" text="Significantly, tumors grow when the glioblastoma-derived cell lines are transfected with anti-mir-21 and siRNA to Pdcd4, confirming that the tumor growth is specifically regulated by Pdcd4. ">
            <entity charOffset="36-47" id="miRNA-corp.d19.s8.e0" text="glioblastoma" type="Diseases"/>
            <entity charOffset="15-20" id="miRNA-corp.d19.s8.e1" text="tumors" type="Diseases"/>
            <entity charOffset="114-118" id="miRNA-corp.d19.s8.e2" text="Pdcd4" type="Genes/Proteins"/>
            <entity charOffset="141-145" id="miRNA-corp.d19.s8.e3" text="tumor" type="Diseases"/>
            <entity charOffset="170-178" id="miRNA-corp.d19.s8.e4" text="regulated" type="Relation_Trigger"/>
            <entity charOffset="183-187" id="miRNA-corp.d19.s8.e5" text="Pdcd4" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d19.s9" origId="21636706.s9" text="These critical in vivo findings demonstrate an important functional linkage between mir-21 and Pdcd4 and further elucidate the molecular mechanisms by which the known high level of mir-21 expression in glioblastoma can attribute to tumorigenesis--namely, inhibition of Pdcd4 and its tumor-suppressive functions.   ">
            <entity charOffset="167-176" id="miRNA-corp.d19.s9.e0" text="high level" type="Relation_Trigger"/>
            <entity charOffset="84-89" id="miRNA-corp.d19.s9.e1" text="mir-21" type="Specific_miRNAs"/>
            <entity charOffset="95-99" id="miRNA-corp.d19.s9.e2" text="Pdcd4" type="Genes/Proteins"/>
            <entity charOffset="181-186" id="miRNA-corp.d19.s9.e3" text="mir-21" type="Specific_miRNAs"/>
            <entity charOffset="202-213" id="miRNA-corp.d19.s9.e4" text="glioblastoma" type="Diseases"/>
            <entity charOffset="255-264" id="miRNA-corp.d19.s9.e5" text="inhibition" type="Relation_Trigger"/>
            <entity charOffset="269-273" id="miRNA-corp.d19.s9.e6" text="Pdcd4" type="Genes/Proteins"/>
            <entity charOffset="283-299" id="miRNA-corp.d19.s9.e7" text="tumor-suppressive" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d19.s9.e1" e2="miRNA-corp.d19.s9.e2" id="miRNA-corp.d19.s9.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s9.e1" e2="miRNA-corp.d19.s9.e4" id="miRNA-corp.d19.s9.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s9.e1" e2="miRNA-corp.d19.s9.e6" id="miRNA-corp.d19.s9.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s9.e3" e2="miRNA-corp.d19.s9.e2" id="miRNA-corp.d19.s9.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s9.e3" e2="miRNA-corp.d19.s9.e4" id="miRNA-corp.d19.s9.p4" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s9.e3" e2="miRNA-corp.d19.s9.e6" id="miRNA-corp.d19.s9.p5" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d20" origId="21821026">
        <sentence id="miRNA-corp.d20.s0" origId="21821026.s0" text="New insights into non-coding RNA networks in Huntington's disease.     ">
            <entity charOffset="45-64" id="miRNA-corp.d20.s0.e0" text="Huntington's disease" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d21" origId="21857495">
        <sentence id="miRNA-corp.d21.s0" origId="21857495.s13" text="Plasma miRNAs should be investigated further as leading indicators of HIV diseases as early as acute infection.   ">
            <entity charOffset="7-12" id="miRNA-corp.d21.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="95-109" id="miRNA-corp.d21.s0.e1" text="acute infection" type="Diseases"/>
            <entity charOffset="70-81" id="miRNA-corp.d21.s0.e2" text="HIV diseases" type="Diseases"/>
            <pair e1="miRNA-corp.d21.s0.e0" e2="miRNA-corp.d21.s0.e1" id="miRNA-corp.d21.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d21.s0.e0" e2="miRNA-corp.d21.s0.e2" id="miRNA-corp.d21.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d21.s1" origId="21857495.s12" text="CONCLUSION: : Acute-phase differential expression of plasma miRNAs predicts CNS disease and suggests that CNS damage or predisposition to disease progression begins in the earliest phase of infection. ">
            <entity charOffset="106-115" id="miRNA-corp.d21.s1.e0" text="CNS damage" type="Diseases"/>
            <entity charOffset="190-198" id="miRNA-corp.d21.s1.e1" text="infection" type="Diseases"/>
            <entity charOffset="60-65" id="miRNA-corp.d21.s1.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="26-48" id="miRNA-corp.d21.s1.e3" text="differential expression" type="Relation_Trigger"/>
            <entity charOffset="76-86" id="miRNA-corp.d21.s1.e4" text="CNS disease" type="Diseases"/>
            <pair e1="miRNA-corp.d21.s1.e2" e2="miRNA-corp.d21.s1.e0" id="miRNA-corp.d21.s1.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d21.s1.e2" e2="miRNA-corp.d21.s1.e1" id="miRNA-corp.d21.s1.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d21.s1.e2" e2="miRNA-corp.d21.s1.e4" id="miRNA-corp.d21.s1.p2" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d21.s2" origId="21857495.s11" text="At least six miRNAs were significantly differentially expressed in individuals with severe versus no CNS disease; in an unweighted expression test, they predicted CNS disease. ">
            <entity charOffset="13-18" id="miRNA-corp.d21.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="39-62" id="miRNA-corp.d21.s2.e1" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="101-111" id="miRNA-corp.d21.s2.e2" text="CNS disease" type="Diseases"/>
            <entity charOffset="163-173" id="miRNA-corp.d21.s2.e3" text="CNS disease" type="Diseases"/>
            <pair e1="miRNA-corp.d21.s2.e0" e2="miRNA-corp.d21.s2.e2" id="miRNA-corp.d21.s2.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d21.s2.e0" e2="miRNA-corp.d21.s2.e3" id="miRNA-corp.d21.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d21.s3" origId="21857495.s10" text="miRNAs tracked with viral load and platelet count were also predictors of CNS disease. ">
            <entity charOffset="0-5" id="miRNA-corp.d21.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="74-84" id="miRNA-corp.d21.s3.e1" text="CNS disease" type="Diseases"/>
			<pair e1="miRNA-corp.d21.s3.e0" e2="miRNA-corp.d21.s3.e1" id="miRNA-corp.d21.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d21.s4" origId="21857495.s1" text="OBJECTIVE: : Plasma microRNAs (miRNAs) are modulated during disease and are emerging biomarkers; they have not been characterized in HIV infection. ">
            <entity charOffset="20-28" id="miRNA-corp.d21.s4.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="31-36" id="miRNA-corp.d21.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="43-51" id="miRNA-corp.d21.s4.e2" text="modulated" type="Relation_Trigger"/>
            <entity charOffset="133-145" id="miRNA-corp.d21.s4.e3" text="HIV infection" type="Diseases"/>
            <pair e1="miRNA-corp.d21.s4.e0" e2="miRNA-corp.d21.s4.e3" id="miRNA-corp.d21.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d21.s4.e1" e2="miRNA-corp.d21.s4.e3" id="miRNA-corp.d21.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d21.s5" origId="21857495.s0" text="A plasma microRNA signature of acute lentiviral infection:  biomarkers of central nervous system disease.  ">
            <entity charOffset="9-16" id="miRNA-corp.d21.s5.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="31-56" id="miRNA-corp.d21.s5.e1" text="acute lentiviral infection" type="Diseases"/>
            <entity charOffset="74-103" id="miRNA-corp.d21.s5.e2" text="central nervous system disease" type="Diseases"/>
            <pair e1="miRNA-corp.d21.s5.e0" e2="miRNA-corp.d21.s5.e1" id="miRNA-corp.d21.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d21.s5.e0" e2="miRNA-corp.d21.s5.e2" id="miRNA-corp.d21.s5.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d21.s6" origId="21857495.s5" text="miRNA expression was compared with levels of cytokines, virus, and plasma platelet count. ">
            <entity charOffset="0-4" id="miRNA-corp.d21.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d21.s7" origId="21857495.s4" text="METHODS: : Plasma miRNA expression profiles were determined by TaqMan low-density array for six individuals. ">
            <entity charOffset="18-22" id="miRNA-corp.d21.s7.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d21.s8" origId="21857495.s3" text="DESIGN: : Plasma samples were obtained before inoculation and 10 days after inoculation from SIV-infected macaques. ">
            <entity charOffset="106-113" id="miRNA-corp.d21.s8.e0" text="macaques" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d21.s9" origId="21857495.s2" text="Using our macaque/simian immunodeficiency virus (SIV) model of HIV, we sought to identify a plasma miRNA profile of acute lentiviral infection, evaluate its relationship with known cellular and viral determinants of lentivirus-associated central nervous system (CNS) disease, and explore the potential of miRNAs to predict CNS disease. ">
            <entity charOffset="99-103" id="miRNA-corp.d21.s9.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="116-141" id="miRNA-corp.d21.s9.e1" text="acute lentiviral infection" type="Diseases"/>
            <entity charOffset="305-310" id="miRNA-corp.d21.s9.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="238-273" id="miRNA-corp.d21.s9.e3" text="central nervous system (CNS) disease" type="Diseases"/>
            <entity charOffset="323-333" id="miRNA-corp.d21.s9.e4" text="CNS disease" type="Diseases"/>
            <pair e1="miRNA-corp.d21.s9.e0" e2="miRNA-corp.d21.s9.e3" id="miRNA-corp.d21.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d21.s9.e0" e2="miRNA-corp.d21.s9.e4" id="miRNA-corp.d21.s9.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d21.s9.e0" e2="miRNA-corp.d21.s9.e1" id="miRNA-corp.d21.s9.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d21.s9.e2" e2="miRNA-corp.d21.s9.e3" id="miRNA-corp.d21.s9.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d21.s9.e2" e2="miRNA-corp.d21.s9.e4" id="miRNA-corp.d21.s9.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d21.s9.e2" e2="miRNA-corp.d21.s9.e1" id="miRNA-corp.d21.s9.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d21.s10" origId="21857495.s9" text="Several differentially expressed miRNAs correlated with CNS disease-associated cytokines interleukin-6 and CCL2 and included predicted and/or validated regulators of the corresponding mRNAs. ">
            <entity charOffset="40-49" id="miRNA-corp.d21.s10.e0" text="correlated" type="Relation_Trigger"/>
            <entity charOffset="8-31" id="miRNA-corp.d21.s10.e1" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="56-66" id="miRNA-corp.d21.s10.e2" text="CNS disease" type="Diseases"/>
            <entity charOffset="68-77" id="miRNA-corp.d21.s10.e3" text="associated" type="Relation_Trigger"/>
            <entity charOffset="89-101" id="miRNA-corp.d21.s10.e4" text="interleukin-6" type="Genes/Proteins"/>
            <entity charOffset="107-110" id="miRNA-corp.d21.s10.e5" text="CCL2" type="Genes/Proteins"/>
            <entity charOffset="152-161" id="miRNA-corp.d21.s10.e6" text="regulators" type="Relation_Trigger"/>
            <entity charOffset="33-38" id="miRNA-corp.d21.s10.e7" text="miRNAs" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d21.s10.e7" e2="miRNA-corp.d21.s10.e2" id="miRNA-corp.d21.s10.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d21.s10.e7" e2="miRNA-corp.d21.s10.e4" id="miRNA-corp.d21.s10.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d21.s10.e7" e2="miRNA-corp.d21.s10.e5" id="miRNA-corp.d21.s10.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d21.s11" origId="21857495.s8" text="RESULTS: : A 45-miRNA signature of acute infection (differential expression with P &lt; 0.05 after multiple comparison correction) classified plasma as infected or not. ">
            <entity charOffset="16-20" id="miRNA-corp.d21.s11.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="35-49" id="miRNA-corp.d21.s11.e1" text="acute infection" type="Diseases"/>
            <entity charOffset="52-74" id="miRNA-corp.d21.s11.e2" text="differential expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d21.s11.e0" e2="miRNA-corp.d21.s11.e1" id="miRNA-corp.d21.s11.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d21.s12" origId="21857495.s7" text="Nineteen individuals were used to validate a disease prediction test. "/>
        <sentence id="miRNA-corp.d21.s13" origId="21857495.s6" text="miRNA results were confirmed by single miRNA-specific assays for 10 macaques. ">
            <entity charOffset="0-4" id="miRNA-corp.d21.s13.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="39-43" id="miRNA-corp.d21.s13.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="68-75" id="miRNA-corp.d21.s13.e2" text="macaques" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d22" origId="21051629">
        <sentence id="miRNA-corp.d22.s0" origId="21051629.s0" text="Regulation of oligodendrocyte differentiation and myelination.  ">
            <entity charOffset="0-9" id="miRNA-corp.d22.s0.e0" text="Regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d22.s1" origId="21051629.s4" text="These recent advances provide new insight into how remyelination may be stimulated in demyelinating disorders such as multiple sclerosis.   ">
            <entity charOffset="118-135" id="miRNA-corp.d22.s1.e0" text="multiple sclerosis" type="Diseases"/>
            <entity charOffset="86-108" id="miRNA-corp.d22.s1.e1" text="demyelinating disorders" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d22.s2" origId="21051629.s3" text="Studies have also demonstrated an unexpected level of plasticity of myelin in the adult CNS. "/>
        <sentence id="miRNA-corp.d22.s3" origId="21051629.s2" text="Recent results have greatly advanced this understanding, identifying new transcriptional regulators of myelin gene expression, elucidating vital roles for microRNAs in controlling myelination, and clarifying the extracellular signaling mechanisms that orchestrate the development of myelin. ">
            <entity charOffset="89-98" id="miRNA-corp.d22.s3.e0" text="regulators" type="Relation_Trigger"/>
            <entity charOffset="155-163" id="miRNA-corp.d22.s3.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d22.s4" origId="21051629.s1" text="Despite the importance of myelin for the rapid conduction of action potentials, the molecular bases of oligodendrocyte differentiation and central nervous system (CNS) myelination are still incompletely understood. "/>
    </document>
    <document id="miRNA-corp.d23" origId="20472885">
        <sentence id="miRNA-corp.d23.s0" origId="20472885.s0" text="miR-182 as a prognostic marker for glioma progression and patient survival.  ">
            <entity charOffset="0-6" id="miRNA-corp.d23.s0.e0" text="miR-182" type="Specific_miRNAs"/>
            <entity charOffset="35-40" id="miRNA-corp.d23.s0.e1" text="glioma" type="Diseases"/>
            <entity charOffset="58-64" id="miRNA-corp.d23.s0.e2" text="patient" type="Species"/>
            <pair e1="miRNA-corp.d23.s0.e0" e2="miRNA-corp.d23.s0.e1" id="miRNA-corp.d23.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d23.s1" origId="20472885.s8" text="Taken together, our results suggest that miR-182 could be a valuable marker of glioma progression and that high miR-182 expression is associated with poor overall survival in patients with malignant glioma.   ">
            <entity charOffset="41-47" id="miRNA-corp.d23.s1.e0" text="miR-182" type="Specific_miRNAs"/>
            <entity charOffset="79-84" id="miRNA-corp.d23.s1.e1" text="glioma" type="Diseases"/>
            <entity charOffset="112-118" id="miRNA-corp.d23.s1.e2" text="miR-182" type="Specific_miRNAs"/>
            <entity charOffset="107-129" id="miRNA-corp.d23.s1.e3" text="high miR-182 expression" type="Relation_Trigger"/>
            <entity charOffset="134-143" id="miRNA-corp.d23.s1.e4" text="associated" type="Relation_Trigger"/>
            <entity charOffset="175-182" id="miRNA-corp.d23.s1.e5" text="patients" type="Species"/>
            <entity charOffset="189-204" id="miRNA-corp.d23.s1.e6" text="malignant glioma" type="Diseases"/>
            <pair e1="miRNA-corp.d23.s1.e0" e2="miRNA-corp.d23.s1.e1" id="miRNA-corp.d23.s1.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d23.s1.e0" e2="miRNA-corp.d23.s1.e6" id="miRNA-corp.d23.s1.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d23.s1.e2" e2="miRNA-corp.d23.s1.e1" id="miRNA-corp.d23.s1.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d23.s1.e2" e2="miRNA-corp.d23.s1.e6" id="miRNA-corp.d23.s1.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d23.s2" origId="20472885.s7" text="Moreover, the correlations of miR-182 level with the clinical features of glioma suggested in the in situ hybridization analysis were further verified by the real-time RT-PCR analysis. ">
            <entity charOffset="14-25" id="miRNA-corp.d23.s2.e0" text="correlations" type="Relation_Trigger"/>
            <entity charOffset="30-36" id="miRNA-corp.d23.s2.e1" text="miR-182" type="Specific_miRNAs"/>
            <entity charOffset="74-79" id="miRNA-corp.d23.s2.e2" text="glioma" type="Diseases"/>
            <pair e1="miRNA-corp.d23.s2.e1" e2="miRNA-corp.d23.s2.e2" id="miRNA-corp.d23.s2.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d23.s3" origId="20472885.s6" text="The cumulative 5-year survival rate of glioma patients was 51.54% (95% confidence interval, 0.435 to 0.596) in the low miR-182-expression group, whereas it was only 7.23% (95% confidence interval, 0.027 to 0.118) in the high miR-182-expression group (P = 0.001), and multivariate Cox regression analysis indicated that miR-182 expression was an independent prognostic indicator for the survival of glioma patients. ">
            <entity charOffset="357-376" id="miRNA-corp.d23.s3.e0" text="prognostic indicator" type="Relation_Trigger"/>
            <entity charOffset="46-53" id="miRNA-corp.d23.s3.e1" text="patients" type="Species"/>
            <entity charOffset="39-44" id="miRNA-corp.d23.s3.e2" text="glioma" type="Diseases"/>
            <entity charOffset="119-125" id="miRNA-corp.d23.s3.e3" text="miR-182" type="Specific_miRNAs"/>
            <entity charOffset="115-136" id="miRNA-corp.d23.s3.e4" text="low miR-182-expression" type="Relation_Trigger"/>
            <entity charOffset="225-231" id="miRNA-corp.d23.s3.e5" text="miR-182" type="Specific_miRNAs"/>
            <entity charOffset="220-242" id="miRNA-corp.d23.s3.e6" text="high miR-182-expression" type="Relation_Trigger"/>
            <entity charOffset="319-325" id="miRNA-corp.d23.s3.e7" text="miR-182" type="Specific_miRNAs"/>
            <entity charOffset="398-403" id="miRNA-corp.d23.s3.e8" text="glioma" type="Diseases"/>
            <entity charOffset="405-412" id="miRNA-corp.d23.s3.e9" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d23.s3.e3" e2="miRNA-corp.d23.s3.e2" id="miRNA-corp.d23.s3.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d23.s3.e3" e2="miRNA-corp.d23.s3.e8" id="miRNA-corp.d23.s3.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d23.s3.e5" e2="miRNA-corp.d23.s3.e2" id="miRNA-corp.d23.s3.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d23.s3.e5" e2="miRNA-corp.d23.s3.e8" id="miRNA-corp.d23.s3.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d23.s3.e7" e2="miRNA-corp.d23.s3.e2" id="miRNA-corp.d23.s3.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d23.s3.e7" e2="miRNA-corp.d23.s3.e8" id="miRNA-corp.d23.s3.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d23.s4" origId="20472885.s5" text="Statistical analysis revealed a significant correlation between miR-182 expression and World Health Organization glioma grading (P &lt; 0.001). ">
            <entity charOffset="113-118" id="miRNA-corp.d23.s4.e0" text="glioma" type="Diseases"/>
            <entity charOffset="44-54" id="miRNA-corp.d23.s4.e1" text="correlation" type="Relation_Trigger"/>
            <entity charOffset="64-70" id="miRNA-corp.d23.s4.e2" text="miR-182" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d23.s4.e2" e2="miRNA-corp.d23.s4.e0" id="miRNA-corp.d23.s4.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d23.s5" origId="20472885.s4" text="Elevated expression of miR-182 was further identified by in situ hybridization in 248 of 253 (98%) archived human glioma biopsies tested. ">
            <entity charOffset="0-18" id="miRNA-corp.d23.s5.e0" text="Elevated expression" type="Relation_Trigger"/>
            <entity charOffset="23-29" id="miRNA-corp.d23.s5.e1" text="miR-182" type="Specific_miRNAs"/>
            <entity charOffset="108-112" id="miRNA-corp.d23.s5.e2" text="human" type="Species"/>
            <entity charOffset="114-119" id="miRNA-corp.d23.s5.e3" text="glioma" type="Diseases"/>
            <pair e1="miRNA-corp.d23.s5.e1" e2="miRNA-corp.d23.s5.e3" id="miRNA-corp.d23.s5.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d23.s6" origId="20472885.s3" text="Quantitative PCR analysis showed that miR-182 was significantly increased by up to 32-fold in glioma tumors compared with the adjacent nontumor brain tissues obtained from the same patient. ">
            <entity charOffset="38-44" id="miRNA-corp.d23.s6.e0" text="miR-182" type="Specific_miRNAs"/>
            <entity charOffset="50-72" id="miRNA-corp.d23.s6.e1" text="significantly increased" type="Relation_Trigger"/>
            <entity charOffset="94-106" id="miRNA-corp.d23.s6.e2" text="glioma tumors" type="Diseases"/>
            <entity charOffset="181-187" id="miRNA-corp.d23.s6.e3" text="patient" type="Species"/>
            <pair e1="miRNA-corp.d23.s6.e0" e2="miRNA-corp.d23.s6.e2" id="miRNA-corp.d23.s6.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d23.s7" origId="20472885.s2" text="We report that the expression level of miR-182 was markedly up-regulated in glioma cell lines and in human primary glioma specimens. ">
            <entity charOffset="76-81" id="miRNA-corp.d23.s7.e0" text="glioma" type="Diseases"/>
            <entity charOffset="19-34" id="miRNA-corp.d23.s7.e1" text="expression level" type="Relation_Trigger"/>
            <entity charOffset="60-71" id="miRNA-corp.d23.s7.e2" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="39-45" id="miRNA-corp.d23.s7.e3" text="miR-182" type="Specific_miRNAs"/>
            <entity charOffset="101-120" id="miRNA-corp.d23.s7.e4" text="human primary glioma" type="Diseases"/>
            <entity charOffset="101-105" id="miRNA-corp.d23.s7.e5" text="human" type="Species"/>
            <pair e1="miRNA-corp.d23.s7.e3" e2="miRNA-corp.d23.s7.e0" id="miRNA-corp.d23.s7.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d23.s7.e3" e2="miRNA-corp.d23.s7.e4" id="miRNA-corp.d23.s7.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d23.s8" origId="20472885.s1" text="Accumulating evidence indicates that miRNA expression can be used as a diagnostic and prognostic marker for human cancers. ">
            <entity charOffset="37-41" id="miRNA-corp.d23.s8.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="108-120" id="miRNA-corp.d23.s8.e1" text="human cancers" type="Diseases"/>
            <entity charOffset="108-112" id="miRNA-corp.d23.s8.e2" text="human" type="Species"/>
            <pair e1="miRNA-corp.d23.s8.e0" e2="miRNA-corp.d23.s8.e1" id="miRNA-corp.d23.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d24" origId="21306246">
        <sentence id="miRNA-corp.d24.s0" origId="21306246.s0" text="Leukodystrophy and gene therapy with a dimmer switch.     ">
            <entity charOffset="0-13" id="miRNA-corp.d24.s0.e0" text="Leukodystrophy" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d25" origId="19542014">
        <sentence id="miRNA-corp.d25.s0" origId="19542014.s2" text="Recently, we have found that microRNA (miRNA) miR-145 is the most abundant miRNA in normal vascular walls and in freshly isolated VSMCs; however, the role of miR-145 in VSMC phenotypic modulation and vascular diseases is currently unknown. ">
            <entity charOffset="29-36" id="miRNA-corp.d25.s0.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="39-43" id="miRNA-corp.d25.s0.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="46-52" id="miRNA-corp.d25.s0.e2" text="miR-145" type="Specific_miRNAs"/>
            <entity charOffset="75-79" id="miRNA-corp.d25.s0.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="158-164" id="miRNA-corp.d25.s0.e4" text="miR-145" type="Specific_miRNAs"/>
            <entity charOffset="200-216" id="miRNA-corp.d25.s0.e5" text="vascular diseases" type="Diseases"/>
            <entity charOffset="185-194" id="miRNA-corp.d25.s0.e6" text="modulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d25.s0.e0" e2="miRNA-corp.d25.s0.e5" id="miRNA-corp.d25.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d25.s0.e1" e2="miRNA-corp.d25.s0.e5" id="miRNA-corp.d25.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d25.s0.e2" e2="miRNA-corp.d25.s0.e5" id="miRNA-corp.d25.s0.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d25.s0.e3" e2="miRNA-corp.d25.s0.e5" id="miRNA-corp.d25.s0.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d25.s0.e4" e2="miRNA-corp.d25.s0.e5" id="miRNA-corp.d25.s0.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d25.s1" origId="19542014.s1" text="Phenotypic modulation of vascular smooth muscle cells (VSMCs) plays a critical role in the pathogenesis of a variety of proliferative vascular diseases. ">
            <entity charOffset="134-150" id="miRNA-corp.d25.s1.e0" text="vascular diseases" type="Diseases"/>
            <entity charOffset="11-20" id="miRNA-corp.d25.s1.e1" text="modulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d25.s2" origId="19542014.s4" text="More importantly, both in cultured rat VSMCs in vitro and in balloon-injured rat carotid arteries in vivo, we demonstrate that the noncoding RNA miR-145 is a novel phenotypic marker and a novel phenotypic modulator of VSMCs. ">
            <entity charOffset="145-151" id="miRNA-corp.d25.s2.e0" text="miR-145" type="Specific_miRNAs"/>
            <entity charOffset="61-75" id="miRNA-corp.d25.s2.e1" text="balloon-injured" type="Diseases"/>
            <entity charOffset="77-79" id="miRNA-corp.d25.s2.e2" text="rat" type="Species"/>
            <entity charOffset="205-213" id="miRNA-corp.d25.s2.e3" text="modulator" type="Relation_Trigger"/>
            <entity charOffset="35-37" id="miRNA-corp.d25.s2.e4" text="rat" type="Species"/>
            <pair e1="miRNA-corp.d25.s2.e0" e2="miRNA-corp.d25.s2.e1" id="miRNA-corp.d25.s2.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d25.s3" origId="19542014.s3" text="Here we find that miR-145 is selectively expressed in VSMCs of the vascular wall and its expression is significantly downregulated in the vascular walls with neointimal lesion formation and in cultured dedifferentiated VSMCs. ">
            <entity charOffset="18-24" id="miRNA-corp.d25.s3.e0" text="miR-145" type="Specific_miRNAs"/>
            <entity charOffset="89-129" id="miRNA-corp.d25.s3.e1" text="expression is significantly downregulated" type="Relation_Trigger"/>
            <entity charOffset="158-174" id="miRNA-corp.d25.s3.e2" text="neointimal lesion" type="Diseases"/>
            <pair e1="miRNA-corp.d25.s3.e0" e2="miRNA-corp.d25.s3.e2" id="miRNA-corp.d25.s3.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d25.s4" origId="19542014.s0" text="MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation.  ">
            <entity charOffset="0-11" id="miRNA-corp.d25.s4.e0" text="MicroRNA-145" type="Specific_miRNAs"/>
            <entity charOffset="63-71" id="miRNA-corp.d25.s4.e1" text="modulator" type="Relation_Trigger"/>
            <entity charOffset="83-108" id="miRNA-corp.d25.s4.e2" text="vascular neointimal lesion" type="Diseases"/>
            <pair e1="miRNA-corp.d25.s4.e0" e2="miRNA-corp.d25.s4.e2" id="miRNA-corp.d25.s4.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d25.s5" origId="19542014.s9" text="These novel findings may have extensive implications for the diagnosis and therapy of a variety of proliferative vascular diseases.   ">
            <entity charOffset="113-129" id="miRNA-corp.d25.s5.e0" text="vascular diseases" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d25.s6" origId="19542014.s6" text="We have further identified that miR-145-mediated phenotypic modulation of VSMCs is through its target gene KLF5 and its downstream signaling molecule, myocardin. ">
            <entity charOffset="32-38" id="miRNA-corp.d25.s6.e0" text="miR-145" type="Specific_miRNAs"/>
            <entity charOffset="60-69" id="miRNA-corp.d25.s6.e1" text="modulation" type="Relation_Trigger"/>
            <entity charOffset="95-100" id="miRNA-corp.d25.s6.e2" text="target" type="Relation_Trigger"/>
            <entity charOffset="107-110" id="miRNA-corp.d25.s6.e3" text="KLF5" type="Genes/Proteins"/>
            <entity charOffset="151-159" id="miRNA-corp.d25.s6.e4" text="myocardin" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d25.s6.e0" e2="miRNA-corp.d25.s6.e3" id="miRNA-corp.d25.s6.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d25.s6.e0" e2="miRNA-corp.d25.s6.e4" id="miRNA-corp.d25.s6.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d25.s7" origId="19542014.s5" text="VSMC differentiation marker genes such as SM alpha-actin, calponin, and SM-MHC are upregulated by premiR-145 or adenovirus expressing miR-145 (Ad-miR-145) but are downregulated by the miR-145 inhibitor 2'OMe-miR-145. ">
            <entity charOffset="134-140" id="miRNA-corp.d25.s7.e0" text="miR-145" type="Specific_miRNAs"/>
            <entity charOffset="146-152" id="miRNA-corp.d25.s7.e1" text="miR-145" type="Specific_miRNAs"/>
            <entity charOffset="98-107" id="miRNA-corp.d25.s7.e2" text="premiR-145" type="Specific_miRNAs"/>
            <entity charOffset="83-93" id="miRNA-corp.d25.s7.e3" text="upregulated" type="Relation_Trigger"/>
            <entity charOffset="163-175" id="miRNA-corp.d25.s7.e4" text="downregulated" type="Relation_Trigger"/>
            <entity charOffset="192-200" id="miRNA-corp.d25.s7.e5" text="inhibitor" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d25.s8" origId="19542014.s8" text="We conclude that miR-145 is a novel VSMC phenotypic marker and modulator that is able of controlling vascular neointimal lesion formation. ">
            <entity charOffset="17-23" id="miRNA-corp.d25.s8.e0" text="miR-145" type="Specific_miRNAs"/>
            <entity charOffset="63-71" id="miRNA-corp.d25.s8.e1" text="modulator" type="Relation_Trigger"/>
            <entity charOffset="101-126" id="miRNA-corp.d25.s8.e2" text="vascular neointimal lesion" type="Diseases"/>
            <pair e1="miRNA-corp.d25.s8.e0" e2="miRNA-corp.d25.s8.e2" id="miRNA-corp.d25.s8.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d25.s9" origId="19542014.s7" text="Finally, restoration of miR-145 in balloon-injured arteries via Ad-miR-145 inhibits neointimal growth. ">
            <entity charOffset="67-73" id="miRNA-corp.d25.s9.e0" text="miR-145" type="Specific_miRNAs"/>
            <entity charOffset="24-30" id="miRNA-corp.d25.s9.e1" text="miR-145" type="Specific_miRNAs"/>
            <entity charOffset="35-49" id="miRNA-corp.d25.s9.e2" text="balloon-injured" type="Diseases"/>
            <entity charOffset="75-82" id="miRNA-corp.d25.s9.e3" text="inhibits" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d25.s9.e0" e2="miRNA-corp.d25.s9.e2" id="miRNA-corp.d25.s9.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d25.s9.e1" e2="miRNA-corp.d25.s9.e2" id="miRNA-corp.d25.s9.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d26" origId="17465892">
        <sentence id="miRNA-corp.d26.s0" origId="17465892.s0" text="MicroRNAs and regenerative medicine.  ">
            <entity charOffset="0-8" id="miRNA-corp.d26.s0.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d26.s1" origId="17465892.s4" text="Recently, researchers have demonstrated the crucial roles of microRNAs, not only in the differentiation and proliferation of stem cells, which have a key function in the regeneration and transplantation of organs, but also in oncogenesis. ">
            <entity charOffset="61-69" id="miRNA-corp.d26.s1.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d26.s2" origId="17465892.s3" text="In this paper, we review the prospects of microRNAs as future therapies in regenerative medicine. ">
            <entity charOffset="42-50" id="miRNA-corp.d26.s2.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d26.s3" origId="17465892.s2" text="The combination of microRNAs and regenerative medicine is an emerging interdisciplinary medical field that can yield exciting new possibilities for clinical medicine. ">
            <entity charOffset="19-27" id="miRNA-corp.d26.s3.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d26.s4" origId="17465892.s1" text="MicroRNAs, identified only relatively recently, are regulators of gene expression with potential medical benefits. ">
            <entity charOffset="0-8" id="miRNA-corp.d26.s4.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="52-80" id="miRNA-corp.d26.s4.e1" text="regulators of gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d26.s5" origId="17465892.s6" text="Further, microRNAs have been indicated to be involved in diverse biological processes, suggesting the potential role of these molecules in the treatment of diseases.   ">
            <entity charOffset="9-17" id="miRNA-corp.d26.s5.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d26.s6" origId="17465892.s5" text="Several lines of indirect evidence show that the initiation and maintenance of cancer stem cells might also be under the control of microRNAs. ">
            <entity charOffset="132-140" id="miRNA-corp.d26.s6.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="79-84" id="miRNA-corp.d26.s6.e1" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d26.s6.e0" e2="miRNA-corp.d26.s6.e1" id="miRNA-corp.d26.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d27" origId="21053309">
        <sentence id="miRNA-corp.d27.s0" origId="21053309.s0" text="MicroRNAs in CNS injury: potential roles and therapeutic implications.     ">
            <entity charOffset="0-8" id="miRNA-corp.d27.s0.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="13-22" id="miRNA-corp.d27.s0.e1" text="CNS injury" type="Diseases"/>
            <pair e1="miRNA-corp.d27.s0.e0" e2="miRNA-corp.d27.s0.e1" id="miRNA-corp.d27.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d28" origId="20220193">
        <sentence id="miRNA-corp.d28.s0" origId="20220193.s0" text="Ameliorating amyotrophic lateral sclerosis.     ">
            <entity charOffset="0-41" id="miRNA-corp.d28.s0.e0" text="Ameliorating amyotrophic lateral sclerosis" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d29" origId="20303929">
        <sentence id="miRNA-corp.d29.s0" origId="20303929.s6" text="Pathway analyses showed that majority of these miRNAs are involved in the neuronal development and function. ">
            <entity charOffset="47-52" id="miRNA-corp.d29.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d29.s1" origId="20303929.s5" text="In this study, we report for the first time that VEEV infection in mice brain causes modulation of miRNA expression. ">
            <entity charOffset="49-62" id="miRNA-corp.d29.s1.e0" text="VEEV infection" type="Diseases"/>
            <entity charOffset="67-70" id="miRNA-corp.d29.s1.e1" text="mice" type="Species"/>
            <entity charOffset="85-94" id="miRNA-corp.d29.s1.e2" text="modulation" type="Relation_Trigger"/>
            <entity charOffset="99-103" id="miRNA-corp.d29.s1.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d29.s1.e3" e2="miRNA-corp.d29.s1.e0" id="miRNA-corp.d29.s1.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d29.s2" origId="20303929.s7" text="Target gene prediction of the modulated miRNAs correlates with our recently reported mRNA expression in VEEV infected mice brain.   ">
            <entity charOffset="0-5" id="miRNA-corp.d29.s2.e0" text="Target" type="Relation_Trigger"/>
            <entity charOffset="40-45" id="miRNA-corp.d29.s2.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="30-38" id="miRNA-corp.d29.s2.e2" text="modulated" type="Relation_Trigger"/>
            <entity charOffset="118-121" id="miRNA-corp.d29.s2.e3" text="mice" type="Species"/>
            <entity charOffset="104-116" id="miRNA-corp.d29.s2.e4" text="VEEV infected" type="Diseases"/>
            <entity charOffset="47-56" id="miRNA-corp.d29.s2.e5" text="correlates" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d29.s2.e1" e2="miRNA-corp.d29.s2.e4" id="miRNA-corp.d29.s2.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d29.s3" origId="20303929.s2" text="Recent studies have shown that cellular miRNA plays a very important role in the pathogenesis of viral infection. ">
            <entity charOffset="40-44" id="miRNA-corp.d29.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="97-111" id="miRNA-corp.d29.s3.e1" text="viral infection" type="Diseases"/>
            <pair e1="miRNA-corp.d29.s3.e0" e2="miRNA-corp.d29.s3.e1" id="miRNA-corp.d29.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d29.s4" origId="20303929.s1" text="MicroRNAs (miRNA) are small RNA (approximately 22nts) molecules that are expressed endogenously in cells and play an important role in regulating gene expression. ">
            <entity charOffset="0-8" id="miRNA-corp.d29.s4.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-15" id="miRNA-corp.d29.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="135-161" id="miRNA-corp.d29.s4.e2" text="regulating gene expression." type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d29.s5" origId="20303929.s4" text="VEEV is infectious in aerosol form and is a potential biothreat agent. "/>
        <sentence id="miRNA-corp.d29.s6" origId="20303929.s3" text="Venezuelan equine encephalitis virus (VEEV) is an RNA virus and is a member of the genus Alphavirus in the family Togaviridae. "/>
        <sentence id="miRNA-corp.d29.s7" origId="20303929.s0" text="Analysis of microRNAs induced by Venezuelan equine encephalitis virus infection in mouse brain.  ">
            <entity charOffset="12-20" id="miRNA-corp.d29.s7.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="33-78" id="miRNA-corp.d29.s7.e1" text="Venezuelan equine encephalitis virus infection" type="Diseases"/>
            <entity charOffset="83-87" id="miRNA-corp.d29.s7.e2" text="mouse" type="Species"/>
            <pair e1="miRNA-corp.d29.s7.e0" e2="miRNA-corp.d29.s7.e1" id="miRNA-corp.d29.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d30" origId="18624795">
        <sentence id="miRNA-corp.d30.s0" origId="18624795.s2" text="The accurate diagnosis of brain malignancies is essential for selection of proper treatment. "/>
        <sentence id="miRNA-corp.d30.s1" origId="18624795.s1" text="A recurring challenge for brain pathologists is to diagnose whether a brain malignancy is a primary tumor or a metastasis from some other tissue. ">
            <entity charOffset="92-104" id="miRNA-corp.d30.s1.e0" text="primary tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d30.s2" origId="18624795.s0" text="MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors.  ">
            <entity charOffset="0-6" id="miRNA-corp.d30.s2.e0" text="MiR-92b" type="Specific_miRNAs"/>
            <entity charOffset="12-18" id="miRNA-corp.d30.s2.e1" text="miR-9/9" type="Specific_miRNAs"/>
            <entity charOffset="25-46" id="miRNA-corp.d30.s2.e2" text="specifically expressed" type="Relation_Trigger"/>
            <entity charOffset="118-140" id="miRNA-corp.d30.s2.e3" text="metastatic brain tumors" type="Diseases"/>
            <entity charOffset="57-70" id="miRNA-corp.d30.s2.e4" text="primary tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d30.s2.e0" e2="miRNA-corp.d30.s2.e3" id="miRNA-corp.d30.s2.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d30.s2.e0" e2="miRNA-corp.d30.s2.e4" id="miRNA-corp.d30.s2.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d30.s2.e1" e2="miRNA-corp.d30.s2.e3" id="miRNA-corp.d30.s2.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d30.s2.e1" e2="miRNA-corp.d30.s2.e4" id="miRNA-corp.d30.s2.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d30.s3" origId="18624795.s6" text="These microRNAs thus represent excellent biomarkers for brain primary tumors. ">
            <entity charOffset="6-14" id="miRNA-corp.d30.s3.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="56-75" id="miRNA-corp.d30.s3.e1" text="brain primary tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d30.s3.e0" e2="miRNA-corp.d30.s3.e1" id="miRNA-corp.d30.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d30.s4" origId="18624795.s5" text="By considering the expression of only these two microRNAs, it is possible to distinguish between primary and metastatic brain tumors with very high accuracy. ">
            <entity charOffset="48-56" id="miRNA-corp.d30.s4.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="109-131" id="miRNA-corp.d30.s4.e1" text="metastatic brain tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d30.s4.e0" e2="miRNA-corp.d30.s4.e1" id="miRNA-corp.d30.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d30.s5" origId="18624795.s4" text="Using microRNA expression profiling, we found that hsa-miR-92b and hsa-miR-9/hsa-miR-9* are over-expressed, specifically in brain primary tumors, as compared to primary tumors from other tissues and their metastases to the brain. ">
            <entity charOffset="67-85" id="miRNA-corp.d30.s5.e0" text="hsa-miR-9/hsa-miR-9" type="Specific_miRNAs"/>
            <entity charOffset="6-13" id="miRNA-corp.d30.s5.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="51-61" id="miRNA-corp.d30.s5.e2" text="hsa-miR-92b" type="Specific_miRNAs"/>
            <entity charOffset="92-105" id="miRNA-corp.d30.s5.e3" text="over-expressed" type="Relation_Trigger"/>
            <entity charOffset="161-174" id="miRNA-corp.d30.s5.e4" text="primary tumors" type="Diseases"/>
            <entity charOffset="124-143" id="miRNA-corp.d30.s5.e5" text="brain primary tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d30.s5.e0" e2="miRNA-corp.d30.s5.e4" id="miRNA-corp.d30.s5.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d30.s5.e0" e2="miRNA-corp.d30.s5.e5" id="miRNA-corp.d30.s5.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d30.s5.e1" e2="miRNA-corp.d30.s5.e4" id="miRNA-corp.d30.s5.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d30.s5.e1" e2="miRNA-corp.d30.s5.e5" id="miRNA-corp.d30.s5.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d30.s5.e2" e2="miRNA-corp.d30.s5.e4" id="miRNA-corp.d30.s5.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d30.s5.e2" e2="miRNA-corp.d30.s5.e5" id="miRNA-corp.d30.s5.p5" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d30.s6" origId="18624795.s3" text="MicroRNAs are a class of small non-coding RNA species that regulate gene expression; many exhibit tissue-specific expression and are misregulated in cancer. ">
            <entity charOffset="0-8" id="miRNA-corp.d30.s6.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="133-144" id="miRNA-corp.d30.s6.e1" text="misregulated" type="Relation_Trigger"/>
            <entity charOffset="149-154" id="miRNA-corp.d30.s6.e2" text="cancer" type="Diseases"/>
            <entity charOffset="59-82" id="miRNA-corp.d30.s6.e3" text="regulate gene expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d30.s6.e0" e2="miRNA-corp.d30.s6.e2" id="miRNA-corp.d30.s6.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d30.s7" origId="18624795.s7" text="Previous reports have found that hsa-miR-92b and hsa-miR-9/hsa-miR-9* are expressed more strongly in developing neurons and brain than in adult brain. ">
            <entity charOffset="49-67" id="miRNA-corp.d30.s7.e0" text="hsa-miR-9/hsa-miR-9" type="Specific_miRNAs"/>
            <entity charOffset="33-43" id="miRNA-corp.d30.s7.e1" text="hsa-miR-92b" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d30.s8" origId="18624795.s8" text="Thus, their specific over-expression in brain primary tumors supports a functional role for these microRNAs or a link between neuronal stem cells and brain tumorigenesis.   ">
            <entity charOffset="21-35" id="miRNA-corp.d30.s8.e0" text="over-expression" type="Relation_Trigger"/>
            <entity charOffset="40-59" id="miRNA-corp.d30.s8.e1" text="brain primary tumors" type="Diseases"/>
            <entity charOffset="98-106" id="miRNA-corp.d30.s8.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d30.s8.e2" e2="miRNA-corp.d30.s8.e1" id="miRNA-corp.d30.s8.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d31" origId="17363563">
        <sentence id="miRNA-corp.d31.s0" origId="17363563.s10" text="These findings call attention to the potential of microRNAs to provide etiologic insights as well as to serve as both diagnostic markers and therapeutic targets for many different tumor types.   ">
            <entity charOffset="50-58" id="miRNA-corp.d31.s0.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="141-159" id="miRNA-corp.d31.s0.e1" text="therapeutic targets" type="Relation_Trigger"/>
            <entity charOffset="180-184" id="miRNA-corp.d31.s0.e2" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d31.s0.e0" e2="miRNA-corp.d31.s0.e2" id="miRNA-corp.d31.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d31.s1" origId="17363563.s9" text="Our results provide evidence that microRNA expression patterns may mark specific biological characteristics of tumors and/or mediate biological activities important for the pathobiology of malignant tumors. ">
            <entity charOffset="34-41" id="miRNA-corp.d31.s1.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="111-116" id="miRNA-corp.d31.s1.e1" text="tumors" type="Diseases"/>
            <entity charOffset="189-204" id="miRNA-corp.d31.s1.e2" text="malignant tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d31.s1.e0" e2="miRNA-corp.d31.s1.e1" id="miRNA-corp.d31.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d31.s1.e0" e2="miRNA-corp.d31.s1.e2" id="miRNA-corp.d31.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d31.s2" origId="17363563.s6" text="Agglomerative hierarchical clustering analysis of microRNA expression revealed four groups among the NCI-60 cell lines consisting of hematologic, colon, central nervous system, and melanoma tumor-derived cell lines clustered in a manner that reflected their tissue of origin. ">
            <entity charOffset="181-194" id="miRNA-corp.d31.s2.e0" text="melanoma tumor" type="Diseases"/>
            <entity charOffset="50-57" id="miRNA-corp.d31.s2.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d31.s2.e1" e2="miRNA-corp.d31.s2.e0" id="miRNA-corp.d31.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d31.s3" origId="17363563.s5" text="Most microRNAs were expressed at lower levels in tumor-derived cell lines compared with the corresponding normal tissue. ">
            <entity charOffset="5-13" id="miRNA-corp.d31.s3.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="20-44" id="miRNA-corp.d31.s3.e1" text="expressed at lower levels" type="Relation_Trigger"/>
            <entity charOffset="49-53" id="miRNA-corp.d31.s3.e2" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d31.s3.e0" e2="miRNA-corp.d31.s3.e2" id="miRNA-corp.d31.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d31.s4" origId="17363563.s8" text="We also identified specific microRNA expression patterns that correlated with the proliferation indices of the NCI-60 cell lines, and we developed evidence for the identification of specific microRNAs as candidate oncogenes and tumor suppressor genes in different tumor types. ">
            <entity charOffset="28-35" id="miRNA-corp.d31.s4.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="62-71" id="miRNA-corp.d31.s4.e1" text="correlated" type="Relation_Trigger"/>
            <entity charOffset="191-199" id="miRNA-corp.d31.s4.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="228-243" id="miRNA-corp.d31.s4.e3" text="tumor suppressor" type="Relation_Trigger"/>
            <entity charOffset="264-268" id="miRNA-corp.d31.s4.e4" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d31.s4.e0" e2="miRNA-corp.d31.s4.e4" id="miRNA-corp.d31.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d31.s4.e2" e2="miRNA-corp.d31.s4.e4" id="miRNA-corp.d31.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d31.s5" origId="17363563.s7" text="We identified specific subsets of microRNAs that provide candidate molecular signatures characteristic of the tumor-derived cell lines belonging to these four clusters. ">
            <entity charOffset="34-42" id="miRNA-corp.d31.s5.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="110-114" id="miRNA-corp.d31.s5.e1" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d31.s5.e0" e2="miRNA-corp.d31.s5.e1" id="miRNA-corp.d31.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d31.s6" origId="17363563.s2" text="They play a critical role in developmental and physiologic processes and are implicated in the pathogenesis of several human diseases including cancer. ">
            <entity charOffset="144-149" id="miRNA-corp.d31.s6.e0" text="cancer" type="Diseases"/>
            <entity charOffset="119-123" id="miRNA-corp.d31.s6.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d31.s7" origId="17363563.s1" text="MicroRNAs are small noncoding RNAs that function by regulating target gene expression posttranscriptionally. ">
            <entity charOffset="0-8" id="miRNA-corp.d31.s7.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="52-84" id="miRNA-corp.d31.s7.e1" text="regulating target gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d31.s8" origId="17363563.s4" text="To quantify microRNA expression, we employed a highly sensitive technique that uses stem-loop primers for reverse transcription followed by real-time PCR. ">
            <entity charOffset="12-19" id="miRNA-corp.d31.s8.e0" text="microRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d31.s9" origId="17363563.s3" text="We examined the expression profiles of 241 human microRNAs in normal tissues and the NCI-60 panel of human tumor-derived cell lines. ">
            <entity charOffset="49-57" id="miRNA-corp.d31.s9.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="43-47" id="miRNA-corp.d31.s9.e1" text="human" type="Species"/>
            <entity charOffset="101-105" id="miRNA-corp.d31.s9.e2" text="human" type="Species"/>
            <entity charOffset="101-111" id="miRNA-corp.d31.s9.e3" text="human tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d31.s9.e0" e2="miRNA-corp.d31.s9.e3" id="miRNA-corp.d31.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d31.s10" origId="17363563.s0" text="Characterization of microRNA expression levels and their biological correlates in human cancer cell lines.  ">
            <entity charOffset="20-27" id="miRNA-corp.d31.s10.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="29-45" id="miRNA-corp.d31.s10.e1" text="expression levels" type="Relation_Trigger"/>
            <entity charOffset="68-77" id="miRNA-corp.d31.s10.e2" text="correlates" type="Relation_Trigger"/>
            <entity charOffset="82-86" id="miRNA-corp.d31.s10.e3" text="human" type="Species"/>
            <entity charOffset="82-93" id="miRNA-corp.d31.s10.e4" text="human cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d31.s10.e0" e2="miRNA-corp.d31.s10.e4" id="miRNA-corp.d31.s10.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d32" origId="19297398">
        <sentence id="miRNA-corp.d32.s0" origId="19297398.s2" text="Recent evidence suggests that both development and proper function of central nervous system require intricate spatiotemporal expression of a wide repertoire of small regulatory RNAs. "/>
        <sentence id="miRNA-corp.d32.s1" origId="19297398.s1" text="Increasingly complex networks of small RNAs act through RNA interference pathway to regulate gene expression. ">
            <entity charOffset="84-107" id="miRNA-corp.d32.s1.e0" text="regulate gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d32.s2" origId="19297398.s0" text="Small regulatory RNAs in neurodevelopmental disorders.  ">
            <entity charOffset="6-15" id="miRNA-corp.d32.s2.e0" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="25-52" id="miRNA-corp.d32.s2.e1" text="neurodevelopmental disorders" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d32.s3" origId="19297398.s4" text="Here, we will review recent progress made toward understanding roles of small regulatory RNAs in neurodevelopmental disorders and discuss the potential involvement of newly discovered classes of small RNAs in these disorders.   ">
            <entity charOffset="78-87" id="miRNA-corp.d32.s3.e0" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="97-124" id="miRNA-corp.d32.s3.e1" text="neurodevelopmental disorders" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d32.s4" origId="19297398.s3" text="Misregulation of these small regulatory RNAs could contribute to the abnormalities in brain development that are associated with neurodevelopmental disorders. ">
            <entity charOffset="129-156" id="miRNA-corp.d32.s4.e0" text="neurodevelopmental disorders" type="Diseases"/>
            <entity charOffset="0-12" id="miRNA-corp.d32.s4.e1" text="Misregulation" type="Relation_Trigger"/>
            <entity charOffset="113-122" id="miRNA-corp.d32.s4.e2" text="associated" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d33" origId="21425446">
        <sentence id="miRNA-corp.d33.s0" origId="21425446.s0" text="MicroRNA expression profiling for molecular classification of pediatric brain tumors.     ">
            <entity charOffset="0-7" id="miRNA-corp.d33.s0.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="62-83" id="miRNA-corp.d33.s0.e1" text="pediatric brain tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d33.s0.e0" e2="miRNA-corp.d33.s0.e1" id="miRNA-corp.d33.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d34" origId="19521422">
        <sentence id="miRNA-corp.d34.s0" origId="19521422.s6" text="These concepts will be explored in this article.   "/>
        <sentence id="miRNA-corp.d34.s1" origId="19521422.s5" text="This encourages the idea that certain miRs allow continued tumor growth through the suppression of differentiation and the maintenance of the stem cell-like properties of tumor cells. ">
            <entity charOffset="38-41" id="miRNA-corp.d34.s1.e0" text="miRs" type="Non-Specific_miRNAs"/>
            <entity charOffset="59-63" id="miRNA-corp.d34.s1.e1" text="tumor" type="Diseases"/>
            <entity charOffset="84-94" id="miRNA-corp.d34.s1.e2" text="suppression" type="Relation_Trigger"/>
            <entity charOffset="171-175" id="miRNA-corp.d34.s1.e3" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d34.s1.e0" e2="miRNA-corp.d34.s1.e1" id="miRNA-corp.d34.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d34.s1.e0" e2="miRNA-corp.d34.s1.e3" id="miRNA-corp.d34.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d34.s2" origId="19521422.s2" text="At the same time, it has become clear that one of the major roles that microRNAs play is in the regulation of stem cell biology, differentiation, and cell 'identity'. ">
            <entity charOffset="71-79" id="miRNA-corp.d34.s2.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="96-105" id="miRNA-corp.d34.s2.e1" text="regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d34.s3" origId="19521422.s1" text="Recent data draw close parallels between cancer, including glial brain tumors, and the biology of stem and progenitor cells. ">
            <entity charOffset="41-46" id="miRNA-corp.d34.s3.e0" text="cancer" type="Diseases"/>
            <entity charOffset="59-76" id="miRNA-corp.d34.s3.e1" text="glial brain tumors" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d34.s4" origId="19521422.s4" text="Interestingly, initial studies in the incurable brain tumor glioblastoma multiforme strongly suggest that microRNAs involved in neural development play a role in this disease. ">
            <entity charOffset="48-82" id="miRNA-corp.d34.s4.e0" text="brain tumor glioblastoma multiforme" type="Diseases"/>
            <entity charOffset="106-114" id="miRNA-corp.d34.s4.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d34.s4.e1" e2="miRNA-corp.d34.s4.e0" id="miRNA-corp.d34.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d34.s5" origId="19521422.s3" text="For example, microRNAs have been increasingly implicated in the regulation of neural differentiation. ">
            <entity charOffset="13-21" id="miRNA-corp.d34.s5.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="64-73" id="miRNA-corp.d34.s5.e1" text="regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d34.s6" origId="19521422.s0" text="MicroRNAs and glioblastoma; the stem cell connection.  ">
            <entity charOffset="0-8" id="miRNA-corp.d34.s6.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="14-25" id="miRNA-corp.d34.s6.e1" text="glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d34.s6.e0" e2="miRNA-corp.d34.s6.e1" id="miRNA-corp.d34.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d35" origId="21295111">
        <sentence id="miRNA-corp.d35.s0" origId="21295111.s0" text="MicroRNA-223 expression in neutrophils in the early phase of secondary damage after spinal cord injury.  ">
            <entity charOffset="0-11" id="miRNA-corp.d35.s0.e0" text="MicroRNA-223" type="Specific_miRNAs"/>
            <entity charOffset="84-101" id="miRNA-corp.d35.s0.e1" text="spinal cord injury" type="Diseases"/>
            <pair e1="miRNA-corp.d35.s0.e0" e2="miRNA-corp.d35.s0.e1" id="miRNA-corp.d35.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d35.s1" origId="21295111.s1" text="MicroRNA (miR)s are short non-coding RNAs that suppress the translation of target genes, and play an important role in gene regulation. ">
            <entity charOffset="75-80" id="miRNA-corp.d35.s1.e0" text="target" type="Relation_Trigger"/>
            <entity charOffset="0-7" id="miRNA-corp.d35.s1.e1" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="10-12" id="miRNA-corp.d35.s1.e2" text="miR" type="Non-Specific_miRNAs"/>
            <entity charOffset="47-54" id="miRNA-corp.d35.s1.e3" text="suppress" type="Relation_Trigger"/>
            <entity charOffset="124-133" id="miRNA-corp.d35.s1.e4" text="regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d35.s2" origId="21295111.s2" text="Despite this prominence, there are few reports that refer to the expression of miRs after spinal cord injury (SCI). ">
            <entity charOffset="79-82" id="miRNA-corp.d35.s2.e0" text="miRs" type="Non-Specific_miRNAs"/>
            <entity charOffset="90-107" id="miRNA-corp.d35.s2.e1" text="spinal cord injury" type="Diseases"/>
            <entity charOffset="110-112" id="miRNA-corp.d35.s2.e2" text="SCI" type="Diseases"/>
            <pair e1="miRNA-corp.d35.s2.e0" e2="miRNA-corp.d35.s2.e1" id="miRNA-corp.d35.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d35.s2.e0" e2="miRNA-corp.d35.s2.e2" id="miRNA-corp.d35.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d35.s3" origId="21295111.s3" text="Previously, we reported on miR-223 expression after SCI in mice. ">
            <entity charOffset="27-33" id="miRNA-corp.d35.s3.e0" text="miR-223" type="Specific_miRNAs"/>
            <entity charOffset="59-62" id="miRNA-corp.d35.s3.e1" text="mice" type="Species"/>
            <entity charOffset="52-54" id="miRNA-corp.d35.s3.e2" text="SCI" type="Diseases"/>
            <pair e1="miRNA-corp.d35.s3.e0" e2="miRNA-corp.d35.s3.e2" id="miRNA-corp.d35.s3.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d35.s4" origId="21295111.s4" text="The purpose of this study is to reveal the distribution of miR-223 and identify the cells that express miR-223 in the injured spinal cord. ">
            <entity charOffset="59-65" id="miRNA-corp.d35.s4.e0" text="miR-223" type="Specific_miRNAs"/>
            <entity charOffset="103-109" id="miRNA-corp.d35.s4.e1" text="miR-223" type="Specific_miRNAs"/>
            <entity charOffset="118-136" id="miRNA-corp.d35.s4.e2" text="injured spinal cord" type="Diseases"/>
            <pair e1="miRNA-corp.d35.s4.e0" e2="miRNA-corp.d35.s4.e2" id="miRNA-corp.d35.s4.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d35.s4.e1" e2="miRNA-corp.d35.s4.e2" id="miRNA-corp.d35.s4.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d35.s5" origId="21295111.s5" text="Quantitative polymerase chain reaction analysis revealed high expression of miR-223 at 12h after SCI. Double staining of in situ hybridization and immunohistochemistry showed that the signals of miR-223 merged with Gr-1 positive neutrophils. ">
            <entity charOffset="57-71" id="miRNA-corp.d35.s5.e0" text="high expression" type="Relation_Trigger"/>
            <entity charOffset="76-82" id="miRNA-corp.d35.s5.e1" text="miR-223" type="Specific_miRNAs"/>
            <entity charOffset="97-99" id="miRNA-corp.d35.s5.e2" text="SCI" type="Diseases"/>
            <entity charOffset="195-201" id="miRNA-corp.d35.s5.e3" text="miR-223" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d35.s5.e1" e2="miRNA-corp.d35.s5.e2" id="miRNA-corp.d35.s5.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d35.s5.e3" e2="miRNA-corp.d35.s5.e2" id="miRNA-corp.d35.s5.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d35.s6" origId="21295111.s6" text="Our data indicate that miR-223 might regulate neutrophils in the early phase after SCI.   ">
            <entity charOffset="23-29" id="miRNA-corp.d35.s6.e0" text="miR-223" type="Specific_miRNAs"/>
            <entity charOffset="37-44" id="miRNA-corp.d35.s6.e1" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="83-85" id="miRNA-corp.d35.s6.e2" text="SCI" type="Diseases"/>
            <pair e1="miRNA-corp.d35.s6.e0" e2="miRNA-corp.d35.s6.e2" id="miRNA-corp.d35.s6.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d36" origId="21196113">
        <sentence id="miRNA-corp.d36.s0" origId="21196113.s10" text="Our results suggest that miR-124a may play a role in GBM migration, and that targeted delivery of miR-124a may be a novel inhibitor of GBM invasion.   ">
            <entity charOffset="122-130" id="miRNA-corp.d36.s0.e0" text="inhibitor" type="Relation_Trigger"/>
            <entity charOffset="25-32" id="miRNA-corp.d36.s0.e1" text="miR-124a" type="Specific_miRNAs"/>
            <entity charOffset="53-55" id="miRNA-corp.d36.s0.e2" text="GBM" type="Diseases"/>
            <entity charOffset="77-84" id="miRNA-corp.d36.s0.e3" text="targeted" type="Relation_Trigger"/>
            <entity charOffset="98-105" id="miRNA-corp.d36.s0.e4" text="miR-124a" type="Specific_miRNAs"/>
            <entity charOffset="135-137" id="miRNA-corp.d36.s0.e5" text="GBM" type="Diseases"/>
            <pair e1="miRNA-corp.d36.s0.e1" e2="miRNA-corp.d36.s0.e2" id="miRNA-corp.d36.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d36.s0.e1" e2="miRNA-corp.d36.s0.e5" id="miRNA-corp.d36.s0.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d36.s0.e4" e2="miRNA-corp.d36.s0.e2" id="miRNA-corp.d36.s0.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d36.s0.e4" e2="miRNA-corp.d36.s0.e5" id="miRNA-corp.d36.s0.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d36.s1" origId="21196113.s1" text="Glioblastoma (GBM) represents a formidable clinical challenge for both patients and treating physicians. ">
            <entity charOffset="0-11" id="miRNA-corp.d36.s1.e0" text="Glioblastoma" type="Diseases"/>
            <entity charOffset="14-16" id="miRNA-corp.d36.s1.e1" text="GBM" type="Diseases"/>
            <entity charOffset="71-78" id="miRNA-corp.d36.s1.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d36.s2" origId="21196113.s2" text="Due to better local treatments and prolonged patient survival, remote recurrences are increasingly observed, underpinning the importance of targeting tumour migration and attachment. ">
            <entity charOffset="45-51" id="miRNA-corp.d36.s2.e0" text="patient" type="Species"/>
            <entity charOffset="140-148" id="miRNA-corp.d36.s2.e1" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="150-155" id="miRNA-corp.d36.s2.e2" text="tumour" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d36.s3" origId="21196113.s3" text="Aberrant expression of microRNA (miRNA) is commonly associated with cancer and loss of miR-124a has previously been implicated to function as a tumour suppressor. ">
            <entity charOffset="0-18" id="miRNA-corp.d36.s3.e0" text="Aberrant expression" type="Relation_Trigger"/>
            <entity charOffset="23-30" id="miRNA-corp.d36.s3.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="33-37" id="miRNA-corp.d36.s3.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="52-61" id="miRNA-corp.d36.s3.e3" text="associated" type="Relation_Trigger"/>
            <entity charOffset="68-73" id="miRNA-corp.d36.s3.e4" text="cancer" type="Diseases"/>
            <entity charOffset="87-94" id="miRNA-corp.d36.s3.e5" text="miR-124a" type="Specific_miRNAs"/>
            <entity charOffset="144-160" id="miRNA-corp.d36.s3.e6" text="tumour suppressor" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d36.s3.e1" e2="miRNA-corp.d36.s3.e4" id="miRNA-corp.d36.s3.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d36.s3.e2" e2="miRNA-corp.d36.s3.e4" id="miRNA-corp.d36.s3.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d36.s3.e5" e2="miRNA-corp.d36.s3.e4" id="miRNA-corp.d36.s3.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d36.s4" origId="21196113.s4" text="The assessment of miR-124a in clinical specimens has been limited and a potential role in migration and invasion has been unexplored until now. ">
            <entity charOffset="18-25" id="miRNA-corp.d36.s4.e0" text="miR-124a" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d36.s5" origId="21196113.s5" text="We measured the expression levels of mature miR-124a in a retrospective series of 119 cases of histologically confirmed GBM and found its expression was markedly lower in over 80% of the GBM clinical specimens compared to normal brain tissue. ">
            <entity charOffset="138-166" id="miRNA-corp.d36.s5.e0" text="expression was markedly lower" type="Relation_Trigger"/>
            <entity charOffset="16-32" id="miRNA-corp.d36.s5.e1" text="expression levels" type="Relation_Trigger"/>
            <entity charOffset="44-51" id="miRNA-corp.d36.s5.e2" text="miR-124a" type="Specific_miRNAs"/>
            <entity charOffset="120-122" id="miRNA-corp.d36.s5.e3" text="GBM" type="Diseases"/>
            <entity charOffset="187-189" id="miRNA-corp.d36.s5.e4" text="GBM" type="Diseases"/>
            <pair e1="miRNA-corp.d36.s5.e2" e2="miRNA-corp.d36.s5.e3" id="miRNA-corp.d36.s5.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d36.s5.e2" e2="miRNA-corp.d36.s5.e4" id="miRNA-corp.d36.s5.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d36.s6" origId="21196113.s6" text="The level of reduction in the clinical cohort varied significantly and patients with lower than the average miR-124a expression levels displayed shorter survival times. ">
            <entity charOffset="4-21" id="miRNA-corp.d36.s6.e0" text="level of reduction" type="Relation_Trigger"/>
            <entity charOffset="117-133" id="miRNA-corp.d36.s6.e1" text="expression levels" type="Relation_Trigger"/>
            <entity charOffset="71-78" id="miRNA-corp.d36.s6.e2" text="patients" type="Species"/>
            <entity charOffset="108-115" id="miRNA-corp.d36.s6.e3" text="miR-124a" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d36.s7" origId="21196113.s7" text="Endogenous miR-124a expression and the protein expression of three of its targets; IQ motif containing GTPase activating protein 1 (IQGAP1), laminin γ1 (LAMC1) and integrin β1 (ITGB1) were significantly reciprocally associated in the majority of the clinical cases. ">
            <entity charOffset="74-80" id="miRNA-corp.d36.s7.e0" text="targets" type="Relation_Trigger"/>
            <entity charOffset="11-18" id="miRNA-corp.d36.s7.e1" text="miR-124a" type="Specific_miRNAs"/>
            <entity charOffset="132-137" id="miRNA-corp.d36.s7.e2" text="IQGAP1" type="Genes/Proteins"/>
            <entity charOffset="83-129" id="miRNA-corp.d36.s7.e3" text="IQ motif containing GTPase activating protein 1" type="Genes/Proteins"/>
            <entity charOffset="141-150" id="miRNA-corp.d36.s7.e4" text="laminin γ1" type="Genes/Proteins"/>
            <entity charOffset="153-157" id="miRNA-corp.d36.s7.e5" text="LAMC1" type="Genes/Proteins"/>
            <entity charOffset="164-174" id="miRNA-corp.d36.s7.e6" text="integrin β1" type="Genes/Proteins"/>
            <entity charOffset="177-181" id="miRNA-corp.d36.s7.e7" text="ITGB1" type="Genes/Proteins"/>
            <entity charOffset="216-225" id="miRNA-corp.d36.s7.e8" text="associated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d36.s7.e1" e2="miRNA-corp.d36.s7.e2" id="miRNA-corp.d36.s7.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d36.s7.e1" e2="miRNA-corp.d36.s7.e3" id="miRNA-corp.d36.s7.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d36.s7.e1" e2="miRNA-corp.d36.s7.e4" id="miRNA-corp.d36.s7.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d36.s7.e1" e2="miRNA-corp.d36.s7.e5" id="miRNA-corp.d36.s7.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d36.s7.e1" e2="miRNA-corp.d36.s7.e6" id="miRNA-corp.d36.s7.p4" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d36.s7.e1" e2="miRNA-corp.d36.s7.e7" id="miRNA-corp.d36.s7.p5" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d36.s8" origId="21196113.s8" text="We confirmed this association in our in vitro model. ">
            <entity charOffset="18-28" id="miRNA-corp.d36.s8.e0" text="association" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d36.s9" origId="21196113.s0" text="miR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion.  ">
            <entity charOffset="0-7" id="miRNA-corp.d36.s9.e0" text="miR-124a" type="Specific_miRNAs"/>
            <entity charOffset="23-36" id="miRNA-corp.d36.s9.e1" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="41-52" id="miRNA-corp.d36.s9.e2" text="glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d36.s9.e0" e2="miRNA-corp.d36.s9.e2" id="miRNA-corp.d36.s9.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d36.s10" origId="21196113.s9" text="Functionally, the ectopic expression of mature miR-124a in a GBM cell line resulted in significant inhibition of migration and invasion, demonstrating a role for miR-124a in promoting tumour invasiveness. ">
            <entity charOffset="18-35" id="miRNA-corp.d36.s10.e0" text="ectopic expression" type="Relation_Trigger"/>
            <entity charOffset="47-54" id="miRNA-corp.d36.s10.e1" text="miR-124a" type="Specific_miRNAs"/>
            <entity charOffset="99-108" id="miRNA-corp.d36.s10.e2" text="inhibition" type="Relation_Trigger"/>
            <entity charOffset="162-169" id="miRNA-corp.d36.s10.e3" text="miR-124a" type="Specific_miRNAs"/>
            <entity charOffset="184-189" id="miRNA-corp.d36.s10.e4" text="tumour" type="Diseases"/>
            <pair e1="miRNA-corp.d36.s10.e1" e2="miRNA-corp.d36.s10.e4" id="miRNA-corp.d36.s10.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d36.s10.e3" e2="miRNA-corp.d36.s10.e4" id="miRNA-corp.d36.s10.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d37" origId="17439965">
        <sentence id="miRNA-corp.d37.s0" origId="17439965.s0" text="Specificity, duplex degradation and subcellular localization of antagomirs.  "/>
        <sentence id="miRNA-corp.d37.s1" origId="17439965.s7" text="Finally, we show that antagomirs, although incapable of silencing miRNAs in the central nervous system (CNS) when injected systemically, efficiently target miRNAs when injected locally into the mouse cortex. ">
            <entity charOffset="66-71" id="miRNA-corp.d37.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="156-161" id="miRNA-corp.d37.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="149-154" id="miRNA-corp.d37.s1.e2" text="target" type="Relation_Trigger"/>
            <entity charOffset="194-198" id="miRNA-corp.d37.s1.e3" text="mouse" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d37.s2" origId="17439965.s8" text="Our data further validate the effectiveness of antagomirs in vivo and should facilitate future studies to silence miRNAs for functional analysis and in clinically relevant settings.   ">
            <entity charOffset="114-119" id="miRNA-corp.d37.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d37.s3" origId="17439965.s5" text="We demonstrate that antagomirs harbor optimized phosphorothioate modifications, require &gt;19-nt length for highest efficiency and can discriminate between single nucleotide mismatches of the targeted miRNA. ">
            <entity charOffset="199-203" id="miRNA-corp.d37.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="190-197" id="miRNA-corp.d37.s3.e1" text="targeted" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d37.s4" origId="17439965.s6" text="Degradation of different chemically protected miRNA/antagomir duplexes in mouse livers and localization of antagomirs in a cytosolic compartment that is distinct from processing (P)-bodies indicates a degradation mechanism independent of the RNA interference (RNAi) pathway. ">
            <entity charOffset="46-50" id="miRNA-corp.d37.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="74-78" id="miRNA-corp.d37.s4.e1" text="mouse" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d37.s5" origId="17439965.s3" text="We recently demonstrated silencing miRNA function in mice using chemically modified and cholesterol-conjugated RNAs termed 'antagomirs'. ">
            <entity charOffset="35-39" id="miRNA-corp.d37.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="53-56" id="miRNA-corp.d37.s5.e1" text="mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d37.s6" origId="17439965.s4" text="Here, we further characterize the properties and function of antagomirs in mice. ">
            <entity charOffset="75-78" id="miRNA-corp.d37.s6.e0" text="mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d37.s7" origId="17439965.s1" text="MicroRNAs (miRNAs) are an abundant class of 20-23-nt long regulators of gene expression. ">
            <entity charOffset="0-8" id="miRNA-corp.d37.s7.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d37.s7.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="58-86" id="miRNA-corp.d37.s7.e2" text="regulators of gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d37.s8" origId="17439965.s2" text="The study of miRNA function in mice and potential therapeutic approaches largely depend on modified oligonucleotides. ">
            <entity charOffset="13-17" id="miRNA-corp.d37.s8.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="31-34" id="miRNA-corp.d37.s8.e1" text="mice" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d38" origId="21295689">
        <sentence id="miRNA-corp.d38.s0" origId="21295689.s2" text="Many of these pathways were first identified in genetic screens in Drosophila and other lower organisms. ">
            <entity charOffset="67-76" id="miRNA-corp.d38.s0.e0" text="Drosophila" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d38.s1" origId="21295689.s1" text="In the last 20 years, it has become clear that developmental genes and their regulators, noncoding RNAs including microRNAs and long-noncoding RNAs, within signaling pathways play a critical role in the pathogenesis of cancer. ">
            <entity charOffset="77-86" id="miRNA-corp.d38.s1.e0" text="regulators" type="Relation_Trigger"/>
            <entity charOffset="114-122" id="miRNA-corp.d38.s1.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="219-224" id="miRNA-corp.d38.s1.e2" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d38.s1.e1" e2="miRNA-corp.d38.s1.e2" id="miRNA-corp.d38.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d38.s2" origId="21295689.s4" text="Genes and pathways expressed during embryonic development, including the Notch, Wnt/β-Catenin, TGF-β/BMP, Shh/Patched, and Hippo pathways are mutated, lost, or aberrantly regulated in a wide variety of human cancers, including skin, breast, blood, and brain cancers, including medulloblastoma. ">
            <entity charOffset="277-291" id="miRNA-corp.d38.s2.e0" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="84-92" id="miRNA-corp.d38.s2.e1" text="β-Catenin" type="Genes/Proteins"/>
            <entity charOffset="106-108" id="miRNA-corp.d38.s2.e2" text="Shh" type="Genes/Proteins"/>
            <entity charOffset="252-264" id="miRNA-corp.d38.s2.e3" text="brain cancers" type="Diseases"/>
            <entity charOffset="95-99" id="miRNA-corp.d38.s2.e4" text="TGF-β" type="Genes/Proteins"/>
            <entity charOffset="160-179" id="miRNA-corp.d38.s2.e5" text="aberrantly regulated" type="Relation_Trigger"/>
            <entity charOffset="202-214" id="miRNA-corp.d38.s2.e6" text="human cancers" type="Diseases"/>
            <entity charOffset="202-206" id="miRNA-corp.d38.s2.e7" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d38.s3" origId="21295689.s3" text="Mammalian orthologs were subsequently identified and genes within the pathways cloned and found to regulate cell growth. ">
            <entity charOffset="99-106" id="miRNA-corp.d38.s3.e0" text="regulate" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d38.s4" origId="21295689.s0" text="Cerebellum development and medulloblastoma.  ">
            <entity charOffset="27-41" id="miRNA-corp.d38.s4.e0" text="medulloblastoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d38.s5" origId="21295689.s6" text="Medulloblastoma, the most common malignant nervous system tumor in childhood, are thought to arise from disruptions in cerebellar development [reviewed by Marino, S. (2005)]. ">
            <entity charOffset="0-14" id="miRNA-corp.d38.s5.e0" text="Medulloblastoma" type="Diseases"/>
            <entity charOffset="58-62" id="miRNA-corp.d38.s5.e1" text="tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d38.s6" origId="21295689.s5" text="These biochemical pathways affect cell fate determination, axis formation, and patterning during development and regulate tissue homeostasis and regeneration in adults. ">
            <entity charOffset="113-120" id="miRNA-corp.d38.s6.e0" text="regulate" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d38.s7" origId="21295689.s8" text="In this chapter, we will review the development of the cerebellar cortex, highlighting signaling pathways of potential relevance to tumorigenesis.   "/>
        <sentence id="miRNA-corp.d38.s8" origId="21295689.s7" text="Defining the extracellular cues and intracellular signaling pathways that control cerebellar neurogenesis, especially granule cell progenitor (GCP) proliferation and differentiation has been useful for developing models to unravel the mechanisms underlying medulloblastoma formation and growth. ">
            <entity charOffset="257-271" id="miRNA-corp.d38.s8.e0" text="medulloblastoma" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d39" origId="21561454">
        <sentence id="miRNA-corp.d39.s0" origId="21561454.s0" text="A specific miRNA signature in the peripheral blood of glioblastoma patients.  ">
            <entity charOffset="11-15" id="miRNA-corp.d39.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="54-65" id="miRNA-corp.d39.s0.e1" text="glioblastoma" type="Diseases"/>
            <entity charOffset="67-74" id="miRNA-corp.d39.s0.e2" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d39.s0.e0" e2="miRNA-corp.d39.s0.e1" id="miRNA-corp.d39.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d39.s1" origId="21561454.s2" text="Biomarkers for the disease would be desirable in order to allow for an early detection of tumor progression or to indicate rapidly growing tumor subtypes requiring more intensive therapy. ">
            <entity charOffset="90-94" id="miRNA-corp.d39.s1.e0" text="tumor" type="Diseases"/>
            <entity charOffset="139-143" id="miRNA-corp.d39.s1.e1" text="tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d39.s2" origId="21561454.s1" text="The prognosis of patients afflicted by glioblastoma remains poor. ">
            <entity charOffset="17-24" id="miRNA-corp.d39.s2.e0" text="patients" type="Species"/>
            <entity charOffset="39-50" id="miRNA-corp.d39.s2.e1" text="glioblastoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d39.s3" origId="21561454.s4" text="To this end, miRNA profiles from the blood of 20 patients with glioblastoma and 20 age- and sex-matched healthy controls were compared. ">
            <entity charOffset="13-17" id="miRNA-corp.d39.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="49-56" id="miRNA-corp.d39.s3.e1" text="patients" type="Species"/>
            <entity charOffset="63-74" id="miRNA-corp.d39.s3.e2" text="glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d39.s3.e0" e2="miRNA-corp.d39.s3.e2" id="miRNA-corp.d39.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d39.s4" origId="21561454.s3" text="In this study, we investigated whether a blood-derived specific miRNA fingerprint can be defined in patients with glioblastoma. ">
            <entity charOffset="64-68" id="miRNA-corp.d39.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="100-107" id="miRNA-corp.d39.s4.e1" text="patients" type="Species"/>
            <entity charOffset="114-125" id="miRNA-corp.d39.s4.e2" text="glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d39.s4.e0" e2="miRNA-corp.d39.s4.e2" id="miRNA-corp.d39.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d39.s5" origId="21561454.s6" text="Of these, two candidates, miR-128 (up-regulated) and miR-342-3p (down-regulated), remained significant after correcting for multiple testing by Benjamini-Hochberg adjustment with a p-value of 0.025. ">
            <entity charOffset="26-32" id="miRNA-corp.d39.s5.e0" text="miR-128" type="Specific_miRNAs"/>
            <entity charOffset="53-62" id="miRNA-corp.d39.s5.e1" text="miR-342-3p" type="Specific_miRNAs"/>
            <entity charOffset="35-46" id="miRNA-corp.d39.s5.e2" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="65-78" id="miRNA-corp.d39.s5.e3" text="down-regulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d39.s6" origId="21561454.s5" text="Of 1158 tested miRNAs, 52 were significantly deregulated, as assessed by unadjusted Student's t-test at an alpha level of 0.05. ">
            <entity charOffset="15-20" id="miRNA-corp.d39.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="45-55" id="miRNA-corp.d39.s6.e1" text="deregulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d39.s7" origId="21561454.s7" text="The altered expression of these two biomarkers was confirmed in a second cohort of glioblastoma patients and healthy controls by real-time PCR and validated for patients who had received neither radio- nor chemotherapy and for patients who had their glioblastomas resected more than 6 months ago. ">
            <entity charOffset="4-21" id="miRNA-corp.d39.s7.e0" text="altered expression" type="Relation_Trigger"/>
            <entity charOffset="83-94" id="miRNA-corp.d39.s7.e1" text="glioblastoma" type="Diseases"/>
            <entity charOffset="96-103" id="miRNA-corp.d39.s7.e2" text="patients" type="Species"/>
            <entity charOffset="161-168" id="miRNA-corp.d39.s7.e3" text="patients" type="Species"/>
            <entity charOffset="227-234" id="miRNA-corp.d39.s7.e4" text="patients" type="Species"/>
            <entity charOffset="250-262" id="miRNA-corp.d39.s7.e5" text="glioblastomas" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d39.s8" origId="21561454.s8" text="Moreover, using machine learning, a comprehensive miRNA signature was obtained that allowed for the discrimination between blood samples of glioblastoma patients and healthy controls with an accuracy of 81% [95% confidence interval (CI) 78-84%], specificity of 79% (95% CI 75-83%) and sensitivity of 83% (95% CI 71-85%). ">
            <entity charOffset="50-54" id="miRNA-corp.d39.s8.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="140-151" id="miRNA-corp.d39.s8.e1" text="glioblastoma" type="Diseases"/>
            <entity charOffset="153-160" id="miRNA-corp.d39.s8.e2" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d39.s8.e0" e2="miRNA-corp.d39.s8.e1" id="miRNA-corp.d39.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d39.s9" origId="21561454.s9" text="In summary, our proof-of-concept study demonstrates that blood-derived glioblastoma-associated characteristic miRNA fingerprints may be suitable biomarkers and warrant further exploration.   ">
            <entity charOffset="110-114" id="miRNA-corp.d39.s9.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="71-82" id="miRNA-corp.d39.s9.e1" text="glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d39.s9.e0" e2="miRNA-corp.d39.s9.e1" id="miRNA-corp.d39.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d40" origId="20181935">
        <sentence id="miRNA-corp.d40.s0" origId="20181935.s6" text="The clinical relevance of our findings was evaluated in HIV-encephalitis (HIVE) brain samples in which decreased levels of MCP-2 and increased levels of mir-146a were observed, suggesting a role for mir-146a in the maintenance of HIV-mediated chronic inflammation of the brain.   ">
            <entity charOffset="153-160" id="miRNA-corp.d40.s0.e0" text="mir-146a" type="Specific_miRNAs"/>
            <entity charOffset="199-206" id="miRNA-corp.d40.s0.e1" text="mir-146a" type="Specific_miRNAs"/>
            <entity charOffset="230-262" id="miRNA-corp.d40.s0.e2" text="HIV-mediated chronic inflammation" type="Diseases"/>
            <entity charOffset="133-148" id="miRNA-corp.d40.s0.e3" text="increased levels" type="Relation_Trigger"/>
            <entity charOffset="56-71" id="miRNA-corp.d40.s0.e4" text="HIV-encephalitis" type="Diseases"/>
            <entity charOffset="74-77" id="miRNA-corp.d40.s0.e5" text="HIVE" type="Diseases"/>
            <entity charOffset="123-127" id="miRNA-corp.d40.s0.e6" text="MCP-2" type="Genes/Proteins"/>
            <entity charOffset="103-118" id="miRNA-corp.d40.s0.e7" text="decreased levels" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d40.s0.e0" e2="miRNA-corp.d40.s0.e2" id="miRNA-corp.d40.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d40.s0.e0" e2="miRNA-corp.d40.s0.e4" id="miRNA-corp.d40.s0.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d40.s0.e0" e2="miRNA-corp.d40.s0.e5" id="miRNA-corp.d40.s0.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d40.s0.e0" e2="miRNA-corp.d40.s0.e6" id="miRNA-corp.d40.s0.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d40.s0.e1" e2="miRNA-corp.d40.s0.e2" id="miRNA-corp.d40.s0.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d40.s0.e1" e2="miRNA-corp.d40.s0.e4" id="miRNA-corp.d40.s0.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d40.s0.e1" e2="miRNA-corp.d40.s0.e5" id="miRNA-corp.d40.s0.p6" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d40.s0.e1" e2="miRNA-corp.d40.s0.e6" id="miRNA-corp.d40.s0.p7" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d40.s1" origId="20181935.s5" text="We further show that CCL8/MCP-2 is a target for mir-146a in HIV-1 infected microglia, as overexpression of mir-146a prevented HIV-induced secretion of MCP-2 chemokine. ">
            <entity charOffset="48-55" id="miRNA-corp.d40.s1.e0" text="mir-146a" type="Specific_miRNAs"/>
            <entity charOffset="107-114" id="miRNA-corp.d40.s1.e1" text="mir-146a" type="Specific_miRNAs"/>
            <entity charOffset="21-24" id="miRNA-corp.d40.s1.e2" text="CCL8" type="Genes/Proteins"/>
            <entity charOffset="26-30" id="miRNA-corp.d40.s1.e3" text="MCP-2" type="Genes/Proteins"/>
            <entity charOffset="37-42" id="miRNA-corp.d40.s1.e4" text="target" type="Relation_Trigger"/>
            <entity charOffset="89-102" id="miRNA-corp.d40.s1.e5" text="overexpression" type="Relation_Trigger"/>
            <entity charOffset="151-165" id="miRNA-corp.d40.s1.e6" text="MCP-2 chemokine" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d40.s1.e0" e2="miRNA-corp.d40.s1.e2" id="miRNA-corp.d40.s1.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d40.s1.e0" e2="miRNA-corp.d40.s1.e3" id="miRNA-corp.d40.s1.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d40.s1.e0" e2="miRNA-corp.d40.s1.e6" id="miRNA-corp.d40.s1.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d40.s1.e1" e2="miRNA-corp.d40.s1.e2" id="miRNA-corp.d40.s1.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d40.s1.e1" e2="miRNA-corp.d40.s1.e3" id="miRNA-corp.d40.s1.p4" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d40.s1.e1" e2="miRNA-corp.d40.s1.e6" id="miRNA-corp.d40.s1.p5" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d40.s2" origId="20181935.s4" text="In the present study, we have analyzed changes in the expression of mir-146a in primary human fetal microglial cells upon infection with HIV-1 and found increased expression of mir-146a. ">
            <entity charOffset="122-141" id="miRNA-corp.d40.s2.e0" text="infection with HIV-1" type="Diseases"/>
            <entity charOffset="68-75" id="miRNA-corp.d40.s2.e1" text="mir-146a" type="Specific_miRNAs"/>
            <entity charOffset="88-92" id="miRNA-corp.d40.s2.e2" text="human" type="Species"/>
            <entity charOffset="177-184" id="miRNA-corp.d40.s2.e3" text="mir-146a" type="Specific_miRNAs"/>
            <entity charOffset="39-63" id="miRNA-corp.d40.s2.e4" text="changes in the expression" type="Relation_Trigger"/>
            <entity charOffset="153-172" id="miRNA-corp.d40.s2.e5" text="increased expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d40.s2.e1" e2="miRNA-corp.d40.s2.e0" id="miRNA-corp.d40.s2.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d40.s2.e3" e2="miRNA-corp.d40.s2.e0" id="miRNA-corp.d40.s2.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d40.s3" origId="20181935.s1" text="MicroRNA-mediated regulation of gene expression appears to be involved in a variety of cellular processes, including development, differentiation, proliferation, and apoptosis. ">
            <entity charOffset="0-7" id="miRNA-corp.d40.s3.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="18-46" id="miRNA-corp.d40.s3.e1" text="regulation of gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d40.s4" origId="20181935.s0" text="CCL8/MCP-2 is a target for mir-146a in HIV-1-infected human microglial cells.  ">
            <entity charOffset="16-21" id="miRNA-corp.d40.s4.e0" text="target" type="Relation_Trigger"/>
            <entity charOffset="0-3" id="miRNA-corp.d40.s4.e1" text="CCL8" type="Genes/Proteins"/>
            <entity charOffset="5-9" id="miRNA-corp.d40.s4.e2" text="MCP-2" type="Genes/Proteins"/>
            <entity charOffset="27-34" id="miRNA-corp.d40.s4.e3" text="mir-146a" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d40.s4.e3" e2="miRNA-corp.d40.s4.e1" id="miRNA-corp.d40.s4.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d40.s4.e3" e2="miRNA-corp.d40.s4.e2" id="miRNA-corp.d40.s4.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d40.s5" origId="20181935.s3" text="Among the predicted gene targets for mir-146a, the chemokine CCL8/MCP-2 is a ligand for the CCR5 chemokine receptor and a potent inhibitor of CD4/CCR5-mediated HIV-1 entry and replication. ">
            <entity charOffset="129-137" id="miRNA-corp.d40.s5.e0" text="inhibitor" type="Relation_Trigger"/>
            <entity charOffset="37-44" id="miRNA-corp.d40.s5.e1" text="mir-146a" type="Specific_miRNAs"/>
            <entity charOffset="51-64" id="miRNA-corp.d40.s5.e2" text="chemokine CCL8" type="Genes/Proteins"/>
            <entity charOffset="66-70" id="miRNA-corp.d40.s5.e3" text="MCP-2" type="Genes/Proteins"/>
            <entity charOffset="10-31" id="miRNA-corp.d40.s5.e4" text="predicted gene targets" type="Relation_Trigger"/>
            <entity charOffset="92-114" id="miRNA-corp.d40.s5.e5" text="CCR5 chemokine receptor" type="Genes/Proteins"/>
            <entity charOffset="142-144" id="miRNA-corp.d40.s5.e6" text="CD4" type="Genes/Proteins"/>
            <entity charOffset="146-149" id="miRNA-corp.d40.s5.e7" text="CCR5" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d40.s5.e1" e2="miRNA-corp.d40.s5.e2" id="miRNA-corp.d40.s5.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d40.s5.e1" e2="miRNA-corp.d40.s5.e3" id="miRNA-corp.d40.s5.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d40.s5.e1" e2="miRNA-corp.d40.s5.e5" id="miRNA-corp.d40.s5.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d40.s5.e1" e2="miRNA-corp.d40.s5.e6" id="miRNA-corp.d40.s5.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d40.s5.e1" e2="miRNA-corp.d40.s5.e7" id="miRNA-corp.d40.s5.p4" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d40.s6" origId="20181935.s2" text="Mir-146a is thought to be involved in the regulation of the innate immune response, and its expression is increased in tissues associated with chronic inflammation. ">
            <entity charOffset="0-7" id="miRNA-corp.d40.s6.e0" text="Mir-146a" type="Specific_miRNAs"/>
            <entity charOffset="42-51" id="miRNA-corp.d40.s6.e1" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="92-114" id="miRNA-corp.d40.s6.e2" text="expression is increased" type="Relation_Trigger"/>
            <entity charOffset="127-136" id="miRNA-corp.d40.s6.e3" text="associated" type="Relation_Trigger"/>
            <entity charOffset="143-162" id="miRNA-corp.d40.s6.e4" text="chronic inflammation" type="Diseases"/>
            <pair e1="miRNA-corp.d40.s6.e0" e2="miRNA-corp.d40.s6.e4" id="miRNA-corp.d40.s6.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d41" origId="19775293">
        <sentence id="miRNA-corp.d41.s0" origId="19775293.s2" text="We explored the role of microRNAs (miRNAs) in glioma progression by investigating the expression profiles of 157 miRNAs in four patients with primary WHO grade II gliomas that spontaneously progressed to WHO grade IV secondary glioblastomas. ">
            <entity charOffset="24-32" id="miRNA-corp.d41.s0.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="35-40" id="miRNA-corp.d41.s0.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="46-51" id="miRNA-corp.d41.s0.e2" text="glioma" type="Diseases"/>
            <entity charOffset="113-118" id="miRNA-corp.d41.s0.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="128-135" id="miRNA-corp.d41.s0.e4" text="patients" type="Species"/>
            <entity charOffset="154-169" id="miRNA-corp.d41.s0.e5" text="grade II gliomas" type="Diseases"/>
            <entity charOffset="208-239" id="miRNA-corp.d41.s0.e6" text="grade IV secondary glioblastomas" type="Diseases"/>
            <pair e1="miRNA-corp.d41.s0.e0" e2="miRNA-corp.d41.s0.e5" id="miRNA-corp.d41.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d41.s0.e0" e2="miRNA-corp.d41.s0.e6" id="miRNA-corp.d41.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d41.s0.e0" e2="miRNA-corp.d41.s0.e2" id="miRNA-corp.d41.s0.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d41.s0.e1" e2="miRNA-corp.d41.s0.e5" id="miRNA-corp.d41.s0.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d41.s0.e1" e2="miRNA-corp.d41.s0.e6" id="miRNA-corp.d41.s0.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d41.s0.e1" e2="miRNA-corp.d41.s0.e2" id="miRNA-corp.d41.s0.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d41.s0.e3" e2="miRNA-corp.d41.s0.e5" id="miRNA-corp.d41.s0.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d41.s0.e3" e2="miRNA-corp.d41.s0.e6" id="miRNA-corp.d41.s0.p7" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d41.s0.e3" e2="miRNA-corp.d41.s0.e2" id="miRNA-corp.d41.s0.p8" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d41.s1" origId="19775293.s3" text="Thereby, we identified 12 miRNAs (miR-9, miR-15a, miR-16, miR-17, miR-19a, miR-20a, miR-21, miR-25, miR-28, miR-130b, miR-140 and miR-210) showing increased expression, and two miRNAs (miR-184 and miR-328) showing reduced expression upon progression. ">
            <entity charOffset="26-31" id="miRNA-corp.d41.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="34-38" id="miRNA-corp.d41.s1.e1" text="miR-9" type="Specific_miRNAs"/>
            <entity charOffset="41-47" id="miRNA-corp.d41.s1.e2" text="miR-15a" type="Specific_miRNAs"/>
            <entity charOffset="50-55" id="miRNA-corp.d41.s1.e3" text="miR-16" type="Specific_miRNAs"/>
            <entity charOffset="58-63" id="miRNA-corp.d41.s1.e4" text="miR-17" type="Specific_miRNAs"/>
            <entity charOffset="66-72" id="miRNA-corp.d41.s1.e5" text="miR-19a" type="Specific_miRNAs"/>
            <entity charOffset="75-81" id="miRNA-corp.d41.s1.e6" text="miR-20a" type="Specific_miRNAs"/>
            <entity charOffset="84-89" id="miRNA-corp.d41.s1.e7" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="92-97" id="miRNA-corp.d41.s1.e8" text="miR-25" type="Specific_miRNAs"/>
            <entity charOffset="100-105" id="miRNA-corp.d41.s1.e9" text="miR-28" type="Specific_miRNAs"/>
            <entity charOffset="108-115" id="miRNA-corp.d41.s1.e10" text="miR-130b" type="Specific_miRNAs"/>
            <entity charOffset="118-124" id="miRNA-corp.d41.s1.e11" text="miR-140" type="Specific_miRNAs"/>
            <entity charOffset="130-136" id="miRNA-corp.d41.s1.e12" text="miR-210" type="Specific_miRNAs"/>
            <entity charOffset="147-166" id="miRNA-corp.d41.s1.e13" text="increased expression" type="Relation_Trigger"/>
            <entity charOffset="177-182" id="miRNA-corp.d41.s1.e14" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="185-191" id="miRNA-corp.d41.s1.e15" text="miR-184" type="Specific_miRNAs"/>
            <entity charOffset="197-203" id="miRNA-corp.d41.s1.e16" text="miR-328" type="Specific_miRNAs"/>
            <entity charOffset="214-231" id="miRNA-corp.d41.s1.e17" text="reduced expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d41.s2" origId="19775293.s0" text="Identification and functional characterization of microRNAs involved in the malignant progression of gliomas.  ">
            <entity charOffset="50-58" id="miRNA-corp.d41.s2.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="101-107" id="miRNA-corp.d41.s2.e1" text="gliomas" type="Diseases"/>
            <pair e1="miRNA-corp.d41.s2.e0" e2="miRNA-corp.d41.s2.e1" id="miRNA-corp.d41.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d41.s3" origId="19775293.s1" text="Diffuse astrocytoma of World Health Organization (WHO) grade II has an inherent tendency to spontaneously progress to anaplastic astrocytoma WHO grade III or secondary glioblastoma WHO grade IV. ">
            <entity charOffset="168-179" id="miRNA-corp.d41.s3.e0" text="glioblastoma" type="Diseases"/>
            <entity charOffset="8-18" id="miRNA-corp.d41.s3.e1" text="astrocytoma" type="Diseases"/>
            <entity charOffset="129-139" id="miRNA-corp.d41.s3.e2" text="astrocytoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d41.s4" origId="19775293.s7" text="Taken together, our results support an important role of altered miRNA expression in gliomas, and suggest miR-17 and miR-184 as interesting candidates contributing to glioma progression.   ">
            <entity charOffset="65-69" id="miRNA-corp.d41.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="85-91" id="miRNA-corp.d41.s4.e1" text="gliomas" type="Diseases"/>
            <entity charOffset="106-111" id="miRNA-corp.d41.s4.e2" text="miR-17" type="Specific_miRNAs"/>
            <entity charOffset="117-123" id="miRNA-corp.d41.s4.e3" text="miR-184" type="Specific_miRNAs"/>
            <entity charOffset="167-172" id="miRNA-corp.d41.s4.e4" text="glioma" type="Diseases"/>
            <entity charOffset="57-80" id="miRNA-corp.d41.s4.e5" text="altered miRNA expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d41.s4.e0" e2="miRNA-corp.d41.s4.e1" id="miRNA-corp.d41.s4.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d41.s4.e0" e2="miRNA-corp.d41.s4.e4" id="miRNA-corp.d41.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d41.s4.e2" e2="miRNA-corp.d41.s4.e1" id="miRNA-corp.d41.s4.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d41.s4.e2" e2="miRNA-corp.d41.s4.e4" id="miRNA-corp.d41.s4.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d41.s4.e3" e2="miRNA-corp.d41.s4.e1" id="miRNA-corp.d41.s4.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d41.s4.e3" e2="miRNA-corp.d41.s4.e4" id="miRNA-corp.d41.s4.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d41.s5" origId="19775293.s6" text="Using mRNA and protein expression profiling, we identified distinct sets of transcripts and proteins that were differentially expressed after inhibition of miR-17 or overexpression of miR-184 in glioma cells. ">
            <entity charOffset="111-134" id="miRNA-corp.d41.s5.e0" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="156-161" id="miRNA-corp.d41.s5.e1" text="miR-17" type="Specific_miRNAs"/>
            <entity charOffset="166-179" id="miRNA-corp.d41.s5.e2" text="overexpression" type="Relation_Trigger"/>
            <entity charOffset="184-190" id="miRNA-corp.d41.s5.e3" text="miR-184" type="Specific_miRNAs"/>
            <entity charOffset="195-200" id="miRNA-corp.d41.s5.e4" text="glioma" type="Diseases"/>
            <entity charOffset="142-151" id="miRNA-corp.d41.s5.e5" text="inhibition" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d41.s5.e1" e2="miRNA-corp.d41.s5.e4" id="miRNA-corp.d41.s5.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d41.s5.e3" e2="miRNA-corp.d41.s5.e4" id="miRNA-corp.d41.s5.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d41.s6" origId="19775293.s5" text="These studies revealed miRNA-specific influences on the viability, proliferation, apoptosis and invasive growth properties of A172 and T98G glioma cells in vitro. ">
            <entity charOffset="23-27" id="miRNA-corp.d41.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="140-145" id="miRNA-corp.d41.s6.e1" text="glioma" type="Diseases"/>
            <pair e1="miRNA-corp.d41.s6.e0" e2="miRNA-corp.d41.s6.e1" id="miRNA-corp.d41.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d41.s7" origId="19775293.s4" text="Validation experiments on independent series of primary low-grade and secondary high-grade astrocytomas confirmed miR-17 and miR-184 as promising candidates, which were selected for functional analyses. ">
            <entity charOffset="114-119" id="miRNA-corp.d41.s7.e0" text="miR-17" type="Specific_miRNAs"/>
            <entity charOffset="125-131" id="miRNA-corp.d41.s7.e1" text="miR-184" type="Specific_miRNAs"/>
            <entity charOffset="70-102" id="miRNA-corp.d41.s7.e2" text="secondary high-grade astrocytomas" type="Diseases"/>
            <pair e1="miRNA-corp.d41.s7.e0" e2="miRNA-corp.d41.s7.e2" id="miRNA-corp.d41.s7.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d41.s7.e1" e2="miRNA-corp.d41.s7.e2" id="miRNA-corp.d41.s7.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d42" origId="20885358">
        <sentence id="miRNA-corp.d42.s0" origId="20885358.s3" text="MicroRNA-328 (miR-328) is underexpressed in many cancers including glioblastoma multiforme and contributes to tumor resistance to chemotherapy. ">
            <entity charOffset="0-11" id="miRNA-corp.d42.s0.e0" text="MicroRNA-328" type="Specific_miRNAs"/>
            <entity charOffset="14-20" id="miRNA-corp.d42.s0.e1" text="miR-328" type="Specific_miRNAs"/>
            <entity charOffset="26-39" id="miRNA-corp.d42.s0.e2" text="underexpressed" type="Relation_Trigger"/>
            <entity charOffset="49-55" id="miRNA-corp.d42.s0.e3" text="cancers" type="Diseases"/>
            <entity charOffset="67-89" id="miRNA-corp.d42.s0.e4" text="glioblastoma multiforme" type="Diseases"/>
            <entity charOffset="110-114" id="miRNA-corp.d42.s0.e5" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d42.s0.e0" e2="miRNA-corp.d42.s0.e3" id="miRNA-corp.d42.s0.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d42.s0.e0" e2="miRNA-corp.d42.s0.e4" id="miRNA-corp.d42.s0.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d42.s0.e0" e2="miRNA-corp.d42.s0.e5" id="miRNA-corp.d42.s0.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d42.s0.e1" e2="miRNA-corp.d42.s0.e3" id="miRNA-corp.d42.s0.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d42.s0.e1" e2="miRNA-corp.d42.s0.e4" id="miRNA-corp.d42.s0.p4" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d42.s0.e1" e2="miRNA-corp.d42.s0.e5" id="miRNA-corp.d42.s0.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d42.s1" origId="20885358.s2" text="MicroRNAs control a wide array of biological processes (e.g., cell differentiation, proliferation and apoptosis) whose dysregulation is a hallmark of cancer. ">
            <entity charOffset="0-8" id="miRNA-corp.d42.s1.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="150-155" id="miRNA-corp.d42.s1.e1" text="cancer" type="Diseases"/>
            <entity charOffset="119-131" id="miRNA-corp.d42.s1.e2" text="dysregulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d42.s1.e0" e2="miRNA-corp.d42.s1.e1" id="miRNA-corp.d42.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d42.s2" origId="20885358.s1" text="ABCG2, which encodes an ATP-binding cassette transporter protein, is associated with the phenotype of cancer stem cells and is used to define the pluripotential side population cells by flow cytometry and slide-cytometry. ">
            <entity charOffset="0-4" id="miRNA-corp.d42.s2.e0" text="ABCG2" type="Genes/Proteins"/>
            <entity charOffset="69-78" id="miRNA-corp.d42.s2.e1" text="associated" type="Relation_Trigger"/>
            <entity charOffset="102-107" id="miRNA-corp.d42.s2.e2" text="cancer" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d42.s3" origId="20885358.s0" text="Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance.  ">
            <entity charOffset="18-22" id="miRNA-corp.d42.s3.e0" text="ABCG2" type="Genes/Proteins"/>
            <entity charOffset="0-33" id="miRNA-corp.d42.s3.e1" text="Downregulation of ABCG2 expression" type="Relation_Trigger"/>
            <entity charOffset="38-56" id="miRNA-corp.d42.s3.e2" text="glioblastoma cancer" type="Diseases"/>
            <entity charOffset="74-82" id="miRNA-corp.d42.s3.e3" text="miRNA-328" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d42.s3.e3" e2="miRNA-corp.d42.s3.e0" id="miRNA-corp.d42.s3.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d42.s3.e3" e2="miRNA-corp.d42.s3.e2" id="miRNA-corp.d42.s3.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d42.s4" origId="20885358.s6" text="Thus, we hypothesize that modulating ABCG2 expression by targeting miRNA-328 in glioblastoma cancer stem cells could represent a promising strategy for therapeutic manipulation to increase the efficacy of chemotherapeutic agents for glioblastoma, a highly lethal type of cancer.   ">
            <entity charOffset="26-52" id="miRNA-corp.d42.s4.e0" text="modulating ABCG2 expression" type="Relation_Trigger"/>
            <entity charOffset="37-41" id="miRNA-corp.d42.s4.e1" text="ABCG2" type="Genes/Proteins"/>
            <entity charOffset="57-65" id="miRNA-corp.d42.s4.e2" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="67-75" id="miRNA-corp.d42.s4.e3" text="miRNA-328" type="Specific_miRNAs"/>
            <entity charOffset="80-98" id="miRNA-corp.d42.s4.e4" text="glioblastoma cancer" type="Diseases"/>
            <entity charOffset="233-244" id="miRNA-corp.d42.s4.e5" text="glioblastoma" type="Diseases"/>
            <entity charOffset="271-276" id="miRNA-corp.d42.s4.e6" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d42.s4.e3" e2="miRNA-corp.d42.s4.e1" id="miRNA-corp.d42.s4.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d42.s4.e3" e2="miRNA-corp.d42.s4.e4" id="miRNA-corp.d42.s4.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d42.s4.e3" e2="miRNA-corp.d42.s4.e5" id="miRNA-corp.d42.s4.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d42.s4.e3" e2="miRNA-corp.d42.s4.e6" id="miRNA-corp.d42.s4.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d42.s5" origId="20885358.s4" text="ABCG2 is associated with multi-drug resistance and is also highly expressed in glioblastoma. ">
            <entity charOffset="0-4" id="miRNA-corp.d42.s5.e0" text="ABCG2" type="Genes/Proteins"/>
            <entity charOffset="9-18" id="miRNA-corp.d42.s5.e1" text="associated" type="Relation_Trigger"/>
            <entity charOffset="59-74" id="miRNA-corp.d42.s5.e2" text="highly expressed" type="Relation_Trigger"/>
            <entity charOffset="79-90" id="miRNA-corp.d42.s5.e3" text="glioblastoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d42.s6" origId="20885358.s5" text="Some preliminary studies have shown that ABCG2 is the target gene for miRNA-328. ">
            <entity charOffset="41-45" id="miRNA-corp.d42.s6.e0" text="ABCG2" type="Genes/Proteins"/>
            <entity charOffset="70-78" id="miRNA-corp.d42.s6.e1" text="miRNA-328" type="Specific_miRNAs"/>
            <entity charOffset="54-64" id="miRNA-corp.d42.s6.e2" text="target gene" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d42.s6.e1" e2="miRNA-corp.d42.s6.e0" id="miRNA-corp.d42.s6.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d43" origId="21421997">
        <sentence id="miRNA-corp.d43.s0" origId="21421997.s10" text="This is the first study suggesting that plasma miRs might be used as biomarkers for HD.   ">
            <entity charOffset="47-50" id="miRNA-corp.d43.s0.e0" text="miRs" type="Non-Specific_miRNAs"/>
            <entity charOffset="84-85" id="miRNA-corp.d43.s0.e1" text="HD" type="Diseases"/>
            <pair e1="miRNA-corp.d43.s0.e0" e2="miRNA-corp.d43.s0.e1" id="miRNA-corp.d43.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d43.s1" origId="21421997.s1" text="Huntington's disease (HD) is a devastating, neurodegenerative condition, which lacks effective treatment. ">
            <entity charOffset="0-19" id="miRNA-corp.d43.s1.e0" text="Huntington's disease" type="Diseases"/>
            <entity charOffset="22-23" id="miRNA-corp.d43.s1.e1" text="HD" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d43.s2" origId="21421997.s0" text="Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease.  ">
            <entity charOffset="0-10" id="miRNA-corp.d43.s2.e0" text="Hsa-miR-34b" type="Specific_miRNAs"/>
            <entity charOffset="31-38" id="miRNA-corp.d43.s2.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="73-92" id="miRNA-corp.d43.s2.e2" text="Huntington's disease" type="Diseases"/>
            <pair e1="miRNA-corp.d43.s2.e0" e2="miRNA-corp.d43.s2.e2" id="miRNA-corp.d43.s2.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d43.s2.e1" e2="miRNA-corp.d43.s2.e2" id="miRNA-corp.d43.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d43.s3" origId="21421997.s3" text="Importantly, miRs are present in a bio-stable form in human peripheral blood plasma and have recently been shown to be useful biomarkers in other diseases. ">
            <entity charOffset="13-16" id="miRNA-corp.d43.s3.e0" text="miRs" type="Non-Specific_miRNAs"/>
            <entity charOffset="54-58" id="miRNA-corp.d43.s3.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d43.s4" origId="21421997.s2" text="Normal Huntingtin (HTT) and mutant Huntingtin (mHTT) are expressed in multiple tissues and can alter transcription of microRNAs (miRs). ">
            <entity charOffset="7-16" id="miRNA-corp.d43.s4.e0" text="Huntingtin" type="Genes/Proteins"/>
            <entity charOffset="19-21" id="miRNA-corp.d43.s4.e1" text="HTT" type="Genes/Proteins"/>
            <entity charOffset="118-126" id="miRNA-corp.d43.s4.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="129-132" id="miRNA-corp.d43.s4.e3" text="miRs" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d43.s4.e2" e2="miRNA-corp.d43.s4.e0" id="miRNA-corp.d43.s4.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d43.s4.e2" e2="miRNA-corp.d43.s4.e1" id="miRNA-corp.d43.s4.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d43.s4.e3" e2="miRNA-corp.d43.s4.e0" id="miRNA-corp.d43.s4.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d43.s4.e3" e2="miRNA-corp.d43.s4.e1" id="miRNA-corp.d43.s4.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d43.s5" origId="21421997.s5" text="In a cell line over-expressing mHTT-Exon-1, miR microarray analysis was used to identify candidate miRs. ">
            <entity charOffset="15-29" id="miRNA-corp.d43.s5.e0" text="over-expressing" type="Relation_Trigger"/>
            <entity charOffset="44-46" id="miRNA-corp.d43.s5.e1" text="miR" type="Non-Specific_miRNAs"/>
            <entity charOffset="99-102" id="miRNA-corp.d43.s5.e2" text="miRs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d43.s6" origId="21421997.s4" text="We therefore sought to identify potential miR biomarkers of HD that are present in, and have functional consequences for, neuronal and non-neuronal tissues. ">
            <entity charOffset="42-44" id="miRNA-corp.d43.s6.e0" text="miR" type="Non-Specific_miRNAs"/>
            <entity charOffset="60-61" id="miRNA-corp.d43.s6.e1" text="HD" type="Diseases"/>
            <pair e1="miRNA-corp.d43.s6.e0" e2="miRNA-corp.d43.s6.e1" id="miRNA-corp.d43.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d43.s7" origId="21421997.s7" text="We found that miR-34b is significantly elevated in response to mHTT-Exon-1, and its blockade alters the toxicity of mHTT-Exon-1 in vitro. ">
            <entity charOffset="25-46" id="miRNA-corp.d43.s7.e0" text="significantly elevated" type="Relation_Trigger"/>
            <entity charOffset="14-20" id="miRNA-corp.d43.s7.e1" text="miR-34b" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d43.s8" origId="21421997.s6" text="We then examined their presence and bio-stability in control and HD plasma. ">
            <entity charOffset="65-66" id="miRNA-corp.d43.s8.e0" text="HD" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d43.s9" origId="21421997.s8" text="We also show that miR-34b is detectable in plasma from small input volumes and is insensitive to freeze-thaw-induced RNA degradation. ">
            <entity charOffset="18-24" id="miRNA-corp.d43.s9.e0" text="miR-34b" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d43.s10" origId="21421997.s9" text="Interestingly, miR-34b is significantly elevated in plasma from HD gene carriers prior to symptom onset. ">
            <entity charOffset="15-21" id="miRNA-corp.d43.s10.e0" text="miR-34b" type="Specific_miRNAs"/>
            <entity charOffset="26-47" id="miRNA-corp.d43.s10.e1" text="significantly elevated" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d44" origId="21075073">
        <sentence id="miRNA-corp.d44.s0" origId="21075073.s10" text="Additionally, gene ontology analyses of the target genes suggested a distinct role for each miRNA. ">
            <entity charOffset="44-49" id="miRNA-corp.d44.s0.e0" text="target" type="Relation_Trigger"/>
            <entity charOffset="92-96" id="miRNA-corp.d44.s0.e1" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s1" origId="21075073.s11" text="Our results show that NPC fibroblasts have an altered miRNA expression profile and certain miRNAs have importance in disease pathogenesis as well as the therapeutic capacity to correct lipid related pathophysiologies in the NPC cells.   ">
            <entity charOffset="22-24" id="miRNA-corp.d44.s1.e0" text="NPC" type="Diseases"/>
            <entity charOffset="54-58" id="miRNA-corp.d44.s1.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="46-69" id="miRNA-corp.d44.s1.e2" text="altered miRNA expression" type="Relation_Trigger"/>
            <entity charOffset="91-96" id="miRNA-corp.d44.s1.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="224-226" id="miRNA-corp.d44.s1.e4" text="NPC" type="Diseases"/>
            <pair e1="miRNA-corp.d44.s1.e1" e2="miRNA-corp.d44.s1.e0" id="miRNA-corp.d44.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d44.s1.e1" e2="miRNA-corp.d44.s1.e4" id="miRNA-corp.d44.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d44.s1.e3" e2="miRNA-corp.d44.s1.e0" id="miRNA-corp.d44.s1.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d44.s1.e3" e2="miRNA-corp.d44.s1.e4" id="miRNA-corp.d44.s1.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s2" origId="21075073.s6" text="Expression differences between the healthy and NPC cells were detected according to the relative quantification values. ">
            <entity charOffset="47-49" id="miRNA-corp.d44.s2.e0" text="NPC" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s3" origId="21075073.s7" text="Target genes were predicted by using three different algorithms and classified regarding NPC related biological processes and cellular components. ">
            <entity charOffset="0-26" id="miRNA-corp.d44.s3.e0" text="Target genes were predicted" type="Relation_Trigger"/>
            <entity charOffset="89-91" id="miRNA-corp.d44.s3.e1" text="NPC" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s4" origId="21075073.s8" text="We found that three miRNAs, miR-196a, miR-196b and miR-296 were up-regulated (&gt;3.5-fold increase, p&lt;0.05) whereas 38 miRNAs were significantly down-regulated in NPC cells (&gt;3.5-fold decrease, p&lt;0.05). ">
            <entity charOffset="28-35" id="miRNA-corp.d44.s4.e0" text="miR-196a" type="Specific_miRNAs"/>
            <entity charOffset="38-45" id="miRNA-corp.d44.s4.e1" text="miR-196b" type="Specific_miRNAs"/>
            <entity charOffset="51-57" id="miRNA-corp.d44.s4.e2" text="miR-296" type="Specific_miRNAs"/>
            <entity charOffset="20-25" id="miRNA-corp.d44.s4.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="64-75" id="miRNA-corp.d44.s4.e4" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="117-122" id="miRNA-corp.d44.s4.e5" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="143-156" id="miRNA-corp.d44.s4.e6" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="161-163" id="miRNA-corp.d44.s4.e7" text="NPC" type="Diseases"/>
            <pair e1="miRNA-corp.d44.s4.e0" e2="miRNA-corp.d44.s4.e7" id="miRNA-corp.d44.s4.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d44.s4.e1" e2="miRNA-corp.d44.s4.e7" id="miRNA-corp.d44.s4.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d44.s4.e2" e2="miRNA-corp.d44.s4.e7" id="miRNA-corp.d44.s4.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d44.s4.e3" e2="miRNA-corp.d44.s4.e7" id="miRNA-corp.d44.s4.p3" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d44.s4.e5" e2="miRNA-corp.d44.s4.e7" id="miRNA-corp.d44.s4.p4" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s5" origId="21075073.s9" text="Among these non-coding RNAs, miR-98 was the most down-regulated (-33.3-fold) miRNA and miR-143, the lipid biosynthesis associated miRNA, had a 20-fold decreased expression in the NPC cells. ">
            <entity charOffset="29-34" id="miRNA-corp.d44.s5.e0" text="miR-98" type="Specific_miRNAs"/>
            <entity charOffset="49-62" id="miRNA-corp.d44.s5.e1" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="77-81" id="miRNA-corp.d44.s5.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="87-93" id="miRNA-corp.d44.s5.e3" text="miR-143" type="Specific_miRNAs"/>
            <entity charOffset="119-128" id="miRNA-corp.d44.s5.e4" text="associated" type="Relation_Trigger"/>
            <entity charOffset="130-134" id="miRNA-corp.d44.s5.e5" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="179-181" id="miRNA-corp.d44.s5.e6" text="NPC" type="Diseases"/>
            <entity charOffset="151-170" id="miRNA-corp.d44.s5.e7" text="decreased expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d44.s5.e0" e2="miRNA-corp.d44.s5.e6" id="miRNA-corp.d44.s5.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d44.s5.e2" e2="miRNA-corp.d44.s5.e6" id="miRNA-corp.d44.s5.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d44.s5.e3" e2="miRNA-corp.d44.s5.e6" id="miRNA-corp.d44.s5.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d44.s5.e5" e2="miRNA-corp.d44.s5.e6" id="miRNA-corp.d44.s5.p3" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s6" origId="21075073.s2" text="Dysregulation of miRNA expression may lead to severe pathophysiologies in human cells. ">
            <entity charOffset="0-12" id="miRNA-corp.d44.s6.e0" text="Dysregulation" type="Relation_Trigger"/>
            <entity charOffset="17-21" id="miRNA-corp.d44.s6.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="74-78" id="miRNA-corp.d44.s6.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s7" origId="21075073.s3" text="Niemann-Pick type C (NPC) disease is a complex lipid storage disease characterized by late endosomal-lysosomal accumulation of multiple lipid molecules. ">
            <entity charOffset="0-32" id="miRNA-corp.d44.s7.e0" text="Niemann-Pick type C (NPC) disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s8" origId="21075073.s4" text="Our aim was to characterize the miRNA profile in NPC fibroblasts as they may play an active role in the NPC disease associated changes in the cellular physiology. ">
            <entity charOffset="32-36" id="miRNA-corp.d44.s8.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="49-51" id="miRNA-corp.d44.s8.e1" text="NPC" type="Diseases"/>
            <entity charOffset="116-125" id="miRNA-corp.d44.s8.e2" text="associated" type="Relation_Trigger"/>
            <entity charOffset="104-114" id="miRNA-corp.d44.s8.e3" text="NPC disease" type="Diseases"/>
            <pair e1="miRNA-corp.d44.s8.e0" e2="miRNA-corp.d44.s8.e1" id="miRNA-corp.d44.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d44.s8.e0" e2="miRNA-corp.d44.s8.e3" id="miRNA-corp.d44.s8.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s9" origId="21075073.s5" text="To investigate the miRNA expression, total RNAs were isolated from cultured human NPC fibroblasts and healthy fibroblasts and then, TaqMan Low-Density Array system containing 365 mature human miRNAs was used. ">
            <entity charOffset="19-23" id="miRNA-corp.d44.s9.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="82-84" id="miRNA-corp.d44.s9.e1" text="NPC" type="Diseases"/>
            <entity charOffset="76-80" id="miRNA-corp.d44.s9.e2" text="human" type="Species"/>
            <entity charOffset="192-197" id="miRNA-corp.d44.s9.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="186-190" id="miRNA-corp.d44.s9.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d44.s9.e0" e2="miRNA-corp.d44.s9.e1" id="miRNA-corp.d44.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d44.s9.e3" e2="miRNA-corp.d44.s9.e1" id="miRNA-corp.d44.s9.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s10" origId="21075073.s1" text="MicroRNAs (miRNAs) are non-coding RNAs that regulate gene expression at post-transcriptional level. ">
            <entity charOffset="0-8" id="miRNA-corp.d44.s10.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d44.s10.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="44-67" id="miRNA-corp.d44.s10.e2" text="regulate gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s11" origId="21075073.s0" text="Niemann-Pick type C fibroblasts have a distinct microRNA profile related to lipid metabolism and certain cellular components.  ">
            <entity charOffset="48-55" id="miRNA-corp.d44.s11.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="0-18" id="miRNA-corp.d44.s11.e1" text="Niemann-Pick type C" type="Diseases"/>
            <pair e1="miRNA-corp.d44.s11.e0" e2="miRNA-corp.d44.s11.e1" id="miRNA-corp.d44.s11.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d45" origId="19962671">
        <sentence id="miRNA-corp.d45.s0" origId="19962671.s0" text="Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors.  ">
            <entity charOffset="9-21" id="miRNA-corp.d45.s0.e0" text="amplification" type="Relation_Trigger"/>
			<entity charOffset="40-47" id="miRNA-corp.d45.s0.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="85-112" id="miRNA-corp.d45.s0.e1" text="neuroectodermal brain tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d45.s0.e0" e2="miRNA-corp.d45.s0.e1" id="miRNA-corp.d45.s0.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d45.s1" origId="19962671.s2" text="microRNA (miRNA) cluster (C19MC) in 11/45 ( approximately 25%) primary CNS-PNET, which results in striking overexpression of miR-517c and 520g. ">
            <entity charOffset="63-78" id="miRNA-corp.d45.s1.e0" text="primary CNS-PNET" type="Diseases"/>
            <entity charOffset="0-7" id="miRNA-corp.d45.s1.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="10-14" id="miRNA-corp.d45.s1.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="107-120" id="miRNA-corp.d45.s1.e3" text="overexpression" type="Relation_Trigger"/>
            <entity charOffset="125-141" id="miRNA-corp.d45.s1.e4" text="miR-517c and 520g" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d45.s1.e4" e2="miRNA-corp.d45.s1.e0" id="miRNA-corp.d45.s1.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d45.s1.e1" e2="miRNA-corp.d45.s1.e0" id="miRNA-corp.d45.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d45.s1.e2" e2="miRNA-corp.d45.s1.e0" id="miRNA-corp.d45.s1.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d45.s2" origId="19962671.s1" text="We discovered a high-level amplicon involving the chr19q13.41 ">
            <entity charOffset="16-25" id="miRNA-corp.d45.s2.e0" text="high-level" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d45.s3" origId="19962671.s4" text="Remarkably, the C19MC amplicon, which is very rare in other brain tumors (1/263), identifies an aggressive subgroup of CNS-PNET with distinct gene-expression profiles, characteristic histology, and dismal survival. ">
            <entity charOffset="119-126" id="miRNA-corp.d45.s3.e0" text="CNS-PNET" type="Diseases"/>
            <entity charOffset="60-71" id="miRNA-corp.d45.s3.e1" text="brain tumors" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d45.s4" origId="19962671.s3" text="Constitutive expression of miR-517c or 520g promotes in vitro and in vivo oncogenicity, modulates cell survival, and robustly enhances growth of untransformed human neural stem cells (hNSCs) in part by upregulating WNT pathway signaling and restricting differentiation of hNSCs. ">
            <entity charOffset="27-34" id="miRNA-corp.d45.s4.e0" text="miR-517c" type="Specific_miRNAs"/>
            <entity charOffset="88-96" id="miRNA-corp.d45.s4.e1" text="modulates" type="Relation_Trigger"/>
            <entity charOffset="202-213" id="miRNA-corp.d45.s4.e2" text="upregulating" type="Relation_Trigger"/>
            <entity charOffset="159-163" id="miRNA-corp.d45.s4.e3" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d45.s5" origId="19962671.s5" text="Our data implicate miR-517c and 520g as oncogenes and promising biological markers for CNS-PNET and provide important insights into oncogenic properties of the C19MC locus.   ">
            <entity charOffset="87-94" id="miRNA-corp.d45.s5.e0" text="CNS-PNET" type="Diseases"/>
            <entity charOffset="19-26" id="miRNA-corp.d45.s5.e1" text="miR-517c" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d45.s5.e1" e2="miRNA-corp.d45.s5.e0" id="miRNA-corp.d45.s5.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d46" origId="21385897">
        <sentence id="miRNA-corp.d46.s0" origId="21385897.s7" text="Our findings suggest that microRNAs are important determinants of glioblastoma subclasses through their ability to regulate developmental growth and differentiation programs in several transformed neural precursor cell types. ">
            <entity charOffset="26-34" id="miRNA-corp.d46.s0.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="66-77" id="miRNA-corp.d46.s0.e1" text="glioblastoma" type="Diseases"/>
            <entity charOffset="115-122" id="miRNA-corp.d46.s0.e2" text="regulate" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d46.s0.e0" e2="miRNA-corp.d46.s0.e1" id="miRNA-corp.d46.s0.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d46.s1" origId="21385897.s6" text="Foremost among these is miR-9, which suppresses mesenchymal differentiation in glioblastoma by downregulating expression of JAK kinases and inhibiting activation of STAT3. ">
            <entity charOffset="140-149" id="miRNA-corp.d46.s1.e0" text="inhibiting" type="Relation_Trigger"/>
            <entity charOffset="151-160" id="miRNA-corp.d46.s1.e1" text="activation" type="Relation_Trigger"/>
            <entity charOffset="24-28" id="miRNA-corp.d46.s1.e2" text="miR-9" type="Specific_miRNAs"/>
            <entity charOffset="37-46" id="miRNA-corp.d46.s1.e3" text="suppresses" type="Relation_Trigger"/>
            <entity charOffset="95-119" id="miRNA-corp.d46.s1.e4" text="downregulating expression" type="Relation_Trigger"/>
            <entity charOffset="79-90" id="miRNA-corp.d46.s1.e5" text="glioblastoma" type="Diseases"/>
            <entity charOffset="165-169" id="miRNA-corp.d46.s1.e6" text="STAT3" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d46.s1.e2" e2="miRNA-corp.d46.s1.e5" id="miRNA-corp.d46.s1.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d46.s1.e2" e2="miRNA-corp.d46.s1.e6" id="miRNA-corp.d46.s1.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d46.s2" origId="21385897.s8" text="Taken together, our results define developmental microRNA expression signatures that both characterize and contribute to the phenotypic diversity of glioblastoma subclasses, thereby providing an expanded framework for understanding the pathogenesis of glioblastoma in a human neurodevelopmental context.   ">
            <entity charOffset="49-56" id="miRNA-corp.d46.s2.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="149-160" id="miRNA-corp.d46.s2.e1" text="glioblastoma" type="Diseases"/>
            <entity charOffset="252-263" id="miRNA-corp.d46.s2.e2" text="glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d46.s2.e0" e2="miRNA-corp.d46.s2.e1" id="miRNA-corp.d46.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d46.s2.e0" e2="miRNA-corp.d46.s2.e2" id="miRNA-corp.d46.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d46.s3" origId="21385897.s3" text="These microRNA-based glioblastoma subclasses displayed microRNA and mRNA expression signatures resembling those of radial glia, oligoneuronal precursors, neuronal precursors, neuroepithelial/neural crest precursors, or astrocyte precursors. ">
            <entity charOffset="6-13" id="miRNA-corp.d46.s3.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="21-32" id="miRNA-corp.d46.s3.e1" text="glioblastoma" type="Diseases"/>
            <entity charOffset="55-62" id="miRNA-corp.d46.s3.e2" text="microRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d46.s3.e2" e2="miRNA-corp.d46.s3.e1" id="miRNA-corp.d46.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d46.s3.e0" e2="miRNA-corp.d46.s3.e1" id="miRNA-corp.d46.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d46.s4" origId="21385897.s2" text="In this study, we analyzed 261 microRNA expression profiles from The Cancer Genome Atlas (TCGA), identifying five clinically and genetically distinct subclasses of glioblastoma that each related to a different neural precursor cell type. ">
            <entity charOffset="31-38" id="miRNA-corp.d46.s4.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="164-175" id="miRNA-corp.d46.s4.e1" text="glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d46.s4.e0" e2="miRNA-corp.d46.s4.e1" id="miRNA-corp.d46.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d46.s5" origId="21385897.s5" text="We also identified several microRNAs as potent regulators of subclass-specific gene expression networks in glioblastoma. ">
            <entity charOffset="47-56" id="miRNA-corp.d46.s5.e0" text="regulators" type="Relation_Trigger"/>
            <entity charOffset="27-35" id="miRNA-corp.d46.s5.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="107-118" id="miRNA-corp.d46.s5.e2" text="glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d46.s5.e1" e2="miRNA-corp.d46.s5.e2" id="miRNA-corp.d46.s5.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d46.s6" origId="21385897.s4" text="Each subclass was determined to be genetically distinct, based on the significant differences they displayed in terms of patient race, age, treatment response, and survival. ">
            <entity charOffset="121-127" id="miRNA-corp.d46.s6.e0" text="patient" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d46.s7" origId="21385897.s1" text="mRNA expression profiling has suggested the existence of multiple glioblastoma subclasses, but their number and characteristics vary among studies and the etiology underlying their development is unclear. ">
            <entity charOffset="66-77" id="miRNA-corp.d46.s7.e0" text="glioblastoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d46.s8" origId="21385897.s0" text="A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs.  ">
            <entity charOffset="28-39" id="miRNA-corp.d46.s8.e0" text="glioblastoma" type="Diseases"/>
            <entity charOffset="67-75" id="miRNA-corp.d46.s8.e1" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d46.s8.e1" e2="miRNA-corp.d46.s8.e0" id="miRNA-corp.d46.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d47" origId="21171923">
        <sentence id="miRNA-corp.d47.s0" origId="21171923.s1" text="miRNAs are small, endogenously expressed noncoding RNAs that regulate gene expression, mainly at the post-transcriptional level, via degradation or translational inhibition of their target mRNAs. ">
            <entity charOffset="61-84" id="miRNA-corp.d47.s0.e0" text="regulate gene expression" type="Relation_Trigger"/>
            <entity charOffset="182-187" id="miRNA-corp.d47.s0.e1" text="target" type="Relation_Trigger"/>
            <entity charOffset="0-5" id="miRNA-corp.d47.s0.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="148-171" id="miRNA-corp.d47.s0.e3" text="translational inhibition" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d47.s1" origId="21171923.s2" text="Functionally, an individual miRNA can regulate the expression of multiple target genes. ">
            <entity charOffset="74-79" id="miRNA-corp.d47.s1.e0" text="target" type="Relation_Trigger"/>
            <entity charOffset="28-32" id="miRNA-corp.d47.s1.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="38-60" id="miRNA-corp.d47.s1.e2" text="regulate the expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d47.s2" origId="21171923.s0" text="miRNAs: roles and clinical applications in vascular disease.  ">
            <entity charOffset="0-5" id="miRNA-corp.d47.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="43-58" id="miRNA-corp.d47.s2.e1" text="vascular disease" type="Diseases"/>
            <pair e1="miRNA-corp.d47.s2.e0" e2="miRNA-corp.d47.s2.e1" id="miRNA-corp.d47.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d47.s3" origId="21171923.s3" text="The study of miRNAs is rapidly growing and recent studies have revealed a significant role of miRNAs in vascular biology and disease. ">
            <entity charOffset="13-18" id="miRNA-corp.d47.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="94-99" id="miRNA-corp.d47.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d47.s4" origId="21171923.s4" text="Many miRNAs are highly expressed in the vasculature, and their expression is dysregulated in diseased vessels. ">
            <entity charOffset="16-31" id="miRNA-corp.d47.s4.e0" text="highly expressed" type="Relation_Trigger"/>
            <entity charOffset="5-10" id="miRNA-corp.d47.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="77-88" id="miRNA-corp.d47.s4.e2" text="dysregulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d47.s5" origId="21171923.s5" text="Several miRNAs have been found to be critical modulators of vascular pathologies, such as atherosclerosis, lipoprotein metabolism, inflammation, arterial remodeling, angiogenesis, smooth muscle cell regeneration, hypertension, apoptosis, neointimal hyperplasia and signal transduction pathways. ">
            <entity charOffset="8-13" id="miRNA-corp.d47.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="46-55" id="miRNA-corp.d47.s5.e1" text="modulators" type="Relation_Trigger"/>
            <entity charOffset="60-79" id="miRNA-corp.d47.s5.e2" text="vascular pathologies" type="Diseases"/>
            <entity charOffset="90-104" id="miRNA-corp.d47.s5.e3" text="atherosclerosis" type="Diseases"/>
            <entity charOffset="131-142" id="miRNA-corp.d47.s5.e4" text="inflammation" type="Diseases"/>
            <entity charOffset="213-224" id="miRNA-corp.d47.s5.e5" text="hypertension" type="Diseases"/>
            <entity charOffset="238-259" id="miRNA-corp.d47.s5.e6" text="neointimal hyperplasia" type="Diseases"/>
            <pair e1="miRNA-corp.d47.s5.e0" e2="miRNA-corp.d47.s5.e2" id="miRNA-corp.d47.s5.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d47.s5.e0" e2="miRNA-corp.d47.s5.e3" id="miRNA-corp.d47.s5.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d47.s5.e0" e2="miRNA-corp.d47.s5.e4" id="miRNA-corp.d47.s5.p2" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d47.s5.e0" e2="miRNA-corp.d47.s5.e5" id="miRNA-corp.d47.s5.p3" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d47.s5.e0" e2="miRNA-corp.d47.s5.e6" id="miRNA-corp.d47.s5.p4" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d47.s6" origId="21171923.s6" text="Thus, miRNAs may serve as novel biomarkers and/or therapeutic targets for vascular disease. ">
            <entity charOffset="6-11" id="miRNA-corp.d47.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="50-68" id="miRNA-corp.d47.s6.e1" text="therapeutic targets" type="Relation_Trigger"/>
            <entity charOffset="74-89" id="miRNA-corp.d47.s6.e2" text="vascular disease" type="Diseases"/>
            <pair e1="miRNA-corp.d47.s6.e0" e2="miRNA-corp.d47.s6.e2" id="miRNA-corp.d47.s6.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d47.s7" origId="21171923.s7" text="This article summarizes the current studies related to the disease correlations and functional roles of miRNAs in the vascular system and discusses the potential applications of miRNAs in vascular disease.   ">
            <entity charOffset="67-78" id="miRNA-corp.d47.s7.e0" text="correlations" type="Relation_Trigger"/>
            <entity charOffset="104-109" id="miRNA-corp.d47.s7.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="178-183" id="miRNA-corp.d47.s7.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="188-203" id="miRNA-corp.d47.s7.e3" text="vascular disease" type="Diseases"/>
            <pair e1="miRNA-corp.d47.s7.e1" e2="miRNA-corp.d47.s7.e3" id="miRNA-corp.d47.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d47.s7.e2" e2="miRNA-corp.d47.s7.e3" id="miRNA-corp.d47.s7.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d48" origId="19424584">
        <sentence id="miRNA-corp.d48.s0" origId="19424584.s4" text="Co-suppression of miR-221/222 directly resulted in the up-regulation of p27Kip1 in the tested cells, consequently, affects their growth potential by reducing a G1 to S shift in the cell cycle. ">
            <entity charOffset="0-13" id="miRNA-corp.d48.s0.e0" text="Co-suppression" type="Relation_Trigger"/>
            <entity charOffset="18-28" id="miRNA-corp.d48.s0.e1" text="miR-221/222" type="Specific_miRNAs"/>
            <entity charOffset="55-67" id="miRNA-corp.d48.s0.e2" text="up-regulation" type="Relation_Trigger"/>
            <entity charOffset="72-78" id="miRNA-corp.d48.s0.e3" text="p27Kip1" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d48.s0.e1" e2="miRNA-corp.d48.s0.e3" id="miRNA-corp.d48.s0.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d48.s1" origId="19424584.s5" text="Consistently, miR-221/222 knocked-down through antisense 2'-OME-oligonucleotides increased p27Kip1 in U251 glioma subcutaneous mice and strongly reduced tumor growth in vivo through up regulation of p27Kip1. ">
            <entity charOffset="14-24" id="miRNA-corp.d48.s1.e0" text="miR-221/222" type="Specific_miRNAs"/>
            <entity charOffset="91-97" id="miRNA-corp.d48.s1.e1" text="p27Kip1" type="Genes/Proteins"/>
            <entity charOffset="107-112" id="miRNA-corp.d48.s1.e2" text="glioma" type="Diseases"/>
            <entity charOffset="127-130" id="miRNA-corp.d48.s1.e3" text="mice" type="Species"/>
            <entity charOffset="153-157" id="miRNA-corp.d48.s1.e4" text="tumor" type="Diseases"/>
            <entity charOffset="182-194" id="miRNA-corp.d48.s1.e5" text="up regulation" type="Relation_Trigger"/>
            <entity charOffset="199-205" id="miRNA-corp.d48.s1.e6" text="p27Kip1" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d48.s1.e0" e2="miRNA-corp.d48.s1.e1" id="miRNA-corp.d48.s1.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d48.s1.e0" e2="miRNA-corp.d48.s1.e2" id="miRNA-corp.d48.s1.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d48.s1.e0" e2="miRNA-corp.d48.s1.e4" id="miRNA-corp.d48.s1.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d48.s1.e0" e2="miRNA-corp.d48.s1.e6" id="miRNA-corp.d48.s1.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d48.s2" origId="19424584.s6" text="Our results suggest that miR-221/222 is a regulator of the tumor suppressor gene p27Kip1, and co-suppression of miR-221/222 expression in advanced gliomas may inhibit glioma cell proliferation by a mechanism involving the up-regulation of p27Kip1 in vitro and in vivo.   ">
            <entity charOffset="159-165" id="miRNA-corp.d48.s2.e0" text="inhibit" type="Relation_Trigger"/>
            <entity charOffset="25-35" id="miRNA-corp.d48.s2.e1" text="miR-221/222" type="Specific_miRNAs"/>
            <entity charOffset="42-50" id="miRNA-corp.d48.s2.e2" text="regulator" type="Relation_Trigger"/>
            <entity charOffset="59-74" id="miRNA-corp.d48.s2.e3" text="tumor suppressor" type="Relation_Trigger"/>
            <entity charOffset="81-87" id="miRNA-corp.d48.s2.e4" text="p27Kip1" type="Genes/Proteins"/>
            <entity charOffset="94-107" id="miRNA-corp.d48.s2.e5" text="co-suppression" type="Relation_Trigger"/>
            <entity charOffset="112-122" id="miRNA-corp.d48.s2.e6" text="miR-221/222" type="Specific_miRNAs"/>
            <entity charOffset="147-153" id="miRNA-corp.d48.s2.e7" text="gliomas" type="Diseases"/>
            <entity charOffset="167-172" id="miRNA-corp.d48.s2.e8" text="glioma" type="Diseases"/>
            <entity charOffset="222-234" id="miRNA-corp.d48.s2.e9" text="up-regulation" type="Relation_Trigger"/>
            <entity charOffset="239-245" id="miRNA-corp.d48.s2.e10" text="p27Kip1" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d48.s2.e1" e2="miRNA-corp.d48.s2.e4" id="miRNA-corp.d48.s2.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d48.s2.e1" e2="miRNA-corp.d48.s2.e7" id="miRNA-corp.d48.s2.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d48.s2.e1" e2="miRNA-corp.d48.s2.e8" id="miRNA-corp.d48.s2.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d48.s2.e1" e2="miRNA-corp.d48.s2.e10" id="miRNA-corp.d48.s2.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d48.s2.e6" e2="miRNA-corp.d48.s2.e4" id="miRNA-corp.d48.s2.p4" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d48.s2.e6" e2="miRNA-corp.d48.s2.e7" id="miRNA-corp.d48.s2.p5" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d48.s2.e6" e2="miRNA-corp.d48.s2.e8" id="miRNA-corp.d48.s2.p6" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d48.s2.e6" e2="miRNA-corp.d48.s2.e10" id="miRNA-corp.d48.s2.p7" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d48.s3" origId="19424584.s0" text="Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo.  ">
            <entity charOffset="18-28" id="miRNA-corp.d48.s3.e0" text="miR-221/222" type="Specific_miRNAs"/>
            <entity charOffset="0-13" id="miRNA-corp.d48.s3.e1" text="Co-suppression" type="Relation_Trigger"/>
            <entity charOffset="38-47" id="miRNA-corp.d48.s3.e2" text="suppresses" type="Relation_Trigger"/>
            <entity charOffset="49-53" id="miRNA-corp.d48.s3.e3" text="human" type="Species"/>
            <entity charOffset="49-60" id="miRNA-corp.d48.s3.e4" text="human glioma" type="Diseases"/>
            <entity charOffset="87-93" id="miRNA-corp.d48.s3.e5" text="p27kip1" type="Genes/Proteins"/>
            <entity charOffset="77-85" id="miRNA-corp.d48.s3.e6" text="targeting" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d48.s3.e0" e2="miRNA-corp.d48.s3.e4" id="miRNA-corp.d48.s3.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d48.s3.e0" e2="miRNA-corp.d48.s3.e5" id="miRNA-corp.d48.s3.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d48.s4" origId="19424584.s1" text="MicroRNAs are short regulatory RNAs that negatively modulate protein expression at a post-transcriptional level. ">
            <entity charOffset="0-8" id="miRNA-corp.d48.s4.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="41-78" id="miRNA-corp.d48.s4.e1" text="negatively modulate protein expression" type="Relation_Trigger"/>
            <entity charOffset="20-29" id="miRNA-corp.d48.s4.e2" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d48.s5" origId="19424584.s2" text="Emerging evidence suggests that altered regulation of miRNA may be involved in the pathogenesis of several types of cancers. ">
            <entity charOffset="32-49" id="miRNA-corp.d48.s5.e0" text="altered regulation" type="Relation_Trigger"/>
            <entity charOffset="54-58" id="miRNA-corp.d48.s5.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="116-122" id="miRNA-corp.d48.s5.e2" text="cancers" type="Diseases"/>
            <pair e1="miRNA-corp.d48.s5.e1" e2="miRNA-corp.d48.s5.e2" id="miRNA-corp.d48.s5.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d48.s6" origId="19424584.s3" text="In the current study, an inverse relationship between the expression of miR-221/miR-222 and the cell cycle inhibitor p27Kip1 was identified in U251 glioma cells. ">
            <entity charOffset="107-115" id="miRNA-corp.d48.s6.e0" text="inhibitor" type="Relation_Trigger"/>
            <entity charOffset="72-78" id="miRNA-corp.d48.s6.e1" text="miR-221" type="Specific_miRNAs"/>
            <entity charOffset="80-86" id="miRNA-corp.d48.s6.e2" text="miR-222" type="Specific_miRNAs"/>
            <entity charOffset="117-123" id="miRNA-corp.d48.s6.e3" text="p27Kip1" type="Genes/Proteins"/>
            <entity charOffset="148-153" id="miRNA-corp.d48.s6.e4" text="glioma" type="Diseases"/>
            <pair e1="miRNA-corp.d48.s6.e1" e2="miRNA-corp.d48.s6.e3" id="miRNA-corp.d48.s6.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d48.s6.e1" e2="miRNA-corp.d48.s6.e4" id="miRNA-corp.d48.s6.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d48.s6.e2" e2="miRNA-corp.d48.s6.e3" id="miRNA-corp.d48.s6.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d48.s6.e2" e2="miRNA-corp.d48.s6.e4" id="miRNA-corp.d48.s6.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d49" origId="19809402">
        <sentence id="miRNA-corp.d49.s0" origId="19809402.s4" text="The therapy employed, in a single baculoviral vector, a glial fibrillary acidic protein (GFAP) gene promoter and the repeated target sequences of three miRNAs that are enriched in astrocytes but downregulated in glioblastoma cells to control the expression of the herpes simplex virus thymidine kinase (HSVtk) gene. ">
            <entity charOffset="56-86" id="miRNA-corp.d49.s0.e0" text="glial fibrillary acidic protein" type="Genes/Proteins"/>
            <entity charOffset="89-92" id="miRNA-corp.d49.s0.e1" text="GFAP" type="Genes/Proteins"/>
            <entity charOffset="126-131" id="miRNA-corp.d49.s0.e2" text="target" type="Relation_Trigger"/>
            <entity charOffset="152-157" id="miRNA-corp.d49.s0.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="195-207" id="miRNA-corp.d49.s0.e4" text="downregulated" type="Relation_Trigger"/>
            <entity charOffset="212-223" id="miRNA-corp.d49.s0.e5" text="glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d49.s0.e3" e2="miRNA-corp.d49.s0.e0" id="miRNA-corp.d49.s0.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d49.s0.e3" e2="miRNA-corp.d49.s0.e1" id="miRNA-corp.d49.s0.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d49.s0.e3" e2="miRNA-corp.d49.s0.e5" id="miRNA-corp.d49.s0.p2" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d49.s1" origId="19809402.s5" text="This resulted in significantly improved in vivo selectivity over the use of a control vector without miRNA regulation, enabling effective elimination of human glioma xenografts while producing negligible toxic effects on normal astrocytes. ">
            <entity charOffset="101-105" id="miRNA-corp.d49.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="107-116" id="miRNA-corp.d49.s1.e1" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="153-164" id="miRNA-corp.d49.s1.e2" text="human glioma" type="Diseases"/>
            <entity charOffset="153-157" id="miRNA-corp.d49.s1.e3" text="human" type="Species"/>
            <pair e1="miRNA-corp.d49.s1.e0" e2="miRNA-corp.d49.s1.e2" id="miRNA-corp.d49.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d49.s2" origId="19809402.s2" text="In the context of cancer suicide gene therapy, this approach may lead to cytotoxic effects in both cancer and nontarget normal cells. ">
            <entity charOffset="18-23" id="miRNA-corp.d49.s2.e0" text="cancer" type="Diseases"/>
            <entity charOffset="99-104" id="miRNA-corp.d49.s2.e1" text="cancer" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d49.s3" origId="19809402.s3" text="Considering microRNA (miRNA) function in post-transcriptional regulation of gene expression, we have developed a viral vector platform combining cellular promoter-based transcriptional targeting with miRNA regulation for a glioma suicide gene therapy in the mouse brain. ">
            <entity charOffset="62-90" id="miRNA-corp.d49.s3.e0" text="regulation of gene expression" type="Relation_Trigger"/>
            <entity charOffset="12-19" id="miRNA-corp.d49.s3.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="22-26" id="miRNA-corp.d49.s3.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="185-193" id="miRNA-corp.d49.s3.e3" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="200-204" id="miRNA-corp.d49.s3.e4" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="206-215" id="miRNA-corp.d49.s3.e5" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="223-228" id="miRNA-corp.d49.s3.e6" text="glioma" type="Diseases"/>
            <entity charOffset="258-262" id="miRNA-corp.d49.s3.e7" text="mouse" type="Species"/>
            <pair e1="miRNA-corp.d49.s3.e4" e2="miRNA-corp.d49.s3.e6" id="miRNA-corp.d49.s3.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d49.s3.e1" e2="miRNA-corp.d49.s3.e6" id="miRNA-corp.d49.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d49.s3.e2" e2="miRNA-corp.d49.s3.e6" id="miRNA-corp.d49.s3.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d49.s4" origId="19809402.s6" text="Thus, incorporating miRNA regulation into a transcriptional targeting vector adds an extra layer of security to prevent off-target transgene expression and should be useful for the development of gene delivery vectors with high targeting specificity for cancer therapy.   ">
            <entity charOffset="20-24" id="miRNA-corp.d49.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="26-35" id="miRNA-corp.d49.s4.e1" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="60-68" id="miRNA-corp.d49.s4.e2" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="228-236" id="miRNA-corp.d49.s4.e3" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="254-259" id="miRNA-corp.d49.s4.e4" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d49.s4.e0" e2="miRNA-corp.d49.s4.e4" id="miRNA-corp.d49.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d49.s5" origId="19809402.s1" text="Transcriptional targeting using a tissue-specific cellular promoter is proving to be a powerful means for restricting transgene expression in targeted tissues. ">
            <entity charOffset="16-24" id="miRNA-corp.d49.s5.e0" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="142-149" id="miRNA-corp.d49.s5.e1" text="targeted" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d49.s6" origId="19809402.s0" text="Combinatorial control of suicide gene expression by tissue-specific promoter and microRNA regulation for cancer therapy.  ">
            <entity charOffset="81-88" id="miRNA-corp.d49.s6.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="90-99" id="miRNA-corp.d49.s6.e1" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="105-110" id="miRNA-corp.d49.s6.e2" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d49.s6.e0" e2="miRNA-corp.d49.s6.e2" id="miRNA-corp.d49.s6.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d50" origId="20344871">
        <sentence id="miRNA-corp.d50.s0" origId="20344871.s0" text="[AD-FTLD spectrum--new findings on risk genes in neurodegenerative diseases].     ">
            <entity charOffset="49-74" id="miRNA-corp.d50.s0.e0" text="neurodegenerative diseases" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d51" origId="20113523">
        <sentence id="miRNA-corp.d51.s0" origId="20113523.s11" text="Interestingly, the above data suggested that in both the PTEN mutant and the wild-type GBM cells, miR-21 blockage increased the chemosensitivity to taxol. ">
            <entity charOffset="87-89" id="miRNA-corp.d51.s0.e0" text="GBM" type="Diseases"/>
            <entity charOffset="98-103" id="miRNA-corp.d51.s0.e1" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="105-112" id="miRNA-corp.d51.s0.e2" text="blockage" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d51.s0.e1" e2="miRNA-corp.d51.s0.e0" id="miRNA-corp.d51.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s1" origId="20113523.s12" text="It is worth noting that the miR-21 inhibitor additively interacted with taxol on U251cells and synergistically on LN229 cells. "/>
        <sentence id="miRNA-corp.d51.s2" origId="20113523.s10" text="Furthermore, the miR-21 inhibitor significantly enhanced apoptosis in both U251 cells and LN229 cells, and cell invasiveness was obviously weakened. ">
            <entity charOffset="24-32" id="miRNA-corp.d51.s2.e0" text="inhibitor" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s3" origId="20113523.s15" text="The data strongly suggested that a regulatory loop between miR-21 and STAT3 might provide an insight into the mechanism of modulating EGFR/STAT3 signaling. ">
            <entity charOffset="35-44" id="miRNA-corp.d51.s3.e0" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="59-64" id="miRNA-corp.d51.s3.e1" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="70-74" id="miRNA-corp.d51.s3.e2" text="STAT3" type="Genes/Proteins"/>
            <entity charOffset="134-137" id="miRNA-corp.d51.s3.e3" text="EGFR" type="Genes/Proteins"/>
            <entity charOffset="139-143" id="miRNA-corp.d51.s3.e4" text="STAT3" type="Genes/Proteins"/>
            <entity charOffset="123-132" id="miRNA-corp.d51.s3.e5" text="modulating" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d51.s3.e1" e2="miRNA-corp.d51.s3.e2" id="miRNA-corp.d51.s3.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d51.s3.e1" e2="miRNA-corp.d51.s3.e3" id="miRNA-corp.d51.s3.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d51.s3.e1" e2="miRNA-corp.d51.s3.e4" id="miRNA-corp.d51.s3.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s4" origId="20113523.s16" text="CONCLUSIONS: Taken together, the miR-21 inhibitor could enhance the chemo-sensitivity of human glioblastoma cells to taxol. ">
            <entity charOffset="89-93" id="miRNA-corp.d51.s4.e0" text="human" type="Species"/>
            <entity charOffset="89-106" id="miRNA-corp.d51.s4.e1" text="human glioblastoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s5" origId="20113523.s13" text="Thus, the miR-21 inhibitor might interrupt the activity of EGFR pathways, independently of PTEN status. ">
            <entity charOffset="59-62" id="miRNA-corp.d51.s5.e0" text="EGFR" type="Genes/Proteins"/>
            <entity charOffset="91-94" id="miRNA-corp.d51.s5.e1" text="PTEN" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s6" origId="20113523.s14" text="Meanwhile, the expression of STAT3 and p-STAT3 decreased to relatively low levels after miR-21 inhibitor and taxol treatment. ">
            <entity charOffset="29-33" id="miRNA-corp.d51.s6.e0" text="STAT3" type="Genes/Proteins"/>
            <entity charOffset="39-45" id="miRNA-corp.d51.s6.e1" text="p-STAT3" type="Genes/Proteins"/>
            <entity charOffset="15-55" id="miRNA-corp.d51.s6.e2" text="expression of STAT3 and p-STAT3 decreased" type="Relation_Trigger"/>
            <entity charOffset="71-80" id="miRNA-corp.d51.s6.e3" text="low levels" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s7" origId="20113523.s17" text="A combination of miR-21 inhibitor and taxol could be an effective therapeutic strategy for controlling the growth of GBM by inhibiting STAT3 expression and phosphorylation.   ">
            <entity charOffset="117-119" id="miRNA-corp.d51.s7.e0" text="GBM" type="Diseases"/>
            <entity charOffset="135-139" id="miRNA-corp.d51.s7.e1" text="STAT3" type="Genes/Proteins"/>
            <entity charOffset="124-150" id="miRNA-corp.d51.s7.e2" text="inhibiting STAT3 expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s8" origId="20113523.s8" text="Expression of miR-21 was investigated by RT-PCR, and western blotting was performed to evaluate malignancy related protein alteration. ">
            <entity charOffset="14-19" id="miRNA-corp.d51.s8.e0" text="miR-21" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s9" origId="20113523.s9" text="RESULTS: IC(50) values were dramatically decreased in cells treated with miR-21 inhibitor combine with taxol, to a greater extent than those treated with taxol alone. ">
            <entity charOffset="80-88" id="miRNA-corp.d51.s9.e0" text="inhibitor" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s10" origId="20113523.s6" text="The mechanism between the miR-21 inhibitor and the anticancer drug taxol was analyzed using the Zheng-Jun Jin method. ">
            <entity charOffset="33-41" id="miRNA-corp.d51.s10.e0" text="inhibitor" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s11" origId="20113523.s7" text="Annexin V/PI staining was performed, and apoptosis and the cell cycle were evaluated by flow cytometry analysis. "/>
        <sentence id="miRNA-corp.d51.s12" origId="20113523.s1" text="BACKGROUND: Substantial data indicate that the oncogene microRNA 21 (miR-21) is significantly elevated in glioblastoma multiforme (GBM) and regulates multiple genes associated with cancer cell proliferation, apoptosis, and invasiveness. ">
            <entity charOffset="56-66" id="miRNA-corp.d51.s12.e0" text="microRNA 21" type="Specific_miRNAs"/>
            <entity charOffset="69-74" id="miRNA-corp.d51.s12.e1" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="80-101" id="miRNA-corp.d51.s12.e2" text="significantly elevated" type="Relation_Trigger"/>
            <entity charOffset="106-128" id="miRNA-corp.d51.s12.e3" text="glioblastoma multiforme" type="Diseases"/>
            <entity charOffset="131-133" id="miRNA-corp.d51.s12.e4" text="GBM" type="Diseases"/>
            <entity charOffset="140-148" id="miRNA-corp.d51.s12.e5" text="regulates" type="Relation_Trigger"/>
            <entity charOffset="181-186" id="miRNA-corp.d51.s12.e6" text="cancer" type="Diseases"/>
            <entity charOffset="165-174" id="miRNA-corp.d51.s12.e7" text="associated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d51.s12.e0" e2="miRNA-corp.d51.s12.e3" id="miRNA-corp.d51.s12.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d51.s12.e0" e2="miRNA-corp.d51.s12.e4" id="miRNA-corp.d51.s12.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d51.s12.e0" e2="miRNA-corp.d51.s12.e6" id="miRNA-corp.d51.s12.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d51.s12.e1" e2="miRNA-corp.d51.s12.e3" id="miRNA-corp.d51.s12.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d51.s12.e1" e2="miRNA-corp.d51.s12.e4" id="miRNA-corp.d51.s12.p4" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d51.s12.e1" e2="miRNA-corp.d51.s12.e6" id="miRNA-corp.d51.s12.p5" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s13" origId="20113523.s0" text="MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol.  ">
            <entity charOffset="12-20" id="miRNA-corp.d51.s13.e0" text="inhibitor" type="Relation_Trigger"/>
            <entity charOffset="33-37" id="miRNA-corp.d51.s13.e1" text="human" type="Species"/>
            <entity charOffset="33-50" id="miRNA-corp.d51.s13.e2" text="human glioblastoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s14" origId="20113523.s5" text="The 50% inhibitory concentration and cell viability were determined by the MTT assay. ">
            <entity charOffset="8-17" id="miRNA-corp.d51.s14.e0" text="inhibitory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s15" origId="20113523.s4" text="METHODS: Human glioblastoma U251 (PTEN-mutant) and LN229 (PTEN wild-type) cells were treated with taxol and the miR-21 inhibitor (in a poly (amidoamine) (PAMAM) dendrimer), alone or in combination. ">
            <entity charOffset="119-127" id="miRNA-corp.d51.s15.e0" text="inhibitor" type="Relation_Trigger"/>
            <entity charOffset="58-61" id="miRNA-corp.d51.s15.e1" text="PTEN" type="Genes/Proteins"/>
            <entity charOffset="9-26" id="miRNA-corp.d51.s15.e2" text="Human glioblastoma" type="Diseases"/>
            <entity charOffset="9-13" id="miRNA-corp.d51.s15.e3" text="Human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s16" origId="20113523.s3" text="So far, the effect of downregulating miR-21 to enhance the chemotherapeutic effect to taxol has not been studied in human GBM. ">
            <entity charOffset="22-35" id="miRNA-corp.d51.s16.e0" text="downregulating" type="Relation_Trigger"/>
            <entity charOffset="37-42" id="miRNA-corp.d51.s16.e1" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="116-120" id="miRNA-corp.d51.s16.e2" text="human" type="Species"/>
            <entity charOffset="116-124" id="miRNA-corp.d51.s16.e3" text="human GBM" type="Diseases"/>
            <pair e1="miRNA-corp.d51.s16.e1" e2="miRNA-corp.d51.s16.e3" id="miRNA-corp.d51.s16.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s17" origId="20113523.s2" text="Thus, miR-21 can theoretically become a target to enhance the chemotherapeutic effect in cancer therapy. ">
            <entity charOffset="6-11" id="miRNA-corp.d51.s17.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="40-45" id="miRNA-corp.d51.s17.e1" text="target" type="Relation_Trigger"/>
            <entity charOffset="89-94" id="miRNA-corp.d51.s17.e2" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d51.s17.e0" e2="miRNA-corp.d51.s17.e2" id="miRNA-corp.d51.s17.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d52" origId="18226105">
        <sentence id="miRNA-corp.d52.s0" origId="18226105.s0" text="MicroRNAs: biology and roles in neurodegeneration and brain tumours. ">
            <entity charOffset="0-8" id="miRNA-corp.d52.s0.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="54-66" id="miRNA-corp.d52.s0.e1" text="brain tumours" type="Diseases"/>
            <pair e1="miRNA-corp.d52.s0.e0" e2="miRNA-corp.d52.s0.e1" id="miRNA-corp.d52.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d52.s1" origId="18226105.s1" text="Introduction and historical background.     "/>
    </document>
    <document id="miRNA-corp.d53" origId="20479936">
        <sentence id="miRNA-corp.d53.s0" origId="20479936.s6" text="Ectopic expression of miR-29b decreased hPGRN expression at the both mRNA and protein levels. ">
            <entity charOffset="30-55" id="miRNA-corp.d53.s0.e0" text="decreased hPGRN expression" type="Relation_Trigger"/>
            <entity charOffset="22-28" id="miRNA-corp.d53.s0.e1" text="miR-29b" type="Specific_miRNAs"/>
            <entity charOffset="0-17" id="miRNA-corp.d53.s0.e2" text="Ectopic expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d53.s1" origId="20479936.s5" text="To examine the direct effect of manipulating endogenous miR-29b on hPGRN expression, we established a stable NIH3T3 cell line that expresses hPGRN under the control of the cytomegalovirus promoter. ">
            <entity charOffset="56-62" id="miRNA-corp.d53.s1.e0" text="miR-29b" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d53.s2" origId="20479936.s8" text="Endogenous hPGRN in HEK 293 cells was also regulated by miR-29b. ">
            <entity charOffset="56-62" id="miRNA-corp.d53.s2.e0" text="miR-29b" type="Specific_miRNAs"/>
            <entity charOffset="43-51" id="miRNA-corp.d53.s2.e1" text="regulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d53.s3" origId="20479936.s7" text="Conversely, knockdown of endogenous miR-29b with locked nucleic acid increased the production and secretion of hPGRN in NIH3T3 cells. ">
            <entity charOffset="36-42" id="miRNA-corp.d53.s3.e0" text="miR-29b" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d53.s4" origId="20479936.s2" text="How progranulin (PGRN) expression is regulated is largely unknown. ">
            <entity charOffset="4-14" id="miRNA-corp.d53.s4.e0" text="progranulin" type="Genes/Proteins"/>
            <entity charOffset="17-20" id="miRNA-corp.d53.s4.e1" text="PGRN" type="Genes/Proteins"/>
            <entity charOffset="23-45" id="miRNA-corp.d53.s4.e2" text="expression is regulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d53.s5" origId="20479936.s1" text="Progranulin deficiency is thought to cause some forms of frontotemporal dementia (FTD), a major early-onset age-dependent neurodegenerative disease. ">
            <entity charOffset="0-10" id="miRNA-corp.d53.s5.e0" text="Progranulin" type="Genes/Proteins"/>
            <entity charOffset="57-79" id="miRNA-corp.d53.s5.e1" text="frontotemporal dementia" type="Diseases"/>
            <entity charOffset="82-84" id="miRNA-corp.d53.s5.e2" text="FTD" type="Diseases"/>
            <entity charOffset="122-146" id="miRNA-corp.d53.s5.e3" text="neurodegenerative disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d53.s6" origId="20479936.s4" text="miR-29b downregulates the expression of luciferase through hPGRN or mouse PGRN (mPGRN) 3'UTRs, and the regulation was abolished by mutations in the miR-29b binding site. ">
            <entity charOffset="156-167" id="miRNA-corp.d53.s6.e0" text="binding site" type="Relation_Trigger"/>
            <entity charOffset="0-6" id="miRNA-corp.d53.s6.e1" text="miR-29b" type="Specific_miRNAs"/>
            <entity charOffset="8-35" id="miRNA-corp.d53.s6.e2" text="downregulates the expression" type="Relation_Trigger"/>
            <entity charOffset="68-72" id="miRNA-corp.d53.s6.e3" text="mouse" type="Species"/>
            <entity charOffset="74-77" id="miRNA-corp.d53.s6.e4" text="PGRN" type="Genes/Proteins"/>
            <entity charOffset="103-112" id="miRNA-corp.d53.s6.e5" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="148-154" id="miRNA-corp.d53.s6.e6" text="miR-29b" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d53.s6.e1" e2="miRNA-corp.d53.s6.e4" id="miRNA-corp.d53.s6.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d53.s6.e6" e2="miRNA-corp.d53.s6.e4" id="miRNA-corp.d53.s6.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d53.s7" origId="20479936.s3" text="We identified an evolutionarily conserved binding site for microRNA-29b (miR-29b) in the 3' untranslated region (3'UTR) of the human PGRN (hPGRN) mRNA. ">
            <entity charOffset="42-53" id="miRNA-corp.d53.s7.e0" text="binding site" type="Relation_Trigger"/>
            <entity charOffset="59-70" id="miRNA-corp.d53.s7.e1" text="microRNA-29b" type="Specific_miRNAs"/>
            <entity charOffset="73-79" id="miRNA-corp.d53.s7.e2" text="miR-29b" type="Specific_miRNAs"/>
            <entity charOffset="127-131" id="miRNA-corp.d53.s7.e3" text="human" type="Species"/>
            <entity charOffset="133-136" id="miRNA-corp.d53.s7.e4" text="PGRN" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d53.s7.e1" e2="miRNA-corp.d53.s7.e4" id="miRNA-corp.d53.s7.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d53.s7.e2" e2="miRNA-corp.d53.s7.e4" id="miRNA-corp.d53.s7.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d53.s8" origId="20479936.s0" text="MicroRNA-29b regulates the expression level of human progranulin, a secreted glycoprotein implicated in frontotemporal dementia.  ">
            <entity charOffset="0-11" id="miRNA-corp.d53.s8.e0" text="MicroRNA-29b" type="Specific_miRNAs"/>
            <entity charOffset="13-42" id="miRNA-corp.d53.s8.e1" text="regulates the expression level" type="Relation_Trigger"/>
            <entity charOffset="47-51" id="miRNA-corp.d53.s8.e2" text="human" type="Species"/>
            <entity charOffset="53-63" id="miRNA-corp.d53.s8.e3" text="progranulin" type="Genes/Proteins"/>
            <entity charOffset="104-126" id="miRNA-corp.d53.s8.e4" text="frontotemporal dementia" type="Diseases"/>
            <pair e1="miRNA-corp.d53.s8.e0" e2="miRNA-corp.d53.s8.e3" id="miRNA-corp.d53.s8.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d53.s8.e0" e2="miRNA-corp.d53.s8.e4" id="miRNA-corp.d53.s8.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d53.s9" origId="20479936.s9" text="These findings identify miR-29b as a novel posttranscriptional regulator of PGRN expression, raising the possibility that miR-29b or other miRNAs might be targeted therapeutically to increase hPGRN levels in some FTD patients.   ">
            <entity charOffset="155-162" id="miRNA-corp.d53.s9.e0" text="targeted" type="Relation_Trigger"/>
            <entity charOffset="183-203" id="miRNA-corp.d53.s9.e1" text="increase hPGRN levels" type="Relation_Trigger"/>
            <entity charOffset="24-30" id="miRNA-corp.d53.s9.e2" text="miR-29b" type="Specific_miRNAs"/>
            <entity charOffset="122-128" id="miRNA-corp.d53.s9.e3" text="miR-29b" type="Specific_miRNAs"/>
            <entity charOffset="76-79" id="miRNA-corp.d53.s9.e4" text="PGRN" type="Genes/Proteins"/>
            <entity charOffset="63-90" id="miRNA-corp.d53.s9.e5" text="regulator of PGRN expression" type="Relation_Trigger"/>
            <entity charOffset="139-144" id="miRNA-corp.d53.s9.e6" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="213-215" id="miRNA-corp.d53.s9.e7" text="FTD" type="Diseases"/>
            <entity charOffset="217-224" id="miRNA-corp.d53.s9.e8" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d53.s9.e2" e2="miRNA-corp.d53.s9.e4" id="miRNA-corp.d53.s9.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d53.s9.e2" e2="miRNA-corp.d53.s9.e7" id="miRNA-corp.d53.s9.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d53.s9.e3" e2="miRNA-corp.d53.s9.e4" id="miRNA-corp.d53.s9.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d53.s9.e3" e2="miRNA-corp.d53.s9.e7" id="miRNA-corp.d53.s9.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d53.s9.e6" e2="miRNA-corp.d53.s9.e4" id="miRNA-corp.d53.s9.p4" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d53.s9.e6" e2="miRNA-corp.d53.s9.e7" id="miRNA-corp.d53.s9.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d54" origId="20840605">
        <sentence id="miRNA-corp.d54.s0" origId="20840605.s10" text="These novel findings suggest that miR-21 may be an attractive therapeutic molecule for treatment of stroke.   ">
            <entity charOffset="34-39" id="miRNA-corp.d54.s0.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="100-105" id="miRNA-corp.d54.s0.e1" text="stroke" type="Diseases"/>
            <pair e1="miRNA-corp.d54.s0.e0" e2="miRNA-corp.d54.s0.e1" id="miRNA-corp.d54.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d54.s1" origId="20840605.s1" text="MicroRNAs are small RNAs that attenuate protein expression by complementary binding to the 3'-UTR of a target mRNA. ">
            <entity charOffset="30-57" id="miRNA-corp.d54.s1.e0" text="attenuate protein expression" type="Relation_Trigger"/>
            <entity charOffset="76-82" id="miRNA-corp.d54.s1.e1" text="binding" type="Relation_Trigger"/>
            <entity charOffset="0-8" id="miRNA-corp.d54.s1.e2" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="103-108" id="miRNA-corp.d54.s1.e3" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d54.s2" origId="20840605.s0" text="MicroRNA-21 protects neurons from ischemic death.  ">
            <entity charOffset="0-10" id="miRNA-corp.d54.s2.e0" text="MicroRNA-21" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d54.s3" origId="20840605.s3" text="In particular, microRNA-21 (miR-21) is a strong antiapoptotic factor in some biological systems. ">
            <entity charOffset="48-67" id="miRNA-corp.d54.s3.e0" text="antiapoptotic factor" type="Relation_Trigger"/>
            <entity charOffset="15-25" id="miRNA-corp.d54.s3.e1" text="microRNA-21" type="Specific_miRNAs"/>
            <entity charOffset="28-33" id="miRNA-corp.d54.s3.e2" text="miR-21" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d54.s4" origId="20840605.s2" text="Currently, very little is known about microRNAs after cerebral ischemia. ">
            <entity charOffset="38-46" id="miRNA-corp.d54.s4.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="54-70" id="miRNA-corp.d54.s4.e1" text="cerebral ischemia" type="Diseases"/>
            <pair e1="miRNA-corp.d54.s4.e0" e2="miRNA-corp.d54.s4.e1" id="miRNA-corp.d54.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d54.s5" origId="20840605.s5" text="We employed in situ hybridization and laser capture microdissection in combination with real-time RT-PCR to investigate the expression of miR-21 after stroke. ">
            <entity charOffset="138-143" id="miRNA-corp.d54.s5.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="151-156" id="miRNA-corp.d54.s5.e1" text="stroke" type="Diseases"/>
            <pair e1="miRNA-corp.d54.s5.e0" e2="miRNA-corp.d54.s5.e1" id="miRNA-corp.d54.s5.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d54.s6" origId="20840605.s4" text="We investigated the role of miR-21 after stroke in the rat. ">
            <entity charOffset="41-46" id="miRNA-corp.d54.s6.e0" text="stroke" type="Diseases"/>
            <entity charOffset="28-33" id="miRNA-corp.d54.s6.e1" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="55-57" id="miRNA-corp.d54.s6.e2" text="rat" type="Species"/>
            <pair e1="miRNA-corp.d54.s6.e1" e2="miRNA-corp.d54.s6.e0" id="miRNA-corp.d54.s6.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d54.s7" origId="20840605.s7" text="In vitro, overexpression of miR-21 in cultured cortical neurons substantially suppressed oxygen and glucose deprivation-induced apoptotic cell death, whereas attenuation of endogenous miR-21 by antisense inhibition exacerbated cell death after oxygen and glucose deprivation. ">
            <entity charOffset="204-213" id="miRNA-corp.d54.s7.e0" text="inhibition" type="Relation_Trigger"/>
            <entity charOffset="10-23" id="miRNA-corp.d54.s7.e1" text="overexpression" type="Relation_Trigger"/>
            <entity charOffset="28-33" id="miRNA-corp.d54.s7.e2" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="78-87" id="miRNA-corp.d54.s7.e3" text="suppressed" type="Relation_Trigger"/>
            <entity charOffset="184-189" id="miRNA-corp.d54.s7.e4" text="miR-21" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d54.s8" origId="20840605.s6" text="In situ hybridization revealed that miR-21 expression was upregulated in neurons of the ischemic boundary zone, and quantitative real-time RT-PCR analysis revealed that stroke increased mature miR-21 levels by approximately threefold in neurons isolated from the ischemic boundary zone by laser capture microdissection as compared with homologous contralateral neurons 2 days (n = 4; P &lt; 0.05) and 7 days (n = 3; P &lt; 0.05) after stroke. ">
            <entity charOffset="36-41" id="miRNA-corp.d54.s8.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="43-68" id="miRNA-corp.d54.s8.e1" text="expression was upregulated" type="Relation_Trigger"/>
            <entity charOffset="169-174" id="miRNA-corp.d54.s8.e2" text="stroke" type="Diseases"/>
            <entity charOffset="193-198" id="miRNA-corp.d54.s8.e3" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="176-205" id="miRNA-corp.d54.s8.e4" text="increased mature miR-21 levels" type="Relation_Trigger"/>
            <entity charOffset="429-434" id="miRNA-corp.d54.s8.e5" text="stroke" type="Diseases"/>
            <pair e1="miRNA-corp.d54.s8.e0" e2="miRNA-corp.d54.s8.e2" id="miRNA-corp.d54.s8.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d54.s8.e0" e2="miRNA-corp.d54.s8.e5" id="miRNA-corp.d54.s8.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d54.s8.e3" e2="miRNA-corp.d54.s8.e2" id="miRNA-corp.d54.s8.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d54.s8.e3" e2="miRNA-corp.d54.s8.e5" id="miRNA-corp.d54.s8.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d54.s9" origId="20840605.s9" text="Our data indicate that overexpression of miR-21 protects against ischemic neuronal death, and that downregulation of FASLG, a tumor necrosis factor-α family member and an important cell death-inducing ligand whose gene is targeted by miR-21, probably mediates the neuroprotective effect. ">
            <entity charOffset="126-149" id="miRNA-corp.d54.s9.e0" text="tumor necrosis factor-α " type="Genes/Proteins"/>
            <entity charOffset="23-36" id="miRNA-corp.d54.s9.e1" text="overexpression" type="Relation_Trigger"/>
            <entity charOffset="41-46" id="miRNA-corp.d54.s9.e2" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="99-112" id="miRNA-corp.d54.s9.e3" text="downregulation" type="Relation_Trigger"/>
            <entity charOffset="117-121" id="miRNA-corp.d54.s9.e4" text="FASLG" type="Genes/Proteins"/>
            <entity charOffset="222-229" id="miRNA-corp.d54.s9.e5" text="targeted" type="Relation_Trigger"/>
            <entity charOffset="234-239" id="miRNA-corp.d54.s9.e6" text="miR-21" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d54.s9.e2" e2="miRNA-corp.d54.s9.e4" id="miRNA-corp.d54.s9.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d54.s9.e2" e2="miRNA-corp.d54.s9.e0" id="miRNA-corp.d54.s9.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d54.s9.e6" e2="miRNA-corp.d54.s9.e4" id="miRNA-corp.d54.s9.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d54.s9.e6" e2="miRNA-corp.d54.s9.e0" id="miRNA-corp.d54.s9.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d54.s10" origId="20840605.s8" text="Moreover, overexpression of miR-21 in neurons significantly reduced FASLG levels, and introduction of an miR-21 mimic into 293-HEK cells substantially reduced luciferase activity in a reporter system containing the 3'-UTR of Faslg. ">
            <entity charOffset="225-229" id="miRNA-corp.d54.s10.e0" text="Faslg" type="Genes/Proteins"/>
            <entity charOffset="46-66" id="miRNA-corp.d54.s10.e1" text="significantly reduced" type="Relation_Trigger"/>
            <entity charOffset="10-23" id="miRNA-corp.d54.s10.e2" text="overexpression" type="Relation_Trigger"/>
            <entity charOffset="28-33" id="miRNA-corp.d54.s10.e3" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="60-79" id="miRNA-corp.d54.s10.e4" text="reduced FASLG levels" type="Relation_Trigger"/>
            <entity charOffset="68-72" id="miRNA-corp.d54.s10.e5" text="FASLG" type="Genes/Proteins"/>
            <entity charOffset="105-110" id="miRNA-corp.d54.s10.e6" text="miR-21" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d54.s10.e3" e2="miRNA-corp.d54.s10.e0" id="miRNA-corp.d54.s10.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d54.s10.e3" e2="miRNA-corp.d54.s10.e5" id="miRNA-corp.d54.s10.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d54.s10.e6" e2="miRNA-corp.d54.s10.e0" id="miRNA-corp.d54.s10.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d54.s10.e6" e2="miRNA-corp.d54.s10.e5" id="miRNA-corp.d54.s10.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d55" origId="21084244">
        <sentence id="miRNA-corp.d55.s0" origId="21084244.s0" text="[Genetic and molecular abnormalities of glioblastomas (GBM)].  ">
            <entity charOffset="40-52" id="miRNA-corp.d55.s0.e0" text="glioblastomas" type="Diseases"/>
            <entity charOffset="55-57" id="miRNA-corp.d55.s0.e1" text="GBM" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d55.s1" origId="21084244.s1" text="This presentation reports a series of data dealing with recurrent genetic abnormalities and gene expression profiles that characterize primary glioblastomas and secondary glioblastomas resulting from the transformation of low grade tumors (grade II and III astrocytomas and oligodendrogliomas). ">
            <entity charOffset="135-155" id="miRNA-corp.d55.s1.e0" text="primary glioblastomas" type="Diseases"/>
            <entity charOffset="161-183" id="miRNA-corp.d55.s1.e1" text="secondary glioblastomas" type="Diseases"/>
            <entity charOffset="222-237" id="miRNA-corp.d55.s1.e2" text="low grade tumors" type="Diseases"/>
            <entity charOffset="274-291" id="miRNA-corp.d55.s1.e3" text="oligodendrogliomas" type="Diseases"/>
            <entity charOffset="257-268" id="miRNA-corp.d55.s1.e4" text="astrocytomas" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d55.s2" origId="21084244.s6" text="Finally, a short description of exosomes as vectors of tumor information will be presented.   ">
            <entity charOffset="55-59" id="miRNA-corp.d55.s2.e0" text="tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d55.s3" origId="21084244.s2" text="The most recent aspects of the concept of tumor stem cells that may explain the relentless growth of GBM will be reported. ">
            <entity charOffset="42-46" id="miRNA-corp.d55.s3.e0" text="tumor" type="Diseases"/>
            <entity charOffset="101-103" id="miRNA-corp.d55.s3.e1" text="GBM" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d55.s4" origId="21084244.s3" text="Molecular features of tumor neoangiogenesis will be described. ">
            <entity charOffset="22-26" id="miRNA-corp.d55.s4.e0" text="tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d55.s5" origId="21084244.s4" text="Epigenetic alterations and deregulation of gene expression by microRNAs (miRs) will be also included. ">
            <entity charOffset="27-38" id="miRNA-corp.d55.s5.e0" text="deregulation" type="Relation_Trigger"/>
            <entity charOffset="11-57" id="miRNA-corp.d55.s5.e1" text="alterations and deregulation of gene expression" type="Relation_Trigger"/>
            <entity charOffset="62-70" id="miRNA-corp.d55.s5.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="73-76" id="miRNA-corp.d55.s5.e3" text="miRs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d55.s6" origId="21084244.s5" text="Some aspects of tumor predisposition will be also discussed. ">
            <entity charOffset="16-20" id="miRNA-corp.d55.s6.e0" text="tumor" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d56" origId="19952055">
        <sentence id="miRNA-corp.d56.s0" origId="19952055.s10" text="This mechanism may have broad implications for microRNA-regulated macrophage activation in inflammatory diseases.   ">
            <entity charOffset="77-86" id="miRNA-corp.d56.s0.e0" text="activation" type="Relation_Trigger"/>
            <entity charOffset="47-54" id="miRNA-corp.d56.s0.e1" text="microRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d56.s1" origId="19952055.s9" text="Our findings suggest that microRNA dysregulated in multiple sclerosis lesions reduce CD47 in brain resident cells, releasing macrophages from inhibitory control, thereby promoting phagocytosis of myelin. ">
            <entity charOffset="26-33" id="miRNA-corp.d56.s1.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="35-46" id="miRNA-corp.d56.s1.e1" text="dysregulated" type="Relation_Trigger"/>
            <entity charOffset="51-76" id="miRNA-corp.d56.s1.e2" text="multiple sclerosis lesions" type="Diseases"/>
            <entity charOffset="85-88" id="miRNA-corp.d56.s1.e3" text="CD47" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d56.s1.e0" e2="miRNA-corp.d56.s1.e2" id="miRNA-corp.d56.s1.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d56.s1.e0" e2="miRNA-corp.d56.s1.e3" id="miRNA-corp.d56.s1.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d56.s2" origId="19952055.s8" text="Three microRNA upregulated in active multiple sclerosis lesions (microRNA-34a, microRNA-155 and microRNA-326) targeted the 3'-untranslated region of CD47 in reporter assays, with microRNA-155 even at two distinct sites. ">
            <entity charOffset="6-13" id="miRNA-corp.d56.s2.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="15-25" id="miRNA-corp.d56.s2.e1" text="upregulated" type="Relation_Trigger"/>
            <entity charOffset="37-62" id="miRNA-corp.d56.s2.e2" text="multiple sclerosis lesions" type="Diseases"/>
            <entity charOffset="65-76" id="miRNA-corp.d56.s2.e3" text="microRNA-34a" type="Specific_miRNAs"/>
            <entity charOffset="79-90" id="miRNA-corp.d56.s2.e4" text="microRNA-155" type="Specific_miRNAs"/>
            <entity charOffset="96-107" id="miRNA-corp.d56.s2.e5" text="microRNA-326" type="Specific_miRNAs"/>
            <entity charOffset="110-117" id="miRNA-corp.d56.s2.e6" text="targeted" type="Relation_Trigger"/>
            <entity charOffset="149-152" id="miRNA-corp.d56.s2.e7" text="CD47" type="Genes/Proteins"/>
            <entity charOffset="179-190" id="miRNA-corp.d56.s2.e8" text="microRNA-155" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d56.s2.e0" e2="miRNA-corp.d56.s2.e2" id="miRNA-corp.d56.s2.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d56.s2.e0" e2="miRNA-corp.d56.s2.e7" id="miRNA-corp.d56.s2.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d56.s2.e3" e2="miRNA-corp.d56.s2.e2" id="miRNA-corp.d56.s2.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d56.s2.e3" e2="miRNA-corp.d56.s2.e7" id="miRNA-corp.d56.s2.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d56.s2.e4" e2="miRNA-corp.d56.s2.e2" id="miRNA-corp.d56.s2.p4" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d56.s2.e4" e2="miRNA-corp.d56.s2.e7" id="miRNA-corp.d56.s2.p5" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d56.s2.e5" e2="miRNA-corp.d56.s2.e2" id="miRNA-corp.d56.s2.p6" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d56.s2.e5" e2="miRNA-corp.d56.s2.e7" id="miRNA-corp.d56.s2.p7" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d56.s2.e8" e2="miRNA-corp.d56.s2.e2" id="miRNA-corp.d56.s2.p8" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d56.s2.e8" e2="miRNA-corp.d56.s2.e7" id="miRNA-corp.d56.s2.p9" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d56.s3" origId="19952055.s7" text="This converged on CD47, which functions as a 'don't eat me' signal inhibiting macrophage activity. ">
            <entity charOffset="18-21" id="miRNA-corp.d56.s3.e0" text="CD47" type="Genes/Proteins"/>
            <entity charOffset="67-76" id="miRNA-corp.d56.s3.e1" text="inhibiting" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d56.s4" origId="19952055.s1" text="We established microRNA profiles from active and inactive multiple sclerosis lesions. ">
            <entity charOffset="15-22" id="miRNA-corp.d56.s4.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="58-83" id="miRNA-corp.d56.s4.e1" text="multiple sclerosis lesions" type="Diseases"/>
            <pair e1="miRNA-corp.d56.s4.e0" e2="miRNA-corp.d56.s4.e1" id="miRNA-corp.d56.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d56.s5" origId="19952055.s2" text="Using laser capture microdissection from multiple sclerosis lesions to pool single cells and in vitro cultures, we assigned differentially expressed microRNA to specific cell types. ">
            <entity charOffset="41-66" id="miRNA-corp.d56.s5.e0" text="multiple sclerosis lesions" type="Diseases"/>
            <entity charOffset="149-156" id="miRNA-corp.d56.s5.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="124-147" id="miRNA-corp.d56.s5.e2" text="differentially expressed" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d56.s5.e1" e2="miRNA-corp.d56.s5.e0" id="miRNA-corp.d56.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d56.s6" origId="19952055.s0" text="MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47.  ">
            <entity charOffset="0-7" id="miRNA-corp.d56.s6.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="22-47" id="miRNA-corp.d56.s6.e1" text="multiple sclerosis lesions" type="Diseases"/>
            <entity charOffset="60-69" id="miRNA-corp.d56.s6.e2" text="modulators" type="Relation_Trigger"/>
            <entity charOffset="78-87" id="miRNA-corp.d56.s6.e3" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="97-100" id="miRNA-corp.d56.s6.e4" text="CD47" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d56.s6.e0" e2="miRNA-corp.d56.s6.e1" id="miRNA-corp.d56.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d56.s6.e0" e2="miRNA-corp.d56.s6.e4" id="miRNA-corp.d56.s6.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d56.s7" origId="19952055.s5" text="This was confirmed with astrocyte cultures from microRNA-155-|-lacZ mice. ">
            <entity charOffset="48-59" id="miRNA-corp.d56.s7.e0" text="microRNA-155" type="Specific_miRNAs"/>
            <entity charOffset="68-71" id="miRNA-corp.d56.s7.e1" text="mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d56.s8" origId="19952055.s6" text="We matched microRNA upregulated in phagocytically active multiple sclerosis lesions with downregulated protein coding transcripts. ">
            <entity charOffset="11-18" id="miRNA-corp.d56.s8.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="20-30" id="miRNA-corp.d56.s8.e1" text="upregulated" type="Relation_Trigger"/>
            <entity charOffset="57-82" id="miRNA-corp.d56.s8.e2" text="multiple sclerosis lesions" type="Diseases"/>
            <entity charOffset="89-101" id="miRNA-corp.d56.s8.e3" text="downregulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d56.s8.e0" e2="miRNA-corp.d56.s8.e2" id="miRNA-corp.d56.s8.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d56.s9" origId="19952055.s3" text="Astrocytes contained all 10 microRNA that were most strongly upregulated in active multiple sclerosis lesions, including microRNA-155, which is known to modulate immune responses in different ways but so far had not been assigned to central nervous system resident cells. ">
            <entity charOffset="28-35" id="miRNA-corp.d56.s9.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="61-71" id="miRNA-corp.d56.s9.e1" text="upregulated" type="Relation_Trigger"/>
            <entity charOffset="83-108" id="miRNA-corp.d56.s9.e2" text="multiple sclerosis lesions" type="Diseases"/>
            <entity charOffset="121-132" id="miRNA-corp.d56.s9.e3" text="microRNA-155" type="Specific_miRNAs"/>
            <entity charOffset="153-160" id="miRNA-corp.d56.s9.e4" text="modulate" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d56.s9.e0" e2="miRNA-corp.d56.s9.e2" id="miRNA-corp.d56.s9.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d56.s9.e3" e2="miRNA-corp.d56.s9.e2" id="miRNA-corp.d56.s9.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d56.s10" origId="19952055.s4" text="MicroRNA-155 was expressed in human astrocytes in situ, and further induced with cytokines in human astrocytes in vitro. ">
            <entity charOffset="30-34" id="miRNA-corp.d56.s10.e0" text="human" type="Species"/>
            <entity charOffset="94-98" id="miRNA-corp.d56.s10.e1" text="human" type="Species"/>
            <entity charOffset="0-11" id="miRNA-corp.d56.s10.e2" text="MicroRNA-155" type="Specific_miRNAs"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d57" origId="21709246">
        <sentence id="miRNA-corp.d57.s0" origId="21709246.s8" text="MicroRNAs (miRNAs) predominantly induce translational repression and are emerging as a major regulators of mRNA and subsequent protein expression after ischemia. ">
            <entity charOffset="0-8" id="miRNA-corp.d57.s0.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d57.s0.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="93-102" id="miRNA-corp.d57.s0.e2" text="regulators" type="Relation_Trigger"/>
            <entity charOffset="152-159" id="miRNA-corp.d57.s0.e3" text="ischemia" type="Diseases"/>
            <entity charOffset="40-63" id="miRNA-corp.d57.s0.e4" text="translational repression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d57.s0.e0" e2="miRNA-corp.d57.s0.e3" id="miRNA-corp.d57.s0.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d57.s0.e1" e2="miRNA-corp.d57.s0.e3" id="miRNA-corp.d57.s0.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d57.s1" origId="21709246.s9" text="The miRNA miR-23a was predicted to bind XIAP mRNA. ">
            <entity charOffset="10-16" id="miRNA-corp.d57.s1.e0" text="miR-23a" type="Specific_miRNAs"/>
            <entity charOffset="4-8" id="miRNA-corp.d57.s1.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="32-38" id="miRNA-corp.d57.s1.e2" text="to bind" type="Relation_Trigger"/>
            <entity charOffset="40-43" id="miRNA-corp.d57.s1.e3" text="XIAP" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d57.s1.e0" e2="miRNA-corp.d57.s1.e3" id="miRNA-corp.d57.s1.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d57.s1.e1" e2="miRNA-corp.d57.s1.e3" id="miRNA-corp.d57.s1.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d57.s2" origId="21709246.s10" text="miR-23a directly bound the 3' UTR of XIAP, and miR-23a inhibition led to an increase in XIAP mRNA in vitro, demonstrating that XIAP is a previously uncharacterized target for miR-23a. ">
            <entity charOffset="0-6" id="miRNA-corp.d57.s2.e0" text="miR-23a" type="Specific_miRNAs"/>
            <entity charOffset="47-53" id="miRNA-corp.d57.s2.e1" text="miR-23a" type="Specific_miRNAs"/>
            <entity charOffset="55-64" id="miRNA-corp.d57.s2.e2" text="inhibition" type="Relation_Trigger"/>
            <entity charOffset="175-181" id="miRNA-corp.d57.s2.e3" text="miR-23a" type="Specific_miRNAs"/>
            <entity charOffset="37-40" id="miRNA-corp.d57.s2.e4" text="XIAP" type="Genes/Proteins"/>
            <entity charOffset="17-21" id="miRNA-corp.d57.s2.e5" text="bound" type="Relation_Trigger"/>
            <entity charOffset="88-91" id="miRNA-corp.d57.s2.e6" text="XIAP" type="Genes/Proteins"/>
            <entity charOffset="127-130" id="miRNA-corp.d57.s2.e7" text="XIAP" type="Genes/Proteins"/>
            <entity charOffset="164-169" id="miRNA-corp.d57.s2.e8" text="target" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d57.s2.e0" e2="miRNA-corp.d57.s2.e4" id="miRNA-corp.d57.s2.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d57.s2.e0" e2="miRNA-corp.d57.s2.e6" id="miRNA-corp.d57.s2.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d57.s2.e0" e2="miRNA-corp.d57.s2.e7" id="miRNA-corp.d57.s2.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d57.s2.e1" e2="miRNA-corp.d57.s2.e4" id="miRNA-corp.d57.s2.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d57.s2.e1" e2="miRNA-corp.d57.s2.e6" id="miRNA-corp.d57.s2.p4" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d57.s2.e1" e2="miRNA-corp.d57.s2.e7" id="miRNA-corp.d57.s2.p5" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d57.s2.e3" e2="miRNA-corp.d57.s2.e4" id="miRNA-corp.d57.s2.p6" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d57.s2.e3" e2="miRNA-corp.d57.s2.e6" id="miRNA-corp.d57.s2.p7" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d57.s2.e3" e2="miRNA-corp.d57.s2.e7" id="miRNA-corp.d57.s2.p8" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d57.s3" origId="21709246.s13" text="Embelin treatment significantly exacerbated stroke-induced injury in females but had no effect in males, demonstrating that XIAP is an important mediator of sex-specific responses after stroke.   ">
            <entity charOffset="44-64" id="miRNA-corp.d57.s3.e0" text="stroke-induced injury" type="Diseases"/>
            <entity charOffset="186-191" id="miRNA-corp.d57.s3.e1" text="stroke" type="Diseases"/>
            <entity charOffset="124-127" id="miRNA-corp.d57.s3.e2" text="XIAP" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d57.s4" origId="21709246.s11" text="miR-23a levels differed in male and female ischemic brains, providing evidence for sex-specific miRNA expression in stroke. ">
            <entity charOffset="0-6" id="miRNA-corp.d57.s4.e0" text="miR-23a" type="Specific_miRNAs"/>
            <entity charOffset="96-100" id="miRNA-corp.d57.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="116-121" id="miRNA-corp.d57.s4.e2" text="stroke" type="Diseases"/>
            <pair e1="miRNA-corp.d57.s4.e0" e2="miRNA-corp.d57.s4.e2" id="miRNA-corp.d57.s4.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d57.s4.e1" e2="miRNA-corp.d57.s4.e2" id="miRNA-corp.d57.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d57.s5" origId="21709246.s12" text="Embelin, a small-molecule inhibitor of XIAP, decreased the interaction between XIAP and caspase-3 and led to enhanced caspase activity. ">
            <entity charOffset="26-34" id="miRNA-corp.d57.s5.e0" text="inhibitor" type="Relation_Trigger"/>
            <entity charOffset="88-96" id="miRNA-corp.d57.s5.e1" text="caspase-3" type="Genes/Proteins"/>
            <entity charOffset="39-42" id="miRNA-corp.d57.s5.e2" text="XIAP" type="Genes/Proteins"/>
            <entity charOffset="79-82" id="miRNA-corp.d57.s5.e3" text="XIAP" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d57.s6" origId="21709246.s1" text="It is increasingly recognized that the mechanisms underlying ischemic cell death are sexually dimorphic. "/>
        <sentence id="miRNA-corp.d57.s7" origId="21709246.s0" text="miR-23a regulation of X-linked inhibitor of apoptosis (XIAP) contributes to sex differences in the response to cerebral ischemia.  ">
            <entity charOffset="0-6" id="miRNA-corp.d57.s7.e0" text="miR-23a" type="Specific_miRNAs"/>
            <entity charOffset="8-17" id="miRNA-corp.d57.s7.e1" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="31-39" id="miRNA-corp.d57.s7.e2" text="inhibitor" type="Relation_Trigger"/>
            <entity charOffset="111-127" id="miRNA-corp.d57.s7.e3" text="cerebral ischemia" type="Diseases"/>
            <entity charOffset="22-52" id="miRNA-corp.d57.s7.e4" text="X-linked inhibitor of apoptosis" type="Genes/Proteins"/>
            <entity charOffset="55-58" id="miRNA-corp.d57.s7.e5" text="XIAP" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d57.s7.e0" e2="miRNA-corp.d57.s7.e4" id="miRNA-corp.d57.s7.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d57.s7.e0" e2="miRNA-corp.d57.s7.e5" id="miRNA-corp.d57.s7.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d57.s7.e0" e2="miRNA-corp.d57.s7.e3" id="miRNA-corp.d57.s7.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d57.s8" origId="21709246.s3" text="In contrast, ischemic cell death in females is primarily triggered by mitochondrial cytochrome c release with subsequent caspase activation. ">
            <entity charOffset="129-138" id="miRNA-corp.d57.s8.e0" text="activation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d57.s9" origId="21709246.s2" text="Stroke-induced cell death in males is initiated by the mitochondrial release of apoptosis-inducing factor, resulting in caspase-independent cell death. ">
            <entity charOffset="80-104" id="miRNA-corp.d57.s9.e0" text="apoptosis-inducing factor" type="Genes/Proteins"/>
            <entity charOffset="0-5" id="miRNA-corp.d57.s9.e1" text="Stroke" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d57.s10" origId="21709246.s5" text="XIAP mRNA levels were higher in females at baseline. ">
            <entity charOffset="10-27" id="miRNA-corp.d57.s10.e0" text="levels were higher" type="Relation_Trigger"/>
            <entity charOffset="0-3" id="miRNA-corp.d57.s10.e1" text="XIAP" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d57.s11" origId="21709246.s4" text="Because X-linked inhibitor of apoptosis (XIAP) is the primary endogenous inhibitor of caspases, its regulation may play a unique role in the response to injury in females. ">
            <entity charOffset="153-158" id="miRNA-corp.d57.s11.e0" text="injury" type="Diseases"/>
            <entity charOffset="73-81" id="miRNA-corp.d57.s11.e1" text="inhibitor" type="Relation_Trigger"/>
            <entity charOffset="100-109" id="miRNA-corp.d57.s11.e2" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="8-38" id="miRNA-corp.d57.s11.e3" text="X-linked inhibitor of apoptosis" type="Genes/Proteins"/>
            <entity charOffset="41-44" id="miRNA-corp.d57.s11.e4" text="XIAP" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d57.s12" origId="21709246.s7" text="However, XIAP protein levels were decreased in both sexes after stroke. ">
            <entity charOffset="64-69" id="miRNA-corp.d57.s12.e0" text="stroke" type="Diseases"/>
            <entity charOffset="22-42" id="miRNA-corp.d57.s12.e1" text="levels were decreased" type="Relation_Trigger"/>
            <entity charOffset="9-12" id="miRNA-corp.d57.s12.e2" text="XIAP" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d57.s13" origId="21709246.s6" text="Stroke induced a significant decrease in XIAP mRNA in females, whereas no changes were seen in the male brain. ">
            <entity charOffset="0-5" id="miRNA-corp.d57.s13.e0" text="Stroke" type="Diseases"/>
            <entity charOffset="41-44" id="miRNA-corp.d57.s13.e1" text="XIAP" type="Genes/Proteins"/>
            <entity charOffset="17-36" id="miRNA-corp.d57.s13.e2" text="significant decrease" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d58" origId="15223312">
        <sentence id="miRNA-corp.d58.s0" origId="15223312.s5" text="We also demonstrate that the single-nucleotide polymorphism (SNP) that is located immediately adjacent (3') to the repeats of the SCA3 transcript modulates the structures formed by these sequences, and may have functional significance, as only one of its variants is selected in human evolution.     ">
            <entity charOffset="130-133" id="miRNA-corp.d58.s0.e0" text="SCA3" type="Diseases"/>
            <entity charOffset="146-154" id="miRNA-corp.d58.s0.e1" text="modulates" type="Relation_Trigger"/>
            <entity charOffset="279-283" id="miRNA-corp.d58.s0.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d58.s1" origId="15223312.s4" text="We provide evidence that the hairpin structure formed by CAG repeats in mRNA fragments is preserved in full-length mRNA. "/>
        <sentence id="miRNA-corp.d58.s2" origId="15223312.s3" text="Here, we show that the structures formed by the repeats and their natural flanking sequences in the spinocerebellar ataxia (SCA) type 3 and type 6, and dentatorubral-palidoluysian atrophy (DRPLA) transcripts have different molecular architectures which may have functional meaning. ">
            <entity charOffset="100-132" id="miRNA-corp.d58.s2.e0" text="spinocerebellar ataxia (SCA) type" type="Genes/Proteins"/>
            <entity charOffset="152-185" id="miRNA-corp.d58.s2.e1" text="dentatorubral-palidoluysian atroph" type="Genes/Proteins"/>
            <entity charOffset="189-192" id="miRNA-corp.d58.s2.e2" text="DRPL" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d58.s3" origId="15223312.s2" text="The expanded CAG repeats are present in transcripts from several mutant genes associated with hereditary neurodegenerative diseases but their contribution to pathogenesis has not been documented convincingly. ">
            <entity charOffset="105-129" id="miRNA-corp.d58.s3.e0" text="neurodegenerative disease" type="Diseases"/>
            <entity charOffset="78-87" id="miRNA-corp.d58.s3.e1" text="associated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d58.s4" origId="15223312.s1" text="CAG repeats are present in numerous human transcripts but neither their structures nor physiological functions have been satisfactorily recognized. ">
            <entity charOffset="36-40" id="miRNA-corp.d58.s4.e0" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d58.s5" origId="15223312.s0" text="Molecular architecture of CAG repeats in human disease related transcripts.   ">
            <entity charOffset="41-45" id="miRNA-corp.d58.s5.e0" text="human" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d59" origId="20193638">
        <sentence id="miRNA-corp.d59.s0" origId="20193638.s6" text="The rapid and exciting pace of advances in glioblastoma genetics has prompted this up-to-date review.   ">
            <entity charOffset="43-54" id="miRNA-corp.d59.s0.e0" text="glioblastoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d59.s1" origId="20193638.s5" text="The likely impact on care delivery in the clinic may only be a few years away. "/>
        <sentence id="miRNA-corp.d59.s2" origId="20193638.s4" text="Within the last few years, high-throughput efforts such as The Cancer Genome Atlas and a massive sequencing project have yielded novel insights and classifications of this dreaded cancer. ">
            <entity charOffset="180-185" id="miRNA-corp.d59.s2.e0" text="cancer" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d59.s3" origId="20193638.s3" text="It has been hoped that dissection of the genetics of this cancer would lead to more targeted and effective treatments, and new advances may finally be bringing this closer to fruition. ">
            <entity charOffset="58-63" id="miRNA-corp.d59.s3.e0" text="cancer" type="Diseases"/>
            <entity charOffset="84-91" id="miRNA-corp.d59.s3.e1" text="targeted" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d59.s4" origId="20193638.s0" text="Glioblastoma genetics: in rapid flux.  ">
            <entity charOffset="0-11" id="miRNA-corp.d59.s4.e0" text="Glioblastoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d59.s5" origId="20193638.s1" text="Glioblastoma is the most common and most lethal primary brain tumor. ">
            <entity charOffset="0-11" id="miRNA-corp.d59.s5.e0" text="Glioblastoma" type="Diseases"/>
            <entity charOffset="48-66" id="miRNA-corp.d59.s5.e1" text="primary brain tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d59.s6" origId="20193638.s2" text="While small progress has been made in treating this cancer in recent years, glioblastoma remains largely resistant to all existing therapies. ">
            <entity charOffset="52-57" id="miRNA-corp.d59.s6.e0" text="cancer" type="Diseases"/>
            <entity charOffset="76-87" id="miRNA-corp.d59.s6.e1" text="glioblastoma" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d60" origId="21805824">
        <sentence id="miRNA-corp.d60.s0" origId="21805824.s0" text="Biomarkers associated with metastasis of lung cancer to brain predict patient survival.  ">
            <entity charOffset="11-20" id="miRNA-corp.d60.s0.e0" text="associated" type="Relation_Trigger"/>
            <entity charOffset="41-51" id="miRNA-corp.d60.s0.e1" text="lung cancer" type="Diseases"/>
            <entity charOffset="70-76" id="miRNA-corp.d60.s0.e2" text="patient" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d60.s1" origId="21805824.s4" text="This research involves comprehensive miRNA expression profiling, evaluation of normalisation techniques and combination of miRNA with imaging features FDG-PET/CT and CT Scan. ">
            <entity charOffset="37-41" id="miRNA-corp.d60.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="123-127" id="miRNA-corp.d60.s1.e1" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d60.s2" origId="21805824.s3" text="We combine validated miRNA expression values with imaging features to classify NSCLC brain mets from non-brain mets and identify possible biomarkers of brain mets. ">
            <entity charOffset="21-25" id="miRNA-corp.d60.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d60.s3" origId="21805824.s2" text="Generally, one miRNA is predicted to regulate several hundred genes, and as a result, miRNAs could serve as a better classifier than gene expression. ">
            <entity charOffset="15-19" id="miRNA-corp.d60.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="37-44" id="miRNA-corp.d60.s3.e1" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="86-91" id="miRNA-corp.d60.s3.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d60.s4" origId="21805824.s1" text="MicroRNAs influence cell physiology; alteration in miRNA regulation can be implicated in carcinogenesis and disease progression. ">
            <entity charOffset="0-8" id="miRNA-corp.d60.s4.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="51-55" id="miRNA-corp.d60.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="37-66" id="miRNA-corp.d60.s4.e2" text="alteration in miRNA regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d60.s5" origId="21805824.s5" text="The biomarkers were validated on an independent data set to predict potential brain mets.   "/>
    </document>
    <document id="miRNA-corp.d61" origId="20607356">
        <sentence id="miRNA-corp.d61.s0" origId="20607356.s1" text="MicroRNAs (miRNAs) are small noncoding RNAs comprising 21-23 nucleotides that regulate gene expression by transcriptionally repressing their complementary mRNAs. ">
            <entity charOffset="0-8" id="miRNA-corp.d61.s0.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d61.s0.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="78-101" id="miRNA-corp.d61.s0.e2" text="regulate gene expression" type="Relation_Trigger"/>
            <entity charOffset="106-133" id="miRNA-corp.d61.s0.e3" text="transcriptionally repressing" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d61.s1" origId="20607356.s0" text="Let-7 microRNA inhibits the proliferation of human glioblastoma cells.  ">
            <entity charOffset="0-4" id="miRNA-corp.d61.s1.e0" text="Let-7" type="Specific_miRNAs"/>
            <entity charOffset="6-13" id="miRNA-corp.d61.s1.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="15-22" id="miRNA-corp.d61.s1.e2" text="inhibits" type="Relation_Trigger"/>
            <entity charOffset="45-62" id="miRNA-corp.d61.s1.e3" text="human glioblastoma" type="Diseases"/>
            <entity charOffset="45-49" id="miRNA-corp.d61.s1.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d61.s1.e0" e2="miRNA-corp.d61.s1.e3" id="miRNA-corp.d61.s1.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s1.e1" e2="miRNA-corp.d61.s1.e3" id="miRNA-corp.d61.s1.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d61.s2" origId="20607356.s5" text="Transfection of let-7 miRNA reduced expression of pan-RAS, N-RAS, and K-RAS in the glioblastoma cells. ">
            <entity charOffset="50-56" id="miRNA-corp.d61.s2.e0" text="pan-RAS" type="Genes/Proteins"/>
            <entity charOffset="59-63" id="miRNA-corp.d61.s2.e1" text="N-RAS" type="Genes/Proteins"/>
            <entity charOffset="70-74" id="miRNA-corp.d61.s2.e2" text="K-RAS" type="Genes/Proteins"/>
            <entity charOffset="16-20" id="miRNA-corp.d61.s2.e3" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="22-26" id="miRNA-corp.d61.s2.e4" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="28-45" id="miRNA-corp.d61.s2.e5" text="reduced expression" type="Relation_Trigger"/>
            <entity charOffset="83-94" id="miRNA-corp.d61.s2.e6" text="glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d61.s2.e3" e2="miRNA-corp.d61.s2.e0" id="miRNA-corp.d61.s2.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d61.s2.e3" e2="miRNA-corp.d61.s2.e1" id="miRNA-corp.d61.s2.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d61.s2.e3" e2="miRNA-corp.d61.s2.e2" id="miRNA-corp.d61.s2.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d61.s2.e3" e2="miRNA-corp.d61.s2.e6" id="miRNA-corp.d61.s2.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s2.e4" e2="miRNA-corp.d61.s2.e0" id="miRNA-corp.d61.s2.p4" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d61.s2.e4" e2="miRNA-corp.d61.s2.e1" id="miRNA-corp.d61.s2.p5" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d61.s2.e4" e2="miRNA-corp.d61.s2.e2" id="miRNA-corp.d61.s2.p6" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d61.s2.e4" e2="miRNA-corp.d61.s2.e6" id="miRNA-corp.d61.s2.p7" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d61.s3" origId="20607356.s4" text="Human glioblastoma cells (U251 or U87 cells) were transfected with let-7 miRNA and assayed for in-vitro proliferation, migration, and in-vivo tumor formation. ">
            <entity charOffset="0-17" id="miRNA-corp.d61.s3.e0" text="Human glioblastoma" type="Diseases"/>
            <entity charOffset="0-4" id="miRNA-corp.d61.s3.e1" text="Human" type="Species"/>
            <entity charOffset="67-71" id="miRNA-corp.d61.s3.e2" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="73-77" id="miRNA-corp.d61.s3.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="142-146" id="miRNA-corp.d61.s3.e4" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d61.s3.e2" e2="miRNA-corp.d61.s3.e0" id="miRNA-corp.d61.s3.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s3.e2" e2="miRNA-corp.d61.s3.e4" id="miRNA-corp.d61.s3.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s3.e3" e2="miRNA-corp.d61.s3.e0" id="miRNA-corp.d61.s3.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s3.e3" e2="miRNA-corp.d61.s3.e4" id="miRNA-corp.d61.s3.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d61.s4" origId="20607356.s3" text="In this study, we investigated the anti-tumorigenic effect of let-7 miRNA in glioblastoma cells. ">
            <entity charOffset="62-66" id="miRNA-corp.d61.s4.e0" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="68-72" id="miRNA-corp.d61.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="77-88" id="miRNA-corp.d61.s4.e2" text="glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d61.s4.e0" e2="miRNA-corp.d61.s4.e2" id="miRNA-corp.d61.s4.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s4.e1" e2="miRNA-corp.d61.s4.e2" id="miRNA-corp.d61.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d61.s5" origId="20607356.s2" text="In particular, let-7 miRNA has been postulated to function as a tumor suppressor in various cancer cells, but not yet in glioblastoma. ">
            <entity charOffset="15-19" id="miRNA-corp.d61.s5.e0" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="21-25" id="miRNA-corp.d61.s5.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="64-79" id="miRNA-corp.d61.s5.e2" text="tumor suppressor" type="Relation_Trigger"/>
            <entity charOffset="92-97" id="miRNA-corp.d61.s5.e3" text="cancer" type="Diseases"/>
            <entity charOffset="121-132" id="miRNA-corp.d61.s5.e4" text="glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d61.s5.e0" e2="miRNA-corp.d61.s5.e3" id="miRNA-corp.d61.s5.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s5.e0" e2="miRNA-corp.d61.s5.e4" id="miRNA-corp.d61.s5.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s5.e1" e2="miRNA-corp.d61.s5.e3" id="miRNA-corp.d61.s5.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s5.e1" e2="miRNA-corp.d61.s5.e4" id="miRNA-corp.d61.s5.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d61.s6" origId="20607356.s8" text="These results indicate that let-7 miRNA has an anti-tumorigenic effect on glioblastoma cells, and suggest possible use of let-7 miRNA for treating glioblastoma.   ">
            <entity charOffset="28-32" id="miRNA-corp.d61.s6.e0" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="34-38" id="miRNA-corp.d61.s6.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="74-85" id="miRNA-corp.d61.s6.e2" text="glioblastoma" type="Diseases"/>
            <entity charOffset="122-126" id="miRNA-corp.d61.s6.e3" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="128-132" id="miRNA-corp.d61.s6.e4" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="147-158" id="miRNA-corp.d61.s6.e5" text="glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d61.s6.e0" e2="miRNA-corp.d61.s6.e2" id="miRNA-corp.d61.s6.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s6.e0" e2="miRNA-corp.d61.s6.e5" id="miRNA-corp.d61.s6.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s6.e1" e2="miRNA-corp.d61.s6.e2" id="miRNA-corp.d61.s6.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s6.e1" e2="miRNA-corp.d61.s6.e5" id="miRNA-corp.d61.s6.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s6.e3" e2="miRNA-corp.d61.s6.e2" id="miRNA-corp.d61.s6.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s6.e3" e2="miRNA-corp.d61.s6.e5" id="miRNA-corp.d61.s6.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s6.e4" e2="miRNA-corp.d61.s6.e2" id="miRNA-corp.d61.s6.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s6.e4" e2="miRNA-corp.d61.s6.e5" id="miRNA-corp.d61.s6.p7" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d61.s7" origId="20607356.s7" text="However, let-7 miRNA exerted no effect on the proliferation of normal human astrocytes. ">
            <entity charOffset="9-13" id="miRNA-corp.d61.s7.e0" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="15-19" id="miRNA-corp.d61.s7.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="70-74" id="miRNA-corp.d61.s7.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d61.s8" origId="20607356.s6" text="Let-7 miRNA also reduced the in-vitro proliferation and migration of the cells, and reduced the sizes of the tumors produced after transplantation into nude mice. ">
            <entity charOffset="0-4" id="miRNA-corp.d61.s8.e0" text="Let-7" type="Specific_miRNAs"/>
            <entity charOffset="6-10" id="miRNA-corp.d61.s8.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="109-114" id="miRNA-corp.d61.s8.e2" text="tumors" type="Diseases"/>
            <entity charOffset="152-160" id="miRNA-corp.d61.s8.e3" text="nude mice" type="Species"/>
            <pair e1="miRNA-corp.d61.s8.e0" e2="miRNA-corp.d61.s8.e2" id="miRNA-corp.d61.s8.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s8.e1" e2="miRNA-corp.d61.s8.e2" id="miRNA-corp.d61.s8.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d62" origId="21506120">
        <sentence id="miRNA-corp.d62.s0" origId="21506120.s0" text="Proteasomal degradation of myocardin is required for its transcriptional activity in vascular smooth muscle cells.  ">
            <entity charOffset="27-35" id="miRNA-corp.d62.s0.e0" text="myocardin" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d62.s1" origId="21506120.s1" text="Myocardin is a transcriptional co-activator of serum response factor (SRF) and can be degraded through ubiquitin-proteasome system. ">
            <entity charOffset="103-111" id="miRNA-corp.d62.s1.e0" text="ubiquitin" type="Genes/Proteins"/>
            <entity charOffset="0-8" id="miRNA-corp.d62.s1.e1" text="Myocardin" type="Genes/Proteins"/>
            <entity charOffset="47-67" id="miRNA-corp.d62.s1.e2" text="serum response factor" type="Genes/Proteins"/>
            <entity charOffset="70-72" id="miRNA-corp.d62.s1.e3" text="SRF" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d62.s2" origId="21506120.s2" text="Our preliminary studies unexpectedly revealed that accumulation of myocardin in response to proteasome inhibition by MG132 or lactacystin resulted in decrease of transcriptional activity of myocardin as indicated by reduced expression of SMC contractile marker genes (SM α-actin, SM22, and calponin) and muscle-enriched microRNAs (miR-143/145 and miR-1/133a), and reduced contractility of human vascular smooth muscle cells (SMCs) embedded in collagen gel lattices, suggesting that myocardin degradation is required for its transcriptional activity. ">
            <entity charOffset="280-283" id="miRNA-corp.d62.s2.e0" text="SM22" type="Genes/Proteins"/>
            <entity charOffset="290-297" id="miRNA-corp.d62.s2.e1" text="calponin" type="Genes/Proteins"/>
            <entity charOffset="67-75" id="miRNA-corp.d62.s2.e2" text="myocardin" type="Genes/Proteins"/>
            <entity charOffset="103-112" id="miRNA-corp.d62.s2.e3" text="inhibition" type="Relation_Trigger"/>
            <entity charOffset="190-198" id="miRNA-corp.d62.s2.e4" text="myocardin" type="Genes/Proteins"/>
            <entity charOffset="216-233" id="miRNA-corp.d62.s2.e5" text="reduced expression" type="Relation_Trigger"/>
            <entity charOffset="320-328" id="miRNA-corp.d62.s2.e6" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="331-341" id="miRNA-corp.d62.s2.e7" text="miR-143/145" type="Specific_miRNAs"/>
            <entity charOffset="347-356" id="miRNA-corp.d62.s2.e8" text="miR-1/133a" type="Specific_miRNAs"/>
            <entity charOffset="389-393" id="miRNA-corp.d62.s2.e9" text="human" type="Species"/>
            <entity charOffset="482-490" id="miRNA-corp.d62.s2.e10" text="myocardin" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d62.s2.e6" e2="miRNA-corp.d62.s2.e0" id="miRNA-corp.d62.s2.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d62.s2.e6" e2="miRNA-corp.d62.s2.e1" id="miRNA-corp.d62.s2.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d62.s2.e6" e2="miRNA-corp.d62.s2.e4" id="miRNA-corp.d62.s2.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d62.s2.e6" e2="miRNA-corp.d62.s2.e10" id="miRNA-corp.d62.s2.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d62.s2.e6" e2="miRNA-corp.d62.s2.e2" id="miRNA-corp.d62.s2.p4" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d62.s2.e7" e2="miRNA-corp.d62.s2.e0" id="miRNA-corp.d62.s2.p5" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d62.s2.e7" e2="miRNA-corp.d62.s2.e1" id="miRNA-corp.d62.s2.p6" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d62.s2.e7" e2="miRNA-corp.d62.s2.e4" id="miRNA-corp.d62.s2.p7" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d62.s2.e7" e2="miRNA-corp.d62.s2.e10" id="miRNA-corp.d62.s2.p8" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d62.s2.e7" e2="miRNA-corp.d62.s2.e2" id="miRNA-corp.d62.s2.p9" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d62.s2.e8" e2="miRNA-corp.d62.s2.e0" id="miRNA-corp.d62.s2.p10" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d62.s2.e8" e2="miRNA-corp.d62.s2.e1" id="miRNA-corp.d62.s2.p11" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d62.s2.e8" e2="miRNA-corp.d62.s2.e4" id="miRNA-corp.d62.s2.p12" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d62.s2.e8" e2="miRNA-corp.d62.s2.e10" id="miRNA-corp.d62.s2.p13" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d62.s2.e8" e2="miRNA-corp.d62.s2.e2" id="miRNA-corp.d62.s2.p14" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d62.s3" origId="21506120.s3" text="Further studies using chromatin immunoprecipitation assay revealed that proteasome inhibition, although increased the occupancy of myocardin and SRF on the promoter of SM α-actin gene, abolished myocardin-dependent recruitment of RNA polymerase II. ">
            <entity charOffset="83-92" id="miRNA-corp.d62.s3.e0" text="inhibition" type="Relation_Trigger"/>
            <entity charOffset="131-139" id="miRNA-corp.d62.s3.e1" text="myocardin" type="Genes/Proteins"/>
            <entity charOffset="145-147" id="miRNA-corp.d62.s3.e2" text="SRF" type="Genes/Proteins"/>
            <entity charOffset="195-203" id="miRNA-corp.d62.s3.e3" text="myocardin" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d62.s4" origId="21506120.s4" text="We further examined the degradation of myocardin in epithelioid and spindle-shaped SMCs and revealed that myocardin in more differentiated spindle-shaped SMCs was more quickly degraded and had shorter half-life than in epithelioid SMCs. ">
            <entity charOffset="24-34" id="miRNA-corp.d62.s4.e0" text="degradation" type="Relation_Trigger"/>
            <entity charOffset="39-47" id="miRNA-corp.d62.s4.e1" text="myocardin" type="Genes/Proteins"/>
            <entity charOffset="106-114" id="miRNA-corp.d62.s4.e2" text="myocardin" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d62.s5" origId="21506120.s5" text="In neointimal lesions, we found that stabilization of myocardin protein was companied by downregulation of transcripts of ubiquitin and proteasome subunits, further illustrating the mechanism underlying reduction of myocardin transcriptional activity. ">
            <entity charOffset="3-20" id="miRNA-corp.d62.s5.e0" text="neointimal lesions" type="Diseases"/>
            <entity charOffset="122-130" id="miRNA-corp.d62.s5.e1" text="ubiquitin" type="Genes/Proteins"/>
            <entity charOffset="54-62" id="miRNA-corp.d62.s5.e2" text="myocardin" type="Genes/Proteins"/>
            <entity charOffset="89-102" id="miRNA-corp.d62.s5.e3" text="downregulation" type="Relation_Trigger"/>
            <entity charOffset="203-211" id="miRNA-corp.d62.s5.e4" text="reduction" type="Relation_Trigger"/>
            <entity charOffset="216-224" id="miRNA-corp.d62.s5.e5" text="myocardin" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d62.s6" origId="21506120.s6" text="In summary, our results have suggested that proteasomal degradation of myocardin is required for its transcriptional activity.   ">
            <entity charOffset="71-79" id="miRNA-corp.d62.s6.e0" text="myocardin" type="Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d63" origId="20106983">
        <sentence id="miRNA-corp.d63.s0" origId="20106983.s6" text="These findings reveal a significant additional mechanism by which alpha-synuclein is regulated and point toward new therapeutic regimes for lowering endogenous alpha-synuclein levels in patients with familial or sporadic Parkinson disease.   ">
            <entity charOffset="66-80" id="miRNA-corp.d63.s0.e0" text="alpha-synuclein" type="Genes/Proteins"/>
            <entity charOffset="85-93" id="miRNA-corp.d63.s0.e1" text="regulated" type="Relation_Trigger"/>
            <entity charOffset="160-174" id="miRNA-corp.d63.s0.e2" text="alpha-synuclein" type="Genes/Proteins"/>
            <entity charOffset="140-181" id="miRNA-corp.d63.s0.e3" text="lowering endogenous alpha-synuclein levels" type="Relation_Trigger"/>
            <entity charOffset="186-193" id="miRNA-corp.d63.s0.e4" text="patients" type="Species"/>
            <entity charOffset="212-237" id="miRNA-corp.d63.s0.e5" text="sporadic Parkinson disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d63.s1" origId="20106983.s5" text="Overexpression of mir-7 and mir-153 significantly reduces endogenous alpha-synuclein levels, whereas inhibition of mir-7 and mir-153 enhances translation of a luciferase construct bearing the alpha-synuclein 3'-untranslated region in primary neurons. ">
            <entity charOffset="0-13" id="miRNA-corp.d63.s1.e0" text="Overexpression" type="Relation_Trigger"/>
            <entity charOffset="18-22" id="miRNA-corp.d63.s1.e1" text="mir-7" type="Specific_miRNAs"/>
            <entity charOffset="28-34" id="miRNA-corp.d63.s1.e2" text="mir-153" type="Specific_miRNAs"/>
            <entity charOffset="36-56" id="miRNA-corp.d63.s1.e3" text="significantly reduces" type="Relation_Trigger"/>
            <entity charOffset="69-83" id="miRNA-corp.d63.s1.e4" text="alpha-synuclein" type="Genes/Proteins"/>
            <entity charOffset="101-110" id="miRNA-corp.d63.s1.e5" text="inhibition" type="Relation_Trigger"/>
            <entity charOffset="115-119" id="miRNA-corp.d63.s1.e6" text="mir-7" type="Specific_miRNAs"/>
            <entity charOffset="125-131" id="miRNA-corp.d63.s1.e7" text="mir-153" type="Specific_miRNAs"/>
            <entity charOffset="192-206" id="miRNA-corp.d63.s1.e8" text="alpha-synuclein" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d63.s1.e1" e2="miRNA-corp.d63.s1.e4" id="miRNA-corp.d63.s1.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d63.s1.e1" e2="miRNA-corp.d63.s1.e8" id="miRNA-corp.d63.s1.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d63.s1.e2" e2="miRNA-corp.d63.s1.e4" id="miRNA-corp.d63.s1.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d63.s1.e2" e2="miRNA-corp.d63.s1.e8" id="miRNA-corp.d63.s1.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d63.s1.e6" e2="miRNA-corp.d63.s1.e4" id="miRNA-corp.d63.s1.p4" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d63.s1.e6" e2="miRNA-corp.d63.s1.e8" id="miRNA-corp.d63.s1.p5" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d63.s1.e7" e2="miRNA-corp.d63.s1.e4" id="miRNA-corp.d63.s1.p6" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d63.s1.e7" e2="miRNA-corp.d63.s1.e8" id="miRNA-corp.d63.s1.p7" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d63.s2" origId="20106983.s4" text="They are expressed predominantly in the brain with a pattern that mirrors synuclein expression in different tissues as well as during neuronal development, indicating that they play a tuning role in the amount of alpha-synuclein produced. ">
            <entity charOffset="213-227" id="miRNA-corp.d63.s2.e0" text="alpha-synuclein" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d63.s3" origId="20106983.s3" text="These microRNAs bind specifically to the 3'-untranslated region of alpha-synuclein and down-regulate its mRNA and protein levels, with their effect being additive. ">
            <entity charOffset="6-14" id="miRNA-corp.d63.s3.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="16-62" id="miRNA-corp.d63.s3.e1" text="bind specifically to the 3'-untranslated region" type="Relation_Trigger"/>
            <entity charOffset="67-81" id="miRNA-corp.d63.s3.e2" text="alpha-synuclein" type="Genes/Proteins"/>
            <entity charOffset="87-99" id="miRNA-corp.d63.s3.e3" text="down-regulate" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d63.s3.e0" e2="miRNA-corp.d63.s3.e2" id="miRNA-corp.d63.s3.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d63.s4" origId="20106983.s2" text="Here, two microRNAs, namely mir-7 and mir-153, have been identified to regulate alpha-synuclein levels post-transcriptionally. ">
            <entity charOffset="10-18" id="miRNA-corp.d63.s4.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="28-32" id="miRNA-corp.d63.s4.e1" text="mir-7" type="Specific_miRNAs"/>
            <entity charOffset="38-44" id="miRNA-corp.d63.s4.e2" text="mir-153" type="Specific_miRNAs"/>
            <entity charOffset="80-94" id="miRNA-corp.d63.s4.e3" text="alpha-synuclein" type="Genes/Proteins"/>
            <entity charOffset="71-101" id="miRNA-corp.d63.s4.e4" text="regulate alpha-synuclein levels" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d63.s4.e0" e2="miRNA-corp.d63.s4.e3" id="miRNA-corp.d63.s4.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d63.s4.e1" e2="miRNA-corp.d63.s4.e3" id="miRNA-corp.d63.s4.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d63.s4.e2" e2="miRNA-corp.d63.s4.e3" id="miRNA-corp.d63.s4.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d63.s5" origId="20106983.s1" text="Genetic and biochemical studies have established a central role for alpha-synuclein accumulation in the pathogenesis of Parkinson disease. ">
            <entity charOffset="68-82" id="miRNA-corp.d63.s5.e0" text="alpha-synuclein" type="Genes/Proteins"/>
            <entity charOffset="120-136" id="miRNA-corp.d63.s5.e1" text="Parkinson disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d63.s6" origId="20106983.s0" text="Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153.  ">
            <entity charOffset="35-49" id="miRNA-corp.d63.s6.e0" text="alpha-synuclein" type="Genes/Proteins"/>
            <entity charOffset="65-69" id="miRNA-corp.d63.s6.e1" text="mir-7" type="Specific_miRNAs"/>
            <entity charOffset="75-81" id="miRNA-corp.d63.s6.e2" text="mir-153" type="Specific_miRNAs"/>
            <entity charOffset="21-60" id="miRNA-corp.d63.s6.e3" text="regulation of alpha-synuclein expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d63.s6.e1" e2="miRNA-corp.d63.s6.e0" id="miRNA-corp.d63.s6.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d63.s6.e2" e2="miRNA-corp.d63.s6.e0" id="miRNA-corp.d63.s6.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d64" origId="21908875">
        <sentence id="miRNA-corp.d64.s0" origId="21908875.s11" text="The findings also indicate that allopregnanolone and perhaps other neurosteroid-like compounds might represent potential biomarkers or therapies for multiple sclerosis. ">
            <entity charOffset="149-166" id="miRNA-corp.d64.s0.e0" text="multiple sclerosis" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d64.s1" origId="21908875.s10" text="These multi-platform studies point to impaired neurosteroidogenesis in both multiple sclerosis and experimental autoimmune encephalomyelitis. ">
            <entity charOffset="76-93" id="miRNA-corp.d64.s1.e0" text="multiple sclerosis" type="Diseases"/>
            <entity charOffset="112-139" id="miRNA-corp.d64.s1.e1" text="autoimmune encephalomyelitis" type="Diseases"/>
            <entity charOffset="38-45" id="miRNA-corp.d64.s1.e2" text="impaired" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d64.s2" origId="21908875.s9" text="Allopregnanolone treatment of the experimental autoimmune encephalomyelitis mouse model limited the associated neuropathology, including neuroinflammation, myelin and axonal injury and reduced neurobehavioral deficits (P &lt; 0.05). ">
            <entity charOffset="47-74" id="miRNA-corp.d64.s2.e0" text="autoimmune encephalomyelitis" type="Diseases"/>
            <entity charOffset="76-80" id="miRNA-corp.d64.s2.e1" text="mouse" type="Species"/>
            <entity charOffset="100-109" id="miRNA-corp.d64.s2.e2" text="associated" type="Relation_Trigger"/>
            <entity charOffset="167-179" id="miRNA-corp.d64.s2.e3" text="axonal injury" type="Diseases"/>
            <entity charOffset="137-153" id="miRNA-corp.d64.s2.e4" text="neuroinflammation" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d64.s3" origId="21908875.s7" text="Levels of important neurosteroids, including allopregnanolone, were suppressed in the white matter of patients with multiple sclerosis (P &lt; 0.05). ">
            <entity charOffset="68-77" id="miRNA-corp.d64.s3.e0" text="suppressed" type="Relation_Trigger"/>
            <entity charOffset="102-109" id="miRNA-corp.d64.s3.e1" text="patients" type="Species"/>
            <entity charOffset="116-133" id="miRNA-corp.d64.s3.e2" text="multiple sclerosis" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d64.s4" origId="21908875.s8" text="Induction of the murine micro-RNAs, miR-338 and miR-155, accompanied by diminished expression of neurosteroidogenic enzymes and allopregnanolone, was also observed in the brains of mice with experimental autoimmune encephalomyelitis (P &lt; 0.05). ">
            <entity charOffset="17-22" id="miRNA-corp.d64.s4.e0" text="murine" type="Species"/>
            <entity charOffset="24-33" id="miRNA-corp.d64.s4.e1" text="micro-RNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="36-42" id="miRNA-corp.d64.s4.e2" text="miR-338" type="Specific_miRNAs"/>
            <entity charOffset="48-54" id="miRNA-corp.d64.s4.e3" text="miR-155" type="Specific_miRNAs"/>
            <entity charOffset="181-184" id="miRNA-corp.d64.s4.e4" text="mice" type="Species"/>
            <entity charOffset="204-231" id="miRNA-corp.d64.s4.e5" text="autoimmune encephalomyelitis" type="Diseases"/>
            <entity charOffset="72-92" id="miRNA-corp.d64.s4.e6" text="diminished expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d64.s4.e1" e2="miRNA-corp.d64.s4.e5" id="miRNA-corp.d64.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d64.s4.e2" e2="miRNA-corp.d64.s4.e5" id="miRNA-corp.d64.s4.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d64.s4.e3" e2="miRNA-corp.d64.s4.e5" id="miRNA-corp.d64.s4.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d64.s5" origId="21908875.s5" text="Analysis of the neurosteroidogenic pathways targeted by micro-RNAs revealed suppression of enzyme transcript and protein levels in the white matter of patients with multiple sclerosis (P &lt; 0.05). ">
            <entity charOffset="56-65" id="miRNA-corp.d64.s5.e0" text="micro-RNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="44-51" id="miRNA-corp.d64.s5.e1" text="targeted" type="Relation_Trigger"/>
            <entity charOffset="76-86" id="miRNA-corp.d64.s5.e2" text="suppression" type="Relation_Trigger"/>
            <entity charOffset="151-158" id="miRNA-corp.d64.s5.e3" text="patients" type="Species"/>
            <entity charOffset="165-182" id="miRNA-corp.d64.s5.e4" text="multiple sclerosis" type="Diseases"/>
            <pair e1="miRNA-corp.d64.s5.e0" e2="miRNA-corp.d64.s5.e4" id="miRNA-corp.d64.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d64.s6" origId="21908875.s6" text="This was confirmed by firefly/Renilla luciferase micro-RNA target knockdown experiments (P &lt; 0.05) and detection of specific micro-RNAs by in situ hybridization in the brains of patients with or without multiple sclerosis. ">
            <entity charOffset="49-57" id="miRNA-corp.d64.s6.e0" text="micro-RNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="59-64" id="miRNA-corp.d64.s6.e1" text="target" type="Relation_Trigger"/>
            <entity charOffset="125-134" id="miRNA-corp.d64.s6.e2" text="micro-RNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="178-185" id="miRNA-corp.d64.s6.e3" text="patients" type="Species"/>
            <entity charOffset="203-220" id="miRNA-corp.d64.s6.e4" text="multiple sclerosis" type="Diseases"/>
            <pair e1="miRNA-corp.d64.s6.e0" e2="miRNA-corp.d64.s6.e4" id="miRNA-corp.d64.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d64.s6.e2" e2="miRNA-corp.d64.s6.e4" id="miRNA-corp.d64.s6.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d64.s7" origId="21908875.s3" text="These observations were verified using the in vivo multiple sclerosis model, experimental autoimmune encephalomyelitis. ">
            <entity charOffset="90-117" id="miRNA-corp.d64.s7.e0" text="autoimmune encephalomyelitis" type="Diseases"/>
            <entity charOffset="51-68" id="miRNA-corp.d64.s7.e1" text="multiple sclerosis" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d64.s8" origId="21908875.s4" text="Brains of patients with or without multiple sclerosis demonstrated differential expression of multiple micro-RNAs, but expression of three neurosteroid synthesis enzyme-specific micro-RNAs (miR-338, miR-155 and miR-491) showed a bias towards induction in patients with multiple sclerosis (P &lt; 0.05). ">
            <entity charOffset="10-17" id="miRNA-corp.d64.s8.e0" text="patients" type="Species"/>
            <entity charOffset="35-52" id="miRNA-corp.d64.s8.e1" text="multiple sclerosis" type="Diseases"/>
            <entity charOffset="103-112" id="miRNA-corp.d64.s8.e2" text="micro-RNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="178-187" id="miRNA-corp.d64.s8.e3" text="micro-RNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="190-196" id="miRNA-corp.d64.s8.e4" text="miR-338" type="Specific_miRNAs"/>
            <entity charOffset="199-205" id="miRNA-corp.d64.s8.e5" text="miR-155" type="Specific_miRNAs"/>
            <entity charOffset="211-217" id="miRNA-corp.d64.s8.e6" text="miR-491" type="Specific_miRNAs"/>
            <entity charOffset="255-262" id="miRNA-corp.d64.s8.e7" text="patients" type="Species"/>
            <entity charOffset="269-286" id="miRNA-corp.d64.s8.e8" text="multiple sclerosis" type="Diseases"/>
            <entity charOffset="67-89" id="miRNA-corp.d64.s8.e9" text="differential expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d64.s8.e3" e2="miRNA-corp.d64.s8.e8" id="miRNA-corp.d64.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d64.s8.e3" e2="miRNA-corp.d64.s8.e1" id="miRNA-corp.d64.s8.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d64.s8.e4" e2="miRNA-corp.d64.s8.e8" id="miRNA-corp.d64.s8.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d64.s8.e4" e2="miRNA-corp.d64.s8.e1" id="miRNA-corp.d64.s8.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d64.s8.e5" e2="miRNA-corp.d64.s8.e8" id="miRNA-corp.d64.s8.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d64.s8.e5" e2="miRNA-corp.d64.s8.e1" id="miRNA-corp.d64.s8.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d64.s8.e6" e2="miRNA-corp.d64.s8.e8" id="miRNA-corp.d64.s8.p6" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d64.s8.e6" e2="miRNA-corp.d64.s8.e1" id="miRNA-corp.d64.s8.p7" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d64.s8.e2" e2="miRNA-corp.d64.s8.e8" id="miRNA-corp.d64.s8.p8" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d64.s8.e2" e2="miRNA-corp.d64.s8.e1" id="miRNA-corp.d64.s8.p9" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d64.s9" origId="21908875.s1" text="High-throughput technologies have led to advances in the recognition of disease pathways and their underlying mechanisms. "/>
        <sentence id="miRNA-corp.d64.s10" origId="21908875.s2" text="To investigate the impact of micro-RNAs on the disease process in multiple sclerosis, a prototypic inflammatory neurological disorder, we examined cerebral white matter from patients with or without the disease by micro-RNA profiling, together with confirmatory reverse transcription-polymerase chain reaction analysis, immunoblotting and gas chromatography-mass spectrometry. ">
            <entity charOffset="29-38" id="miRNA-corp.d64.s10.e0" text="micro-RNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="66-83" id="miRNA-corp.d64.s10.e1" text="multiple sclerosis" type="Diseases"/>
            <entity charOffset="88-132" id="miRNA-corp.d64.s10.e2" text="prototypic inflammatory neurological disorder" type="Diseases"/>
            <entity charOffset="174-181" id="miRNA-corp.d64.s10.e3" text="patients" type="Species"/>
            <entity charOffset="214-222" id="miRNA-corp.d64.s10.e4" text="micro-RNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d64.s10.e0" e2="miRNA-corp.d64.s10.e1" id="miRNA-corp.d64.s10.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d64.s10.e0" e2="miRNA-corp.d64.s10.e2" id="miRNA-corp.d64.s10.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d64.s10.e4" e2="miRNA-corp.d64.s10.e1" id="miRNA-corp.d64.s10.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d64.s10.e4" e2="miRNA-corp.d64.s10.e2" id="miRNA-corp.d64.s10.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d64.s11" origId="21908875.s0" text="Impaired neurosteroid synthesis in multiple sclerosis.  ">
            <entity charOffset="35-52" id="miRNA-corp.d64.s11.e0" text="multiple sclerosis" type="Diseases"/>
            <entity charOffset="0-7" id="miRNA-corp.d64.s11.e1" text="Impaired" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d65" origId="21468006">
        <sentence id="miRNA-corp.d65.s0" origId="21468006.s3" text="Since neuron-specific microRNA-7 is downregulated in gliomas but highly expressed in normal brain tissue, we engineered a microRNA-sensitive virus containing target sites for microRNA-7 in the 3'-untranslated region of the viral fusion gene. ">
            <entity charOffset="158-163" id="miRNA-corp.d65.s0.e0" text="target" type="Relation_Trigger"/>
            <entity charOffset="22-31" id="miRNA-corp.d65.s0.e1" text="microRNA-7" type="Specific_miRNAs"/>
            <entity charOffset="36-48" id="miRNA-corp.d65.s0.e2" text="downregulated" type="Relation_Trigger"/>
            <entity charOffset="53-59" id="miRNA-corp.d65.s0.e3" text="gliomas" type="Diseases"/>
            <entity charOffset="65-80" id="miRNA-corp.d65.s0.e4" text="highly expressed" type="Relation_Trigger"/>
            <entity charOffset="122-129" id="miRNA-corp.d65.s0.e5" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="175-184" id="miRNA-corp.d65.s0.e6" text="microRNA-7" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d65.s0.e1" e2="miRNA-corp.d65.s0.e3" id="miRNA-corp.d65.s0.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d65.s0.e5" e2="miRNA-corp.d65.s0.e3" id="miRNA-corp.d65.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d65.s0.e6" e2="miRNA-corp.d65.s0.e3" id="miRNA-corp.d65.s0.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d65.s1" origId="21468006.s2" text="Recent preclinical studies have shown that the cellular tropism of several viruses can be controlled by inserting microRNA-target sequences into their genomes, thereby inhibiting spread in tissues expressing cognate microRNAs. ">
            <entity charOffset="123-128" id="miRNA-corp.d65.s1.e0" text="target" type="Relation_Trigger"/>
            <entity charOffset="114-121" id="miRNA-corp.d65.s1.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="168-177" id="miRNA-corp.d65.s1.e2" text="inhibiting" type="Relation_Trigger"/>
            <entity charOffset="216-224" id="miRNA-corp.d65.s1.e3" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d65.s2" origId="21468006.s1" text="Oncolytic measles viruses (MV) derived from the live attenuated vaccine strain have been engineered for increased tumor-cell specificity, and are currently under investigation in clinical trials including a phase I study for glioblastoma multiforme (GBM). ">
            <entity charOffset="114-118" id="miRNA-corp.d65.s2.e0" text="tumor" type="Diseases"/>
            <entity charOffset="225-247" id="miRNA-corp.d65.s2.e1" text="glioblastoma multiforme" type="Diseases"/>
            <entity charOffset="250-252" id="miRNA-corp.d65.s2.e2" text="GBM" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d65.s3" origId="21468006.s0" text="MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism.  ">
            <entity charOffset="0-7" id="miRNA-corp.d65.s3.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="49-54" id="miRNA-corp.d65.s3.e1" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d65.s3.e0" e2="miRNA-corp.d65.s3.e1" id="miRNA-corp.d65.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d65.s4" origId="21468006.s8" text="This is proof-of-concept that tropism restriction by tissue-specific microRNAs can be adapted to oncolytic MV to regulate viral replication and gene expression to maximize tumor specificity without compromising oncolytic efficacy.   ">
            <entity charOffset="69-77" id="miRNA-corp.d65.s4.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="113-120" id="miRNA-corp.d65.s4.e1" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="172-176" id="miRNA-corp.d65.s4.e2" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d65.s4.e0" e2="miRNA-corp.d65.s4.e2" id="miRNA-corp.d65.s4.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d65.s5" origId="21468006.s6" text="Furthermore, microRNA-mediated inhibition protected genetically modified mice susceptible to MV infection from a potentially lethal intracerebral challenge. ">
            <entity charOffset="93-104" id="miRNA-corp.d65.s5.e0" text="MV infection" type="Diseases"/>
            <entity charOffset="13-20" id="miRNA-corp.d65.s5.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="31-40" id="miRNA-corp.d65.s5.e2" text="inhibition" type="Relation_Trigger"/>
            <entity charOffset="73-76" id="miRNA-corp.d65.s5.e3" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d65.s5.e1" e2="miRNA-corp.d65.s5.e0" id="miRNA-corp.d65.s5.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d65.s6" origId="21468006.s7" text="Importantly, endogenous microRNA-7 expression in primary human brain resections tightly restricted replication and spread of microRNA-sensitive virus. ">
            <entity charOffset="24-33" id="miRNA-corp.d65.s6.e0" text="microRNA-7" type="Specific_miRNAs"/>
            <entity charOffset="57-61" id="miRNA-corp.d65.s6.e1" text="human" type="Species"/>
            <entity charOffset="125-132" id="miRNA-corp.d65.s6.e2" text="microRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d65.s7" origId="21468006.s4" text="In presence of microRNA-7 this modification inhibits translation of envelope proteins, restricts viral spread, and progeny production. ">
            <entity charOffset="15-24" id="miRNA-corp.d65.s7.e0" text="microRNA-7" type="Specific_miRNAs"/>
            <entity charOffset="44-63" id="miRNA-corp.d65.s7.e1" text="inhibits translation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d65.s8" origId="21468006.s5" text="Even though highly attenuated in presence of microRNA-7, this virus retained full efficacy against glioblastoma xenografts. ">
            <entity charOffset="45-54" id="miRNA-corp.d65.s8.e0" text="microRNA-7" type="Specific_miRNAs"/>
            <entity charOffset="99-110" id="miRNA-corp.d65.s8.e1" text="glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d65.s8.e0" e2="miRNA-corp.d65.s8.e1" id="miRNA-corp.d65.s8.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d66" origId="20378606">
        <sentence id="miRNA-corp.d66.s0" origId="20378606.s7" text="Finally, the association of the variant with stroke was tested in 438 stroke patients and 890 controls, and replicated in an independent population of 1791 stroke patients and 1843 controls. ">
            <entity charOffset="13-23" id="miRNA-corp.d66.s0.e0" text="association" type="Relation_Trigger"/>
            <entity charOffset="45-50" id="miRNA-corp.d66.s0.e1" text="stroke" type="Diseases"/>
            <entity charOffset="70-75" id="miRNA-corp.d66.s0.e2" text="stroke" type="Diseases"/>
            <entity charOffset="156-161" id="miRNA-corp.d66.s0.e3" text="stroke" type="Diseases"/>
            <entity charOffset="163-170" id="miRNA-corp.d66.s0.e4" text="patients" type="Species"/>
            <entity charOffset="77-84" id="miRNA-corp.d66.s0.e5" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s1" origId="20378606.s8" text="The TT genotype resulted in a significant reduction in overall stroke risk {OR, 0.51 [95% confidence interval (CI), 0.36-0.74], P = 0.0003}, ischemic stroke [OR, 0.56 (95% CI, 0.36-0.85), P = 0.007] and hemorrhagic stroke [OR, 0.46 (95% CI, 0.26-0.80), P = 0.007]. ">
            <entity charOffset="63-68" id="miRNA-corp.d66.s1.e0" text="stroke" type="Diseases"/>
            <entity charOffset="30-50" id="miRNA-corp.d66.s1.e1" text="significant reduction" type="Relation_Trigger"/>
            <entity charOffset="141-155" id="miRNA-corp.d66.s1.e2" text="ischemic stroke" type="Diseases"/>
            <entity charOffset="203-220" id="miRNA-corp.d66.s1.e3" text="hemorrhagic stroke" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s2" origId="20378606.s5" text="We found that the A allele of rs2507800 suppressed angiopoietin-1 translation by facilitating miR-211 binding, but not the T allele. ">
            <entity charOffset="51-64" id="miRNA-corp.d66.s2.e0" text="angiopoietin-1" type="Genes/Proteins"/>
            <entity charOffset="40-49" id="miRNA-corp.d66.s2.e1" text="suppressed" type="Relation_Trigger"/>
            <entity charOffset="94-100" id="miRNA-corp.d66.s2.e2" text="miR-211" type="Specific_miRNAs"/>
            <entity charOffset="102-108" id="miRNA-corp.d66.s2.e3" text="binding" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d66.s2.e2" e2="miRNA-corp.d66.s2.e0" id="miRNA-corp.d66.s2.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s3" origId="20378606.s6" text="Subjects carrying the TT genotype had higher plasma angiopoietin-1 levels than those with the A allele. ">
            <entity charOffset="52-65" id="miRNA-corp.d66.s3.e0" text="angiopoietin-1" type="Genes/Proteins"/>
            <entity charOffset="38-72" id="miRNA-corp.d66.s3.e1" text="higher plasma angiopoietin-1 levels" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s4" origId="20378606.s3" text="To test our hypothesis, a predicted microRNA-binding site was found in the 3'-UTR of angiopoietin-1 using bioinformatics; variant rs2507800 was identified to be located in the miR-211-binding site of angiopoietin-1. ">
            <entity charOffset="36-43" id="miRNA-corp.d66.s4.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="85-98" id="miRNA-corp.d66.s4.e1" text="angiopoietin-1" type="Genes/Proteins"/>
            <entity charOffset="176-182" id="miRNA-corp.d66.s4.e2" text="miR-211" type="Specific_miRNAs"/>
            <entity charOffset="200-213" id="miRNA-corp.d66.s4.e3" text="angiopoietin-1" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d66.s4.e2" e2="miRNA-corp.d66.s4.e3" id="miRNA-corp.d66.s4.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d66.s4.e2" e2="miRNA-corp.d66.s4.e1" id="miRNA-corp.d66.s4.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d66.s4.e0" e2="miRNA-corp.d66.s4.e3" id="miRNA-corp.d66.s4.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d66.s4.e0" e2="miRNA-corp.d66.s4.e1" id="miRNA-corp.d66.s4.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s5" origId="20378606.s4" text="Secondly, the effects of the identified variant on angiopoietin-1 translation were assessed using a luciferase reporter assay and ELISA. ">
            <entity charOffset="51-64" id="miRNA-corp.d66.s5.e0" text="angiopoietin-1" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s6" origId="20378606.s1" text="Angiopoietin-1 is a vascular strengthening factor during vascular development and a protective factor for pathological vascular inflammation and leakage. ">
            <entity charOffset="0-13" id="miRNA-corp.d66.s6.e0" text="Angiopoietin-1" type="Genes/Proteins"/>
            <entity charOffset="119-139" id="miRNA-corp.d66.s6.e1" text="vascular inflammation" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s7" origId="20378606.s2" text="Brain vascular leaking and inflammation are two important pathological processes of stroke; therefore, we hypothesized that variants of the microRNA-binding site in angiopoietin-1 would affect its expression and confer a risk of stroke. ">
            <entity charOffset="84-89" id="miRNA-corp.d66.s7.e0" text="stroke" type="Diseases"/>
            <entity charOffset="140-147" id="miRNA-corp.d66.s7.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="165-178" id="miRNA-corp.d66.s7.e2" text="angiopoietin-1" type="Genes/Proteins"/>
            <entity charOffset="229-234" id="miRNA-corp.d66.s7.e3" text="stroke" type="Diseases"/>
            <entity charOffset="186-206" id="miRNA-corp.d66.s7.e4" text="affect its expression" type="Relation_Trigger"/>
            <entity charOffset="27-38" id="miRNA-corp.d66.s7.e5" text="inflammation" type="Diseases"/>
            <pair e1="miRNA-corp.d66.s7.e1" e2="miRNA-corp.d66.s7.e5" id="miRNA-corp.d66.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d66.s7.e1" e2="miRNA-corp.d66.s7.e0" id="miRNA-corp.d66.s7.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d66.s7.e1" e2="miRNA-corp.d66.s7.e2" id="miRNA-corp.d66.s7.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d66.s7.e1" e2="miRNA-corp.d66.s7.e3" id="miRNA-corp.d66.s7.p3" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s8" origId="20378606.s0" text="A functional variant in the 3'-UTR of angiopoietin-1 might reduce stroke risk by interfering with the binding efficiency of microRNA 211.  ">
            <entity charOffset="38-51" id="miRNA-corp.d66.s8.e0" text="angiopoietin-1" type="Genes/Proteins"/>
            <entity charOffset="66-71" id="miRNA-corp.d66.s8.e1" text="stroke" type="Diseases"/>
            <entity charOffset="124-135" id="miRNA-corp.d66.s8.e2" text="microRNA 211" type="Specific_miRNAs"/>
            <entity charOffset="102-108" id="miRNA-corp.d66.s8.e3" text="binding" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d66.s8.e2" e2="miRNA-corp.d66.s8.e0" id="miRNA-corp.d66.s8.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d66.s8.e2" e2="miRNA-corp.d66.s8.e1" id="miRNA-corp.d66.s8.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s9" origId="20378606.s10" text="Our results provide evidence that the TT genotype (rs2507800) in the 3'-UTR of angiopoietin-1 might reduce the risk of stroke by interfering with miR-211 binding.   ">
            <entity charOffset="119-124" id="miRNA-corp.d66.s9.e0" text="stroke" type="Diseases"/>
            <entity charOffset="146-152" id="miRNA-corp.d66.s9.e1" text="miR-211" type="Specific_miRNAs"/>
            <entity charOffset="79-92" id="miRNA-corp.d66.s9.e2" text="angiopoietin-1" type="Genes/Proteins"/>
            <entity charOffset="154-160" id="miRNA-corp.d66.s9.e3" text="binding" type="Relation_Trigger"/>
            <entity charOffset="154-160" id="miRNA-corp.d66.s9.e4" text="binding" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d66.s9.e1" e2="miRNA-corp.d66.s9.e0" id="miRNA-corp.d66.s9.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d66.s9.e1" e2="miRNA-corp.d66.s9.e2" id="miRNA-corp.d66.s9.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s10" origId="20378606.s9" text="These results were confirmed in an independent study. "/>
    </document>
    <document id="miRNA-corp.d67" origId="18467632">
        <sentence id="miRNA-corp.d67.s0" origId="18467632.s0" text="Does the effect of microRNAs in vascular neointimal formation depend on cell cycle phase?     ">
            <entity charOffset="19-27" id="miRNA-corp.d67.s0.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d68" origId="20939912">
        <sentence id="miRNA-corp.d68.s0" origId="20939912.s5" text="The characteristics of tumors induced in NG2-KO were compared to those of tumors induced in wild type mice by immunostaining for different cell lineage markers and by transplantation assays in adult mice. ">
            <entity charOffset="41-43" id="miRNA-corp.d68.s0.e0" text="NG2" type="Genes/Proteins"/>
            <entity charOffset="23-28" id="miRNA-corp.d68.s0.e1" text="tumors" type="Diseases"/>
            <entity charOffset="74-79" id="miRNA-corp.d68.s0.e2" text="tumors" type="Diseases"/>
            <entity charOffset="102-105" id="miRNA-corp.d68.s0.e3" text="mice" type="Species"/>
            <entity charOffset="199-202" id="miRNA-corp.d68.s0.e4" text="mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d68.s1" origId="20939912.s4" text="METHODS: The survival curves of NG2-KO mice overexpressing PDGF-B were compared to controls by using a Log-rank test. ">
            <entity charOffset="39-42" id="miRNA-corp.d68.s1.e0" text="mice" type="Species"/>
            <entity charOffset="44-57" id="miRNA-corp.d68.s1.e1" text="overexpressing" type="Relation_Trigger"/>
            <entity charOffset="59-64" id="miRNA-corp.d68.s1.e2" text="PDGF-B" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d68.s2" origId="20939912.s3" text="We have recently generated a glioma model based on the overexpression of PDGF-B in neural progenitors and here we investigated the possible relevance of NG2 during PDGF-driven gliomagenesis. ">
            <entity charOffset="29-34" id="miRNA-corp.d68.s2.e0" text="glioma" type="Diseases"/>
            <entity charOffset="55-68" id="miRNA-corp.d68.s2.e1" text="overexpression" type="Relation_Trigger"/>
            <entity charOffset="73-78" id="miRNA-corp.d68.s2.e2" text="PDGF-B" type="Genes/Proteins"/>
            <entity charOffset="153-155" id="miRNA-corp.d68.s2.e3" text="NG2" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d68.s3" origId="20939912.s2" text="NG2 has been shown to function as a co-receptor for PDGF ligands whose aberrant expression is common in gliomas. ">
            <entity charOffset="0-2" id="miRNA-corp.d68.s3.e0" text="NG2" type="Genes/Proteins"/>
            <entity charOffset="71-89" id="miRNA-corp.d68.s3.e1" text="aberrant expression" type="Relation_Trigger"/>
            <entity charOffset="104-110" id="miRNA-corp.d68.s3.e2" text="gliomas" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d68.s4" origId="20939912.s1" text="BACKGROUND: In the last years, the transmembrane proteoglycan NG2 has gained interest as a therapeutic target for the treatment of diverse tumor types, including gliomas, because increases of its expression correlate with dismal prognosis. ">
            <entity charOffset="179-205" id="miRNA-corp.d68.s4.e0" text="increases of its expression" type="Relation_Trigger"/>
            <entity charOffset="49-64" id="miRNA-corp.d68.s4.e1" text="proteoglycan NG2" type="Genes/Proteins"/>
            <entity charOffset="91-108" id="miRNA-corp.d68.s4.e2" text="therapeutic target" type="Relation_Trigger"/>
            <entity charOffset="139-143" id="miRNA-corp.d68.s4.e3" text="tumor" type="Diseases"/>
            <entity charOffset="162-168" id="miRNA-corp.d68.s4.e4" text="gliomas" type="Diseases"/>
            <entity charOffset="207-215" id="miRNA-corp.d68.s4.e5" text="correlate" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d68.s5" origId="20939912.s0" text="PDGF-B-driven gliomagenesis can occur in the absence of the proteoglycan NG2.  ">
            <entity charOffset="0-5" id="miRNA-corp.d68.s5.e0" text="PDGF-B" type="Genes/Proteins"/>
            <entity charOffset="60-75" id="miRNA-corp.d68.s5.e1" text="proteoglycan NG2" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d68.s6" origId="20939912.s8" text="On the basis of the data obtained, we therefore suggest that the role of NG2 as a target molecule for glioma treatment should be carefully reconsidered.   ">
            <entity charOffset="102-107" id="miRNA-corp.d68.s6.e0" text="glioma" type="Diseases"/>
            <entity charOffset="73-75" id="miRNA-corp.d68.s6.e1" text="NG2" type="Genes/Proteins"/>
            <entity charOffset="82-87" id="miRNA-corp.d68.s6.e2" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d68.s7" origId="20939912.s7" text="CONCLUSIONS: Our analysis, using both NG2-KO mice and a miRNA based silencing approach, clearly demonstrates that NG2 is not required for PDGF-B to efficiently induce and maintain gliomas from neural progenitors. ">
            <entity charOffset="38-40" id="miRNA-corp.d68.s7.e0" text="NG2" type="Genes/Proteins"/>
            <entity charOffset="45-48" id="miRNA-corp.d68.s7.e1" text="mice" type="Species"/>
            <entity charOffset="56-60" id="miRNA-corp.d68.s7.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="114-116" id="miRNA-corp.d68.s7.e3" text="NG2" type="Genes/Proteins"/>
            <entity charOffset="138-143" id="miRNA-corp.d68.s7.e4" text="PDGF-B" type="Genes/Proteins"/>
            <entity charOffset="180-186" id="miRNA-corp.d68.s7.e5" text="gliomas" type="Diseases"/>
            <pair e1="miRNA-corp.d68.s7.e2" e2="miRNA-corp.d68.s7.e3" id="miRNA-corp.d68.s7.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d68.s7.e2" e2="miRNA-corp.d68.s7.e4" id="miRNA-corp.d68.s7.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d68.s7.e2" e2="miRNA-corp.d68.s7.e0" id="miRNA-corp.d68.s7.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d68.s7.e2" e2="miRNA-corp.d68.s7.e5" id="miRNA-corp.d68.s7.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d68.s8" origId="20939912.s6" text="RESULTS: We showed that the lack of NG2 does not appreciably affect any of the characterized steps of PDGF-driven brain tumorigenesis, such as oligodendrocyte progenitor cells (OPC) induction, the recruitment of bystander OPCs and the progression to full malignancy, which take place as in wild type animals. ">
            <entity charOffset="36-38" id="miRNA-corp.d68.s8.e0" text="NG2" type="Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d69" origId="20489155">
        <sentence id="miRNA-corp.d69.s0" origId="20489155.s12" text="These findings indicate that miR-107 contributes to GRN expression regulation with implications for brain disorders.   ">
            <entity charOffset="29-35" id="miRNA-corp.d69.s0.e0" text="miR-107" type="Specific_miRNAs"/>
            <entity charOffset="52-54" id="miRNA-corp.d69.s0.e1" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="100-114" id="miRNA-corp.d69.s0.e2" text="brain disorders" type="Diseases"/>
            <entity charOffset="56-76" id="miRNA-corp.d69.s0.e3" text="expression regulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d69.s0.e0" e2="miRNA-corp.d69.s0.e1" id="miRNA-corp.d69.s0.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d69.s0.e0" e2="miRNA-corp.d69.s0.e2" id="miRNA-corp.d69.s0.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s1" origId="20489155.s11" text="In brain tissue subjacent to 1.0 mm depth controlled cortical impact, surviving hippocampal neurons show decreased miR-107 with augmentation of neuronal GRN expression. ">
            <entity charOffset="115-121" id="miRNA-corp.d69.s1.e0" text="miR-107" type="Specific_miRNAs"/>
            <entity charOffset="153-155" id="miRNA-corp.d69.s1.e1" text="GRN" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d69.s1.e0" e2="miRNA-corp.d69.s1.e1" id="miRNA-corp.d69.s1.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s2" origId="20489155.s10" text="We also tested a mouse model where miR-107 has been shown to be down-regulated. ">
            <entity charOffset="17-21" id="miRNA-corp.d69.s2.e0" text="mouse" type="Species"/>
            <entity charOffset="35-41" id="miRNA-corp.d69.s2.e1" text="miR-107" type="Specific_miRNAs"/>
            <entity charOffset="64-77" id="miRNA-corp.d69.s2.e2" text="down-regulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s3" origId="20489155.s3" text="However, GRN regulation expression is poorly understood. ">
            <entity charOffset="9-11" id="miRNA-corp.d69.s3.e0" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="13-33" id="miRNA-corp.d69.s3.e1" text="regulation expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s4" origId="20489155.s4" text="A high-throughput experimental microRNA assay showed that GRN is the strongest target for miR-107 in human H4 neuroglioma cells. ">
            <entity charOffset="31-38" id="miRNA-corp.d69.s4.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="58-60" id="miRNA-corp.d69.s4.e1" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="69-84" id="miRNA-corp.d69.s4.e2" text="strongest target" type="Relation_Trigger"/>
            <entity charOffset="90-96" id="miRNA-corp.d69.s4.e3" text="miR-107" type="Specific_miRNAs"/>
            <entity charOffset="101-105" id="miRNA-corp.d69.s4.e4" text="human" type="Species"/>
            <entity charOffset="110-120" id="miRNA-corp.d69.s4.e5" text="neuroglioma" type="Diseases"/>
            <pair e1="miRNA-corp.d69.s4.e0" e2="miRNA-corp.d69.s4.e1" id="miRNA-corp.d69.s4.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d69.s4.e0" e2="miRNA-corp.d69.s4.e5" id="miRNA-corp.d69.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d69.s4.e3" e2="miRNA-corp.d69.s4.e1" id="miRNA-corp.d69.s4.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d69.s4.e3" e2="miRNA-corp.d69.s4.e5" id="miRNA-corp.d69.s4.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s5" origId="20489155.s5" text="miR-107 has been implicated in Alzheimer's disease pathogenesis, and sequence elements in the open reading frame-rather than the 3' untranslated region-of GRN mRNA are recognized by miR-107 and are highly conserved among vertebrate species. ">
            <entity charOffset="31-49" id="miRNA-corp.d69.s5.e0" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="0-6" id="miRNA-corp.d69.s5.e1" text="miR-107" type="Specific_miRNAs"/>
            <entity charOffset="155-157" id="miRNA-corp.d69.s5.e2" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="182-188" id="miRNA-corp.d69.s5.e3" text="miR-107" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d69.s5.e1" e2="miRNA-corp.d69.s5.e0" id="miRNA-corp.d69.s5.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d69.s5.e1" e2="miRNA-corp.d69.s5.e2" id="miRNA-corp.d69.s5.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d69.s5.e3" e2="miRNA-corp.d69.s5.e0" id="miRNA-corp.d69.s5.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d69.s5.e3" e2="miRNA-corp.d69.s5.e2" id="miRNA-corp.d69.s5.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s6" origId="20489155.s6" text="To better understand the mechanism of this interaction, FLAG-tagged Argonaute constructs were used following miR-107 transfection. ">
            <entity charOffset="109-115" id="miRNA-corp.d69.s6.e0" text="miR-107" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s7" origId="20489155.s0" text="miR-107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegenerative disease.  ">
            <entity charOffset="0-6" id="miRNA-corp.d69.s7.e0" text="miR-107" type="Specific_miRNAs"/>
            <entity charOffset="8-16" id="miRNA-corp.d69.s7.e1" text="regulates" type="Relation_Trigger"/>
            <entity charOffset="18-25" id="miRNA-corp.d69.s7.e2" text="granulin" type="Genes/Proteins"/>
            <entity charOffset="27-37" id="miRNA-corp.d69.s7.e3" text="progranulin" type="Genes/Proteins"/>
            <entity charOffset="61-82" id="miRNA-corp.d69.s7.e4" text="traumatic brain injury" type="Diseases"/>
            <entity charOffset="88-112" id="miRNA-corp.d69.s7.e5" text="neurodegenerative disease" type="Diseases"/>
            <pair e1="miRNA-corp.d69.s7.e0" e2="miRNA-corp.d69.s7.e2" id="miRNA-corp.d69.s7.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d69.s7.e0" e2="miRNA-corp.d69.s7.e3" id="miRNA-corp.d69.s7.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d69.s7.e0" e2="miRNA-corp.d69.s7.e4" id="miRNA-corp.d69.s7.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d69.s7.e0" e2="miRNA-corp.d69.s7.e5" id="miRNA-corp.d69.s7.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s8" origId="20489155.s1" text="Granulin (GRN, or progranulin) is a protein involved in wound repair, inflammation, and neoplasia. ">
            <entity charOffset="56-60" id="miRNA-corp.d69.s8.e0" text="wound" type="Diseases"/>
            <entity charOffset="0-7" id="miRNA-corp.d69.s8.e1" text="Granulin" type="Genes/Proteins"/>
            <entity charOffset="10-12" id="miRNA-corp.d69.s8.e2" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="18-28" id="miRNA-corp.d69.s8.e3" text="progranulin" type="Genes/Proteins"/>
            <entity charOffset="70-81" id="miRNA-corp.d69.s8.e4" text="inflammation" type="Diseases"/>
            <entity charOffset="88-96" id="miRNA-corp.d69.s8.e5" text="neoplasia" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s9" origId="20489155.s2" text="GRN has also been directly implicated in frontotemporal dementia and may contribute to Alzheimer's disease pathogenesis. ">
            <entity charOffset="0-2" id="miRNA-corp.d69.s9.e0" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="41-63" id="miRNA-corp.d69.s9.e1" text="frontotemporal dementia" type="Diseases"/>
            <entity charOffset="87-105" id="miRNA-corp.d69.s9.e2" text="Alzheimer's disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s10" origId="20489155.s7" text="GRN mRNA interacts preferentially with Argonaute 2. In vitro and in vivo studies indicate that regulation of GRN by miR-107 may be functionally important. ">
            <entity charOffset="39-49" id="miRNA-corp.d69.s10.e0" text="Argonaute 2" type="Genes/Proteins"/>
            <entity charOffset="0-2" id="miRNA-corp.d69.s10.e1" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="95-104" id="miRNA-corp.d69.s10.e2" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="109-111" id="miRNA-corp.d69.s10.e3" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="116-122" id="miRNA-corp.d69.s10.e4" text="miR-107" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d69.s10.e4" e2="miRNA-corp.d69.s10.e0" id="miRNA-corp.d69.s10.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d69.s10.e4" e2="miRNA-corp.d69.s10.e1" id="miRNA-corp.d69.s10.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d69.s10.e4" e2="miRNA-corp.d69.s10.e3" id="miRNA-corp.d69.s10.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s11" origId="20489155.s8" text="Glucose supplementation in cultured cells that leads to increased miR-107 levels also results in decreased GRN expression, including changes in cell compartmentation and decreased secretion of GRN protein. ">
            <entity charOffset="170-203" id="miRNA-corp.d69.s11.e0" text="decreased secretion of GRN protein" type="Relation_Trigger"/>
            <entity charOffset="66-72" id="miRNA-corp.d69.s11.e1" text="miR-107" type="Specific_miRNAs"/>
            <entity charOffset="107-109" id="miRNA-corp.d69.s11.e2" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="97-120" id="miRNA-corp.d69.s11.e3" text="decreased GRN expression" type="Relation_Trigger"/>
            <entity charOffset="56-79" id="miRNA-corp.d69.s11.e4" text="increased miR-107 levels" type="Relation_Trigger"/>
            <entity charOffset="193-195" id="miRNA-corp.d69.s11.e5" text="GRN" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d69.s11.e1" e2="miRNA-corp.d69.s11.e2" id="miRNA-corp.d69.s11.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d69.s11.e1" e2="miRNA-corp.d69.s11.e5" id="miRNA-corp.d69.s11.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s12" origId="20489155.s9" text="This effect was eliminated following miR-107 transfection. ">
            <entity charOffset="37-43" id="miRNA-corp.d69.s12.e0" text="miR-107" type="Specific_miRNAs"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d70" origId="20633539">
        <sentence id="miRNA-corp.d70.s0" origId="20633539.s1" text="MicroRNAs (miRNAs) are small noncoding RNA molecules that regulate protein expression by cleaving or repressing the translation of target mRNAs. ">
            <entity charOffset="58-84" id="miRNA-corp.d70.s0.e0" text="regulate protein expression" type="Relation_Trigger"/>
            <entity charOffset="131-136" id="miRNA-corp.d70.s0.e1" text="target" type="Relation_Trigger"/>
            <entity charOffset="0-8" id="miRNA-corp.d70.s0.e2" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d70.s0.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="101-126" id="miRNA-corp.d70.s0.e4" text="repressing the translation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s1" origId="20633539.s0" text="MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.  ">
            <entity charOffset="0-5" id="miRNA-corp.d70.s1.e0" text="MiR-21" type="Specific_miRNAs"/>
            <entity charOffset="17-34" id="miRNA-corp.d70.s1.e1" text="human glioblastoma" type="Diseases"/>
            <entity charOffset="17-21" id="miRNA-corp.d70.s1.e2" text="human" type="Species"/>
            <entity charOffset="120-122" id="miRNA-corp.d70.s1.e3" text="Bax" type="Genes/Proteins"/>
            <entity charOffset="124-128" id="miRNA-corp.d70.s1.e4" text="Bcl-2" type="Genes/Proteins"/>
            <entity charOffset="140-148" id="miRNA-corp.d70.s1.e5" text="caspase-3" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d70.s1.e0" e2="miRNA-corp.d70.s1.e5" id="miRNA-corp.d70.s1.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d70.s1.e0" e2="miRNA-corp.d70.s1.e1" id="miRNA-corp.d70.s1.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d70.s1.e0" e2="miRNA-corp.d70.s1.e3" id="miRNA-corp.d70.s1.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d70.s1.e0" e2="miRNA-corp.d70.s1.e4" id="miRNA-corp.d70.s1.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s2" origId="20633539.s3" text="Several miRNAs have been recently reported to be involved in modulation of glioma development, especially some up-regulated miRNAs, such as microRNA-21 (miR-21), which has been found to function as an oncogene in cultured glioblastoma multiforme cells. ">
            <entity charOffset="8-13" id="miRNA-corp.d70.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="61-70" id="miRNA-corp.d70.s2.e1" text="modulation" type="Relation_Trigger"/>
            <entity charOffset="75-80" id="miRNA-corp.d70.s2.e2" text="glioma" type="Diseases"/>
            <entity charOffset="111-122" id="miRNA-corp.d70.s2.e3" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="124-129" id="miRNA-corp.d70.s2.e4" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="140-150" id="miRNA-corp.d70.s2.e5" text="microRNA-21" type="Specific_miRNAs"/>
            <entity charOffset="153-158" id="miRNA-corp.d70.s2.e6" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="222-244" id="miRNA-corp.d70.s2.e7" text="glioblastoma multiforme" type="Diseases"/>
            <pair e1="miRNA-corp.d70.s2.e0" e2="miRNA-corp.d70.s2.e2" id="miRNA-corp.d70.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d70.s2.e0" e2="miRNA-corp.d70.s2.e7" id="miRNA-corp.d70.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d70.s2.e4" e2="miRNA-corp.d70.s2.e2" id="miRNA-corp.d70.s2.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d70.s2.e4" e2="miRNA-corp.d70.s2.e7" id="miRNA-corp.d70.s2.p3" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d70.s2.e5" e2="miRNA-corp.d70.s2.e2" id="miRNA-corp.d70.s2.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d70.s2.e5" e2="miRNA-corp.d70.s2.e7" id="miRNA-corp.d70.s2.p5" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d70.s2.e6" e2="miRNA-corp.d70.s2.e2" id="miRNA-corp.d70.s2.p6" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d70.s2.e6" e2="miRNA-corp.d70.s2.e7" id="miRNA-corp.d70.s2.p7" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s3" origId="20633539.s2" text="In mammal animals, their function mainly represses the target mRNAs transcripts via imperfectly complementary to the 3'UTR of target mRNAs. ">
            <entity charOffset="126-131" id="miRNA-corp.d70.s3.e0" text="target" type="Relation_Trigger"/>
            <entity charOffset="55-60" id="miRNA-corp.d70.s3.e1" text="target" type="Relation_Trigger"/>
            <entity charOffset="41-49" id="miRNA-corp.d70.s3.e2" text="represses" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s4" origId="20633539.s5" text="However, resistance develops quickly and with high frequency. "/>
        <sentence id="miRNA-corp.d70.s5" origId="20633539.s4" text="Temozolomide (TMZ), an alkylating agent, is a promising chemotherapeutic agent for treating glioblastoma. ">
            <entity charOffset="92-103" id="miRNA-corp.d70.s5.e0" text="glioblastoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s6" origId="20633539.s7" text="Our studies showed that TMZ markedly enhanced apoptosis in U87MG cells compared with untreated cells (P&lt;0.05). "/>
        <sentence id="miRNA-corp.d70.s7" origId="20633539.s6" text="To explore the mechanism of resistance, we found that miR-21 could protect human glioblastoma U87MG cells from TMZ induced apoptosis. ">
            <entity charOffset="54-59" id="miRNA-corp.d70.s7.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="75-79" id="miRNA-corp.d70.s7.e1" text="human" type="Species"/>
            <entity charOffset="75-92" id="miRNA-corp.d70.s7.e2" text="human glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d70.s7.e0" e2="miRNA-corp.d70.s7.e2" id="miRNA-corp.d70.s7.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s8" origId="20633539.s8" text="However, over-express miR-21 in U87MG cells could significantly reduce TMZ-induced apoptosis (P&lt;0.05). ">
            <entity charOffset="50-69" id="miRNA-corp.d70.s8.e0" text="significantly reduce" type="Relation_Trigger"/>
            <entity charOffset="9-20" id="miRNA-corp.d70.s8.e1" text="over-express" type="Relation_Trigger"/>
            <entity charOffset="22-27" id="miRNA-corp.d70.s8.e2" text="miR-21" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s9" origId="20633539.s9" text="Pro-apoptotic Bax and anti-apoptotic Bcl-2 proteins are known to regulate the apoptosis of glioma cells. ">
            <entity charOffset="14-16" id="miRNA-corp.d70.s9.e0" text="Bax" type="Genes/Proteins"/>
            <entity charOffset="37-41" id="miRNA-corp.d70.s9.e1" text="Bcl-2" type="Genes/Proteins"/>
            <entity charOffset="65-72" id="miRNA-corp.d70.s9.e2" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="91-96" id="miRNA-corp.d70.s9.e3" text="glioma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s10" origId="20633539.s12" text="Further research demonstrated that the mechanism was associated with a shift in Bax/Bcl-2 ratio and change in caspase-3 activity. ">
            <entity charOffset="53-62" id="miRNA-corp.d70.s10.e0" text="associated" type="Relation_Trigger"/>
            <entity charOffset="80-82" id="miRNA-corp.d70.s10.e1" text="Bax" type="Genes/Proteins"/>
            <entity charOffset="84-88" id="miRNA-corp.d70.s10.e2" text="Bcl-2" type="Genes/Proteins"/>
            <entity charOffset="110-118" id="miRNA-corp.d70.s10.e3" text="caspase-3" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s11" origId="20633539.s11" text="Bax is shown to correlate with an increased survival of glioblastoma multiforme patients. ">
            <entity charOffset="0-2" id="miRNA-corp.d70.s11.e0" text="Bax" type="Genes/Proteins"/>
            <entity charOffset="16-24" id="miRNA-corp.d70.s11.e1" text="correlate" type="Relation_Trigger"/>
            <entity charOffset="56-67" id="miRNA-corp.d70.s11.e2" text="glioblastoma" type="Diseases"/>
            <entity charOffset="80-87" id="miRNA-corp.d70.s11.e3" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s12" origId="20633539.s14" text="However, such effect was partly prevented by treatment of cells with miR-21 overexpression before, which appeared to downregulate the Bax expression, upregulate the Bcl-2 expression and decrease caspase-3 activity. ">
            <entity charOffset="76-89" id="miRNA-corp.d70.s12.e0" text="overexpression" type="Relation_Trigger"/>
            <entity charOffset="69-74" id="miRNA-corp.d70.s12.e1" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="117-147" id="miRNA-corp.d70.s12.e2" text="downregulate the Bax expression" type="Relation_Trigger"/>
            <entity charOffset="134-136" id="miRNA-corp.d70.s12.e3" text="Bax" type="Genes/Proteins"/>
            <entity charOffset="150-180" id="miRNA-corp.d70.s12.e4" text="upregulate the Bcl-2 expression" type="Relation_Trigger"/>
            <entity charOffset="165-169" id="miRNA-corp.d70.s12.e5" text="Bcl-2" type="Genes/Proteins"/>
            <entity charOffset="195-203" id="miRNA-corp.d70.s12.e6" text="caspase-3" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d70.s12.e1" e2="miRNA-corp.d70.s12.e3" id="miRNA-corp.d70.s12.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d70.s12.e1" e2="miRNA-corp.d70.s12.e5" id="miRNA-corp.d70.s12.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d70.s12.e1" e2="miRNA-corp.d70.s12.e6" id="miRNA-corp.d70.s12.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s13" origId="20633539.s13" text="Compared to control cells, cells treated with TMZ showed a significant increase in the Bax/Bcl-2 ratio and caspase-3 activity (P&lt;0.01). ">
            <entity charOffset="87-89" id="miRNA-corp.d70.s13.e0" text="Bax" type="Genes/Proteins"/>
            <entity charOffset="91-95" id="miRNA-corp.d70.s13.e1" text="Bcl-2" type="Genes/Proteins"/>
            <entity charOffset="107-115" id="miRNA-corp.d70.s13.e2" text="caspase-3" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s14" origId="20633539.s15" text="Taken together, these results suggested that over-express miR-21 could inhibit TMZ-induced apoptosis in U87MG cells, at least in part, by decreasing Bax/Bcl-2 ratio and caspase-3 activity, which highlighted the possibility of miR-21 overexpression in the clinical resistance to chemotherapeutic therapy of TMZ.   ">
            <entity charOffset="45-56" id="miRNA-corp.d70.s14.e0" text="over-express" type="Relation_Trigger"/>
            <entity charOffset="58-63" id="miRNA-corp.d70.s14.e1" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="71-77" id="miRNA-corp.d70.s14.e2" text="inhibit" type="Relation_Trigger"/>
            <entity charOffset="149-151" id="miRNA-corp.d70.s14.e3" text="Bax" type="Genes/Proteins"/>
            <entity charOffset="153-157" id="miRNA-corp.d70.s14.e4" text="Bcl-2" type="Genes/Proteins"/>
            <entity charOffset="169-177" id="miRNA-corp.d70.s14.e5" text="caspase-3" type="Genes/Proteins"/>
            <entity charOffset="226-231" id="miRNA-corp.d70.s14.e6" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="233-246" id="miRNA-corp.d70.s14.e7" text="overexpression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d70.s14.e1" e2="miRNA-corp.d70.s14.e3" id="miRNA-corp.d70.s14.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d70.s14.e1" e2="miRNA-corp.d70.s14.e4" id="miRNA-corp.d70.s14.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d70.s14.e1" e2="miRNA-corp.d70.s14.e5" id="miRNA-corp.d70.s14.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d70.s14.e6" e2="miRNA-corp.d70.s14.e3" id="miRNA-corp.d70.s14.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d70.s14.e6" e2="miRNA-corp.d70.s14.e4" id="miRNA-corp.d70.s14.p4" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d70.s14.e6" e2="miRNA-corp.d70.s14.e5" id="miRNA-corp.d70.s14.p5" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s15" origId="20633539.s10" text="Bcl-2, resistance to induction of apoptosis, constitutes one major obstacle to chemotherapy in many cancer cells. ">
            <entity charOffset="0-4" id="miRNA-corp.d70.s15.e0" text="Bcl-2" type="Genes/Proteins"/>
            <entity charOffset="100-105" id="miRNA-corp.d70.s15.e1" text="cancer" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d71" origId="18539147">
        <sentence id="miRNA-corp.d71.s0" origId="18539147.s0" text="Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210.  ">
            <entity charOffset="118-124" id="miRNA-corp.d71.s0.e0" text="miR-210" type="Specific_miRNAs"/>
            <entity charOffset="0-6" id="miRNA-corp.d71.s0.e1" text="Hypoxia" type="Diseases"/>
            <entity charOffset="25-31" id="miRNA-corp.d71.s0.e2" text="miR-210" type="Specific_miRNAs"/>
            <entity charOffset="16-23" id="miRNA-corp.d71.s0.e3" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="54-62" id="miRNA-corp.d71.s0.e4" text="ephrin-A3" type="Genes/Proteins"/>
            <entity charOffset="68-87" id="miRNA-corp.d71.s0.e5" text="neuronal pentraxin 1" type="Genes/Proteins"/>
            <entity charOffset="105-113" id="miRNA-corp.d71.s0.e6" text="regulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d71.s0.e0" e2="miRNA-corp.d71.s0.e1" id="miRNA-corp.d71.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d71.s0.e0" e2="miRNA-corp.d71.s0.e4" id="miRNA-corp.d71.s0.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s0.e0" e2="miRNA-corp.d71.s0.e5" id="miRNA-corp.d71.s0.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s0.e2" e2="miRNA-corp.d71.s0.e1" id="miRNA-corp.d71.s0.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d71.s0.e2" e2="miRNA-corp.d71.s0.e4" id="miRNA-corp.d71.s0.p4" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s0.e2" e2="miRNA-corp.d71.s0.e5" id="miRNA-corp.d71.s0.p5" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s0.e3" e2="miRNA-corp.d71.s0.e1" id="miRNA-corp.d71.s0.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d71.s0.e3" e2="miRNA-corp.d71.s0.e4" id="miRNA-corp.d71.s0.p7" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s0.e3" e2="miRNA-corp.d71.s0.e5" id="miRNA-corp.d71.s0.p8" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d71.s1" origId="18539147.s1" text="Shortage of oxygen is one of the prime stress conditions in tissues. "/>
        <sentence id="miRNA-corp.d71.s2" origId="18539147.s2" text="In this study, we looked for microRNAs expressed during hypoxia and showed that miR-210 expression was upregulated in response to hypoxia in vitro and in vivo. ">
            <entity charOffset="29-37" id="miRNA-corp.d71.s2.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="56-62" id="miRNA-corp.d71.s2.e1" text="hypoxia" type="Diseases"/>
            <entity charOffset="80-86" id="miRNA-corp.d71.s2.e2" text="miR-210" type="Specific_miRNAs"/>
            <entity charOffset="130-136" id="miRNA-corp.d71.s2.e3" text="hypoxia" type="Diseases"/>
            <entity charOffset="88-113" id="miRNA-corp.d71.s2.e4" text="expression was upregulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d71.s2.e0" e2="miRNA-corp.d71.s2.e1" id="miRNA-corp.d71.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d71.s2.e0" e2="miRNA-corp.d71.s2.e3" id="miRNA-corp.d71.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d71.s2.e2" e2="miRNA-corp.d71.s2.e1" id="miRNA-corp.d71.s2.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d71.s2.e2" e2="miRNA-corp.d71.s2.e3" id="miRNA-corp.d71.s2.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d71.s3" origId="18539147.s3" text="An active form of the HIF-1alpha induced the expression of miR-210, showing the involvement of the HIF-1 signaling pathway in miR-210 gene transcription. ">
            <entity charOffset="22-31" id="miRNA-corp.d71.s3.e0" text="HIF-1alpha" type="Genes/Proteins"/>
            <entity charOffset="59-65" id="miRNA-corp.d71.s3.e1" text="miR-210" type="Specific_miRNAs"/>
            <entity charOffset="126-132" id="miRNA-corp.d71.s3.e2" text="miR-210" type="Specific_miRNAs"/>
            <entity charOffset="99-103" id="miRNA-corp.d71.s3.e3" text="HIF-1" type="Genes/Proteins"/>
            <entity charOffset="33-54" id="miRNA-corp.d71.s3.e4" text="induced the expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d71.s3.e1" e2="miRNA-corp.d71.s3.e0" id="miRNA-corp.d71.s3.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s3.e1" e2="miRNA-corp.d71.s3.e3" id="miRNA-corp.d71.s3.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s3.e2" e2="miRNA-corp.d71.s3.e0" id="miRNA-corp.d71.s3.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s3.e2" e2="miRNA-corp.d71.s3.e3" id="miRNA-corp.d71.s3.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d71.s4" origId="18539147.s4" text="Furthermore, miR-210 was shown to bind to the predicted target sites of ephrin-A3 or neuronal pentraxin 1, causing repression in luciferase reporter activity. ">
            <entity charOffset="13-19" id="miRNA-corp.d71.s4.e0" text="miR-210" type="Specific_miRNAs"/>
            <entity charOffset="72-80" id="miRNA-corp.d71.s4.e1" text="ephrin-A3" type="Genes/Proteins"/>
            <entity charOffset="85-104" id="miRNA-corp.d71.s4.e2" text="neuronal pentraxin 1" type="Genes/Proteins"/>
            <entity charOffset="115-124" id="miRNA-corp.d71.s4.e3" text="repression" type="Relation_Trigger"/>
            <entity charOffset="34-40" id="miRNA-corp.d71.s4.e4" text="bind to" type="Relation_Trigger"/>
            <entity charOffset="46-61" id="miRNA-corp.d71.s4.e5" text="predicted target" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d71.s4.e0" e2="miRNA-corp.d71.s4.e1" id="miRNA-corp.d71.s4.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s4.e0" e2="miRNA-corp.d71.s4.e2" id="miRNA-corp.d71.s4.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d71.s5" origId="18539147.s6" text="Thus, the regulatory effects of miR-210 on its targets in vivo need to be further characterized.   ">
            <entity charOffset="32-38" id="miRNA-corp.d71.s5.e0" text="miR-210" type="Specific_miRNAs"/>
            <entity charOffset="10-27" id="miRNA-corp.d71.s5.e1" text="regulatory effects" type="Relation_Trigger"/>
            <entity charOffset="47-53" id="miRNA-corp.d71.s5.e2" text="targets" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d71.s6" origId="18539147.s5" text="Contrary to the microRNA-mediated repression hypothesis, ephrin-A3 was expressed at very high levels in post-ischemic mouse hippocampus in vivo. ">
            <entity charOffset="16-23" id="miRNA-corp.d71.s6.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="34-43" id="miRNA-corp.d71.s6.e1" text="repression" type="Relation_Trigger"/>
            <entity charOffset="57-65" id="miRNA-corp.d71.s6.e2" text="ephrin-A3" type="Genes/Proteins"/>
            <entity charOffset="71-99" id="miRNA-corp.d71.s6.e3" text="expressed at very high levels" type="Relation_Trigger"/>
            <entity charOffset="118-122" id="miRNA-corp.d71.s6.e4" text="mouse" type="Species"/>
            <pair e1="miRNA-corp.d71.s6.e0" e2="miRNA-corp.d71.s6.e2" id="miRNA-corp.d71.s6.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d72" origId="20175695">
        <sentence id="miRNA-corp.d72.s0" origId="20175695.s3" text="Cells stably transfected with LAT or trigeminal ganglionic neurons of mice infected with a LAT expressing virus appeared to express the L2 or L8 ORF. "/>
        <sentence id="miRNA-corp.d72.s1" origId="20175695.s2" text="Peptide-specific immunoglobulin G (IgG) was generated against open reading frames (ORFs) that are located within the first 1.5 kb of LAT coding sequences. "/>
        <sentence id="miRNA-corp.d72.s2" origId="20175695.s4" text="Only L2 ORF expression was readily detected in trigeminal ganglionic neurons of latently infected mice.   ">
            <entity charOffset="98-101" id="miRNA-corp.d72.s2.e0" text="mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d72.s3" origId="20175695.s1" text="Expression of the first 1.5 kb of the latency-associated transcript (LAT) that is encoded by herpes simplex virus type 1 (HSV-1) is sufficient for wild-type (wt) levels of reactivation from latency in small animal models. "/>
        <sentence id="miRNA-corp.d72.s4" origId="20175695.s0" text="Identification of herpes simplex virus type 1 proteins encoded within the first 1.5 kb of the latency-associated transcript.  "/>
    </document>
    <document id="miRNA-corp.d73" origId="20888269">
        <sentence id="miRNA-corp.d73.s0" origId="20888269.s6" text="Our study shows that one aspect of miR-155 function is the promotion of T cell-dependent tissue inflammation, suggesting that miR-155 might be a promising therapeutic target for the treatment of autoimmune disorders.   ">
            <entity charOffset="96-107" id="miRNA-corp.d73.s0.e0" text="inflammation" type="Diseases"/>
            <entity charOffset="126-132" id="miRNA-corp.d73.s0.e1" text="miR-155" type="Specific_miRNAs"/>
            <entity charOffset="35-41" id="miRNA-corp.d73.s0.e2" text="miR-155" type="Specific_miRNAs"/>
            <entity charOffset="195-214" id="miRNA-corp.d73.s0.e3" text="autoimmune disorders" type="Diseases"/>
            <entity charOffset="155-172" id="miRNA-corp.d73.s0.e4" text="therapeutic target" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d73.s0.e1" e2="miRNA-corp.d73.s0.e0" id="miRNA-corp.d73.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d73.s0.e1" e2="miRNA-corp.d73.s0.e3" id="miRNA-corp.d73.s0.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d73.s0.e2" e2="miRNA-corp.d73.s0.e0" id="miRNA-corp.d73.s0.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d73.s0.e2" e2="miRNA-corp.d73.s0.e3" id="miRNA-corp.d73.s0.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d73.s1" origId="20888269.s4" text="miR-155 functions in the hematopoietic compartment to promote the development of inflammatory T cells including the T helper 17 (Th17) cell and Th1 cell subsets. ">
            <entity charOffset="0-6" id="miRNA-corp.d73.s1.e0" text="miR-155" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d73.s2" origId="20888269.s5" text="Furthermore, the major contribution of miR-155 to EAE was CD4(+) T cell intrinsic, whereas miR-155 was also required for optimum dendritic cell production of cytokines that promoted Th17 cell formation. ">
            <entity charOffset="50-52" id="miRNA-corp.d73.s2.e0" text="EAE" type="Diseases"/>
            <entity charOffset="39-45" id="miRNA-corp.d73.s2.e1" text="miR-155" type="Specific_miRNAs"/>
            <entity charOffset="91-97" id="miRNA-corp.d73.s2.e2" text="miR-155" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d73.s2.e1" e2="miRNA-corp.d73.s2.e0" id="miRNA-corp.d73.s2.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d73.s2.e2" e2="miRNA-corp.d73.s2.e0" id="miRNA-corp.d73.s2.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d73.s3" origId="20888269.s2" text="Here, we have investigated the role of miR-155 during an autoimmune inflammatory disease. ">
            <entity charOffset="39-45" id="miRNA-corp.d73.s3.e0" text="miR-155" type="Specific_miRNAs"/>
            <entity charOffset="57-87" id="miRNA-corp.d73.s3.e1" text="autoimmune inflammatory disease" type="Diseases"/>
            <pair e1="miRNA-corp.d73.s3.e0" e2="miRNA-corp.d73.s3.e1" id="miRNA-corp.d73.s3.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d73.s4" origId="20888269.s3" text="Consistent with a positive role for miR-155 in mediating inflammatory responses, Mir155(-/-) mice were highly resistant to experimental autoimmune encephalomyelitis (EAE). ">
            <entity charOffset="123-163" id="miRNA-corp.d73.s4.e0" text="experimental autoimmune encephalomyelitis" type="Diseases"/>
            <entity charOffset="166-168" id="miRNA-corp.d73.s4.e1" text="EAE" type="Diseases"/>
            <entity charOffset="36-42" id="miRNA-corp.d73.s4.e2" text="miR-155" type="Specific_miRNAs"/>
            <entity charOffset="81-86" id="miRNA-corp.d73.s4.e3" text="Mir155" type="Specific_miRNAs"/>
            <entity charOffset="93-96" id="miRNA-corp.d73.s4.e4" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d73.s4.e2" e2="miRNA-corp.d73.s4.e0" id="miRNA-corp.d73.s4.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d73.s4.e2" e2="miRNA-corp.d73.s4.e1" id="miRNA-corp.d73.s4.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d73.s4.e3" e2="miRNA-corp.d73.s4.e0" id="miRNA-corp.d73.s4.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d73.s4.e3" e2="miRNA-corp.d73.s4.e1" id="miRNA-corp.d73.s4.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d73.s5" origId="20888269.s0" text="MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development.  ">
            <entity charOffset="22-44" id="miRNA-corp.d73.s5.e0" text="autoimmune inflammation" type="Diseases"/>
            <entity charOffset="0-11" id="miRNA-corp.d73.s5.e1" text="MicroRNA-155" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d73.s5.e1" e2="miRNA-corp.d73.s5.e0" id="miRNA-corp.d73.s5.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d73.s6" origId="20888269.s1" text="Mammalian noncoding microRNAs (miRNAs) are a class of gene regulators that have been linked to immune system function. ">
            <entity charOffset="20-28" id="miRNA-corp.d73.s6.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="31-36" id="miRNA-corp.d73.s6.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="59-68" id="miRNA-corp.d73.s6.e2" text="regulators" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d74" origId="21131957">
        <sentence id="miRNA-corp.d74.s0" origId="21131957.s4" text="During experimental autoimmune encephalomyelitis (EAE), miR-124 was downregulated in activated microglia. ">
            <entity charOffset="7-47" id="miRNA-corp.d74.s0.e0" text="experimental autoimmune encephalomyelitis" type="Diseases"/>
            <entity charOffset="50-52" id="miRNA-corp.d74.s0.e1" text="EAE" type="Diseases"/>
            <entity charOffset="85-93" id="miRNA-corp.d74.s0.e2" text="activated" type="Relation_Trigger"/>
            <entity charOffset="85-93" id="miRNA-corp.d74.s0.e3" text="activated" type="Relation_Trigger"/>
            <entity charOffset="56-62" id="miRNA-corp.d74.s0.e4" text="miR-124" type="Specific_miRNAs"/>
            <entity charOffset="68-80" id="miRNA-corp.d74.s0.e5" text="downregulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d74.s0.e4" e2="miRNA-corp.d74.s0.e0" id="miRNA-corp.d74.s0.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d74.s0.e4" e2="miRNA-corp.d74.s0.e1" id="miRNA-corp.d74.s0.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d74.s1" origId="21131957.s5" text="Peripheral administration of miR-124 in EAE caused systemic deactivation of macrophages, reduced activation of myelin-specific T cells and marked suppression of disease. ">
            <entity charOffset="40-42" id="miRNA-corp.d74.s1.e0" text="EAE" type="Diseases"/>
            <entity charOffset="97-106" id="miRNA-corp.d74.s1.e1" text="activation" type="Relation_Trigger"/>
            <entity charOffset="29-35" id="miRNA-corp.d74.s1.e2" text="miR-124" type="Specific_miRNAs"/>
            <entity charOffset="146-156" id="miRNA-corp.d74.s1.e3" text="suppression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d74.s1.e2" e2="miRNA-corp.d74.s1.e0" id="miRNA-corp.d74.s1.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d74.s2" origId="21131957.s6" text="Conversely, knockdown of miR-124 in microglia and macrophages resulted in activation of these cells in vitro and in vivo. ">
            <entity charOffset="74-83" id="miRNA-corp.d74.s2.e0" text="activation" type="Relation_Trigger"/>
            <entity charOffset="25-31" id="miRNA-corp.d74.s2.e1" text="miR-124" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d74.s3" origId="21131957.s7" text="These findings identify miR-124 both as a key regulator of microglia quiescence in the central nervous system and as a previously unknown modulator of monocyte and macrophage activation.   ">
            <entity charOffset="175-184" id="miRNA-corp.d74.s3.e0" text="activation" type="Relation_Trigger"/>
            <entity charOffset="24-30" id="miRNA-corp.d74.s3.e1" text="miR-124" type="Specific_miRNAs"/>
            <entity charOffset="46-54" id="miRNA-corp.d74.s3.e2" text="regulator" type="Relation_Trigger"/>
            <entity charOffset="138-146" id="miRNA-corp.d74.s3.e3" text="modulator" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d74.s4" origId="21131957.s0" text="MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-α-PU.1 pathway.  ">
            <entity charOffset="58-60" id="miRNA-corp.d74.s4.e0" text="EAE" type="Diseases"/>
            <entity charOffset="0-11" id="miRNA-corp.d74.s4.e1" text="MicroRNA-124" type="Specific_miRNAs"/>
            <entity charOffset="47-56" id="miRNA-corp.d74.s4.e2" text="suppresses" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d74.s4.e1" e2="miRNA-corp.d74.s4.e0" id="miRNA-corp.d74.s4.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d74.s5" origId="21131957.s1" text="MicroRNAs are a family of regulatory molecules involved in many physiological processes, including differentiation and activation of cells of the immune system. ">
            <entity charOffset="0-8" id="miRNA-corp.d74.s5.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="119-128" id="miRNA-corp.d74.s5.e1" text="activation" type="Relation_Trigger"/>
            <entity charOffset="26-35" id="miRNA-corp.d74.s5.e2" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d74.s6" origId="21131957.s2" text="We found that brain-specific miR-124 is expressed in microglia but not in peripheral monocytes or macrophages. ">
            <entity charOffset="29-35" id="miRNA-corp.d74.s6.e0" text="miR-124" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d74.s7" origId="21131957.s3" text="When overexpressed in macrophages, miR-124 directly inhibited the transcription factor CCAAT/enhancer-binding protein-α (C/EBP-α) and its downstream target PU.1, resulting in transformation of these cells from an activated phenotype into a quiescent CD45(low), major histocompatibility complex (MHC) class II(low) phenotype resembling resting microglia. ">
            <entity charOffset="93-118" id="miRNA-corp.d74.s7.e0" text="enhancer-binding protein-α" type="Genes/Proteins"/>
            <entity charOffset="121-127" id="miRNA-corp.d74.s7.e1" text="C/EBP-α" type="Genes/Proteins"/>
            <entity charOffset="156-159" id="miRNA-corp.d74.s7.e2" text="PU.1" type="Genes/Proteins"/>
            <entity charOffset="213-221" id="miRNA-corp.d74.s7.e3" text="activated" type="Relation_Trigger"/>
            <entity charOffset="5-17" id="miRNA-corp.d74.s7.e4" text="overexpressed" type="Relation_Trigger"/>
            <entity charOffset="35-41" id="miRNA-corp.d74.s7.e5" text="miR-124" type="Specific_miRNAs"/>
            <entity charOffset="52-60" id="miRNA-corp.d74.s7.e6" text="inhibited" type="Relation_Trigger"/>
            <entity charOffset="149-154" id="miRNA-corp.d74.s7.e7" text="target" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d74.s7.e5" e2="miRNA-corp.d74.s7.e0" id="miRNA-corp.d74.s7.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d74.s7.e5" e2="miRNA-corp.d74.s7.e1" id="miRNA-corp.d74.s7.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d74.s7.e5" e2="miRNA-corp.d74.s7.e2" id="miRNA-corp.d74.s7.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d75" origId="21205669">
        <sentence id="miRNA-corp.d75.s0" origId="21205669.s2" text="Mutations in the Drosophila gene lethal (3) malignant brain tumor cause malignant growth in the larval brain. ">
            <entity charOffset="44-64" id="miRNA-corp.d75.s0.e0" text="malignant brain tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d75.s1" origId="21205669.s3" text="Here we show that l(3)mbt tumors exhibited a soma-to-germline transformation through the ectopic expression of genes normally required for germline stemness, fitness, or longevity. ">
            <entity charOffset="26-31" id="miRNA-corp.d75.s1.e0" text="tumors" type="Diseases"/>
            <entity charOffset="89-106" id="miRNA-corp.d75.s1.e1" text="ectopic expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d75.s2" origId="21205669.s4" text="Orthologs of some of these genes were also expressed in human somatic tumors. ">
            <entity charOffset="56-60" id="miRNA-corp.d75.s2.e0" text="human" type="Species"/>
            <entity charOffset="62-75" id="miRNA-corp.d75.s2.e1" text="somatic tumors" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d75.s3" origId="21205669.s5" text="In addition, inactivation of any of the germline genes nanos, vasa, piwi, or aubergine suppressed l(3)mbt malignant growth. ">
            <entity charOffset="106-121" id="miRNA-corp.d75.s3.e0" text="malignant growth" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d75.s4" origId="21205669.s0" text="Ectopic expression of germline genes drives malignant brain tumor growth in Drosophila.  ">
            <entity charOffset="0-17" id="miRNA-corp.d75.s4.e0" text="Ectopic expression" type="Relation_Trigger"/>
            <entity charOffset="44-64" id="miRNA-corp.d75.s4.e1" text="malignant brain tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d75.s5" origId="21205669.s1" text="Model organisms such as the fruit fly Drosophila melanogaster can help to elucidate the molecular basis of complex diseases such as cancer. ">
            <entity charOffset="38-60" id="miRNA-corp.d75.s5.e0" text="Drosophila melanogaster" type="Species"/>
            <entity charOffset="132-137" id="miRNA-corp.d75.s5.e1" text="cancer" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d75.s6" origId="21205669.s6" text="Our results demonstrate that germline traits are necessary for tumor growth in this Drosophila model and suggest that inactivation of germline genes might have tumor-suppressing effects in other species.   ">
            <entity charOffset="63-67" id="miRNA-corp.d75.s6.e0" text="tumor" type="Diseases"/>
            <entity charOffset="84-93" id="miRNA-corp.d75.s6.e1" text="Drosophila" type="Species"/>
            <entity charOffset="160-176" id="miRNA-corp.d75.s6.e2" text="tumor-suppressing" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d76" origId="20647762">
        <sentence id="miRNA-corp.d76.s0" origId="20647762.s9" text="We also identified a potential feedback loop between LKB1 and miR-451, which allows a sustained and robust response to glucose deprivation. ">
            <entity charOffset="62-68" id="miRNA-corp.d76.s0.e0" text="miR-451" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d76.s1" origId="20647762.s6" text="We then found that by targeting the LKB1 kinase complex miR-451 suppresses the activity of downstream protein kinases including the major energy biosensor AMPK. ">
            <entity charOffset="22-30" id="miRNA-corp.d76.s1.e0" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="56-62" id="miRNA-corp.d76.s1.e1" text="miR-451" type="Specific_miRNAs"/>
            <entity charOffset="64-73" id="miRNA-corp.d76.s1.e2" text="suppresses" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d76.s2" origId="20647762.s5" text="We initially identified miR-451 due to its downregulation in a glioma cell migration assay. ">
            <entity charOffset="24-30" id="miRNA-corp.d76.s2.e0" text="miR-451" type="Specific_miRNAs"/>
            <entity charOffset="43-56" id="miRNA-corp.d76.s2.e1" text="downregulation" type="Relation_Trigger"/>
            <entity charOffset="63-68" id="miRNA-corp.d76.s2.e2" text="glioma" type="Diseases"/>
            <pair e1="miRNA-corp.d76.s2.e0" e2="miRNA-corp.d76.s2.e2" id="miRNA-corp.d76.s2.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d76.s3" origId="20647762.s8" text="Under conditions of glucose withdrawal, miR-451 downregulation is necessary for AMPK pathway activation, leading to suppressed proliferation rates, increased cell survival and migration. ">
            <entity charOffset="93-102" id="miRNA-corp.d76.s3.e0" text="activation" type="Relation_Trigger"/>
            <entity charOffset="40-46" id="miRNA-corp.d76.s3.e1" text="miR-451" type="Specific_miRNAs"/>
            <entity charOffset="48-61" id="miRNA-corp.d76.s3.e2" text="downregulation" type="Relation_Trigger"/>
            <entity charOffset="116-125" id="miRNA-corp.d76.s3.e3" text="suppressed" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d76.s4" origId="20647762.s7" text="MiR-451 levels are regulated by glucose; under conditions of abundant energy miR-451 expression is high, and the suppression of AMPK signaling allows cells to maintain elevated proliferation rates via unrestrained mTOR activation. ">
            <entity charOffset="85-102" id="miRNA-corp.d76.s4.e0" text="expression is high" type="Relation_Trigger"/>
            <entity charOffset="219-228" id="miRNA-corp.d76.s4.e1" text="activation" type="Relation_Trigger"/>
            <entity charOffset="214-217" id="miRNA-corp.d76.s4.e2" text="mTOR" type="Genes/Proteins"/>
            <entity charOffset="0-6" id="miRNA-corp.d76.s4.e3" text="MiR-451" type="Specific_miRNAs"/>
            <entity charOffset="8-27" id="miRNA-corp.d76.s4.e4" text="levels are regulated" type="Relation_Trigger"/>
            <entity charOffset="77-83" id="miRNA-corp.d76.s4.e5" text="miR-451" type="Specific_miRNAs"/>
            <entity charOffset="113-123" id="miRNA-corp.d76.s4.e6" text="suppression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d76.s4.e3" e2="miRNA-corp.d76.s4.e2" id="miRNA-corp.d76.s4.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d76.s4.e5" e2="miRNA-corp.d76.s4.e2" id="miRNA-corp.d76.s4.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d76.s5" origId="20647762.s2" text="Incomplete knowledge of the molecular biology, genetics, causes and cellular origin of these tumors may limit the development of improved therapeutics. ">
            <entity charOffset="93-98" id="miRNA-corp.d76.s5.e0" text="tumors" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d76.s6" origId="20647762.s1" text="Glioblastoma, the most common and aggressive primary brain tumor, is rapidly growing and highly infiltrative. ">
            <entity charOffset="0-11" id="miRNA-corp.d76.s6.e0" text="Glioblastoma" type="Diseases"/>
            <entity charOffset="45-63" id="miRNA-corp.d76.s6.e1" text="primary brain tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d76.s7" origId="20647762.s4" text="Here we will discuss further our recently published data on the role of miR-451 in the biology of glioblastoma. ">
            <entity charOffset="72-78" id="miRNA-corp.d76.s7.e0" text="miR-451" type="Specific_miRNAs"/>
            <entity charOffset="98-109" id="miRNA-corp.d76.s7.e1" text="glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d76.s7.e0" e2="miRNA-corp.d76.s7.e1" id="miRNA-corp.d76.s7.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d76.s8" origId="20647762.s3" text="A major and fundamental advance in recent years has been the identification of microRNAs as highly conserved regulators of gene expression. ">
            <entity charOffset="79-87" id="miRNA-corp.d76.s8.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="109-137" id="miRNA-corp.d76.s8.e1" text="regulators of gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d76.s9" origId="20647762.s0" text="microRNA-451: A conditional switch controlling glioma cell proliferation and migration.  ">
            <entity charOffset="0-11" id="miRNA-corp.d76.s9.e0" text="microRNA-451" type="Specific_miRNAs"/>
            <entity charOffset="47-52" id="miRNA-corp.d76.s9.e1" text="glioma" type="Diseases"/>
            <pair e1="miRNA-corp.d76.s9.e0" e2="miRNA-corp.d76.s9.e1" id="miRNA-corp.d76.s9.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d76.s10" origId="20647762.s10" text="This data will be discussed in the context of potential biological significance and therapeutic implications.   "/>
    </document>
    <document id="miRNA-corp.d77" origId="20007902">
        <sentence id="miRNA-corp.d77.s0" origId="20007902.s7" text="Thus, miR-206 slows ALS progression by sensing motor neuron injury and promoting the compensatory regeneration of neuromuscular synapses.   ">
            <entity charOffset="6-12" id="miRNA-corp.d77.s0.e0" text="miR-206" type="Specific_miRNAs"/>
            <entity charOffset="20-22" id="miRNA-corp.d77.s0.e1" text="ALS" type="Diseases"/>
            <entity charOffset="39-65" id="miRNA-corp.d77.s0.e2" text="sensing motor neuron injury" type="Diseases"/>
            <pair e1="miRNA-corp.d77.s0.e0" e2="miRNA-corp.d77.s0.e1" id="miRNA-corp.d77.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d77.s0.e0" e2="miRNA-corp.d77.s0.e2" id="miRNA-corp.d77.s0.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d77.s1" origId="20007902.s3" text="Here, we show that a key regulator of this signaling is miR-206, a skeletal muscle-specific microRNA that is dramatically induced in a mouse model of ALS. ">
            <entity charOffset="25-33" id="miRNA-corp.d77.s1.e0" text="regulator" type="Relation_Trigger"/>
            <entity charOffset="56-62" id="miRNA-corp.d77.s1.e1" text="miR-206" type="Specific_miRNAs"/>
            <entity charOffset="92-99" id="miRNA-corp.d77.s1.e2" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="135-139" id="miRNA-corp.d77.s1.e3" text="mouse" type="Species"/>
            <entity charOffset="150-152" id="miRNA-corp.d77.s1.e4" text="ALS" type="Diseases"/>
            <pair e1="miRNA-corp.d77.s1.e1" e2="miRNA-corp.d77.s1.e4" id="miRNA-corp.d77.s1.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d77.s1.e2" e2="miRNA-corp.d77.s1.e4" id="miRNA-corp.d77.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d77.s2" origId="20007902.s4" text="Mice that are genetically deficient in miR-206 form normal neuromuscular synapses during development, but deficiency of miR-206 in the ALS mouse model accelerates disease progression. ">
            <entity charOffset="0-3" id="miRNA-corp.d77.s2.e0" text="Mice" type="Species"/>
            <entity charOffset="39-45" id="miRNA-corp.d77.s2.e1" text="miR-206" type="Specific_miRNAs"/>
            <entity charOffset="120-126" id="miRNA-corp.d77.s2.e2" text="miR-206" type="Specific_miRNAs"/>
            <entity charOffset="135-137" id="miRNA-corp.d77.s2.e3" text="ALS" type="Diseases"/>
            <entity charOffset="139-143" id="miRNA-corp.d77.s2.e4" text="mouse" type="Species"/>
            <entity charOffset="151-161" id="miRNA-corp.d77.s2.e5" text="accelerates" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d77.s2.e1" e2="miRNA-corp.d77.s2.e3" id="miRNA-corp.d77.s2.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d77.s2.e2" e2="miRNA-corp.d77.s2.e3" id="miRNA-corp.d77.s2.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d77.s3" origId="20007902.s5" text="miR-206 is required for efficient regeneration of neuromuscular synapses after acute nerve injury, which probably accounts for its salutary effects in ALS. ">
            <entity charOffset="0-6" id="miRNA-corp.d77.s3.e0" text="miR-206" type="Specific_miRNAs"/>
            <entity charOffset="79-96" id="miRNA-corp.d77.s3.e1" text="acute nerve injury" type="Diseases"/>
            <entity charOffset="151-153" id="miRNA-corp.d77.s3.e2" text="ALS" type="Diseases"/>
            <pair e1="miRNA-corp.d77.s3.e0" e2="miRNA-corp.d77.s3.e1" id="miRNA-corp.d77.s3.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d77.s3.e0" e2="miRNA-corp.d77.s3.e2" id="miRNA-corp.d77.s3.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d77.s4" origId="20007902.s6" text="miR-206 mediates these effects at least in part through histone deacetylase 4 and fibroblast growth factor signaling pathways. ">
            <entity charOffset="56-76" id="miRNA-corp.d77.s4.e0" text="histone deacetylase 4" type="Genes/Proteins"/>
            <entity charOffset="0-6" id="miRNA-corp.d77.s4.e1" text="miR-206" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d77.s4.e1" e2="miRNA-corp.d77.s4.e0" id="miRNA-corp.d77.s4.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d77.s5" origId="20007902.s0" text="MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice.  ">
            <entity charOffset="0-11" id="miRNA-corp.d77.s5.e0" text="MicroRNA-206" type="Specific_miRNAs"/>
            <entity charOffset="91-94" id="miRNA-corp.d77.s5.e1" text="mice" type="Species"/>
            <entity charOffset="20-22" id="miRNA-corp.d77.s5.e2" text="ALS" type="Diseases"/>
            <pair e1="miRNA-corp.d77.s5.e0" e2="miRNA-corp.d77.s5.e2" id="miRNA-corp.d77.s5.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d77.s6" origId="20007902.s1" text="Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by loss of motor neurons, denervation of target muscles, muscle atrophy, and paralysis. ">
            <entity charOffset="0-28" id="miRNA-corp.d77.s6.e0" text="Amyotrophic lateral sclerosis" type="Diseases"/>
            <entity charOffset="31-33" id="miRNA-corp.d77.s6.e1" text="ALS" type="Diseases"/>
            <entity charOffset="41-65" id="miRNA-corp.d77.s6.e2" text="neurodegenerative disease" type="Diseases"/>
            <entity charOffset="122-127" id="miRNA-corp.d77.s6.e3" text="target" type="Relation_Trigger"/>
            <entity charOffset="138-151" id="miRNA-corp.d77.s6.e4" text="muscle atrophy" type="Diseases"/>
            <entity charOffset="158-166" id="miRNA-corp.d77.s6.e5" text="paralysis" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d77.s7" origId="20007902.s2" text="Understanding ALS pathogenesis may require a fuller understanding of the bidirectional signaling between motor neurons and skeletal muscle fibers at neuromuscular synapses. ">
            <entity charOffset="14-16" id="miRNA-corp.d77.s7.e0" text="ALS" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d78" origId="17908999">
        <sentence id="miRNA-corp.d78.s0" origId="17908999.s3" text="In gliomas, microRNA-21 (miR-21) levels have been reported to be elevated and their knockdown is associated with increased apoptotic activity. ">
            <entity charOffset="33-72" id="miRNA-corp.d78.s0.e0" text="levels have been reported to be elevated" type="Relation_Trigger"/>
            <entity charOffset="3-9" id="miRNA-corp.d78.s0.e1" text="gliomas" type="Diseases"/>
            <entity charOffset="12-22" id="miRNA-corp.d78.s0.e2" text="microRNA-21" type="Specific_miRNAs"/>
            <entity charOffset="25-30" id="miRNA-corp.d78.s0.e3" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="97-106" id="miRNA-corp.d78.s0.e4" text="associated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d78.s0.e2" e2="miRNA-corp.d78.s0.e1" id="miRNA-corp.d78.s0.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d78.s0.e3" e2="miRNA-corp.d78.s0.e1" id="miRNA-corp.d78.s0.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d78.s1" origId="17908999.s4" text="We hypothesized that suppression of miR-21 might sensitize gliomas for cytotoxic tumor therapy. ">
            <entity charOffset="36-41" id="miRNA-corp.d78.s1.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="21-31" id="miRNA-corp.d78.s1.e1" text="suppression" type="Relation_Trigger"/>
            <entity charOffset="59-65" id="miRNA-corp.d78.s1.e2" text="gliomas" type="Diseases"/>
            <pair e1="miRNA-corp.d78.s1.e0" e2="miRNA-corp.d78.s1.e2" id="miRNA-corp.d78.s1.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d78.s2" origId="17908999.s5" text="With the use of locked nucleic acid (LNA)-antimiR-21 oligonucleotides, bimodal imaging vectors, and neural precursor cells (NPC) expressing a secretable variant of the cytotoxic agent tumor necrosis factor-related apoptosis inducing ligand (S-TRAIL), we show that the combined suppression of miR-21 and NPC-S-TRAIL leads to a synergistic increase in caspase activity and significantly decreased cell viability in human glioma cells in vitro. ">
            <entity charOffset="371-393" id="miRNA-corp.d78.s2.e0" text="significantly decreased" type="Relation_Trigger"/>
            <entity charOffset="292-297" id="miRNA-corp.d78.s2.e1" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="413-417" id="miRNA-corp.d78.s2.e2" text="human" type="Species"/>
            <entity charOffset="413-424" id="miRNA-corp.d78.s2.e3" text="human glioma" type="Diseases"/>
            <entity charOffset="277-287" id="miRNA-corp.d78.s2.e4" text="suppression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d78.s2.e1" e2="miRNA-corp.d78.s2.e3" id="miRNA-corp.d78.s2.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d78.s3" origId="17908999.s6" text="This phenomenon persists in vivo, as we observed complete eradication of LNA-antimiR-21-treated gliomas subjected to the presence of NPC-S-TRAIL in the murine brain. ">
            <entity charOffset="96-102" id="miRNA-corp.d78.s3.e0" text="gliomas" type="Diseases"/>
            <entity charOffset="152-157" id="miRNA-corp.d78.s3.e1" text="murine" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d78.s4" origId="17908999.s7" text="Our results reveal the efficacy of miR-21 antagonism in murine glioma models and implicate miR-21 as a target for therapeutic intervention. ">
            <entity charOffset="35-40" id="miRNA-corp.d78.s4.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="56-61" id="miRNA-corp.d78.s4.e1" text="murine" type="Species"/>
            <entity charOffset="91-96" id="miRNA-corp.d78.s4.e2" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="63-68" id="miRNA-corp.d78.s4.e3" text="glioma" type="Diseases"/>
            <entity charOffset="103-124" id="miRNA-corp.d78.s4.e4" text="target for therapeutic" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d78.s4.e0" e2="miRNA-corp.d78.s4.e3" id="miRNA-corp.d78.s4.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d78.s4.e2" e2="miRNA-corp.d78.s4.e3" id="miRNA-corp.d78.s4.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d78.s5" origId="17908999.s8" text="Furthermore, our findings provide the basis for developing combination therapies using miRNA modulation and cytotoxic tumor therapies.   ">
            <entity charOffset="87-91" id="miRNA-corp.d78.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="93-102" id="miRNA-corp.d78.s5.e1" text="modulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d78.s6" origId="17908999.s0" text="MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas.  ">
            <entity charOffset="0-10" id="miRNA-corp.d78.s6.e0" text="MicroRNA-21" type="Specific_miRNAs"/>
            <entity charOffset="31-36" id="miRNA-corp.d78.s6.e1" text="glioma" type="Diseases"/>
            <entity charOffset="139-151" id="miRNA-corp.d78.s6.e2" text="human gliomas" type="Diseases"/>
            <entity charOffset="139-143" id="miRNA-corp.d78.s6.e3" text="human" type="Species"/>
            <pair e1="miRNA-corp.d78.s6.e0" e2="miRNA-corp.d78.s6.e1" id="miRNA-corp.d78.s6.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d78.s6.e0" e2="miRNA-corp.d78.s6.e2" id="miRNA-corp.d78.s6.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d78.s7" origId="17908999.s2" text="Mounting evidence indicates that microRNAs (miRNA) might play a fundamental role in tumorigenesis, controlling cell proliferation and apoptosis. ">
            <entity charOffset="33-41" id="miRNA-corp.d78.s7.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="44-48" id="miRNA-corp.d78.s7.e1" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d78.s8" origId="17908999.s1" text="Despite the development of new glioma therapies that allow for tumor-targeted in situ delivery of cytotoxic drugs, tumor resistance to apoptosis remains a key impediment to effective treatment. ">
            <entity charOffset="31-36" id="miRNA-corp.d78.s8.e0" text="glioma" type="Diseases"/>
            <entity charOffset="63-67" id="miRNA-corp.d78.s8.e1" text="tumor" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d79" origId="19906911">
        <sentence id="miRNA-corp.d79.s0" origId="19906911.s3" text="We therefore sought to determine whether microRNA targets could be engineered into VSV to ameliorate its neuropathogenicity. ">
            <entity charOffset="41-48" id="miRNA-corp.d79.s0.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="50-56" id="miRNA-corp.d79.s0.e1" text="targets" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d79.s1" origId="19906911.s4" text="Using a panel of recombinant VSVs incorporating microRNA target sequences corresponding to neuron-specific or control microRNAs (in forward and reverse orientations), we tested viral replication kinetics in cell lines treated with microRNA mimics, neurotoxicity after direct intracerebral inoculation in mice, and antitumor efficacy. ">
            <entity charOffset="248-260" id="miRNA-corp.d79.s1.e0" text="neurotoxicity" type="Diseases"/>
            <entity charOffset="48-55" id="miRNA-corp.d79.s1.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="57-62" id="miRNA-corp.d79.s1.e2" text="target" type="Relation_Trigger"/>
            <entity charOffset="118-126" id="miRNA-corp.d79.s1.e3" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="231-238" id="miRNA-corp.d79.s1.e4" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="304-307" id="miRNA-corp.d79.s1.e5" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d79.s1.e1" e2="miRNA-corp.d79.s1.e0" id="miRNA-corp.d79.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d79.s1.e3" e2="miRNA-corp.d79.s1.e0" id="miRNA-corp.d79.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d79.s1.e4" e2="miRNA-corp.d79.s1.e0" id="miRNA-corp.d79.s1.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d79.s2" origId="19906911.s5" text="Compared to picornaviruses and adenoviruses, the engineered VSVs were relatively resistant to microRNA-mediated inhibition, but neurotoxicity could nevertheless be ameliorated significantly using this approach, without compromise to antitumor efficacy. ">
            <entity charOffset="128-140" id="miRNA-corp.d79.s2.e0" text="neurotoxicity" type="Diseases"/>
            <entity charOffset="94-101" id="miRNA-corp.d79.s2.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="112-121" id="miRNA-corp.d79.s2.e2" text="inhibition" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d79.s2.e1" e2="miRNA-corp.d79.s2.e0" id="miRNA-corp.d79.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d79.s3" origId="19906911.s6" text="Neurotoxicity was most profoundly reduced in a virus carrying four tandem copies of a neuronal mir125 target sequence inserted in the 3'-untranslated region of the viral polymerase (L) gene.   ">
            <entity charOffset="0-12" id="miRNA-corp.d79.s3.e0" text="Neurotoxicity" type="Diseases"/>
            <entity charOffset="95-100" id="miRNA-corp.d79.s3.e1" text="mir125" type="Specific_miRNAs"/>
            <entity charOffset="102-107" id="miRNA-corp.d79.s3.e2" text="target" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d79.s3.e1" e2="miRNA-corp.d79.s3.e0" id="miRNA-corp.d79.s3.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d79.s4" origId="19906911.s0" text="Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting.  ">
            <entity charOffset="0-10" id="miRNA-corp.d79.s4.e0" text="Attenuation" type="Relation_Trigger"/>
            <entity charOffset="72-80" id="miRNA-corp.d79.s4.e1" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="63-70" id="miRNA-corp.d79.s4.e2" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="15-53" id="miRNA-corp.d79.s4.e3" text="vesicular stomatitis virus encephalitis" type="Diseases"/>
            <pair e1="miRNA-corp.d79.s4.e2" e2="miRNA-corp.d79.s4.e3" id="miRNA-corp.d79.s4.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d79.s5" origId="19906911.s1" text="Vesicular stomatitis virus (VSV) has long been regarded as a promising recombinant vaccine platform and oncolytic agent but has not yet been tested in humans because it causes encephalomyelitis in rodents and primates. ">
            <entity charOffset="151-156" id="miRNA-corp.d79.s5.e0" text="humans" type="Species"/>
            <entity charOffset="176-192" id="miRNA-corp.d79.s5.e1" text="encephalomyelitis" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d79.s6" origId="19906911.s2" text="Recent studies have shown that specific tropisms of several viruses could be eliminated by engineering microRNA target sequences into their genomes, thereby inhibiting spread in tissues expressing cognate microRNAs. ">
            <entity charOffset="103-110" id="miRNA-corp.d79.s6.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="112-117" id="miRNA-corp.d79.s6.e1" text="target" type="Relation_Trigger"/>
            <entity charOffset="205-213" id="miRNA-corp.d79.s6.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="157-166" id="miRNA-corp.d79.s6.e3" text="inhibiting" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d80" origId="18607543">
        <sentence id="miRNA-corp.d80.s0" origId="18607543.s10" text="Furthermore, in patient samples expression of miR 124a is significantly decreased. ">
            <entity charOffset="46-53" id="miRNA-corp.d80.s0.e0" text="miR 124a" type="Specific_miRNAs"/>
            <entity charOffset="32-80" id="miRNA-corp.d80.s0.e1" text="expression of miR 124a is significantly decreased" type="Relation_Trigger"/>
            <entity charOffset="46-53" id="miRNA-corp.d80.s0.e2" text="miR 124a" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d80.s1" origId="18607543.s11" text="Our data strongly indicate that CDK6 is regulated by microRNA 124 in medulloblastoma and that miR 124 modulates medulloblastoma cell growth.   ">
            <entity charOffset="32-35" id="miRNA-corp.d80.s1.e0" text="CDK6" type="Genes/Proteins"/>
            <entity charOffset="53-64" id="miRNA-corp.d80.s1.e1" text="microRNA 124" type="Specific_miRNAs"/>
            <entity charOffset="69-83" id="miRNA-corp.d80.s1.e2" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="94-100" id="miRNA-corp.d80.s1.e3" text="miR 124" type="Specific_miRNAs"/>
            <entity charOffset="102-110" id="miRNA-corp.d80.s1.e4" text="modulates" type="Relation_Trigger"/>
            <entity charOffset="112-126" id="miRNA-corp.d80.s1.e5" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="40-48" id="miRNA-corp.d80.s1.e6" text="regulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d80.s1.e1" e2="miRNA-corp.d80.s1.e0" id="miRNA-corp.d80.s1.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d80.s1.e1" e2="miRNA-corp.d80.s1.e2" id="miRNA-corp.d80.s1.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d80.s1.e1" e2="miRNA-corp.d80.s1.e5" id="miRNA-corp.d80.s1.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d80.s1.e3" e2="miRNA-corp.d80.s1.e0" id="miRNA-corp.d80.s1.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d80.s1.e3" e2="miRNA-corp.d80.s1.e2" id="miRNA-corp.d80.s1.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d80.s1.e3" e2="miRNA-corp.d80.s1.e5" id="miRNA-corp.d80.s1.p5" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d80.s2" origId="18607543.s4" text="We hypothesized that CDK6 expression is also regulated by microRNAs in medulloblastoma. ">
            <entity charOffset="21-24" id="miRNA-corp.d80.s2.e0" text="CDK6" type="Genes/Proteins"/>
            <entity charOffset="26-53" id="miRNA-corp.d80.s2.e1" text="expression is also regulated" type="Relation_Trigger"/>
            <entity charOffset="58-66" id="miRNA-corp.d80.s2.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="71-85" id="miRNA-corp.d80.s2.e3" text="medulloblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d80.s2.e2" e2="miRNA-corp.d80.s2.e0" id="miRNA-corp.d80.s2.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d80.s2.e2" e2="miRNA-corp.d80.s2.e3" id="miRNA-corp.d80.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d80.s3" origId="18607543.s3" text="Genomic amplification accounts for some, but not all of the CDK6 over-expression. ">
            <entity charOffset="8-20" id="miRNA-corp.d80.s3.e0" text="amplification" type="Relation_Trigger"/>
            <entity charOffset="60-63" id="miRNA-corp.d80.s3.e1" text="CDK6" type="Genes/Proteins"/>
            <entity charOffset="65-79" id="miRNA-corp.d80.s3.e2" text="over-expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d80.s4" origId="18607543.s6" text="Expression of miR 124a was significantly decreased in medulloblastoma cells compared to normal adult cerebellum. ">
            <entity charOffset="14-21" id="miRNA-corp.d80.s4.e0" text="miR 124a" type="Specific_miRNAs"/>
            <entity charOffset="0-49" id="miRNA-corp.d80.s4.e1" text="Expression of miR 124a was significantly decreased" type="Relation_Trigger"/>
            <entity charOffset="54-68" id="miRNA-corp.d80.s4.e2" text="medulloblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d80.s4.e0" e2="miRNA-corp.d80.s4.e2" id="miRNA-corp.d80.s4.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d80.s5" origId="18607543.s5" text="We identified putative miR sites in the CDK6 including microRNA 124a, a brain enriched microRNA. ">
            <entity charOffset="23-25" id="miRNA-corp.d80.s5.e0" text="miR" type="Non-Specific_miRNAs"/>
            <entity charOffset="40-43" id="miRNA-corp.d80.s5.e1" text="CDK6" type="Genes/Proteins"/>
            <entity charOffset="55-67" id="miRNA-corp.d80.s5.e2" text="microRNA 124a" type="Specific_miRNAs"/>
            <entity charOffset="87-94" id="miRNA-corp.d80.s5.e3" text="microRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d80.s5.e0" e2="miRNA-corp.d80.s5.e1" id="miRNA-corp.d80.s5.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d80.s5.e2" e2="miRNA-corp.d80.s5.e1" id="miRNA-corp.d80.s5.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d80.s5.e3" e2="miRNA-corp.d80.s5.e1" id="miRNA-corp.d80.s5.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d80.s6" origId="18607543.s8" text="Additionally, re-expression of miR 124a in medulloblastoma cells decreased expression of CDK6 protein. ">
            <entity charOffset="31-38" id="miRNA-corp.d80.s6.e0" text="miR 124a" type="Specific_miRNAs"/>
            <entity charOffset="43-57" id="miRNA-corp.d80.s6.e1" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="65-84" id="miRNA-corp.d80.s6.e2" text="decreased expression" type="Relation_Trigger"/>
            <entity charOffset="89-92" id="miRNA-corp.d80.s6.e3" text="CDK6" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d80.s6.e0" e2="miRNA-corp.d80.s6.e1" id="miRNA-corp.d80.s6.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d80.s6.e0" e2="miRNA-corp.d80.s6.e3" id="miRNA-corp.d80.s6.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d80.s7" origId="18607543.s7" text="Functional association between miR 124a and CDK6 in medulloblastoma was established using luciferase assays. ">
            <entity charOffset="11-21" id="miRNA-corp.d80.s7.e0" text="association" type="Relation_Trigger"/>
            <entity charOffset="31-38" id="miRNA-corp.d80.s7.e1" text="miR 124a" type="Specific_miRNAs"/>
            <entity charOffset="44-47" id="miRNA-corp.d80.s7.e2" text="CDK6" type="Genes/Proteins"/>
            <entity charOffset="52-66" id="miRNA-corp.d80.s7.e3" text="medulloblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d80.s7.e1" e2="miRNA-corp.d80.s7.e2" id="miRNA-corp.d80.s7.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d80.s7.e1" e2="miRNA-corp.d80.s7.e3" id="miRNA-corp.d80.s7.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d80.s8" origId="18607543.s9" text="Transfection of miR 124 significantly decreases medulloblastoma cell growth but does not alter apoptosis. ">
            <entity charOffset="16-22" id="miRNA-corp.d80.s8.e0" text="miR 124" type="Specific_miRNAs"/>
            <entity charOffset="24-46" id="miRNA-corp.d80.s8.e1" text="significantly decreases" type="Relation_Trigger"/>
            <entity charOffset="48-62" id="miRNA-corp.d80.s8.e2" text="medulloblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d80.s8.e0" e2="miRNA-corp.d80.s8.e2" id="miRNA-corp.d80.s8.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d80.s9" origId="18607543.s0" text="Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma.  ">
            <entity charOffset="0-9" id="miRNA-corp.d80.s9.e0" text="Regulation" type="Relation_Trigger"/>
            <entity charOffset="43-54" id="miRNA-corp.d80.s9.e1" text="microRNA 124" type="Specific_miRNAs"/>
            <entity charOffset="59-73" id="miRNA-corp.d80.s9.e2" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="14-38" id="miRNA-corp.d80.s9.e3" text="cyclin dependent kinase 6" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d80.s9.e1" e2="miRNA-corp.d80.s9.e2" id="miRNA-corp.d80.s9.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d80.s9.e1" e2="miRNA-corp.d80.s9.e3" id="miRNA-corp.d80.s9.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d80.s10" origId="18607543.s1" text="Despite recent advances in treatment medulloblastoma continues to remain a vexing problem. ">
            <entity charOffset="37-51" id="miRNA-corp.d80.s10.e0" text="medulloblastoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d80.s11" origId="18607543.s2" text="Recently increased expression of cyclin dependent kinase 6 (CDK6) was identified as an adverse prognostic marker in medulloblastoma. ">
            <entity charOffset="9-28" id="miRNA-corp.d80.s11.e0" text="increased expression" type="Relation_Trigger"/>
            <entity charOffset="33-57" id="miRNA-corp.d80.s11.e1" text="cyclin dependent kinase 6" type="Genes/Proteins"/>
            <entity charOffset="60-63" id="miRNA-corp.d80.s11.e2" text="CDK6" type="Genes/Proteins"/>
            <entity charOffset="116-130" id="miRNA-corp.d80.s11.e3" text="medulloblastoma" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d81" origId="19625741">
        <sentence id="miRNA-corp.d81.s0" origId="19625741.s3" text="An association study of rs9897526 and rs5848 was carried out in an Italian population and in a replication population of European American patients and controls. ">
            <entity charOffset="3-13" id="miRNA-corp.d81.s0.e0" text="association" type="Relation_Trigger"/>
            <entity charOffset="139-146" id="miRNA-corp.d81.s0.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d81.s1" origId="19625741.s2" text="The influence of GRN genetic variability on susceptibility to AD and on expression levels in a series of neuropathologically-confirmed AD patients as well as in peripheral mononuclear cells (PBMC) and in cells isolated from cerebrospinal fluid (CSF) was investigated. ">
            <entity charOffset="17-19" id="miRNA-corp.d81.s1.e0" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="62-63" id="miRNA-corp.d81.s1.e1" text="AD" type="Diseases"/>
            <entity charOffset="135-136" id="miRNA-corp.d81.s1.e2" text="AD" type="Diseases"/>
            <entity charOffset="138-145" id="miRNA-corp.d81.s1.e3" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d81.s2" origId="19625741.s1" text="Mutations in the progranulin gene (GRN), causative for Frontotemporal Lobar Degeneration with ubiquitin-immunoreactive neuronal inclusions (FTLD-U), could also be associated with Alzheimer's disease (AD). ">
            <entity charOffset="17-32" id="miRNA-corp.d81.s2.e0" text="progranulin gene" type="Genes/Proteins"/>
            <entity charOffset="35-37" id="miRNA-corp.d81.s2.e1" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="163-172" id="miRNA-corp.d81.s2.e2" text="associated" type="Relation_Trigger"/>
            <entity charOffset="179-197" id="miRNA-corp.d81.s2.e3" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="200-201" id="miRNA-corp.d81.s2.e4" text="AD" type="Diseases"/>
            <entity charOffset="55-137" id="miRNA-corp.d81.s2.e5" text="Frontotemporal Lobar Degeneration with ubiquitin-immunoreactive neuronal inclusions" type="Diseases"/>
            <entity charOffset="140-145" id="miRNA-corp.d81.s2.e6" text="FTLD-U" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d81.s3" origId="19625741.s0" text="Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease.  ">
            <entity charOffset="101-119" id="miRNA-corp.d81.s3.e0" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="26-28" id="miRNA-corp.d81.s3.e1" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="87-94" id="miRNA-corp.d81.s3.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d81.s4" origId="19625741.s7" text="Despite no significant differences were found in the relative PBMC and CSF GRN expression in patients compared to controls, stratifying patients according to the presence of rs5848 T allele, a 0.57-fold decrease in GRN mRNA levels over C carriers was found in PBMC (1.22 +/- 0.23 versus 0.70 +/- 0.12, P = 0.04). ">
            <entity charOffset="93-100" id="miRNA-corp.d81.s4.e0" text="patients" type="Species"/>
            <entity charOffset="75-77" id="miRNA-corp.d81.s4.e1" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="136-143" id="miRNA-corp.d81.s4.e2" text="patients" type="Species"/>
            <entity charOffset="215-217" id="miRNA-corp.d81.s4.e3" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="203-229" id="miRNA-corp.d81.s4.e4" text="decrease in GRN mRNA levels" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d81.s5" origId="19625741.s6" text="Patients carrying the rs5848 TT genotype had the lowest GRN expression levels (0.96 +/- 0.12, P = 0.014). ">
            <entity charOffset="0-7" id="miRNA-corp.d81.s5.e0" text="Patients" type="Species"/>
            <entity charOffset="56-58" id="miRNA-corp.d81.s5.e1" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="49-76" id="miRNA-corp.d81.s5.e2" text="lowest GRN expression levels" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d81.s6" origId="19625741.s5" text="GRN expression in the parietal lobe of AD cases showed a 0.76-fold decrease compared with controls (1.31 +/- 0.07 versus 1.73 +/- 0.12, P = 0.0025). ">
            <entity charOffset="0-2" id="miRNA-corp.d81.s6.e0" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="39-40" id="miRNA-corp.d81.s6.e1" text="AD" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d81.s7" origId="19625741.s4" text="None of the variants tested act as unequivocal susceptibility factor in both populations although rs9897526 anticipated the onset of the disease in the Italian population. "/>
        <sentence id="miRNA-corp.d81.s8" origId="19625741.s8" text="Similarly to data obtained in brain samples, patients carrying the TT genotype showed the lowest GRN mRNA levels (TT = 0.46 +/- 0.14, CC = 1.22 +/- 0.23; P = 0.013). ">
            <entity charOffset="97-99" id="miRNA-corp.d81.s8.e0" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="90-111" id="miRNA-corp.d81.s8.e1" text="lowest GRN mRNA levels" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d81.s9" origId="19625741.s9" text="These data argue against a direct role of GRN as a susceptibility factor for sporadic AD but support a role of GRN as a disease-modifying gene, possibly contributing to the failure of neuronal survival.   ">
            <entity charOffset="42-44" id="miRNA-corp.d81.s9.e0" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="77-87" id="miRNA-corp.d81.s9.e1" text="sporadic AD" type="Diseases"/>
            <entity charOffset="111-113" id="miRNA-corp.d81.s9.e2" text="GRN" type="Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d82" origId="21342133">
        <sentence id="miRNA-corp.d82.s0" origId="21342133.s3" text="Thrombolytic therapy involving recombinant tissue plasminogen activator (rtPA) has been shown to be beneficial only when used within 4.5 hours of onset of acute ischemic stroke. ">
            <entity charOffset="155-175" id="miRNA-corp.d82.s0.e0" text="acute ischemic stroke" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d82.s1" origId="21342133.s2" text="There are two major types of stroke: cerebral ischemia caused by obstruction of blood vessels in the brain and haemorrhagic stroke that is triggered by the disruption of blood vessels. ">
            <entity charOffset="29-34" id="miRNA-corp.d82.s1.e0" text="stroke" type="Diseases"/>
            <entity charOffset="37-53" id="miRNA-corp.d82.s1.e1" text="cerebral ischemia" type="Diseases"/>
            <entity charOffset="111-129" id="miRNA-corp.d82.s1.e2" text="haemorrhagic stroke" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d82.s2" origId="21342133.s1" text="Stroke is one of the leading causes of death and disability worldwide. ">
            <entity charOffset="0-5" id="miRNA-corp.d82.s2.e0" text="Stroke" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d82.s3" origId="21342133.s0" text="microRNAs in stroke pathogenesis.  ">
            <entity charOffset="0-8" id="miRNA-corp.d82.s3.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="13-18" id="miRNA-corp.d82.s3.e1" text="stroke" type="Diseases"/>
            <pair e1="miRNA-corp.d82.s3.e0" e2="miRNA-corp.d82.s3.e1" id="miRNA-corp.d82.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d82.s4" origId="21342133.s6" text="Although the biochemistry of stroke and related diseases is quite well understood, the knowledge on the molecular mechanisms underlying these diseases is still at its infancy. ">
            <entity charOffset="29-34" id="miRNA-corp.d82.s4.e0" text="stroke" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d82.s5" origId="21342133.s7" text="microRNAs that form a unique class of endogenous riboregulators of gene function, offer tremendous potential in unraveling the mechanisms underlying stroke pathogenesis. ">
            <entity charOffset="0-8" id="miRNA-corp.d82.s5.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="149-154" id="miRNA-corp.d82.s5.e1" text="stroke" type="Diseases"/>
            <pair e1="miRNA-corp.d82.s5.e0" e2="miRNA-corp.d82.s5.e1" id="miRNA-corp.d82.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d82.s6" origId="21342133.s4" text="rtPA treatment beyond this time window has been found to be unsuitable and usually resulting in haemorrhagic transformation. "/>
        <sentence id="miRNA-corp.d82.s7" origId="21342133.s5" text="Stroke is a multifactorial disease that forms a possible end state for majority of patients suffering from diabetes, atherosclerosis and hypertension which are known risk factors. ">
            <entity charOffset="83-90" id="miRNA-corp.d82.s7.e0" text="patients" type="Species"/>
            <entity charOffset="0-5" id="miRNA-corp.d82.s7.e1" text="Stroke" type="Diseases"/>
            <entity charOffset="107-114" id="miRNA-corp.d82.s7.e2" text="diabetes" type="Diseases"/>
            <entity charOffset="117-131" id="miRNA-corp.d82.s7.e3" text="atherosclerosis" type="Diseases"/>
            <entity charOffset="137-148" id="miRNA-corp.d82.s7.e4" text="hypertension" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d82.s8" origId="21342133.s8" text="microRNA expression also reflects the response of individuals to drugs and therapy. ">
            <entity charOffset="0-7" id="miRNA-corp.d82.s8.e0" text="microRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d82.s9" origId="21342133.s9" text="Several microRNAs and their target genes, known to be involved in endothelial dysfunction, dysregulation of neurovascular integrity, edema formation, pro-apoptosis, inflammation and extra-cellular matrix remodeling contribute to the critical processes in the pathogenesis of stroke. ">
            <entity charOffset="133-147" id="miRNA-corp.d82.s9.e0" text="edema formation" type="Diseases"/>
            <entity charOffset="28-33" id="miRNA-corp.d82.s9.e1" text="target" type="Relation_Trigger"/>
            <entity charOffset="8-16" id="miRNA-corp.d82.s9.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="66-88" id="miRNA-corp.d82.s9.e3" text="endothelial dysfunction" type="Diseases"/>
            <entity charOffset="91-103" id="miRNA-corp.d82.s9.e4" text="dysregulation" type="Relation_Trigger"/>
            <entity charOffset="165-176" id="miRNA-corp.d82.s9.e5" text="inflammation" type="Diseases"/>
            <entity charOffset="275-280" id="miRNA-corp.d82.s9.e6" text="stroke" type="Diseases"/>
            <pair e1="miRNA-corp.d82.s9.e2" e2="miRNA-corp.d82.s9.e0" id="miRNA-corp.d82.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d82.s9.e2" e2="miRNA-corp.d82.s9.e3" id="miRNA-corp.d82.s9.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d82.s9.e2" e2="miRNA-corp.d82.s9.e5" id="miRNA-corp.d82.s9.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d82.s9.e2" e2="miRNA-corp.d82.s9.e6" id="miRNA-corp.d82.s9.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d82.s10" origId="21342133.s10" text="In this review, we will also be discussing the role of microRNAs as possible diagnostic and prognostic biomarkers as well as potential therapeutic targets in stroke pathogenesis.   ">
            <entity charOffset="135-153" id="miRNA-corp.d82.s10.e0" text="therapeutic targets" type="Relation_Trigger"/>
            <entity charOffset="55-63" id="miRNA-corp.d82.s10.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="158-163" id="miRNA-corp.d82.s10.e2" text="stroke" type="Diseases"/>
            <pair e1="miRNA-corp.d82.s10.e1" e2="miRNA-corp.d82.s10.e2" id="miRNA-corp.d82.s10.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d83" origId="17761871">
        <sentence id="miRNA-corp.d83.s0" origId="17761871.s0" text="Molecular biology. "/>
        <sentence id="miRNA-corp.d83.s1" origId="17761871.s1" text="miRNAs in neurodegeneration.     ">
            <entity charOffset="0-5" id="miRNA-corp.d83.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d84" origId="21471404">
        <sentence id="miRNA-corp.d84.s0" origId="21471404.s4" text="These cellular responses are mediated by augmented expression of the direct targets of miR-10b, including BCL2L11/Bim, TFAP2C/AP-2γ, CDKN1A/p21, and CDKN2A/p16, which normally protect cells from uncontrolled growth. ">
            <entity charOffset="69-82" id="miRNA-corp.d84.s0.e0" text="direct targets" type="Relation_Trigger"/>
            <entity charOffset="87-93" id="miRNA-corp.d84.s0.e1" text="miR-10b" type="Specific_miRNAs"/>
            <entity charOffset="106-112" id="miRNA-corp.d84.s0.e2" text="BCL2L11" type="Genes/Proteins"/>
            <entity charOffset="114-116" id="miRNA-corp.d84.s0.e3" text="Bim" type="Genes/Proteins"/>
            <entity charOffset="119-124" id="miRNA-corp.d84.s0.e4" text="TFAP2C" type="Genes/Proteins"/>
            <entity charOffset="126-130" id="miRNA-corp.d84.s0.e5" text="AP-2γ" type="Genes/Proteins"/>
            <entity charOffset="133-138" id="miRNA-corp.d84.s0.e6" text="CDKN1A" type="Genes/Proteins"/>
            <entity charOffset="140-142" id="miRNA-corp.d84.s0.e7" text="p21" type="Genes/Proteins"/>
            <entity charOffset="149-154" id="miRNA-corp.d84.s0.e8" text="CDKN2A" type="Genes/Proteins"/>
            <entity charOffset="156-158" id="miRNA-corp.d84.s0.e9" text="p16" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d84.s0.e1" e2="miRNA-corp.d84.s0.e2" id="miRNA-corp.d84.s0.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d84.s0.e1" e2="miRNA-corp.d84.s0.e3" id="miRNA-corp.d84.s0.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d84.s0.e1" e2="miRNA-corp.d84.s0.e4" id="miRNA-corp.d84.s0.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d84.s0.e1" e2="miRNA-corp.d84.s0.e5" id="miRNA-corp.d84.s0.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d84.s0.e1" e2="miRNA-corp.d84.s0.e6" id="miRNA-corp.d84.s0.p4" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d84.s0.e1" e2="miRNA-corp.d84.s0.e7" id="miRNA-corp.d84.s0.p5" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d84.s0.e1" e2="miRNA-corp.d84.s0.e8" id="miRNA-corp.d84.s0.p6" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d84.s0.e1" e2="miRNA-corp.d84.s0.e9" id="miRNA-corp.d84.s0.p7" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s1" origId="21471404.s5" text="Analysis of The Cancer Genome Atlas expression data set reveals a strong positive correlation between numerous genes sustaining cellular growth and miR-10b levels in human glioblastomas, while proapoptotic genes anticorrelate with the expression of miR-10b. ">
            <entity charOffset="73-92" id="miRNA-corp.d84.s1.e0" text="positive correlation" type="Relation_Trigger"/>
            <entity charOffset="148-154" id="miRNA-corp.d84.s1.e1" text="miR-10b" type="Specific_miRNAs"/>
            <entity charOffset="166-170" id="miRNA-corp.d84.s1.e2" text="human" type="Species"/>
            <entity charOffset="166-184" id="miRNA-corp.d84.s1.e3" text="human glioblastomas" type="Diseases"/>
            <entity charOffset="249-255" id="miRNA-corp.d84.s1.e4" text="miR-10b" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d84.s1.e1" e2="miRNA-corp.d84.s1.e3" id="miRNA-corp.d84.s1.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d84.s1.e4" e2="miRNA-corp.d84.s1.e3" id="miRNA-corp.d84.s1.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s2" origId="21471404.s2" text="Molecular functions of these miRNAs in gliomagenesis are mainly unknown. ">
            <entity charOffset="29-34" id="miRNA-corp.d84.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s3" origId="21471404.s3" text="We show that inhibition of miR-10b, a miRNA not expressed in human brain and strongly upregulated in both low-grade and high-grade gliomas, reduces glioma cell growth by cell-cycle arrest and apoptosis. ">
            <entity charOffset="38-42" id="miRNA-corp.d84.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="27-33" id="miRNA-corp.d84.s3.e1" text="miR-10b" type="Specific_miRNAs"/>
            <entity charOffset="13-22" id="miRNA-corp.d84.s3.e2" text="inhibition" type="Relation_Trigger"/>
            <entity charOffset="61-65" id="miRNA-corp.d84.s3.e3" text="human" type="Species"/>
            <entity charOffset="86-96" id="miRNA-corp.d84.s3.e4" text="upregulated" type="Relation_Trigger"/>
            <entity charOffset="120-137" id="miRNA-corp.d84.s3.e5" text="high-grade gliomas" type="Diseases"/>
            <entity charOffset="148-153" id="miRNA-corp.d84.s3.e6" text="glioma" type="Diseases"/>
            <pair e1="miRNA-corp.d84.s3.e0" e2="miRNA-corp.d84.s3.e5" id="miRNA-corp.d84.s3.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d84.s3.e0" e2="miRNA-corp.d84.s3.e6" id="miRNA-corp.d84.s3.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d84.s3.e1" e2="miRNA-corp.d84.s3.e5" id="miRNA-corp.d84.s3.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d84.s3.e1" e2="miRNA-corp.d84.s3.e6" id="miRNA-corp.d84.s3.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s4" origId="21471404.s0" text="Human glioma growth is controlled by microRNA-10b.  ">
            <entity charOffset="0-11" id="miRNA-corp.d84.s4.e0" text="Human glioma" type="Diseases"/>
            <entity charOffset="0-4" id="miRNA-corp.d84.s4.e1" text="Human" type="Species"/>
            <entity charOffset="37-48" id="miRNA-corp.d84.s4.e2" text="microRNA-10b" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d84.s4.e2" e2="miRNA-corp.d84.s4.e0" id="miRNA-corp.d84.s4.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s5" origId="21471404.s1" text="MicroRNA (miRNA) expression profiling studies revealed a number of miRNAs dysregulated in the malignant brain tumor glioblastoma. ">
            <entity charOffset="0-7" id="miRNA-corp.d84.s5.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="10-14" id="miRNA-corp.d84.s5.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="67-72" id="miRNA-corp.d84.s5.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="74-85" id="miRNA-corp.d84.s5.e3" text="dysregulated" type="Relation_Trigger"/>
            <entity charOffset="94-127" id="miRNA-corp.d84.s5.e4" text="malignant brain tumor glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d84.s5.e2" e2="miRNA-corp.d84.s5.e4" id="miRNA-corp.d84.s5.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d84.s5.e0" e2="miRNA-corp.d84.s5.e4" id="miRNA-corp.d84.s5.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d84.s5.e1" e2="miRNA-corp.d84.s5.e4" id="miRNA-corp.d84.s5.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s6" origId="21471404.s8" text="Altogether, our experiments validate an important role of miR-10b in gliomagenesis, reveal a novel mechanism of miR-10b-mediated regulation, and suggest the possibility of its future use as a therapeutic target in gliomas.   ">
            <entity charOffset="192-209" id="miRNA-corp.d84.s6.e0" text="therapeutic target" type="Relation_Trigger"/>
            <entity charOffset="58-64" id="miRNA-corp.d84.s6.e1" text="miR-10b" type="Specific_miRNAs"/>
            <entity charOffset="112-118" id="miRNA-corp.d84.s6.e2" text="miR-10b" type="Specific_miRNAs"/>
            <entity charOffset="129-138" id="miRNA-corp.d84.s6.e3" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="214-220" id="miRNA-corp.d84.s6.e4" text="gliomas" type="Diseases"/>
            <pair e1="miRNA-corp.d84.s6.e1" e2="miRNA-corp.d84.s6.e4" id="miRNA-corp.d84.s6.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d84.s6.e2" e2="miRNA-corp.d84.s6.e4" id="miRNA-corp.d84.s6.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s7" origId="21471404.s6" text="Furthermore, survival of glioblastoma patients expressing high levels of miR-10 family members is significantly reduced in comparison to patients with low miR-10 levels, indicating that miR-10 may contribute to glioma growth in vivo. ">
            <entity charOffset="98-118" id="miRNA-corp.d84.s7.e0" text="significantly reduced" type="Relation_Trigger"/>
            <entity charOffset="25-36" id="miRNA-corp.d84.s7.e1" text="glioblastoma" type="Diseases"/>
            <entity charOffset="38-45" id="miRNA-corp.d84.s7.e2" text="patients" type="Species"/>
            <entity charOffset="47-68" id="miRNA-corp.d84.s7.e3" text="expressing high levels" type="Relation_Trigger"/>
            <entity charOffset="73-78" id="miRNA-corp.d84.s7.e4" text="miR-10" type="Specific_miRNAs"/>
            <entity charOffset="137-144" id="miRNA-corp.d84.s7.e5" text="patients" type="Species"/>
            <entity charOffset="155-160" id="miRNA-corp.d84.s7.e6" text="miR-10" type="Specific_miRNAs"/>
            <entity charOffset="151-167" id="miRNA-corp.d84.s7.e7" text="low miR-10 levels" type="Relation_Trigger"/>
            <entity charOffset="186-191" id="miRNA-corp.d84.s7.e8" text="miR-10" type="Specific_miRNAs"/>
            <entity charOffset="211-216" id="miRNA-corp.d84.s7.e9" text="glioma" type="Diseases"/>
            <pair e1="miRNA-corp.d84.s7.e4" e2="miRNA-corp.d84.s7.e1" id="miRNA-corp.d84.s7.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d84.s7.e4" e2="miRNA-corp.d84.s7.e9" id="miRNA-corp.d84.s7.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d84.s7.e6" e2="miRNA-corp.d84.s7.e1" id="miRNA-corp.d84.s7.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d84.s7.e6" e2="miRNA-corp.d84.s7.e9" id="miRNA-corp.d84.s7.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d84.s7.e8" e2="miRNA-corp.d84.s7.e1" id="miRNA-corp.d84.s7.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d84.s7.e8" e2="miRNA-corp.d84.s7.e9" id="miRNA-corp.d84.s7.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s8" origId="21471404.s7" text="Finally, inhibition of miR-10b in a mouse model of human glioma results in significant reduction of tumor growth. ">
            <entity charOffset="75-95" id="miRNA-corp.d84.s8.e0" text="significant reduction" type="Relation_Trigger"/>
            <entity charOffset="9-18" id="miRNA-corp.d84.s8.e1" text="inhibition" type="Relation_Trigger"/>
            <entity charOffset="23-29" id="miRNA-corp.d84.s8.e2" text="miR-10b" type="Specific_miRNAs"/>
            <entity charOffset="36-40" id="miRNA-corp.d84.s8.e3" text="mouse" type="Species"/>
            <entity charOffset="51-55" id="miRNA-corp.d84.s8.e4" text="human" type="Species"/>
            <entity charOffset="51-62" id="miRNA-corp.d84.s8.e5" text="human glioma" type="Diseases"/>
            <entity charOffset="100-104" id="miRNA-corp.d84.s8.e6" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d84.s8.e2" e2="miRNA-corp.d84.s8.e5" id="miRNA-corp.d84.s8.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d84.s8.e2" e2="miRNA-corp.d84.s8.e6" id="miRNA-corp.d84.s8.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d85" origId="21273400">
        <sentence id="miRNA-corp.d85.s0" origId="21273400.s0" text="Adult-onset autosomal dominant leukodystrophy: linking nuclear envelope to myelin.     ">
            <entity charOffset="31-44" id="miRNA-corp.d85.s0.e0" text="leukodystrophy" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d86" origId="20043721">
        <sentence id="miRNA-corp.d86.s0" origId="20043721.s4" text="The advent of next-generation sequencing technologies promises to greatly transform our understanding of medulloblastoma pathogenesis in the next few years, permitting comprehensive analyses of all aspects of the genome and increasing the likelihood that genomic medicine will become part of the routine diagnosis and treatment of medulloblastoma.   ">
            <entity charOffset="105-119" id="miRNA-corp.d86.s0.e0" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="331-345" id="miRNA-corp.d86.s0.e1" text="medulloblastoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d86.s1" origId="20043721.s2" text="The application of high-resolution microarray platforms to the study of medulloblastoma has revealed new oncogenes and tumor suppressors and has implicated changes in DNA copy number, gene expression, and methylation state in its etiology. ">
            <entity charOffset="72-86" id="miRNA-corp.d86.s1.e0" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="119-135" id="miRNA-corp.d86.s1.e1" text="tumor suppressors" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d86.s2" origId="20043721.s3" text="Additionally, the integration of medulloblastoma genomics with patient clinical data has confirmed molecular markers of prognostic significance and highlighted the potential utility of molecular disease stratification. ">
            <entity charOffset="33-47" id="miRNA-corp.d86.s2.e0" text="medulloblastoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d86.s3" origId="20043721.s0" text="Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years.  ">
            <entity charOffset="12-26" id="miRNA-corp.d86.s3.e0" text="medulloblastoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d86.s4" origId="20043721.s1" text="Advances in the field of genomics have recently enabled the unprecedented characterization of the cancer genome, providing novel insight into the molecular mechanisms underlying malignancies in humans. ">
            <entity charOffset="194-199" id="miRNA-corp.d86.s4.e0" text="humans" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d87" origId="19228967">
        <sentence id="miRNA-corp.d87.s0" origId="19228967.s5" text="Here, we report an elegant mechanism of Tau degradation involving the cochaperone BAG2. ">
            <entity charOffset="40-42" id="miRNA-corp.d87.s0.e0" text="Tau" type="Genes/Proteins"/>
            <entity charOffset="70-85" id="miRNA-corp.d87.s0.e1" text="cochaperone BAG2" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d87.s1" origId="19228967.s6" text="The BAG2/Hsp70 complex is tethered to the microtubule and this complex can capture and deliver Tau to the proteasome for ubiquitin-independent degradation. ">
            <entity charOffset="9-13" id="miRNA-corp.d87.s1.e0" text="Hsp70" type="Genes/Proteins"/>
            <entity charOffset="121-129" id="miRNA-corp.d87.s1.e1" text="ubiquitin" type="Genes/Proteins"/>
            <entity charOffset="95-97" id="miRNA-corp.d87.s1.e2" text="Tau" type="Genes/Proteins"/>
            <entity charOffset="4-7" id="miRNA-corp.d87.s1.e3" text="BAG2" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d87.s2" origId="19228967.s3" text="The components of a Tau protein triage system consisting of CHIP/Hsp70 and other chaperones have begun to emerge. ">
            <entity charOffset="20-22" id="miRNA-corp.d87.s2.e0" text="Tau" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d87.s3" origId="19228967.s4" text="However, the site of triage and the master regulatory elements are unknown. ">
            <entity charOffset="43-52" id="miRNA-corp.d87.s3.e0" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d87.s4" origId="19228967.s1" text="Tau inclusions are a prominent feature of many neurodegenerative diseases including Alzheimer's disease. ">
            <entity charOffset="47-72" id="miRNA-corp.d87.s4.e0" text="neurodegenerative diseases" type="Diseases"/>
            <entity charOffset="84-102" id="miRNA-corp.d87.s4.e1" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="0-2" id="miRNA-corp.d87.s4.e2" text="Tau" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d87.s5" origId="19228967.s2" text="Their accumulation in neurons as ubiquitinated filaments suggests a failure in the degradation limb of the Tau pathway. ">
            <entity charOffset="107-109" id="miRNA-corp.d87.s5.e0" text="Tau" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d87.s6" origId="19228967.s0" text="The cochaperone BAG2 sweeps paired helical filament- insoluble tau from the microtubule.  ">
            <entity charOffset="63-65" id="miRNA-corp.d87.s6.e0" text="tau" type="Genes/Proteins"/>
            <entity charOffset="4-19" id="miRNA-corp.d87.s6.e1" text="cochaperone BAG2" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d87.s7" origId="19228967.s9" text="Thus, we propose that ubiquitinated Tau inclusions arise due to shunting of Tau degradation toward a less efficient ubiquitin-dependent pathway.   ">
            <entity charOffset="36-38" id="miRNA-corp.d87.s7.e0" text="Tau" type="Genes/Proteins"/>
            <entity charOffset="76-78" id="miRNA-corp.d87.s7.e1" text="Tau" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d87.s8" origId="19228967.s7" text="This complex preferentially degrades Sarkosyl insoluble Tau and phosphorylated Tau. ">
            <entity charOffset="56-58" id="miRNA-corp.d87.s8.e0" text="Tau" type="Genes/Proteins"/>
            <entity charOffset="79-81" id="miRNA-corp.d87.s8.e1" text="Tau" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d87.s9" origId="19228967.s8" text="BAG2 levels in cells are under the physiological control of the microRNA miR-128a, which can tune paired helical filament Tau levels in neurons. ">
            <entity charOffset="64-71" id="miRNA-corp.d87.s9.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="73-80" id="miRNA-corp.d87.s9.e1" text="miR-128a" type="Specific_miRNAs"/>
            <entity charOffset="122-124" id="miRNA-corp.d87.s9.e2" text="Tau" type="Genes/Proteins"/>
            <entity charOffset="0-3" id="miRNA-corp.d87.s9.e3" text="BAG2" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d87.s9.e0" e2="miRNA-corp.d87.s9.e2" id="miRNA-corp.d87.s9.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d87.s9.e0" e2="miRNA-corp.d87.s9.e3" id="miRNA-corp.d87.s9.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d87.s9.e1" e2="miRNA-corp.d87.s9.e2" id="miRNA-corp.d87.s9.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d87.s9.e1" e2="miRNA-corp.d87.s9.e3" id="miRNA-corp.d87.s9.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d88" origId="15648093">
        <sentence id="miRNA-corp.d88.s0" origId="15648093.s0" text="miR-15a and miR-16-1 down-regulation in pituitary adenomas.  ">
            <entity charOffset="0-6" id="miRNA-corp.d88.s0.e0" text="miR-15a" type="Specific_miRNAs"/>
            <entity charOffset="12-19" id="miRNA-corp.d88.s0.e1" text="miR-16-1" type="Specific_miRNAs"/>
            <entity charOffset="21-35" id="miRNA-corp.d88.s0.e2" text="down-regulation" type="Relation_Trigger"/>
            <entity charOffset="40-57" id="miRNA-corp.d88.s0.e3" text="pituitary adenomas" type="Diseases"/>
            <pair e1="miRNA-corp.d88.s0.e0" e2="miRNA-corp.d88.s0.e3" id="miRNA-corp.d88.s0.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d88.s0.e1" e2="miRNA-corp.d88.s0.e3" id="miRNA-corp.d88.s0.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d88.s1" origId="15648093.s6" text="We found that miR-15a and miR-16-1 are expressed at lower levels in pituitary adenomas as compared to normal pituitary tissue. ">
            <entity charOffset="14-20" id="miRNA-corp.d88.s1.e0" text="miR-15a" type="Specific_miRNAs"/>
            <entity charOffset="26-33" id="miRNA-corp.d88.s1.e1" text="miR-16-1" type="Specific_miRNAs"/>
            <entity charOffset="39-63" id="miRNA-corp.d88.s1.e2" text="expressed at lower levels" type="Relation_Trigger"/>
            <entity charOffset="68-85" id="miRNA-corp.d88.s1.e3" text="pituitary adenomas" type="Diseases"/>
            <pair e1="miRNA-corp.d88.s1.e0" e2="miRNA-corp.d88.s1.e3" id="miRNA-corp.d88.s1.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d88.s1.e1" e2="miRNA-corp.d88.s1.e3" id="miRNA-corp.d88.s1.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d88.s2" origId="15648093.s5" text="We explored miR-15a and miR-16-1 expression in 10 GH-secreting and in 10 PRL-secreting pituitary macroadenomas by Northern blot, and investigated the possible correlation with in vivo and in vitro characteristics. ">
            <entity charOffset="12-18" id="miRNA-corp.d88.s2.e0" text="miR-15a" type="Specific_miRNAs"/>
            <entity charOffset="24-31" id="miRNA-corp.d88.s2.e1" text="miR-16-1" type="Specific_miRNAs"/>
            <entity charOffset="87-109" id="miRNA-corp.d88.s2.e2" text="pituitary macroadenomas" type="Diseases"/>
            <entity charOffset="159-169" id="miRNA-corp.d88.s2.e3" text="correlation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d88.s2.e0" e2="miRNA-corp.d88.s2.e2" id="miRNA-corp.d88.s2.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d88.s2.e1" e2="miRNA-corp.d88.s2.e2" id="miRNA-corp.d88.s2.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d88.s3" origId="15648093.s8" text="Therefore, miR15 and miR16 down-regulation in pituitary adenomas correlates with a greater tumor diameter and a lower p43 secretion, suggesting that these genes may, at least in part, influence tumor growth.   ">
            <entity charOffset="11-15" id="miRNA-corp.d88.s3.e0" text="miR15" type="Specific_miRNAs"/>
            <entity charOffset="21-25" id="miRNA-corp.d88.s3.e1" text="miR16" type="Specific_miRNAs"/>
            <entity charOffset="27-41" id="miRNA-corp.d88.s3.e2" text="down-regulation" type="Relation_Trigger"/>
            <entity charOffset="46-63" id="miRNA-corp.d88.s3.e3" text="pituitary adenomas" type="Diseases"/>
            <entity charOffset="65-74" id="miRNA-corp.d88.s3.e4" text="correlates" type="Relation_Trigger"/>
            <entity charOffset="91-95" id="miRNA-corp.d88.s3.e5" text="tumor" type="Diseases"/>
            <entity charOffset="194-198" id="miRNA-corp.d88.s3.e6" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d88.s3.e0" e2="miRNA-corp.d88.s3.e3" id="miRNA-corp.d88.s3.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d88.s3.e0" e2="miRNA-corp.d88.s3.e5" id="miRNA-corp.d88.s3.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d88.s3.e0" e2="miRNA-corp.d88.s3.e6" id="miRNA-corp.d88.s3.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d88.s3.e1" e2="miRNA-corp.d88.s3.e3" id="miRNA-corp.d88.s3.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d88.s3.e1" e2="miRNA-corp.d88.s3.e5" id="miRNA-corp.d88.s3.p4" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d88.s3.e1" e2="miRNA-corp.d88.s3.e6" id="miRNA-corp.d88.s3.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d88.s4" origId="15648093.s7" text="Moreover, their expression inversely correlates with tumor diameter and with RARS expression (P &lt; 0.05), but directly correlates with p43 secretion (P &lt; 0.02). ">
            <entity charOffset="27-46" id="miRNA-corp.d88.s4.e0" text="inversely correlates" type="Relation_Trigger"/>
            <entity charOffset="53-57" id="miRNA-corp.d88.s4.e1" text="tumor" type="Diseases"/>
            <entity charOffset="77-80" id="miRNA-corp.d88.s4.e2" text="RARS" type="Genes/Proteins"/>
            <entity charOffset="109-127" id="miRNA-corp.d88.s4.e3" text="directly correlates" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d88.s5" origId="15648093.s2" text="miR-15a and miR-16-1 genes are located at chromosome 13q14, a region which is frequently deleted in pituitary tumors. ">
            <entity charOffset="0-6" id="miRNA-corp.d88.s5.e0" text="miR-15a" type="Specific_miRNAs"/>
            <entity charOffset="12-19" id="miRNA-corp.d88.s5.e1" text="miR-16-1" type="Specific_miRNAs"/>
            <entity charOffset="100-115" id="miRNA-corp.d88.s5.e2" text="pituitary tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d88.s5.e0" e2="miRNA-corp.d88.s5.e2" id="miRNA-corp.d88.s5.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d88.s5.e1" e2="miRNA-corp.d88.s5.e2" id="miRNA-corp.d88.s5.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d88.s6" origId="15648093.s1" text="Micro RNAs (miRs) are small noncoding RNAs, functioning as antisense regulators of other RNAs. ">
            <entity charOffset="0-9" id="miRNA-corp.d88.s6.e0" text="Micro RNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="12-15" id="miRNA-corp.d88.s6.e1" text="miRs" type="Non-Specific_miRNAs"/>
            <entity charOffset="69-78" id="miRNA-corp.d88.s6.e2" text="regulators" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d88.s7" origId="15648093.s4" text="When secreted, p43 regulates local inflammatory response and macrophage chemotaxis, and seems to have anti-neoplastic properties in mice. ">
            <entity charOffset="19-27" id="miRNA-corp.d88.s7.e0" text="regulates" type="Relation_Trigger"/>
            <entity charOffset="132-135" id="miRNA-corp.d88.s7.e1" text="mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d88.s8" origId="15648093.s3" text="An inverse correlation has been shown in B cell chronic lymphocytic leukemia (B-CLL) between miR-15a and miR-16-1 expression and the expression levels of arginyl-tRNA synthetase (RARS), an enzyme which associates with the cofactor p43 in the aminoacyl-tRNA synthetase complex. ">
            <entity charOffset="3-21" id="miRNA-corp.d88.s8.e0" text="inverse correlation" type="Relation_Trigger"/>
            <entity charOffset="41-75" id="miRNA-corp.d88.s8.e1" text="B cell chronic lymphocytic leukemia" type="Diseases"/>
            <entity charOffset="78-82" id="miRNA-corp.d88.s8.e2" text="B-CLL" type="Diseases"/>
            <entity charOffset="93-99" id="miRNA-corp.d88.s8.e3" text="miR-15a" type="Specific_miRNAs"/>
            <entity charOffset="105-112" id="miRNA-corp.d88.s8.e4" text="miR-16-1" type="Specific_miRNAs"/>
            <entity charOffset="202-211" id="miRNA-corp.d88.s8.e5" text="associates" type="Relation_Trigger"/>
            <entity charOffset="154-176" id="miRNA-corp.d88.s8.e6" text="arginyl-tRNA synthetase" type="Genes/Proteins"/>
            <entity charOffset="179-182" id="miRNA-corp.d88.s8.e7" text="RARS" type="Genes/Proteins"/>
            <entity charOffset="133-149" id="miRNA-corp.d88.s8.e8" text="expression levels" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d88.s8.e3" e2="miRNA-corp.d88.s8.e1" id="miRNA-corp.d88.s8.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d88.s8.e3" e2="miRNA-corp.d88.s8.e2" id="miRNA-corp.d88.s8.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d88.s8.e3" e2="miRNA-corp.d88.s8.e6" id="miRNA-corp.d88.s8.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d88.s8.e3" e2="miRNA-corp.d88.s8.e7" id="miRNA-corp.d88.s8.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d88.s8.e4" e2="miRNA-corp.d88.s8.e1" id="miRNA-corp.d88.s8.p4" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d88.s8.e4" e2="miRNA-corp.d88.s8.e2" id="miRNA-corp.d88.s8.p5" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d88.s8.e4" e2="miRNA-corp.d88.s8.e6" id="miRNA-corp.d88.s8.p6" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d88.s8.e4" e2="miRNA-corp.d88.s8.e7" id="miRNA-corp.d88.s8.p7" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d89" origId="21149808">
        <sentence id="miRNA-corp.d89.s0" origId="21149808.s0" text="The emerging role of epigenetics in stroke: II. RNA regulatory circuitry. ">
            <entity charOffset="36-41" id="miRNA-corp.d89.s0.e0" text="stroke" type="Diseases"/>
            <entity charOffset="52-61" id="miRNA-corp.d89.s0.e1" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d89.s1" origId="21149808.s3" text="These non-protein-coding RNAs (ncRNAs) include subclasses that are well known, such as transfer RNAs and ribosomal RNAs, as well as those that have more recently been characterized, such as microRNAs, small nucleolar RNAs, and long ncRNAs. ">
            <entity charOffset="190-198" id="miRNA-corp.d89.s1.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d89.s2" origId="21149808.s4" text="In this review, we examine the role of these novel ncRNAs in the nervous system and highlight emerging evidence that implicates RNA-based networks in the molecular pathogenesis of stroke. ">
            <entity charOffset="180-185" id="miRNA-corp.d89.s2.e0" text="stroke" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d89.s3" origId="21149808.s1" text="Recent scientific advances have demonstrated the existence of extensive RNA-based regulatory networks involved in orchestrating nearly every cellular process in health and various disease states. ">
            <entity charOffset="82-91" id="miRNA-corp.d89.s3.e0" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d89.s4" origId="21149808.s2" text="This previously hidden layer of functional RNAs is derived largely from non-protein-coding DNA sequences that constitute more than 98% of the genome in humans. ">
            <entity charOffset="152-157" id="miRNA-corp.d89.s4.e0" text="humans" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d89.s5" origId="21149808.s7" text="These novel approaches for neural cell- and tissue-selective reprogramming of epigenetic regulatory mechanisms are likely to promote more effective neuroprotective and neural regenerative responses for safeguarding and even restoring central nervous system function.   ">
            <entity charOffset="89-98" id="miRNA-corp.d89.s5.e0" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d89.s6" origId="21149808.s5" text="We also describe RNA editing, a related epigenetic mechanism that is partly responsible for generating the exquisite degrees of environmental responsiveness and molecular diversity that characterize ncRNAs. "/>
        <sentence id="miRNA-corp.d89.s7" origId="21149808.s6" text="In addition, we discuss the development of future therapeutic strategies for locus-specific and genome-wide regulation of genes and functional gene networks through the modulation of RNA transcription, posttranscriptional RNA processing (eg, RNA modifications, quality control, intracellular trafficking, and local and long-distance intercellular transport), and RNA translation. ">
            <entity charOffset="169-178" id="miRNA-corp.d89.s7.e0" text="modulation" type="Relation_Trigger"/>
            <entity charOffset="108-117" id="miRNA-corp.d89.s7.e1" text="regulation" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d90" origId="19641252">
        <sentence id="miRNA-corp.d90.s0" origId="19641252.s0" text="Keystone symposium, Neurodegenerative Diseases: New Molecular Mechanisms 17-22 February 2009.     ">
            <entity charOffset="20-45" id="miRNA-corp.d90.s0.e0" text="Neurodegenerative Diseases" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d91" origId="17549006">
        <sentence id="miRNA-corp.d91.s0" origId="17549006.s6" text="Diseases potentially mediated by alterations in RNA processes include tauopathies, myotonic dystrophy, Alzheimer disease, brain cancer, and many others. ">
            <entity charOffset="70-80" id="miRNA-corp.d91.s0.e0" text="tauopathies" type="Diseases"/>
            <entity charOffset="83-100" id="miRNA-corp.d91.s0.e1" text="myotonic dystrophy" type="Diseases"/>
            <entity charOffset="103-119" id="miRNA-corp.d91.s0.e2" text="Alzheimer disease" type="Diseases"/>
            <entity charOffset="122-133" id="miRNA-corp.d91.s0.e3" text="brain cancer" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d91.s1" origId="17549006.s5" text="Some noncoding RNAs have been shown to be involved in human brain diseases. ">
            <entity charOffset="54-73" id="miRNA-corp.d91.s1.e0" text="human brain diseases" type="Diseases"/>
            <entity charOffset="54-58" id="miRNA-corp.d91.s1.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d91.s2" origId="17549006.s4" text="Furthermore, there is poor correlation between mRNA levels and protein levels in mammalian cells, due partly to complicated post-transcriptional regulation by hitherto unknown noncoding RNAs. ">
            <entity charOffset="27-37" id="miRNA-corp.d91.s2.e0" text="correlation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d91.s3" origId="17549006.s3" text="For example, neurologic illnesses may arise because of perturbations in distinct but interrelated tiers of RNA-based genetic regulation: pre-mRNA splicing; nonsplicing RNA modifications; and mRNA translational regulation. ">
            <entity charOffset="13-32" id="miRNA-corp.d91.s3.e0" text="neurologic illnesses" type="Diseases"/>
            <entity charOffset="125-134" id="miRNA-corp.d91.s3.e1" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="196-219" id="miRNA-corp.d91.s3.e2" text="translational regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d91.s4" origId="17549006.s2" text="A variety of unforeseen complexities have been identified, many with relevance to human brain disease. ">
            <entity charOffset="82-86" id="miRNA-corp.d91.s4.e0" text="human" type="Species"/>
            <entity charOffset="82-100" id="miRNA-corp.d91.s4.e1" text="human brain disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d91.s5" origId="17549006.s1" text="RNA research has made great progress in recent years. "/>
        <sentence id="miRNA-corp.d91.s6" origId="17549006.s0" text="RNA in brain disease: no longer just &quot;the messenger in the middle&quot;.  ">
            <entity charOffset="7-19" id="miRNA-corp.d91.s6.e0" text="brain disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d91.s7" origId="17549006.s7" text="Here we present an overview of new research highlighting functions for RNA that far surpass the &quot;messenger in the middle&quot; role and that identify RNA molecules as important agents in the human brain in health and in disease states.   ">
            <entity charOffset="186-190" id="miRNA-corp.d91.s7.e0" text="human" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d92" origId="20406893">
        <sentence id="miRNA-corp.d92.s0" origId="20406893.s0" text="Gliomas display a microRNA expression profile reminiscent of neural precursor cells.  ">
            <entity charOffset="18-25" id="miRNA-corp.d92.s0.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="0-6" id="miRNA-corp.d92.s0.e1" text="Gliomas" type="Diseases"/>
            <pair e1="miRNA-corp.d92.s0.e0" e2="miRNA-corp.d92.s0.e1" id="miRNA-corp.d92.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s1" origId="20406893.s1" text="Gliomas express many genes that play a role in neural precursor cells (NPCs), but no direct comparison between glioma and stem cell (SC) gene expression profiles has been performed. ">
            <entity charOffset="0-6" id="miRNA-corp.d92.s1.e0" text="Gliomas" type="Diseases"/>
            <entity charOffset="111-116" id="miRNA-corp.d92.s1.e1" text="glioma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s2" origId="20406893.s2" text="To investigate the similarities and differences between gliomas and SCs, we compared the microRNA (miRNA) expression signatures of glial tumors, embryonic SCs (ESCs), NPCs, and normal adult brains from both human and mouse tissues. ">
            <entity charOffset="56-62" id="miRNA-corp.d92.s2.e0" text="gliomas" type="Diseases"/>
            <entity charOffset="89-96" id="miRNA-corp.d92.s2.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="99-103" id="miRNA-corp.d92.s2.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="131-142" id="miRNA-corp.d92.s2.e3" text="glial tumors" type="Diseases"/>
            <entity charOffset="207-211" id="miRNA-corp.d92.s2.e4" text="human" type="Species"/>
            <entity charOffset="217-221" id="miRNA-corp.d92.s2.e5" text="mouse" type="Species"/>
            <pair e1="miRNA-corp.d92.s2.e1" e2="miRNA-corp.d92.s2.e0" id="miRNA-corp.d92.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d92.s2.e1" e2="miRNA-corp.d92.s2.e3" id="miRNA-corp.d92.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d92.s2.e2" e2="miRNA-corp.d92.s2.e0" id="miRNA-corp.d92.s2.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d92.s2.e2" e2="miRNA-corp.d92.s2.e3" id="miRNA-corp.d92.s2.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s3" origId="20406893.s3" text="We demonstrated that both human gliomas (regardless of their grade) and methylcholanthrene-induced mouse glioma shared an miRNA expression profile that is reminiscent of NPCs. ">
            <entity charOffset="26-30" id="miRNA-corp.d92.s3.e0" text="human" type="Species"/>
            <entity charOffset="26-38" id="miRNA-corp.d92.s3.e1" text="human gliomas" type="Diseases"/>
            <entity charOffset="99-103" id="miRNA-corp.d92.s3.e2" text="mouse" type="Species"/>
            <entity charOffset="99-110" id="miRNA-corp.d92.s3.e3" text="mouse glioma" type="Diseases"/>
            <entity charOffset="122-126" id="miRNA-corp.d92.s3.e4" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d92.s3.e4" e2="miRNA-corp.d92.s3.e1" id="miRNA-corp.d92.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d92.s3.e4" e2="miRNA-corp.d92.s3.e3" id="miRNA-corp.d92.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s4" origId="20406893.s4" text="About half of the miRNAs expressed in the shared profile clustered in seven genomic regions susceptible to genetic/epigenetic alterations in various cancers. ">
            <entity charOffset="18-23" id="miRNA-corp.d92.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="149-155" id="miRNA-corp.d92.s4.e1" text="cancers" type="Diseases"/>
            <pair e1="miRNA-corp.d92.s4.e0" e2="miRNA-corp.d92.s4.e1" id="miRNA-corp.d92.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s5" origId="20406893.s5" text="These clusters comprised the miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373, which are upregulated in gliomas, ESCs, and NPCs. ">
            <entity charOffset="29-33" id="miRNA-corp.d92.s5.e0" text="miR17" type="Specific_miRNAs"/>
            <entity charOffset="43-52" id="miRNA-corp.d92.s5.e1" text="mir183-182" type="Specific_miRNAs"/>
            <entity charOffset="84-93" id="miRNA-corp.d92.s5.e2" text="mir367-302" type="Specific_miRNAs"/>
            <entity charOffset="99-108" id="miRNA-corp.d92.s5.e3" text="mir371-373" type="Specific_miRNAs"/>
            <entity charOffset="121-131" id="miRNA-corp.d92.s5.e4" text="upregulated" type="Relation_Trigger"/>
            <entity charOffset="136-142" id="miRNA-corp.d92.s5.e5" text="gliomas" type="Diseases"/>
            <pair e1="miRNA-corp.d92.s5.e0" e2="miRNA-corp.d92.s5.e5" id="miRNA-corp.d92.s5.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d92.s5.e1" e2="miRNA-corp.d92.s5.e5" id="miRNA-corp.d92.s5.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d92.s5.e2" e2="miRNA-corp.d92.s5.e5" id="miRNA-corp.d92.s5.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d92.s5.e3" e2="miRNA-corp.d92.s5.e5" id="miRNA-corp.d92.s5.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s6" origId="20406893.s6" text="The bipartite cluster of 7 + 46 miRNAs on chromosome 14q32.31, ">
            <entity charOffset="32-37" id="miRNA-corp.d92.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s7" origId="20406893.s7" text="which might represent the largest tumor suppressor miRNA cluster, was downregulated in the shared expression profile. ">
            <entity charOffset="34-49" id="miRNA-corp.d92.s7.e0" text="tumor suppressor" type="Relation_Trigger"/>
            <entity charOffset="51-55" id="miRNA-corp.d92.s7.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="70-82" id="miRNA-corp.d92.s7.e2" text="downregulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s8" origId="20406893.s8" text="This study provides the first evidence for association between these clusters and gliomas. ">
            <entity charOffset="43-53" id="miRNA-corp.d92.s8.e0" text="association" type="Relation_Trigger"/>
            <entity charOffset="82-88" id="miRNA-corp.d92.s8.e1" text="gliomas" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s9" origId="20406893.s9" text="Despite the broad similarity in the miRNA expression profiles, 15 miRNAs showed disparate expression between SC and gliomas. ">
            <entity charOffset="36-40" id="miRNA-corp.d92.s9.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="66-71" id="miRNA-corp.d92.s9.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="116-122" id="miRNA-corp.d92.s9.e2" text="gliomas" type="Diseases"/>
            <pair e1="miRNA-corp.d92.s9.e0" e2="miRNA-corp.d92.s9.e2" id="miRNA-corp.d92.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d92.s9.e1" e2="miRNA-corp.d92.s9.e2" id="miRNA-corp.d92.s9.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s10" origId="20406893.s10" text="Ten miRNAs belong to the 2 SC-specific clusters and the remaining (mir135b, mir141, mir205, mir200C, and mir301a) have been previously shown to associate with malignancies. ">
            <entity charOffset="4-9" id="miRNA-corp.d92.s10.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="67-73" id="miRNA-corp.d92.s10.e1" text="mir135b" type="Specific_miRNAs"/>
            <entity charOffset="76-81" id="miRNA-corp.d92.s10.e2" text="mir141" type="Specific_miRNAs"/>
            <entity charOffset="84-89" id="miRNA-corp.d92.s10.e3" text="mir205" type="Specific_miRNAs"/>
            <entity charOffset="92-98" id="miRNA-corp.d92.s10.e4" text="mir200C" type="Specific_miRNAs"/>
            <entity charOffset="105-111" id="miRNA-corp.d92.s10.e5" text="mir301a" type="Specific_miRNAs"/>
            <entity charOffset="144-152" id="miRNA-corp.d92.s10.e6" text="associate" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s11" origId="20406893.s11" text="Our finding showed that all gliomas displayed NPC-like miRNA signatures, which may have implications for studies of glioma origins. ">
            <entity charOffset="28-34" id="miRNA-corp.d92.s11.e0" text="gliomas" type="Diseases"/>
            <entity charOffset="55-59" id="miRNA-corp.d92.s11.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="116-121" id="miRNA-corp.d92.s11.e2" text="glioma" type="Diseases"/>
            <pair e1="miRNA-corp.d92.s11.e1" e2="miRNA-corp.d92.s11.e0" id="miRNA-corp.d92.s11.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d92.s11.e1" e2="miRNA-corp.d92.s11.e2" id="miRNA-corp.d92.s11.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s12" origId="20406893.s12" text="Furthermore, careful study of the 15 miRNAs that differ in expression between SCs and gliomas, particularly those 5 that are not SC-specific, may enhance our understanding of gliomagenesis.   ">
            <entity charOffset="37-42" id="miRNA-corp.d92.s12.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="86-92" id="miRNA-corp.d92.s12.e1" text="gliomas" type="Diseases"/>
            <pair e1="miRNA-corp.d92.s12.e0" e2="miRNA-corp.d92.s12.e1" id="miRNA-corp.d92.s12.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d93" origId="20015091">
        <sentence id="miRNA-corp.d93.s0" origId="20015091.s7" text="Finally, we will discuss fundamental issues to be considered in study design when targeting the epigenome.   ">
            <entity charOffset="82-90" id="miRNA-corp.d93.s0.e0" text="targeting" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d93.s1" origId="20015091.s0" text="Pharmacology of epigenetics in brain disorders.  ">
            <entity charOffset="31-45" id="miRNA-corp.d93.s1.e0" text="brain disorders" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d93.s2" origId="20015091.s1" text="Epigenetics is a rapidly growing field and holds great promise for a range of human diseases, including brain disorders such as Rett syndrome, anxiety and depressive disorders, schizophrenia, Alzheimer disease and Huntington disease. ">
            <entity charOffset="78-82" id="miRNA-corp.d93.s2.e0" text="human" type="Species"/>
            <entity charOffset="104-118" id="miRNA-corp.d93.s2.e1" text="brain disorders" type="Diseases"/>
            <entity charOffset="128-140" id="miRNA-corp.d93.s2.e2" text="Rett syndrome" type="Diseases"/>
            <entity charOffset="143-149" id="miRNA-corp.d93.s2.e3" text="anxiety" type="Diseases"/>
            <entity charOffset="155-174" id="miRNA-corp.d93.s2.e4" text="depressive disorders" type="Diseases"/>
            <entity charOffset="177-189" id="miRNA-corp.d93.s2.e5" text="schizophrenia" type="Diseases"/>
            <entity charOffset="192-208" id="miRNA-corp.d93.s2.e6" text="Alzheimer disease" type="Diseases"/>
            <entity charOffset="214-231" id="miRNA-corp.d93.s2.e7" text="Huntington disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d93.s3" origId="20015091.s2" text="This review is concerned with the pharmacology of epigenetics to treat disorders of the epigenome whether induced developmentally or manifested/acquired later in life. "/>
        <sentence id="miRNA-corp.d93.s4" origId="20015091.s3" text="In particular, we will focus on brain disorders and their treatment by drugs that modify the epigenome. ">
            <entity charOffset="32-46" id="miRNA-corp.d93.s4.e0" text="brain disorders" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d93.s5" origId="20015091.s4" text="While the use of DNA methyl transferase inhibitors and histone deacetylase inhibitors in in vitro and in vivo models have demonstrated improvements in disease-related deficits, clinical trials in humans have been less promising. ">
            <entity charOffset="40-49" id="miRNA-corp.d93.s5.e0" text="inhibitors" type="Relation_Trigger"/>
            <entity charOffset="196-201" id="miRNA-corp.d93.s5.e1" text="humans" type="Species"/>
            <entity charOffset="75-84" id="miRNA-corp.d93.s5.e2" text="inhibitors" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d93.s6" origId="20015091.s5" text="We will address recent advances in our understanding of the complexity of the epigenome with its many molecular players, and discuss evidence for a compromised epigenome in the context of an ageing or diseased brain. "/>
        <sentence id="miRNA-corp.d93.s7" origId="20015091.s6" text="We will also draw on examples of species differences that may exist between humans and model systems, emphasizing the need for more robust pre-clinical testing. ">
            <entity charOffset="76-81" id="miRNA-corp.d93.s7.e0" text="humans" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d94" origId="20633035">
        <sentence id="miRNA-corp.d94.s0" origId="20633035.s4" text="This review discusses potential RNAi-based targets that are of interest for epilepsy therapy, including adenosine kinase (ADK), the key negative regulator of the brain's endogenous anticonvulsant adenosine. ">
            <entity charOffset="43-49" id="miRNA-corp.d94.s0.e0" text="targets" type="Relation_Trigger"/>
            <entity charOffset="76-83" id="miRNA-corp.d94.s0.e1" text="epilepsy" type="Diseases"/>
            <entity charOffset="104-119" id="miRNA-corp.d94.s0.e2" text="adenosine kinase" type="Genes/Proteins"/>
            <entity charOffset="122-124" id="miRNA-corp.d94.s0.e3" text="ADK" type="Genes/Proteins"/>
            <entity charOffset="136-153" id="miRNA-corp.d94.s0.e4" text="negative regulator" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d94.s1" origId="20633035.s3" text="Therapeutic RNAi has been widely explored for dominant targets involved in neurodegenerative diseases; however, their use for epilepsy therapy has received less attention. ">
            <entity charOffset="55-61" id="miRNA-corp.d94.s1.e0" text="targets" type="Relation_Trigger"/>
            <entity charOffset="75-100" id="miRNA-corp.d94.s1.e1" text="neurodegenerative diseases" type="Diseases"/>
            <entity charOffset="126-133" id="miRNA-corp.d94.s1.e2" text="epilepsy" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d94.s2" origId="20633035.s6" text="Therefore, RNAi-strategies aimed at reducing ADK (and increasing adenosine) are based on a direct neurochemical rationale that has recently been explored experimentally using ex vivo and in vivo gene therapy approaches. ">
            <entity charOffset="45-47" id="miRNA-corp.d94.s2.e0" text="ADK" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d94.s3" origId="20633035.s5" text="Overexpression of ADK, and the resulting adenosine deficiency, are pathologic hallmarks of the sclerotic epileptic brain, and have been implicated in seizure generation. ">
            <entity charOffset="0-13" id="miRNA-corp.d94.s3.e0" text="Overexpression" type="Relation_Trigger"/>
            <entity charOffset="18-20" id="miRNA-corp.d94.s3.e1" text="ADK" type="Genes/Proteins"/>
            <entity charOffset="150-156" id="miRNA-corp.d94.s3.e2" text="seizure" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d94.s4" origId="20633035.s0" text="Inhibitory RNA in epilepsy: research tools and therapeutic perspectives.  ">
            <entity charOffset="18-25" id="miRNA-corp.d94.s4.e0" text="epilepsy" type="Diseases"/>
            <entity charOffset="0-9" id="miRNA-corp.d94.s4.e1" text="Inhibitory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d94.s5" origId="20633035.s2" text="In contrast to conventional antiepileptic drugs (AEDs) that target specific proteins such as ion channels or receptors, RNAi-based therapeutics exploit an endogenous regulatory mechanism of gene expression and thereby are poised to prevent or reverse pathogenetic mechanisms involved in seizure development. ">
            <entity charOffset="60-65" id="miRNA-corp.d94.s5.e0" text="target" type="Relation_Trigger"/>
            <entity charOffset="166-175" id="miRNA-corp.d94.s5.e1" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="287-293" id="miRNA-corp.d94.s5.e2" text="seizure" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d94.s6" origId="20633035.s1" text="Since its discovery a decade ago, RNA interference (RNAi) has been developed not only into powerful experimental tools but also into promising novel therapeutics. "/>
        <sentence id="miRNA-corp.d94.s7" origId="20633035.s7" text="Technical issues and challenges remain before those promising tools can be developed into future therapeutics for epilepsy.   ">
            <entity charOffset="114-121" id="miRNA-corp.d94.s7.e0" text="epilepsy" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d95" origId="19584924">
        <sentence id="miRNA-corp.d95.s0" origId="19584924.s4" text="A series of novel and established medulloblastoma defects were detected (MYC amplification (n = 4), 17q21.31 high-level gain (n = 1); 9p21.1-p21.3 (n = 1) and 6q23.1 (n = 1) homozygous deletion). ">
            <entity charOffset="77-89" id="miRNA-corp.d95.s0.e0" text="amplification" type="Relation_Trigger"/>
            <entity charOffset="73-75" id="miRNA-corp.d95.s0.e1" text="MYC" type="Genes/Proteins"/>
            <entity charOffset="34-48" id="miRNA-corp.d95.s0.e2" text="medulloblastoma" type="Diseases"/>
			<entity charOffset="109-118" id="miRNA-corp.d95.s0.e3" text="high-level" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d95.s1" origId="19584924.s3" text="METHODOLOGY/PRINCIPAL FINDINGS: We performed a SNP-array based genome-wide copy number analysis in medulloblastoma cell lines, to identify regions of genomic amplification and homozygous deletion, which may harbour critical disease genes. ">
            <entity charOffset="99-113" id="miRNA-corp.d95.s1.e0" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="158-170" id="miRNA-corp.d95.s1.e1" text="amplification" type="Relation_Trigger"/>
            <entity charOffset="158-170" id="miRNA-corp.d95.s1.e2" text="amplification" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d95.s2" origId="19584924.s5" text="Most notably, a novel recurrent region of genomic amplification at 8q24.22-q24.23 was identified (n = 2), and selected for further investigation. ">
            <entity charOffset="50-62" id="miRNA-corp.d95.s2.e0" text="amplification" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d95.s3" origId="19584924.s0" text="Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma.  ">
            <entity charOffset="0-12" id="miRNA-corp.d95.s3.e0" text="Amplification" type="Relation_Trigger"/>
            <entity charOffset="18-31" id="miRNA-corp.d95.s3.e1" text="overexpression" type="Relation_Trigger"/>
            <entity charOffset="36-46" id="miRNA-corp.d95.s3.e2" text="Hsa-miR-30b" type="Specific_miRNAs"/>
            <entity charOffset="49-59" id="miRNA-corp.d95.s3.e3" text="Hsa-miR-30d" type="Specific_miRNAs"/>
            <entity charOffset="65-71" id="miRNA-corp.d95.s3.e4" text="KHDRBS3" type="Genes/Proteins"/>
            <entity charOffset="94-108" id="miRNA-corp.d95.s3.e5" text="medulloblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d95.s3.e2" e2="miRNA-corp.d95.s3.e4" id="miRNA-corp.d95.s3.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d95.s3.e2" e2="miRNA-corp.d95.s3.e5" id="miRNA-corp.d95.s3.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d95.s3.e3" e2="miRNA-corp.d95.s3.e4" id="miRNA-corp.d95.s3.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d95.s3.e3" e2="miRNA-corp.d95.s3.e5" id="miRNA-corp.d95.s3.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d95.s4" origId="19584924.s2" text="The identification of critical genes involved in its pathogenesis will be central to advances in our understanding of its molecular basis, and the development of improved therapeutic approaches. "/>
        <sentence id="miRNA-corp.d95.s5" origId="19584924.s1" text="BACKGROUND: Medulloblastoma is the most common malignant brain tumour of childhood. ">
            <entity charOffset="12-26" id="miRNA-corp.d95.s5.e0" text="Medulloblastoma" type="Diseases"/>
            <entity charOffset="47-68" id="miRNA-corp.d95.s5.e1" text="malignant brain tumour" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d95.s6" origId="19584924.s8" text="Of these, only expression of hsa-miR-30b, hsa-miR-30d and KHDRBS3 correlated with copy number status, and all three of these transcripts also displayed evidence of elevated expression in sub-sets of primary medulloblastomas, measured relative to the normal cerebellum. ">
            <entity charOffset="29-39" id="miRNA-corp.d95.s6.e0" text="hsa-miR-30b" type="Specific_miRNAs"/>
            <entity charOffset="42-52" id="miRNA-corp.d95.s6.e1" text="hsa-miR-30d" type="Specific_miRNAs"/>
            <entity charOffset="58-64" id="miRNA-corp.d95.s6.e2" text="KHDRBS3" type="Genes/Proteins"/>
            <entity charOffset="15-75" id="miRNA-corp.d95.s6.e3" text="expression of hsa-miR-30b, hsa-miR-30d and KHDRBS3 correlated" type="Relation_Trigger"/>
            <entity charOffset="164-182" id="miRNA-corp.d95.s6.e4" text="elevated expression" type="Relation_Trigger"/>
            <entity charOffset="207-222" id="miRNA-corp.d95.s6.e5" text="medulloblastomas" type="Diseases"/>
            <pair e1="miRNA-corp.d95.s6.e0" e2="miRNA-corp.d95.s6.e2" id="miRNA-corp.d95.s6.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d95.s6.e0" e2="miRNA-corp.d95.s6.e5" id="miRNA-corp.d95.s6.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d95.s6.e1" e2="miRNA-corp.d95.s6.e2" id="miRNA-corp.d95.s6.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d95.s6.e1" e2="miRNA-corp.d95.s6.e5" id="miRNA-corp.d95.s6.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d95.s7" origId="19584924.s6" text="Additional analysis by interphase fluorescence in situ hybridisation (iFISH), PCR-based mapping and SNP-array revealed this novel amplification at 8q24.22-q24.23 is independent of MYC amplification at 8q24.21, and is unique to medulloblastoma in over 800 cancer cell lines assessed from different tumour types, suggesting it contains key genes specifically involved in medulloblastoma development. ">
            <entity charOffset="255-260" id="miRNA-corp.d95.s7.e0" text="cancer" type="Diseases"/>
            <entity charOffset="180-182" id="miRNA-corp.d95.s7.e1" text="MYC" type="Genes/Proteins"/>
            <entity charOffset="130-142" id="miRNA-corp.d95.s7.e2" text="amplification" type="Relation_Trigger"/>
            <entity charOffset="184-196" id="miRNA-corp.d95.s7.e3" text="amplification" type="Relation_Trigger"/>
            <entity charOffset="227-241" id="miRNA-corp.d95.s7.e4" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="297-302" id="miRNA-corp.d95.s7.e5" text="tumour" type="Diseases"/>
            <entity charOffset="369-383" id="miRNA-corp.d95.s7.e6" text="medulloblastoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d95.s8" origId="19584924.s7" text="Detailed mapping identified a 3Mb common minimal region of amplification harbouring 3 coding genes (ZFAT1, LOC286094, KHDRBS3) and two genes encoding micro-RNAs (hsa-miR-30b, hsa-miR-30d). ">
            <entity charOffset="59-71" id="miRNA-corp.d95.s8.e0" text="amplification" type="Relation_Trigger"/>
            <entity charOffset="100-104" id="miRNA-corp.d95.s8.e1" text="ZFAT1" type="Genes/Proteins"/>
            <entity charOffset="118-124" id="miRNA-corp.d95.s8.e2" text="KHDRBS3" type="Genes/Proteins"/>
            <entity charOffset="150-159" id="miRNA-corp.d95.s8.e3" text="micro-RNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="162-172" id="miRNA-corp.d95.s8.e4" text="hsa-miR-30b" type="Specific_miRNAs"/>
            <entity charOffset="175-185" id="miRNA-corp.d95.s8.e5" text="hsa-miR-30d" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d95.s8.e3" e2="miRNA-corp.d95.s8.e1" id="miRNA-corp.d95.s8.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d95.s8.e3" e2="miRNA-corp.d95.s8.e2" id="miRNA-corp.d95.s8.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d95.s8.e4" e2="miRNA-corp.d95.s8.e1" id="miRNA-corp.d95.s8.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d95.s8.e4" e2="miRNA-corp.d95.s8.e2" id="miRNA-corp.d95.s8.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d95.s8.e5" e2="miRNA-corp.d95.s8.e1" id="miRNA-corp.d95.s8.p4" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d95.s8.e5" e2="miRNA-corp.d95.s8.e2" id="miRNA-corp.d95.s8.p5" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d95.s9" origId="19584924.s10" text="Our findings suggest critical roles for these genes in medulloblastoma development, and further support the contribution of micro-RNA species to medulloblastoma pathogenesis.   ">
            <entity charOffset="55-69" id="miRNA-corp.d95.s9.e0" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="124-132" id="miRNA-corp.d95.s9.e1" text="micro-RNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="145-159" id="miRNA-corp.d95.s9.e2" text="medulloblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d95.s9.e1" e2="miRNA-corp.d95.s9.e0" id="miRNA-corp.d95.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d95.s9.e1" e2="miRNA-corp.d95.s9.e2" id="miRNA-corp.d95.s9.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d95.s10" origId="19584924.s9" text="CONCLUSIONS/SIGNIFICANCE: These data implicate hsa-miR-30b, hsa-miR-30d and KHDRBS3 as putative oncogenic target(s) of a novel recurrent medulloblastoma amplicon at 8q24.22-q24.23. ">
            <entity charOffset="47-57" id="miRNA-corp.d95.s10.e0" text="hsa-miR-30b" type="Specific_miRNAs"/>
            <entity charOffset="60-70" id="miRNA-corp.d95.s10.e1" text="hsa-miR-30d" type="Specific_miRNAs"/>
            <entity charOffset="76-82" id="miRNA-corp.d95.s10.e2" text="KHDRBS3" type="Genes/Proteins"/>
            <entity charOffset="106-111" id="miRNA-corp.d95.s10.e3" text="target" type="Relation_Trigger"/>
            <entity charOffset="137-151" id="miRNA-corp.d95.s10.e4" text="medulloblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d95.s10.e0" e2="miRNA-corp.d95.s10.e2" id="miRNA-corp.d95.s10.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d95.s10.e0" e2="miRNA-corp.d95.s10.e4" id="miRNA-corp.d95.s10.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d95.s10.e1" e2="miRNA-corp.d95.s10.e2" id="miRNA-corp.d95.s10.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d95.s10.e1" e2="miRNA-corp.d95.s10.e4" id="miRNA-corp.d95.s10.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d96" origId="20665731">
        <sentence id="miRNA-corp.d96.s0" origId="20665731.s2" text="Recently, it was demonstrated that podoplanin membrane sialo-glycoprotein encoded by PDPN gene is over-expressed and related to cellular invasion in astrocytic tumors; however the mechanisms of regulation are still unknown. ">
            <entity charOffset="35-44" id="miRNA-corp.d96.s0.e0" text="podoplanin" type="Genes/Proteins"/>
            <entity charOffset="85-88" id="miRNA-corp.d96.s0.e1" text="PDPN" type="Genes/Proteins"/>
            <entity charOffset="98-111" id="miRNA-corp.d96.s0.e2" text="over-expressed" type="Relation_Trigger"/>
            <entity charOffset="149-165" id="miRNA-corp.d96.s0.e3" text="astrocytic tumors" type="Diseases"/>
            <entity charOffset="194-203" id="miRNA-corp.d96.s0.e4" text="regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d96.s1" origId="20665731.s1" text="Glioblastoma is the most frequent and malignant brain tumor, characterized by an elevated capacity for cellular proliferation and invasion. ">
            <entity charOffset="0-11" id="miRNA-corp.d96.s1.e0" text="Glioblastoma" type="Diseases"/>
            <entity charOffset="38-58" id="miRNA-corp.d96.s1.e1" text="malignant brain tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d96.s2" origId="20665731.s0" text="miR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma.  ">
            <entity charOffset="0-6" id="miRNA-corp.d96.s2.e0" text="miR-29b" type="Specific_miRNAs"/>
            <entity charOffset="12-19" id="miRNA-corp.d96.s2.e1" text="miR-125a" type="Specific_miRNAs"/>
            <entity charOffset="21-28" id="miRNA-corp.d96.s2.e2" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="45-52" id="miRNA-corp.d96.s2.e3" text="suppress" type="Relation_Trigger"/>
            <entity charOffset="66-77" id="miRNA-corp.d96.s2.e4" text="glioblastoma" type="Diseases"/>
            <entity charOffset="30-39" id="miRNA-corp.d96.s2.e5" text="podoplanin" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d96.s2.e0" e2="miRNA-corp.d96.s2.e4" id="miRNA-corp.d96.s2.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d96.s2.e0" e2="miRNA-corp.d96.s2.e5" id="miRNA-corp.d96.s2.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d96.s2.e1" e2="miRNA-corp.d96.s2.e4" id="miRNA-corp.d96.s2.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d96.s2.e1" e2="miRNA-corp.d96.s2.e5" id="miRNA-corp.d96.s2.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d96.s3" origId="20665731.s7" text="Taken together, these results suggest that miR-29b and miR-125a represent potential therapeutic targets in glioblastoma.   ">
            <entity charOffset="43-49" id="miRNA-corp.d96.s3.e0" text="miR-29b" type="Specific_miRNAs"/>
            <entity charOffset="55-62" id="miRNA-corp.d96.s3.e1" text="miR-125a" type="Specific_miRNAs"/>
            <entity charOffset="107-118" id="miRNA-corp.d96.s3.e2" text="glioblastoma" type="Diseases"/>
            <entity charOffset="84-102" id="miRNA-corp.d96.s3.e3" text="therapeutic targets" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d96.s3.e0" e2="miRNA-corp.d96.s3.e2" id="miRNA-corp.d96.s3.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d96.s3.e1" e2="miRNA-corp.d96.s3.e2" id="miRNA-corp.d96.s3.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d96.s4" origId="20665731.s5" text="In this study, we focused on miR-29b and miR-125a, which were predicted to regulate PDPN, and demonstrated that these microRNAs directly target the 3' untranslated region of PDPN and inhibit invasion, apoptosis, and proliferation of glioblastomas. ">
            <entity charOffset="128-142" id="miRNA-corp.d96.s4.e0" text="directly target" type="Relation_Trigger"/>
            <entity charOffset="29-35" id="miRNA-corp.d96.s4.e1" text="miR-29b" type="Specific_miRNAs"/>
            <entity charOffset="41-48" id="miRNA-corp.d96.s4.e2" text="miR-125a" type="Specific_miRNAs"/>
            <entity charOffset="75-82" id="miRNA-corp.d96.s4.e3" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="84-87" id="miRNA-corp.d96.s4.e4" text="PDPN" type="Genes/Proteins"/>
            <entity charOffset="118-126" id="miRNA-corp.d96.s4.e5" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="174-177" id="miRNA-corp.d96.s4.e6" text="PDPN" type="Genes/Proteins"/>
            <entity charOffset="183-189" id="miRNA-corp.d96.s4.e7" text="inhibit" type="Relation_Trigger"/>
            <entity charOffset="233-245" id="miRNA-corp.d96.s4.e8" text="glioblastomas" type="Diseases"/>
            <pair e1="miRNA-corp.d96.s4.e1" e2="miRNA-corp.d96.s4.e4" id="miRNA-corp.d96.s4.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d96.s4.e1" e2="miRNA-corp.d96.s4.e6" id="miRNA-corp.d96.s4.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d96.s4.e1" e2="miRNA-corp.d96.s4.e8" id="miRNA-corp.d96.s4.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d96.s4.e2" e2="miRNA-corp.d96.s4.e4" id="miRNA-corp.d96.s4.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d96.s4.e2" e2="miRNA-corp.d96.s4.e6" id="miRNA-corp.d96.s4.p4" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d96.s4.e2" e2="miRNA-corp.d96.s4.e8" id="miRNA-corp.d96.s4.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d96.s4.e5" e2="miRNA-corp.d96.s4.e4" id="miRNA-corp.d96.s4.p6" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d96.s4.e5" e2="miRNA-corp.d96.s4.e6" id="miRNA-corp.d96.s4.p7" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d96.s4.e5" e2="miRNA-corp.d96.s4.e8" id="miRNA-corp.d96.s4.p8" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d96.s5" origId="20665731.s6" text="Furthermore, we report that miR-29b and miR-125a are downregulated in glioblastomas and also in CD133-positive cells. ">
            <entity charOffset="28-34" id="miRNA-corp.d96.s5.e0" text="miR-29b" type="Specific_miRNAs"/>
            <entity charOffset="40-47" id="miRNA-corp.d96.s5.e1" text="miR-125a" type="Specific_miRNAs"/>
            <entity charOffset="53-65" id="miRNA-corp.d96.s5.e2" text="downregulated" type="Relation_Trigger"/>
            <entity charOffset="70-82" id="miRNA-corp.d96.s5.e3" text="glioblastomas" type="Diseases"/>
            <pair e1="miRNA-corp.d96.s5.e0" e2="miRNA-corp.d96.s5.e3" id="miRNA-corp.d96.s5.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d96.s5.e1" e2="miRNA-corp.d96.s5.e3" id="miRNA-corp.d96.s5.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d96.s6" origId="20665731.s3" text="MicroRNAs are noncoding RNAs that regulate gene expression and several biological processes and diseases, including cancer. ">
            <entity charOffset="34-57" id="miRNA-corp.d96.s6.e0" text="regulate gene expression" type="Relation_Trigger"/>
            <entity charOffset="0-8" id="miRNA-corp.d96.s6.e1" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="116-121" id="miRNA-corp.d96.s6.e2" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d96.s6.e1" e2="miRNA-corp.d96.s6.e2" id="miRNA-corp.d96.s6.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d96.s7" origId="20665731.s4" text="Nevertheless, their roles in invasion, proliferation, and apoptosis of glioblastoma are not completely understood. ">
            <entity charOffset="71-82" id="miRNA-corp.d96.s7.e0" text="glioblastoma" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d97" origId="19838199">
        <sentence id="miRNA-corp.d97.s0" origId="19838199.s5" text="We also found that miR-326 promoted T(H)-17 differentiation by targeting Ets-1, a negative regulator of T(H)-17 differentiation. ">
            <entity charOffset="19-25" id="miRNA-corp.d97.s0.e0" text="miR-326" type="Specific_miRNAs"/>
            <entity charOffset="63-71" id="miRNA-corp.d97.s0.e1" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="73-77" id="miRNA-corp.d97.s0.e2" text="Ets-1" type="Genes/Proteins"/>
            <entity charOffset="82-99" id="miRNA-corp.d97.s0.e3" text="negative regulator" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d97.s0.e0" e2="miRNA-corp.d97.s0.e2" id="miRNA-corp.d97.s0.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d97.s1" origId="19838199.s6" text="Our data show a critical role for microRNA in T(H)-17 differentiation and the pathogenesis of multiple sclerosis.   ">
            <entity charOffset="34-41" id="miRNA-corp.d97.s1.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="94-111" id="miRNA-corp.d97.s1.e1" text="multiple sclerosis" type="Diseases"/>
            <pair e1="miRNA-corp.d97.s1.e0" e2="miRNA-corp.d97.s1.e1" id="miRNA-corp.d97.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d97.s2" origId="19838199.s1" text="Interleukin 17 (IL-17)-producing T helper cells (T(H)-17 cells) are increasingly recognized as key participants in various autoimmune diseases, including multiple sclerosis. ">
            <entity charOffset="0-13" id="miRNA-corp.d97.s2.e0" text="Interleukin 17" type="Genes/Proteins"/>
            <entity charOffset="16-20" id="miRNA-corp.d97.s2.e1" text="IL-17" type="Genes/Proteins"/>
            <entity charOffset="123-141" id="miRNA-corp.d97.s2.e2" text="autoimmune diseases" type="Diseases"/>
            <entity charOffset="154-171" id="miRNA-corp.d97.s2.e3" text="multiple sclerosis" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d97.s3" origId="19838199.s2" text="Although sets of transcription factors and cytokines are known to regulate T(H)-17 differentiation, the role of noncoding RNA is poorly understood. ">
            <entity charOffset="66-73" id="miRNA-corp.d97.s3.e0" text="regulate" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d97.s4" origId="19838199.s3" text="Here we identify a T(H)-17 cell-associated microRNA, miR-326, whose expression was highly correlated with disease severity in patients with multiple sclerosis and mice with experimental autoimmune encephalomyelitis (EAE). ">
            <entity charOffset="68-88" id="miRNA-corp.d97.s4.e0" text="expression was highly" type="Relation_Trigger"/>
            <entity charOffset="43-50" id="miRNA-corp.d97.s4.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="53-59" id="miRNA-corp.d97.s4.e2" text="miR-326" type="Specific_miRNAs"/>
            <entity charOffset="32-41" id="miRNA-corp.d97.s4.e3" text="associated" type="Relation_Trigger"/>
            <entity charOffset="83-99" id="miRNA-corp.d97.s4.e4" text="highly correlated" type="Relation_Trigger"/>
            <entity charOffset="140-157" id="miRNA-corp.d97.s4.e5" text="multiple sclerosis" type="Diseases"/>
            <entity charOffset="163-166" id="miRNA-corp.d97.s4.e6" text="mice" type="Species"/>
            <entity charOffset="186-213" id="miRNA-corp.d97.s4.e7" text="autoimmune encephalomyelitis" type="Diseases"/>
            <entity charOffset="216-218" id="miRNA-corp.d97.s4.e8" text="EAE" type="Diseases"/>
            <entity charOffset="126-133" id="miRNA-corp.d97.s4.e9" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d97.s4.e1" e2="miRNA-corp.d97.s4.e5" id="miRNA-corp.d97.s4.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d97.s4.e1" e2="miRNA-corp.d97.s4.e7" id="miRNA-corp.d97.s4.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d97.s4.e1" e2="miRNA-corp.d97.s4.e8" id="miRNA-corp.d97.s4.p2" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d97.s4.e2" e2="miRNA-corp.d97.s4.e5" id="miRNA-corp.d97.s4.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d97.s4.e2" e2="miRNA-corp.d97.s4.e7" id="miRNA-corp.d97.s4.p4" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d97.s4.e2" e2="miRNA-corp.d97.s4.e8" id="miRNA-corp.d97.s4.p5" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d97.s5" origId="19838199.s4" text="In vivo silencing of miR-326 resulted in fewer T(H)-17 cells and mild EAE, and its overexpression led to more T(H)-17 cells and severe EAE. ">
            <entity charOffset="21-27" id="miRNA-corp.d97.s5.e0" text="miR-326" type="Specific_miRNAs"/>
            <entity charOffset="70-72" id="miRNA-corp.d97.s5.e1" text="EAE" type="Diseases"/>
            <entity charOffset="83-96" id="miRNA-corp.d97.s5.e2" text="overexpression" type="Relation_Trigger"/>
            <entity charOffset="135-137" id="miRNA-corp.d97.s5.e3" text="EAE" type="Diseases"/>
            <pair e1="miRNA-corp.d97.s5.e0" e2="miRNA-corp.d97.s5.e1" id="miRNA-corp.d97.s5.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d97.s5.e0" e2="miRNA-corp.d97.s5.e3" id="miRNA-corp.d97.s5.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d97.s6" origId="19838199.s0" text="MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis.  ">
            <entity charOffset="0-7" id="miRNA-corp.d97.s6.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="9-15" id="miRNA-corp.d97.s6.e1" text="miR-326" type="Specific_miRNAs"/>
            <entity charOffset="17-25" id="miRNA-corp.d97.s6.e2" text="regulates" type="Relation_Trigger"/>
            <entity charOffset="56-65" id="miRNA-corp.d97.s6.e3" text="associated" type="Relation_Trigger"/>
            <entity charOffset="92-109" id="miRNA-corp.d97.s6.e4" text="multiple sclerosis" type="Diseases"/>
            <pair e1="miRNA-corp.d97.s6.e0" e2="miRNA-corp.d97.s6.e4" id="miRNA-corp.d97.s6.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d97.s6.e1" e2="miRNA-corp.d97.s6.e4" id="miRNA-corp.d97.s6.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d98" origId="18252210">
        <sentence id="miRNA-corp.d98.s0" origId="18252210.s1" text="Parkinson disease (PD) is a common neurodegenerative disorder caused by environmental and genetic factors. ">
            <entity charOffset="0-16" id="miRNA-corp.d98.s0.e0" text="Parkinson disease" type="Diseases"/>
            <entity charOffset="19-20" id="miRNA-corp.d98.s0.e1" text="PD" type="Diseases"/>
            <entity charOffset="35-60" id="miRNA-corp.d98.s0.e2" text="neurodegenerative disorder" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d98.s1" origId="18252210.s0" text="Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein.  ">
            <entity charOffset="27-38" id="miRNA-corp.d98.s1.e0" text="binding site" type="Relation_Trigger"/>
            <entity charOffset="17-25" id="miRNA-corp.d98.s1.e1" text="miRNA-433" type="Specific_miRNAs"/>
            <entity charOffset="66-82" id="miRNA-corp.d98.s1.e2" text="Parkinson disease" type="Diseases"/>
            <entity charOffset="87-100" id="miRNA-corp.d98.s1.e3" text="overexpression" type="Relation_Trigger"/>
            <entity charOffset="105-119" id="miRNA-corp.d98.s1.e4" text="alpha-synuclein" type="Genes/Proteins"/>
            <entity charOffset="43-47" id="miRNA-corp.d98.s1.e5" text="FGF20" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d98.s1.e1" e2="miRNA-corp.d98.s1.e5" id="miRNA-corp.d98.s1.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d98.s1.e1" e2="miRNA-corp.d98.s1.e2" id="miRNA-corp.d98.s1.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d98.s1.e1" e2="miRNA-corp.d98.s1.e4" id="miRNA-corp.d98.s1.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d98.s2" origId="18252210.s3" text="Subsequently, fibroblast growth factor 20 (FGF20) at 8p21.3-22 was identified as a risk factor in several association studies. ">
            <entity charOffset="14-40" id="miRNA-corp.d98.s2.e0" text="fibroblast growth factor 20" type="Genes/Proteins"/>
            <entity charOffset="43-47" id="miRNA-corp.d98.s2.e1" text="FGF20" type="Genes/Proteins"/>
            <entity charOffset="106-116" id="miRNA-corp.d98.s2.e2" text="association" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d98.s3" origId="18252210.s2" text="We have previously shown linkage of PD to chromosome 8p. ">
            <entity charOffset="36-37" id="miRNA-corp.d98.s3.e0" text="PD" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d98.s4" origId="18252210.s5" text="In a sample of 729 nuclear families with 1089 affected and 1165 unaffected individuals, the strongest evidence of association came from rs12720208 in the 3' untranslated region of FGF20. ">
            <entity charOffset="114-124" id="miRNA-corp.d98.s4.e0" text="association" type="Relation_Trigger"/>
            <entity charOffset="180-184" id="miRNA-corp.d98.s4.e1" text="FGF20" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d98.s5" origId="18252210.s4" text="To identify the risk-conferring polymorphism in FGF20, we performed genetic and functional analysis of single-nucleotide polymorphisms within the gene. ">
            <entity charOffset="48-52" id="miRNA-corp.d98.s5.e0" text="FGF20" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d98.s6" origId="18252210.s7" text="In a cell-based system and in PD brains, this increase in translation of FGF20 is correlated with increased alpha-synuclein expression, which has previously been shown to cause PD through both overexpression and point mutations. ">
            <entity charOffset="30-31" id="miRNA-corp.d98.s6.e0" text="PD" type="Diseases"/>
            <entity charOffset="73-77" id="miRNA-corp.d98.s6.e1" text="FGF20" type="Genes/Proteins"/>
            <entity charOffset="82-91" id="miRNA-corp.d98.s6.e2" text="correlated" type="Relation_Trigger"/>
            <entity charOffset="98-133" id="miRNA-corp.d98.s6.e3" text="increased alpha-synuclein expression" type="Relation_Trigger"/>
            <entity charOffset="108-122" id="miRNA-corp.d98.s6.e4" text="alpha-synuclein" type="Genes/Proteins"/>
            <entity charOffset="177-178" id="miRNA-corp.d98.s6.e5" text="PD" type="Diseases"/>
            <entity charOffset="193-206" id="miRNA-corp.d98.s6.e6" text="overexpression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d98.s7" origId="18252210.s6" text="We show in several functional assays that the risk allele for rs12720208 disrupts a binding site for microRNA-433, increasing translation of FGF20 in vitro and in vivo. ">
            <entity charOffset="84-95" id="miRNA-corp.d98.s7.e0" text="binding site" type="Relation_Trigger"/>
            <entity charOffset="101-112" id="miRNA-corp.d98.s7.e1" text="microRNA-433" type="Specific_miRNAs"/>
            <entity charOffset="141-145" id="miRNA-corp.d98.s7.e2" text="FGF20" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d98.s7.e1" e2="miRNA-corp.d98.s7.e2" id="miRNA-corp.d98.s7.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d98.s8" origId="18252210.s9" text="We propose this is likely to be a common mechanism of genetic modulation of individual susceptibility to complex disease.   ">
            <entity charOffset="62-71" id="miRNA-corp.d98.s8.e0" text="modulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d98.s9" origId="18252210.s8" text="We suggest a novel mechanism of action for PD risk in which the modulation of the susceptibility gene's translation by common variations interfere with the regulation mechanisms of microRNA. ">
            <entity charOffset="43-44" id="miRNA-corp.d98.s9.e0" text="PD" type="Diseases"/>
            <entity charOffset="64-73" id="miRNA-corp.d98.s9.e1" text="modulation" type="Relation_Trigger"/>
            <entity charOffset="156-165" id="miRNA-corp.d98.s9.e2" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="181-188" id="miRNA-corp.d98.s9.e3" text="microRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d98.s9.e3" e2="miRNA-corp.d98.s9.e0" id="miRNA-corp.d98.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d99" origId="21093685">
        <sentence id="miRNA-corp.d99.s0" origId="21093685.s3" text="The reason why a mild TBI results in varying clinical symptoms is currently unknown. ">
            <entity charOffset="17-24" id="miRNA-corp.d99.s0.e0" text="mild TBI" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d99.s1" origId="21093685.s4" text="Based on evidence that microRNA species in peripheral blood mononuclear cells (PBMCs) may reflect molecular alterations in neurodegenerative disorders, it can be hypothesized that at early, preclinical phases of the disease, PBMC may provide an ideal and clinically assessable &quot;window&quot; into the brain. ">
            <entity charOffset="23-30" id="miRNA-corp.d99.s1.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="123-149" id="miRNA-corp.d99.s1.e1" text="neurodegenerative disorders" type="Diseases"/>
            <pair e1="miRNA-corp.d99.s1.e0" e2="miRNA-corp.d99.s1.e1" id="miRNA-corp.d99.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d99.s2" origId="21093685.s1" text="Patients who have sustained a mild traumatic brain injury (TBI) from both civilian and military populations exhibit clinical symptoms of varying severity with minimal to profound impact on their daily functioning. ">
            <entity charOffset="0-7" id="miRNA-corp.d99.s2.e0" text="Patients" type="Species"/>
            <entity charOffset="30-56" id="miRNA-corp.d99.s2.e1" text="mild traumatic brain injury" type="Diseases"/>
            <entity charOffset="59-61" id="miRNA-corp.d99.s2.e2" text="TBI" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d99.s3" origId="21093685.s2" text="Although most patients make a full recovery, a subgroup of mild TBI patients develop cognitive, somatic, and neurobehavioral sequelae that generally resolve over 3 to 6 months; a smaller subgroup develop persisting symptoms. ">
            <entity charOffset="14-21" id="miRNA-corp.d99.s3.e0" text="patients" type="Species"/>
            <entity charOffset="59-66" id="miRNA-corp.d99.s3.e1" text="mild TBI" type="Diseases"/>
            <entity charOffset="68-75" id="miRNA-corp.d99.s3.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d99.s4" origId="21093685.s0" text="Personalized medicine in traumatic brain injury.  ">
            <entity charOffset="25-46" id="miRNA-corp.d99.s4.e0" text="traumatic brain injury" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d99.s5" origId="21093685.s5" text="Thus, it is conceivable that changes in the expression profile of clinically accessible biological indices (biomarkers), such as microRNA in PBMC, may reflect molecular alterations following TBI that contribute to the onset and progression of TBI phenotypes including chronic traumatic encephalopathy. ">
            <entity charOffset="129-136" id="miRNA-corp.d99.s5.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="191-193" id="miRNA-corp.d99.s5.e1" text="TBI" type="Diseases"/>
            <entity charOffset="243-245" id="miRNA-corp.d99.s5.e2" text="TBI" type="Diseases"/>
            <entity charOffset="268-299" id="miRNA-corp.d99.s5.e3" text="chronic traumatic encephalopathy" type="Diseases"/>
            <entity charOffset="29-53" id="miRNA-corp.d99.s5.e4" text="changes in the expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d99.s5.e0" e2="miRNA-corp.d99.s5.e1" id="miRNA-corp.d99.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d99.s5.e0" e2="miRNA-corp.d99.s5.e2" id="miRNA-corp.d99.s5.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d99.s5.e0" e2="miRNA-corp.d99.s5.e3" id="miRNA-corp.d99.s5.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d99.s6" origId="21093685.s6" text="It is possible that the availability of TBI biomarkers may provide potential elements with clinical relevance to prevention, prognosis, and treatment of postconcussive disorders.   ">
            <entity charOffset="40-42" id="miRNA-corp.d99.s6.e0" text="TBI" type="Diseases"/>
            <entity charOffset="153-176" id="miRNA-corp.d99.s6.e1" text="postconcussive disorders" type="Diseases"/>
        </sentence>
    </document>
</corpus>
